

Mindray Medical International LTD
Form 20-F
April 16, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 20-F

(Mark One)

**..REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR(g) OF THE SECURITIES
EXCHANGE ACT OF 1934**

OR

**..ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
x 1934**

For the fiscal year ended December 31, 2014

OR

**..TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934**

OR

**..SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

Date of event requiring this shell company report

For the transition period from to

Commission file number: 001-33036

Mindray Medical International Limited

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant's name into English)

Cayman Islands

(Jurisdiction of incorporation or organization)

Mindray Building, Keji 12th Road South,

Hi-tech Industrial Park, Nanshan, Shenzhen 518057

The People's Republic of China

(Address of principal executive offices)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of Each Class	Name of Each Exchange on Which Registered
American Depositary Shares, each representing one Class A ordinary share, par value HK\$0.001 per share	New York Stock Exchange

Securities registered or to be registered pursuant to Section 12(g) of the Act.

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act.

None

Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: 88,181,846 Class A ordinary shares and 29,119,907 Class B ordinary shares.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes x No "

Edgar Filing: Mindray Medical International LTD - Form 20-F

If this report is an annual or transaction report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large accelerated filer Accelerated filer Non-accelerated filer

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S.GAAP International Financial Reporting Standards as issued by the International Accounting Standards Board Other

If "Other" has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Table of Contents

<u>INTRODUCTION</u>	3
<u>PART I.</u>	4
ITEM 1. <u>IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</u>	4
ITEM 2. <u>OFFER STATISTICS AND EXPECTED TIMETABLE</u>	4
ITEM 3. <u>KEY INFORMATION</u>	4
ITEM 4. <u>INFORMATION ON THE COMPANY</u>	32
ITEM 4A. <u>UNRESOLVED STAFF COMMENTS</u>	54
ITEM 5. <u>OPERATING AND FINANCIAL REVIEW AND PROSPECTS</u>	54
ITEM 6. <u>DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</u>	81
ITEM 7. <u>MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</u>	92
ITEM 8. <u>FINANCIAL INFORMATION</u>	93
ITEM 9. <u>THE OFFER AND LISTING</u>	94
ITEM 10. <u>ADDITIONAL INFORMATION</u>	95
ITEM 11. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	102
ITEM 12. <u>DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</u>	103
<u>PART II.</u>	104
ITEM 13. <u>DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</u>	104
ITEM 14. <u>MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</u>	104
ITEM 15. <u>CONTROLS AND PROCEDURES</u>	105
ITEM 16A. <u>AUDIT COMMITTEE FINANCIAL EXPERT</u>	105
ITEM 16B. <u>CODE OF ETHICS</u>	106
ITEM 16C. <u>PRINCIPAL ACCOUNTANT FEES AND SERVICES</u>	106
ITEM 16D. <u>EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</u>	107
ITEM 16E. <u>PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS</u>	107
ITEM 16F. <u>CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT</u>	107
ITEM 16G. <u>CORPORATE GOVERNANCE</u>	107
ITEM 16H. <u>MINE SAFETY DISCLOSURE</u>	108
ITEM 17. <u>FINANCIAL STATEMENTS</u>	108
ITEM 18. <u>FINANCIAL STATEMENTS</u>	108
ITEM 19. <u>EXHIBITS</u>	108

INTRODUCTION

Except where the context otherwise requires and for purposes of this annual report only:

“we,” “us,” “our company,” “our,” “Mindray International” and “Mindray” refer to Mindray Medical International Limited, and its consolidated subsidiaries, including, among others, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., or Shenzhen Mindray, Nanjing Mindray Bio-Medical Electronics Co., Ltd., or Nanjing Mindray, Beijing Shen Mindray Medical Electronics Technology Research Institute Co., Ltd., or Beijing Mindray, Shenzhen Mindray Software Technology Co., Ltd., or Shenzhen Mindray Software, Mindray DS USA Inc., or Mindray DS USA, and ZONARE Medical Systems, Inc., or ZONARE;

“China” or “PRC” refers to the People’s Republic of China, excluding, for purposes of this annual report only, Taiwan and the Special Administrative Regions of Hong Kong and Macau;

All references to “Renminbi” or “RMB” are to the legal currency of China, all references to “U.S. dollars,” “dollars,” or “\$” are to the legal currency of the United States, and all references to “HK\$” are to the legal currency of the Hong Kong Special Administrative Region of China;

“ordinary shares” refers to our Class A and Class B ordinary shares, par value HK\$0.001 per share;

“ADSs” refers to our American depositary shares, each of which represents one Class A ordinary share;

“ADRs” refers to American depositary receipts, which, if issued, evidence our ADSs;

“U.S. GAAP” refers to generally accepted accounting principles in the United States; and

“Exchange Act” refers to the United States Securities and Exchange Act of 1934, as amended.

This annual report on Form 20-F includes our audited consolidated financial statements for the years ended December 31, 2012, 2013 and 2014, and as of December 31, 2013 and 2014.

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements that are based on our current expectations, assumptions, estimates and projections about us and our industry. All statements other than statements of historical fact in this annual report are forward-looking statements. These forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “estimate,” “plan,” “believe,” “is/ are likely to” or other similar expressions. The forward-looking statements included in this annual report relate to, among others:

• our goals and strategies;

• our plans to launch new products or product lines;

• our expectations regarding market acceptance of and demand for our products;

• the effects and integration of our former, current and future acquisitions;

• our ability to expand our production and manage our sales and distribution network and other aspects of our operations, including our sales, marketing and service offices, our manufacturing facilities and our research and development centers;

• our intention to pay annual cash dividends to our shareholders;

• competition in the medical device industry in China and internationally;

• relevant government policies, healthcare reform and regulations relating to the medical device industry;

• the projected growth in certain product lines;

• the projected growth of the medical device industry in China and internationally;

• our future business development, financial condition and results of operations;

our ability to stay abreast of market trends and technological advances;

our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others;

the effects of global macroeconomic conditions on our business; and

general economic and business conditions in the countries where our products are sold.

These forward-looking statements involve various risks, assumptions and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may turn out to be incorrect. See Item 3.D, “Key information — Risk Factors” and elsewhere in this annual report for important risks and factors could cause our actual results to be materially different from our expectations.

The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. All forward-looking statements included herein attributable to us or other parties or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except to the extent required by applicable laws and regulations, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

PART I.

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3. KEY INFORMATION

A. Selected Financial Data.

The selected consolidated balance sheet data as of December 31, 2013 and 2014, and the selected consolidated statement of operations data for the years ended December 31, 2012, 2013 and 2014, were derived from our audited consolidated financial statements appearing elsewhere in this annual report. The selected consolidated financial data for the years ended December 31, 2010 and 2011 and as of December 31, 2010, 2011 and 2012 were derived from our audited consolidated financial statements that are not included in this annual report. The following consolidated financial data for the periods and as of the dates indicated should be read in conjunction with, and are qualified in their entirety by reference to our consolidated financial statements and related notes and Item 5, “Operating and Financial Review and Prospects.”

Our audited consolidated financial statements were prepared in accordance with U.S. GAAP, and have been audited by PricewaterhouseCoopers, an independent registered public accounting firm. The report of PricewaterhouseCoopers on those consolidated financial statements is included elsewhere in this annual report.

Our historical results for any prior years are not necessarily indicative of future results.

	Year Ended December 31,				
	2010	2011	2012	2013	2014
	(In thousands, except share and per share data)				
Consolidated Statement of Operations					
Data:					
Net revenues	\$704,309	\$880,743	\$1,060,054	\$1,213,987	\$1,322,814
Cost of revenues(1)	(303,334)	(394,302)	(459,389)	(527,402)	(584,310)
Gross profit	400,975	486,441	600,665	686,585	738,504
Operating expenses:					
Selling expenses(1)	(122,960)	(167,049)	(188,804)	(220,589)	(261,965)
General and administrative expenses(1)	(61,193)	(70,330)	(116,228)	(128,308)	(137,016)
Research and development expenses(1)	(60,316)	(82,024)	(104,302)	(127,464)	(146,997)
Realignment costs — post acquisition	(919)	—	—	—	—
Income from operations	155,587	167,038	191,331	210,224	192,526
Other income, net	8,835	3,108	1,619	3,881	9,363
Interest income	11,575	20,816	30,794	37,047	38,985
Interest expense	(2,900)	(1,390)	(4,093)	(6,345)	(6,400)
Income before income taxes and non-controlling interests	173,097	189,572	219,651	244,807	234,474
Provision for income taxes	(17,631)	(22,647)	(37,369)	(14,260)	(35,485)
Net income	\$155,466	\$166,925	\$182,282	\$230,547	\$198,989
Less: Net income attributable to non-controlling interests	—	(296)	(2,073)	(5,793)	(5,697)
Net income attributable to Mindray shareholders(2)	\$155,466	\$166,629	\$180,209	\$224,754	\$193,292
Basic earnings per share	\$1.37	\$1.45	\$1.54	\$1.91	\$1.65
Diluted earnings per share	\$1.32	\$1.41	\$1.50	\$1.87	\$1.63
Dividends declared per share	\$0.30	\$0.40	\$0.50	\$0.50	\$0.40
Shares used in computation of:					
Basic earnings per share	113,638,024	115,254,095	116,749,213	117,705,414	117,057,116
Diluted earnings per share	117,581,196	118,449,851	119,815,004	120,051,635	118,412,460

	As of December 31,				
	2010	2011	2012	2013	2014
	(In thousands except share data)				
Consolidated Balance Sheet Data:					
Cash and cash equivalents	\$137,502	\$124,311	\$247,859	\$385,224	\$276,598
Working capital(3)	520,043	682,078	818,254	990,653	1,007,179
Total current assets	694,600	939,309	1,220,845	1,647,692	1,531,609
Total assets	1,150,561	1,458,971	1,857,118	2,503,934	2,473,202
Total current liabilities	174,557	257,231	402,591	657,039	524,430

Edgar Filing: Mindray Medical International LTD - Form 20-F

Non-controlling interests	2	8,943	46,272	59,210	73,328
Total shareholders' equity	966,601	1,142,492	1,330,843	1,518,948	1,597,956
Total equity	966,603	1,151,435	1,377,115	1,578,158	1,671,284
Capital Stock	15	15	15	15	15
Number of ordinary shares issued(4)	114,619,759	115,341,581	117,434,531	118,328,437	117,301,753

(1) Share-based compensation charges incurred during the years related to:

	Year Ended December 31,				
	2010	2011	2012	2013	2014
	(In thousands)				
Cost of revenues	\$320	\$762	\$811	\$752	\$1,120
Selling expenses	2,569	4,429	4,457	4,345	6,420
General and administrative expenses	1,591	3,118	4,409	4,819	7,616
Research and development expenses	2,800	4,059	4,307	4,767	4,714

(2) Income attributable to Mindray shareholders includes income attributable to both Class A ordinary share shareholders and Class B ordinary share shareholders on a pro-rata basis.

(3) Working capital is equal to current assets less current liabilities.

(4) Our ordinary shares consist of Class A and Class B ordinary shares. Holders of Class A ordinary shares and holders of Class B ordinary shares have the same rights and liquidation preferences, except for voting rights, of which each Class A ordinary share is entitled to one vote while each Class B ordinary share is entitled to five votes.

B. Capitalization and Indebtedness.

Not applicable.

C. Reasons for the Offer and Use of Proceeds.

Not applicable.

D. Risk Factors.

RISKS RELATING TO OUR BUSINESS AND INDUSTRY

We may fail to effectively develop and commercialize new products, which would materially and adversely affect our business, financial condition, results of operations and prospects.

The medical device market is developing rapidly and related technology trends are constantly evolving. This results in frequent introduction of new products, short product life cycles and significant price competition. Consequently, our success substantially depends on our ability to anticipate technological trends and identify, develop and commercialize

in a timely and cost-effective manner new and advanced products that our customers demand. New products contribute significantly to our net revenues. We expect the medical device market to continue evolving toward newer and more advanced products, many of which we do not currently produce. To develop new products, we may acquire, through acquisitions, products and technologies that are not currently incorporated in our existing product lines. Commercialization of any new product requires relevant government approvals, the timing of which may not be under our control, and is subject to change from time to time. Moreover, it may take an extended period of time for our new products to gain market acceptance, if at all. Furthermore, as the life cycle for a product matures, the average selling price generally decreases. Although we have previously partially offset the effects of declining average selling prices with increases in sales volume and reductions in manufacturing cost, we may be unable to sustain this practice. Lastly, during a product's life cycle, problems may arise regarding regulatory, intellectual property, product liability or other issues which may affect its continued commercial viability.

Our success in developing and commercializing new products is determined primarily by our ability to:

- accurately assess technological trends and customer needs and meet market demands;
- optimize our manufacturing and procurement processes to predict and control costs;
- manufacture and deliver products in a timely manner;
- increase customer awareness and acceptance of our products;
- effectively manage our brands;
- minimize the time and costs required to obtain required regulatory clearances or approvals;
- anticipate competitive trends to compete effectively with other medical device developers, manufacturers and marketers;

- price our products competitively, including providing financing to our customers;

- effectively integrate acquired technology or products into our manufacturing, sales and distribution network; and

- effectively integrate customer feedback into our research and development planning.

We depend on distributors for a substantial portion of our revenues. Failure to establish and maintain relationships with distributors would materially and adversely affect our business, financial condition and results of operations.

We depend on distributors for a substantial portion of our revenues. We typically do not enter into long-term distribution agreements with our distributors, although we sometimes enter into three-year distribution agreements with certain distributors. As our existing distribution agreements expire, we may be unable to renew with our desired distributors on favorable terms or at all. In addition, we seek to limit our dependence on any single distributor by limiting and periodically redefining the scope of each distributor's territory and the range of our products that it sells, which may make us less attractive to some distributors. Furthermore, competition for distributors is intense. We compete for distributors domestically and internationally with other leading medical equipment and device companies that may have higher visibility, greater name recognition and financial resources, and a broader product selection. Our competitors also often enter into long-term distribution agreements that effectively prevent their distributors from selling our products. At times, we may also become engaged in contract disputes or other negotiations with distributors, including distributors for the businesses we acquired. For more details, please see “—We may undertake acquisitions, which may have a material adverse effect on our ability to manage our business, and may end up being unsuccessful.” Consequently, establishing relationships with new distributors, maintaining relationships with existing distributors and replacing distributors may be difficult and time consuming. Any disruption of our distribution network, including our failure to renew distribution agreements on favorable terms or our failure to successfully negotiate contract disputes, could negatively affect our ability to effectively sell our products and could materially and adversely affect our business, financial condition and results of operations.

If we are unable to effectively manage our distribution network, actions taken by our distributors could harm our corporate image and cause us to fail to meet our sales goals.

We have limited ability to manage the activities of our distributors, who are independent from us. Our distributors could take one or more of the following actions, some of which we have previously experienced, any of which could have a material adverse effect on our business, prospects and brand:

- sell products that compete with products that they have contracted to sell for us;

sell our products outside of our pricing guidelines, distorting the market price of our products;

sell our products outside their designated territory or to non-authorized end-users, possibly in violation of the exclusive distribution rights of other distributors;

directly or indirectly distribute products that lack necessary U.S. certifications into the U.S. market or non-U.S. markets in violation of applicable U.S. law;

fail to adequately promote our products; and/or

fail to provide proper training, repair and service to our end-users.

Furthermore, our distributors may focus selling efforts only on those products that provide them with the largest margins at the expense of products that offer them smaller margins.

Failure to adequately manage our distribution network, or non-compliance by distributors with our distribution agreements, could harm our corporate image among end-users of our products and disrupt our sales, resulting in a failure to meet our sales goals.

Our direct sales operations are costly and the related ongoing operational costs could have a material adverse effect on our business.

We maintain direct sales operations in China, the United States, Europe and certain emerging growth countries. We rely on direct sales for a significant portion of our revenues from certain areas, particularly the United States and Western Europe. Maintaining a direct sales force is costly due to the fixed costs we incur, which do not depend on revenue generation. For example, in the United States and Europe, we typically provide our direct sales personnel with payroll and other benefits that we do not provide independent distributors. If we cannot fully utilize these direct operations, including personnel and facilities, the ongoing operational costs could have a material adverse effect on our business and results of operations.

Maintaining a direct sales force and independent distribution network in the same regions could result in potential sales conflicts that negatively impact our revenue and results of operations and ability to attract and retain sales personnel.

We maintain both a direct sales force and an independent distribution network in China, the United States, Europe and certain emerging growth countries, creating the potential for conflict between them. In addition to direct sales efforts, our direct sales force in a region is sometimes responsible for managing our independent distribution network in such region. If our independent distributors and direct sales force compete with each other in any designated territory, our distribution agreements with independent distributors usually do not prohibit them from reducing selling prices for our products to make sales. Further, independent existing and potential distributors may decide not to sell our products or cease selling our products because of this potential conflict. Moreover, sales conflicts could negatively impact the morale of our direct sales force, making it more difficult to attract and retain sales personnel.

We have undertaken and may continue to undertake acquisitions, which may have a material adverse effect on our ability to manage our business, and may end up being unsuccessful.

Our growth strategy involves acquiring new technologies, businesses, products or services and creating strategic alliances that may be in areas in which we do not currently operate. For example, in 2012, we acquired five China-based companies that produce medical equipment, devices or other products. In 2013, we acquired ZONARE, a U.S. ultrasound technology company in the high-end radiology market, and another distributor company to complement our business. In 2014, we continued to pursue growth in part through seeking acquisition opportunities and acquired one reagent manufacturer in early 2014. The integration of these companies and future acquired entities into our business may be unsuccessful and we may be unable to attract and retain the talent required to operate and manage these businesses or to expand into new or existing markets as well as we expect. Acquisitions also require our management to develop expertise in new areas, manage new business relationships and attract new types of customers. We have made, and may in the future make, acquisitions where we acquire control, but not 100%, of the acquired company. We may have disagreements with or different views than the minority shareholders as to the

operation of the acquired company. As a result, we may not fully realize the anticipated benefits of the acquisition. These risks and risks associated with integrating acquired businesses could have an adverse effect upon our business, financial condition, and results of operation.

Acquisitions may also expose us to other potential risks, including risks associated with unforeseen or hidden liabilities, increased exposure to litigation, historical or continuing regulatory issues of the acquired entity and employee matters associated with headcount and other human resources decisions. Also, if we fail to timely and successfully integrate our compliance systems into the newly acquired subsidiaries, we may also face increased exposure to litigation, regulatory issues or other disputes. Additional risks include the diversion of resources from our existing businesses and technologies, our inability to generate sufficient revenue to offset related costs, expenses of acquisitions and potential loss of, or harm to, relationships with distributors, customers, suppliers and employees as a result of our integration of new businesses and new regulations governing international markets. In addition, we may incur costs, including those relating to intangibles or goodwill, in excess of our projected costs for these transactions. The occurrence of any of these events could have a material and adverse effect on our ability to manage our business, our financial condition and our results of operations.

International operations may be costly, time-consuming and difficult. If we do not successfully operate or expand internationally, our profitability and prospects could be materially and adversely affected.

Our success significantly depends upon our ability to operate in and further penetrate our existing international markets and to enter into new international markets. We have entered and intend to continue to enter markets in which we have limited or no experience and in which our brand may be less recognized. Our international operations have experienced increasingly intense competitive conditions and we may fail to anticipate competitive conditions in new or existing markets. These competitive conditions may make it difficult or impossible for us to effectively operate in these markets. To further promote our brand and generate demand for our products so as to attract distributors in international markets, we have and expect to continue to spend more on marketing and promotion than we do in our established markets. We may be unable to attract a sufficient number of distributors, and our selected distributors may not be suitable for selling our products. If our international operations and expansion efforts are unsuccessful, our profitability and prospects could be materially and adversely affected.

We are exposed to other risks associated with international operations, including:

political instability;

economic instability and recessions;

difficulties of administering foreign operations generally;

fluctuations in local currencies against Renminbi and U.S. dollars;

implementation of foreign exchange controls, which may affect customers' ability to remit payment;

limited protection for intellectual property rights and exposure to intellectual property litigation in the countries in which we do business;

obligations and compliance costs associated with a wide variety of foreign laws and regulatory requirements (e.g. import and licensing laws and local employment/labor laws and regulations);

changes in tariffs;

- burdens on working capital due to financing issues for our accounts receivables, particularly in developing markets;
- healthcare reforms;
- increased risk of exposure to terrorist activities;
- difficulties obtaining raw materials or product supplies or other logistical issues due to natural disasters;
- financial condition, expertise and performance of our international distributors;
- unauthorized re-export of our products;
- potentially adverse tax consequences; and
- inability to effectively enforce contractual or legal rights.

Consolidation of our customer base and the formation of group purchasing organizations could adversely affect our business.

Consolidation among healthcare providers, such as the National Health Service in the United Kingdom and the consolidation of hospital groups in the United States, have resulted in consolidated healthcare entities that reduce local competition and increase pricing pressures on us. This consolidation may also lead to changes in our customer portfolios and in the types of products that they will demand. Additionally, as consolidation of such healthcare providers continues, we may require increased costs in order to market our products and successfully maintain our existing sales relationships. Increased pricing pressures and increased costs could adversely affect our revenues and results of operations.

In the United States and Europe, the formation of group purchasing organizations, or GPOs, has resulted in increased competition and pricing pressures, as GPOs historically purchase items at bulk discounts and prefer to buy the majority of products from fewer brands to maximize preferred pricing. Additionally, certain for-profit GPOs may require steep discounts in order to meet their profit margins, and may also be solely responsible for purchases by groups of hospitals or healthcare clinics in a specific region. If we are unable to enter into contracts with GPOs and integrated health networks on satisfactory terms or at all, our revenues and results of operations would be adversely affected.

We depend on our key personnel, and our business and growth may be adversely impacted if we lose their services.

Our success depends upon the continued service of our key executives and other key employees. In November 2012, Mr. Xu Hang, one of our founders, resigned as our co-chief executive officer, a position he had held since 1991. Mr. Xu continues to serve as the chairman of our board of directors. In June 2013, we appointed Mr. Cheng Minghe as our co-chief executive officer alongside Mr. Li Xiting. Mr. Li Xiting was also appointed as the executive chairman of our board of directors in March 2015. In May 2014, Mr. Liu Jie, our then chief operating officer, departed from our company. Prior to his departure, Mr. Liu transitioned his responsibilities to other members of the executive team and Mr. Wang Jianxin was appointed to the position of chief operating officer. Although we have not experienced any significant interruptions to business from these changes in our senior management, further changes may not be equally successful. If we are unable to maintain a strong senior management team or integrate new senior management members, or if we cannot locate suitable and qualified replacements, our business and growth could be adversely impacted.

Furthermore, as we expect to continue to expand our operations and develop new products, we will need to continue attracting and retaining experienced management, key research and development personnel, and salespeople. Competition for personnel in the medical device field is intense, and the pool of suitable and qualified candidates is limited in China, particularly Shenzhen, and certain other markets, including the United States. We compete for qualified research and development personnel against other medical device companies, universities and research institutions. Competition for these individuals could cause us to offer higher compensation and other benefits in order to attract and retain them, which could materially and adversely affect our financial condition and results of operations. Although we grant share incentive awards, such awards may cease to be effective to retain our current employees once the shares vest and bonus amounts are paid. Failure to attract and retain experienced personnel required to achieve our business objectives could adversely impact our business and growth.

Our business faces intense competition, which may reduce demand for our products and materially and adversely affect our business, financial condition, results of operations and prospects.

The medical device market is highly competitive, and we expect competition to intensify. In particular, we face direct competition in China, the United States and globally across all product lines and price points, experiencing significant pricing pressures in recent years. Our competitors include publicly traded and privately held multinational companies, as well as local companies in the markets where we sell our products. We face competition from companies that have or may have:

• greater financial and other resources;

• larger variety of products;

• lower cost structures, and more domestic support or local protection through tariff and non-tariff barriers;

• more products that have received regulatory approvals;

• greater access to public equity markets or financing options;

• greater pricing flexibility;

• availability of financing for customers;

• better research and development and technical capabilities;

• patent portfolios that may present an obstacle to our conduct of business;

• greater knowledge of market conditions in places where we seek to increase our international sales;

• capability to offer vendor financing or offer or facilitate leasing arrangements;

• stronger brand recognition; and

larger sales and distribution networks.

As a result, we may be unable to offer products similar to, or more desirable than, those offered by our competitors, market our products as effectively as our competitors, or otherwise respond successfully to competitive pressures. In addition, our competitors may be able to offer discounts on competing products as part of a bundle of non-competing products, systems and services that they sell to our customers, and we may not be able to match those discounts. Furthermore, our competitors may develop technologies and products that are more effective than those we currently offer or that render our products obsolete or uncompetitive. In addition, the introduction of competing products could affect our products' market acceptance and market share. Our failure to compete successfully could materially and adversely affect our business, financial condition, results of operation and prospects.

Moreover, some of our competitors based outside China have established or are in the process of establishing production and research and development facilities in China, while others have entered into cooperative business arrangements with PRC manufacturers. These actions may improve our competitors' cost structure, distribution capabilities, and market access and acceptance. For details of the competitors, please refer to Item 4, "Information on the Company — Competition." In particular, competition in the market covering county-level hospitals has intensified recently in China. This change is mainly attributable to the increasing entry of multinational companies through acquisitions of established PRC companies. If we are unable to develop competitive products, obtain regulatory approval or clearance and supply sufficient quantities to the market as quickly and effectively as our competitors, market acceptance of our products may be limited, which could result in decreased sales. In addition, we may not be able to maintain our manufacturing cost advantage. In other emerging markets, we have also seen larger competitors setting up sizable local businesses or acquiring local competitors or distributors, which allow them to be more competitive in their pricing and distribution infrastructure. Furthermore, potential competitors may move from their established market segments into market segments we have historically focused on and we may not be able to maintain our lead in our historically dominant market segments.

If we fail to accurately project demand for our products, we may encounter problems of inadequate supply or oversupply, especially with respect to our international markets and government tender sales in China, which would materially and adversely affect our financial condition and results of operations, as well as damage our reputation and brand.

Our distributors typically order our products on a purchase-order basis. We project product demand based on rolling distributor projections, our understanding of anticipated hospital procurement spending, and distributor inventory levels. However, our lack of significant order backlog and the varying sales and purchasing cycles of our distributors and other customers make it difficult for us to accurately forecast demand.

In countries where we lack a direct sales force, our demand projections are generally less reliable than in countries where we have a direct sales force because we have less available information on which to base our projections. Specifically, we lack consistently reliable information regarding international distributor inventory levels in these

markets, and we sometimes lack extensive knowledge of local market conditions or about distributor purchasing patterns, preferences, or cycles. Furthermore, because shipping finished products to international distributors typically takes longer than shipping to domestic distributors, inaccurate demand projections can result more quickly in unmet demand. We additionally may have unpredictably large tender sales orders for which we may have insufficient inventory to fill along with the additional orders in our pipeline.

If we overestimate demand, we may purchase more raw materials or components than required. If we underestimate demand, our third-party suppliers may have inadequate raw material or product component inventories, which could interrupt our manufacturing and delay shipments, and could result in lost sales. In particular, we are seeking to manage our procurement and inventory costs by matching our inventories closely with our projected manufacturing needs and by, from time to time, deferring our purchase of raw materials and components in anticipation of supplier price reductions. As we seek to balance inventory costs and production flexibility, we may fail to accurately forecast demand to predict and maintain appropriate levels of inventory reserve, which could cause uneven and unpredictable sales flow or could affect our ability to coordinate our procurement and production to meet demand on a timely basis. Our inability to accurately predict or timely meet demand could materially and adversely affect our financial conditions and results of operations as well as damage our reputation and brand.

Failure to ensure compliance with anti-corruption laws could materially and adversely affect our financial condition and results of operations, and damage our reputation and sales activities.

We could be liable for violations of applicable anti-corruption law, including China's anti-corruption laws, the U.S. Foreign Corrupt Practices Act, or FCPA, the Bribery Act 2010 of England and Wales, or the UK Bribery Act, and applicable anti-corruption and anti-bribery laws of other jurisdictions in which we do business, arising in connection with the marketing and distribution of our products. Due to the conditions of competition in the markets for medical devices in China and other emerging markets, corrupt practices may still occur within our industry. Such practices in China may involve inappropriate and unlawful payments or favors to influence procurement decision of customers, regulatory approval decisions of the China Food and Drug Administration, or CFDA, and clinical trials conducted by PRC hospitals and medical institutions. Many of the individuals involved in these processes would qualify as "foreign government officials" under the FCPA, and improper payments to such recipients may violate the anti-bribery provisions of the FCPA and other applicable anti-corruption laws. Additionally, as we have sales offices in the United Kingdom and employ UK citizens, we may be subject to the commercial bribery provisions of the UK Bribery Act, which applies to non-government officials. Numerous enforcement actions by government authorities in the United States, China, and other jurisdictions have involved corruption in the medical device industry. Despite our compliance efforts, we cannot guarantee that our employees will not intentionally violate applicable anti-corruption laws. Because individual employees may find it difficult in some circumstances to distinguish appropriate practice from inappropriate practices for establishing and maintaining business relationships with business contacts, our employees could inadvertently violate applicable anti-corruption laws.

We may also be held liable for actions taken by our distributors in some circumstances, even though a majority of our distributors are non-U.S. or non-UK companies. Our distributors may violate applicable anti-corruption law or otherwise engage in illegal practices with respect to their sales or marketing of our products. If we or our distributors violate these laws, we could be required to pay damages or fines, which could materially and adversely affect our financial condition and results of operations. In addition, our brand, reputation and our sales activities could be adversely affected by any negative publicity resulting from actions taken by us or our distributors.

Activities taken by us or our distributors in countries subject to U.S. economic sanctions could have a material and adverse effect on our reputation and have a material and adverse effect on our business, financial condition, results of operations and prospects.

The U.S. Department of the Treasury's Office of Foreign Assets Control, or OFAC, administers U.S. economic sanctions laws that prohibit certain activities with certain countries, governments, entities or individuals. We sell our products in international markets directly and also through independent distributors, which are responsible for interacting with the end-users of our products. Although we have implemented internal controls to screen our customers and prevent our products from being directly sold to or sold through distributors to countries or entities subject to U.S. sanctions, failure of such internal controls could cause our products to inadvertently be sold to customers subject to U.S. sanctions, which could subject us to penalties ranging from fines to prohibitions on imports of our products. Certain of our independent non-U.S. distributors are also located in or conduct business with

countries subject to U.S. economic sanctions, such as Cuba, North Korea, Sudan, Iran, Syria and Myanmar. To the extent that these distributors are not U.S. based and do not sell U.S. origin products in those countries, U.S. economic sanctions may not apply to their activities. Any sales or actions inconsistent with company policy relating to violations of U.S. sanctions laws could materially and adversely affect our reputation and have a material and adverse effect on our business, financial condition, results of operations and prospects.

In the United States, Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 requires specific disclosure of certain dealings with Iran, including, but not limited to, transactions or dealings with government-owned entities and entities sanctioned for activities related to terrorism or the proliferation of weapons of mass destruction. We sell certain non-military use medical devices and equipment through independent distributors who resell such devices in Iran on a purchase-order basis. Our direct activities in Iran are limited to occasional visits to provide distributor training and to conduct customer surveys. In 2014, net revenues generated by distributors covering Iran amounted to \$7.5 million, representing 0.56% of our total net revenues. We do not believe that our Iranian distributors fall within any of the proscribed categories set forth in Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012. However, as we do not have direct knowledge of the identity of the distributors' downstream customers, it is possible that these customers include entities, such as hospitals and pharmacies that are owned or controlled, directly or indirectly, by the Iranian government or by sanctioned persons or entities. Following a review of our business with Iran, we do not anticipate any change in our business operations in Iran in the near future.

New regulations related to "conflict minerals" may cause us to incur additional expenses and could limit the supply and increase the cost of certain metals used in manufacturing our products.

On August 22, 2012, the SEC adopted a new rule requiring disclosures of specified minerals, known as conflict minerals, that are necessary to the functionality or production of products manufactured or contracted to be manufactured by public companies. The rule requires us to perform due diligence, disclose and report annually whether or not such minerals that are used in our products originate from the Democratic Republic of Congo or an adjoining country. Among other things, this new rule could affect sourcing at competitive prices and availability in sufficient quantities of certain minerals used in the manufacture of our products, including tantalum, tin, gold and tungsten. The number of suppliers who provide conflict-free minerals may be limited.

In compliance with this new rule, we have conducted and will continue to conduct due diligence with our suppliers to determine the sources of the relevant minerals used in the parts provided by them. There may be additional costs associated with complying with the disclosure requirements, such as costs related to determining the source of certain minerals used in our products, as well as costs of possible changes to products, processes, or sources of supply as a consequence of such verification activities. Since our supply chain is complex, we may not be able to sufficiently verify the origins of the relevant minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. In addition, we may encounter challenges to satisfy those customers who require that all of the components of our products be certified as conflict-free, which could place us at a competitive disadvantage if we are unable to do so.

Our reputation and trading prices of our securities may be negatively affected by adverse publicity related to our business.

From late 2013 to early 2014, we were subject to negative publicity resulting from a series of reports published by an entity that holds itself out as a research firm resulting in volatility in the trading price of our ADSs. The reports contained numerous allegations with respect to, among other things, the accuracy of our financial statements, the existence of our assets (including cash and capital investments and assets acquired in our 2008 Datascope patient monitoring business acquisition), and our corporate structure and governance matters. Our management and audit committee, and then our full board, evaluated the allegations and determined them not to merit further investigation or changes to our prior year financial statement disclosure. However, additional allegations (such as alleged failures to comply with legal and regulatory requirements or irregular accounting or financial reporting) and any corresponding adverse publicity related to our business, regardless of merit, could harm our reputation, cause the trading price of our securities to decline and fluctuate significantly, require additional responsive actions and delay our public reporting process.

Our business may be adversely affected by recent healthcare reforms, particularly in China and the United States.

In 2011, the PRC government released its 12th Five-Year Plan, the guidance for social, economic and environmental development for the country over the next five years. The 12th Five-Year Plan discussed efforts to deepen the reform of China's healthcare system, including increased allowances for medical insurance plans in both rural and urban areas and expanding the coverage of the country's essential medicine system to village clinics and non-government-run primary healthcare institutions and ensuring universal access to basic healthcare services. These PRC healthcare reform acts and future healthcare reform could adversely affect our business in several ways, including:

Reduced demand for our products. Healthcare reforms may provide funding and incentives for specific products we do not provide or target customers such as larger hospitals that currently account for a smaller portion of our customer base.

Pricing pressures. Our existing customers may be incentivized by healthcare reform subsidies or tax incentives to defer purchases of our products in favor of those which are subsidized or have beneficial tax implications.

Changes in customer spending patterns. Healthcare reform may additionally be targeted at individuals rather than hospitals, which could affect the spending patterns of our customers in ways we may not be able to anticipate. For example, increased insurance coverage for PRC residents under the healthcare reform initiative could potentially increase patronage at larger sized hospitals rather than county-level hospitals and local clinics, lowering our sales to such county-level hospitals and local clinics.

On March 23, 2010, the United States passed the Patient Protection and Affordable Care Act, shortly thereafter amended by the Health Care and Education Reconciliation Act of 2010, or the Reconciliation Act, on March 30, 2010. The Reconciliation Act added section 4191 to the U.S. Internal Revenue Code of 1986, as amended, which imposed an excise tax, effective as of January 1, 2013, on the sale of non-retail medical devices by the manufacturer, producer or importer in the amount equal to 2.3% of the sales price. Under the legislation, the total cost to the medical device industry is expected to be approximately \$20 billion over 10 years. Based on the existing size of our U.S. operations, we do not expect the new tax to materially and adversely affect our business, cash flows and results of operations. We incurred \$1.9 million and \$2.0 million of these excise taxes in 2013 and 2014, respectively. The law also focuses on a number of Medicare provisions aimed at improving quality and decreasing costs. It is uncertain at this point what negative unintended consequences these provisions will have on patient access to new technologies. The Medicare provisions include value-based payment programs, increased funding of comparative effectiveness research, reduced hospital payments for avoidable readmissions and hospital acquired conditions, and pilot programs to evaluate alternative payment methodologies that promote care coordination (such as bundled physician and hospital payments). Additionally, the law includes a reduction in the annual rate of inflation for Medicare payments to hospitals that began in 2011 and the establishment of an independent payment advisory board to recommend ways of reducing the rate of growth in Medicare spending that began in 2014. We cannot predict what healthcare programs and regulations will be ultimately implemented at the federal or state level, or the effect of any future legislation or regulation. However, any changes that lower reimbursement for our products or reduce medical procedure volumes could adversely affect our business and results of operations.

Heightened regulatory scrutiny could divert management's attention, increase our compliance and reporting costs, cause reputational harm and result in litigation.

We believe there has been a heightened U.S. regulatory environment for public companies over the last several years, particularly those based in China. Increased regulatory scrutiny can divert management's attention and increase legal, compliance, and reporting costs. In the past, we have devoted resources, time, and attention providing information to the SEC's divisions of corporation finance as part of a review of our 2011 annual report and enforcement as part of an investigation regarding, among other things, revenue recognition policies, distributor and direct sales, accounts receivable and related collections, and intangible assets. Although we have not received additional correspondence from the SEC since 2012, there can be no assurances that the investigation has been concluded and the SEC may make additional inquiries in the context of an investigation or otherwise. Responding to any additional inquiries from the SEC and other regulators, on those or other matters, could further divert management's attention, increase our legal, compliance, and reporting costs, cause reputational harm, delay our public reporting process depending on timing and result in litigation which may be costly to defend regardless of merit.

We currently principally rely on four facilities for manufacturing, product assembly and storage and to conduct research and development activities. Any disruption to the use or development of our current manufacturing facilities could reduce or restrict our sales, harm our reputation and have a material adverse effect on our business, financial condition, results of operations and prospects.

We manufacture, assemble and store a substantial majority of our products, as well as conduct some of our research and development activities, at our three facilities located in Shenzhen, China. We also manufacture, assemble and store products and conduct some of our research and development activities at our facility in Nanjing, China. A natural disaster or other unanticipated catastrophic events, including power interruptions, water shortage, storms, fires, earthquakes, terrorist attacks and wars, could significantly impair our ability to manufacture our products and operate our business, as well as delay our research and development activities. Our facilities and certain equipment located in these facilities would be difficult to replace and could require substantial replacement lead-time. Catastrophic events may also destroy any inventory located in our facilities. The occurrence of such an event could materially and adversely affect our business.

We may encounter difficulties in constructing and developing our facilities, and we may not fully realize the anticipated benefits from our significant facility investments.

We have made, and expect to continue to make, significant investments in our facilities. For example, we are in the process of expanding our manufacturing facilities in Shenzhen, China and building new research and development facilities in Beijing and Xi'an, China. We may encounter difficulties obtaining regulatory approval for construction and development and face operating difficulties as we begin operations in, or transition operations to, new or expanded facilities. In addition, we may not realize the anticipated benefits from these activities on a timely basis or at all. We typically construct facilities and incur the related costs in anticipation of planned development and introduction of new medical devices and related revenue growth. However, we may experience difficulties and delay in developing, introducing and selling new products and related growth and other assumptions may be inaccurate for a variety of economic and other reasons, many of which may be out of our control. Any of these events could result in significant underutilization of our facilities and have a material adverse effect on our business, financial condition and results of operations.

If we are unable to obtain adequate supplies of required materials and components that meet our production standards at acceptable costs or at all, our ability to accept and fulfill product orders with the required quality and at the required time could be restricted, which could materially and adversely affect our business, financial condition and results of operations.

We purchase raw materials and components from third-party suppliers and manufacture and assemble our products at our facilities. We generally make purchases on a purchase order basis and do not have long-term supply contracts. As a result, our suppliers may cease to provide components or other materials to us with little or no advance notice. From

time to time we may also have contract disputes or other negotiations with our suppliers and our original equipment manufacturers, or OEMs, and original design manufacturers, or ODMs. Interruptions in certain material or component supplies, sometimes caused by natural disasters or factors not within our control, could delay our manufacturing and assembly processes. We also may be unable to secure alternative supply sources in a timely and cost-effective manner. If we are unable to obtain adequate supplies of required materials and components that meet our production standards at acceptable costs or at all, our ability to accept and fulfill product orders with the required quality, and at the required time could be restricted, which, in turn, could impact our working capital, harm our reputation, reduce our sales or gross margins, and cause us to lose market share, each of which could materially and adversely affect our business, financial condition and results of operations.

Pursuing our growth strategy will strain our management, operational and other resources, which could materially and adversely affect our business and prospects.

Our growth strategy includes increasing market penetration of our existing products, developing or acquiring new products, gaining market share in various low- to mid-end markets and mid- to high-end markets, increasing our targeting of private hospitals in China, strengthening our coverage of county-level hospitals, expanding the scale of our sales force and network of distributors, increasing our exports and building our brand. Implementing our growth strategy has resulted in, and will continue to result in, substantial demands on management, operational and other resources. In particular, pursuing our growth strategy requires, among other things:

- enhancing our research and development capabilities;
- hiring and training new personnel;
- managing distribution channels for our increased product portfolio;
- enhancing our information technology and client-relationship management systems;
- implementing more stringent cost controls;
- maintaining sufficient liquidity;
- strengthening financial and management controls;
- increasing marketing, sales and sales support activities; and
- successfully identifying and executing merger and acquisitions initiatives.

If we are unable to successfully implement our growth strategy, our business and prospects could be materially and adversely affected.

Furthermore, certain of our growth strategies focus on long-term growth and require significant investment or longer periods of time to materialize. As a result, these strategies may adversely affect our short-term financial performance and results of operations.

We may need additional capital, and we may be unable to obtain such capital in a timely manner, on acceptable terms, or at all.

We may need additional capital to grow, remain competitive, develop new or enhance existing products, expand our distribution network, for capital improvement projects and/or for acquisitions.

Our ability to obtain additional capital is subject to numerous uncertainties, including:

• our financial condition, results of operations and cash flows;

• general market conditions for capital raising activities by medical device and related companies;

• economic, political and other conditions in China and internationally; and

• PRC government policies relating to the borrowing and remittance of foreign currency into or outside of China.

We may be unable to obtain additional capital or relocate our existing capital, particularly amounts held in Renminbi or RMB-denominated assets, in a timely manner or on acceptable terms or at all. Such inability could materially affect our business, financial condition, results of operations and prospects. For further discussion on the effects of government policies relating to the borrowing and remittance of foreign currency outside of China, please see “— Risks Related to Doing Business in China —We may rely on dividends and other distributions on equity paid by our operating subsidiaries to fund cash and financing requirements, and limitations on the ability of our operating subsidiaries to pay dividends to us may have a material adverse effect on our ability to conduct our business” and “— Restrictions on currency exchange may limit our ability to utilize our capital effectively.”

We depend on information technology, or IT, to support our business operations, and any physical damage to or failure of our IT systems would materially and adversely affect our business, results of operations and prospects.

We have a globally integrated IT infrastructure consistent across our China, the United States and European operations. This integrated IT infrastructure is complicated by broad geographies, differing languages and business models. Our primary China-based IT operations are located in Shenzhen and include our data center, production, standby facilities and backup storage. We also have smaller local IT operations at our sites in the United States and Europe. Any physical damage to our IT systems, including by natural disasters or intentional acts of vandalism, would create significant disruptions to our business and operations and would be costly to repair. Additionally, any failure of our IT systems across our China, U.S. and European operations could result in substantial costs and diversion of resources and management attention, which could harm our business, results of operations and prospects.

The lessors of some of our leased properties may lack authority to enter into the leases. If we are forced to vacate these premises, it could materially disrupt our operations.

Shenzhen Mindray leases properties for manufacturing purposes. The lessors failed to provide us with the ownership certificates for the leased properties. If the lessors entering into the lease agreements with Shenzhen Mindray are not the de facto owners of the leased properties and lacked the authority to enter into these lease agreements, the validity of these lease agreements may be contested and we may be forced to vacate these premises, which could materially disrupt our operations.

If we fail to protect our intellectual property rights, it could harm our business and competitive position.

We rely on a combination of patent, copyright, trademark, trade secret laws and non-disclosure agreements and other methods to protect our intellectual property rights. We have patents issued in China and the United States covering various products and aspects of our products. We also have pending patent applications in China, the United States, Europe and India, which cover some of the more commercially significant aspects of our products and technologies.

Due to the different regulatory bodies and varying requirements in the United States, China and elsewhere, we may be unable to obtain patent protection for certain aspects of our products or technologies in any of these countries. The process of seeking patent protection can be lengthy and expensive, our patent applications may fail to result in patents being issued, and our existing and future patents may be insufficient to provide us with meaningful protection or commercial advantage. Our patents and patent applications may also be challenged, invalidated or circumvented.

We also rely on trade secret rights to protect our business through non-disclosure provisions in employment agreements with employees. If our employees breach their non-disclosure obligations, we may not have adequate remedies, and our trade secrets may become known to our competitors.

Implementation of PRC intellectual property-related laws has historically been lacking, primarily because of ambiguities in the PRC laws and enforcement difficulties. Accordingly, intellectual property rights and confidentiality protections in China may not be as effective as in the United States or other western countries. Furthermore, policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability, scope and validity of our proprietary rights or those of others. Such litigation and an adverse determination in any such litigation, if any, could result in substantial costs and diversion of resources and management attention, which could harm our business and competitive position.

We may be exposed to intellectual property infringement and other claims by third parties which, if successful, could disrupt our business and have a material adverse effect on our financial condition and results of operations.

Our success depends, in large part, on our ability to use and develop our technology and know-how without infringing third-party intellectual property rights. We periodically receive written correspondence regarding alleged intellectual property infringement or other claims by third parties, who may also initiate litigation against us. For example, in December 2012, a patent infringement claim was filed against Mindray DS USA and Shenzhen Mindray. See Item 4, “Information on the Company — Legal Proceedings.” Additionally, as we increase our product sales internationally, as we acquire more companies as part of our expansion efforts and as litigation becomes more common in China, we face a higher risk of being the subject of claims for intellectual property infringement, invalidity or indemnification relating to other parties’ proprietary rights. Our current or potential competitors, many of whom have substantial resources and have made substantial investments in competing technologies, may have or may obtain patents that will prevent, limit or interfere with our ability to make, use or sell our products in China, the United States, or Europe. The validity and scope of claims relating to such patents can involve complex scientific, legal and factual questions and analysis and, as a result, may be highly uncertain. In addition, the defense of intellectual property suits, including patent infringement suits, and related legal and administrative proceedings can be both costly and time consuming and may significantly divert the efforts and resources of our technical and management personnel. We may be unsuccessful in defending all or even some of the claims brought against us. We may also engage in settlement or other negotiated agreements to avoid further costs associated with defense of intellectual property suits. For example, in 2011, we and certain Datascope entities agreed that we would acquire all rights, title and interest in certain trademarks, service marks and other names in exchange for a one-time payment to Datascope of \$7.0 million and the grant to Datascope of an exclusive 20-year limited license of certain of such trademarks, service marks and other names.

An adverse determination in any such litigation or proceedings to which we may become a party could cause us to:

• pay damage awards;

• seek licenses from third parties;

• pay ongoing royalties;

• redesign our products; or

• be restricted by injunctions,

each of which could effectively prevent us from pursuing some or all of our business and result in our customers or potential customers deferring or limiting their purchase or use of our products, which could have a material adverse

effect on our financial condition and results of operations.

Disputes over use of our brand names or the brand names we license, the expenses incurred in developing and preserving the value of our brand name, and any loss of rights to use our brand names or the brand names we license as a result of challenge, may adversely affect our business.

We regard our brand names as critical to our success. In December 2013 the Trademark Office of the PRC State Administration for Industry and Commerce, or SAIC, recognized our “Mindray” name as a Well-Known Trademark in medical analysis instruments, medical devices and instruments, and medical diagnostic equipment. Disputes over use of our brand names or the brand names we license may adversely affect our business and reputation, including the perceived quality and reliability of our products. We rely on trademark law, company brand name protection policies, and agreements with our employees, customers, business partners and others to protect the value of our brand names. Despite our precautions, we may be unable to prevent third parties from using our brand names without authorization, including the unauthorized use of our domain names. We have experienced unauthorized use of our domain names and are currently in the process of reclaiming certain of our domain names with some success in accordance with the Uniform Domain Name Dispute Resolution Policy adopted by the Internet Corporation for Assigned Names and Numbers, or ICANN, or licensing the right to use our trademarks. We are also in the process of resolving a trademark dispute with a third party in the European Union. We have also experienced unauthorized use of our brand names in China and have expended resources and the attention and time of our management to successfully prosecute those who used our brand names without authorization. Moreover, litigation may be necessary to protect our brand names. However, because the validity, enforceability and scope of protection of trademarks in China are uncertain and still evolving, we may not be successful in prosecuting these cases. Litigation could also result in substantial costs, diversion of our resources and loss of trademark rights, and could disrupt our business, as well as have a material adverse effect on our financial condition and results of operations. In addition, we are in the process of registering our brand names and logos as trademarks in countries outside of China. Our registration applications may not be successful in certain countries, which could weaken the protection of our brand names in those countries or may require that we market our products under different names in those countries.

If we fail to obtain or maintain applicable regulatory clearances or approvals for our products, or if such clearances or approvals are delayed, we will be unable to commercially distribute and market our products at all or in a timely manner, which could significantly disrupt our business and materially and adversely affect our sales and profitability.

The sale and marketing of the medical device products we offer are subject to regulation in most countries where they are sold. For a significant portion of our sales, we need to obtain and renew licenses and registrations with the CFDA, the United States Food and Drug Administration, or FDA, and the European regulators administering CE marks in the European Union. The processes for obtaining regulatory clearances or approvals can be lengthy and expensive, and the results are unpredictable. In addition, the relevant regulatory authorities may (as a result of change of regulatory or political environment or otherwise) introduce additional requirements or procedures that have the effect of delaying or prolonging the regulatory clearance or approval for our existing or new products. For example, substantial regulatory or political environment change and healthcare system reform in China may result in the delay of certain regulatory clearance or approval for certain of our products.

From time to time, we are subject to regulatory inspections related to our quality systems and regulatory compliance. For example, in late 2012, following an inspection of our Mahwah, New Jersey, facility, Mindray DS USA received an FDA warning letter. The warning letter, subsequently made available on the FDA's website, addressed certain findings and issues regarding our quality systems related processes at our Mahwah, New Jersey, facility. With the assistance of outside consulting, we evaluated the letter and commenced a process to address these observations and issues. In September 2013, the FDA concluded a re-inspection of our Mahwah, New Jersey, facility noting additional observations and issues. We met with the FDA regarding how we can satisfactorily and timely address their concerns. In March 2015, the FDA district office concluded a follow-up inspection of our Mahwah, New Jersey, facility and noted few observations, which we believe are addressable. We are communicating with the FDA regarding these observations. The FDA has also notified Shenzhen Mindray of an upcoming audit in 2015, relating to a routine quality system inspection and prior findings during the audits of our Mahwah, New Jersey, facility. Failure to satisfactorily and timely address the FDA's observations or other concerns or findings (including those identified upon any re-inspection) could result in or subject us to additional inspections in the United States or China; additional warning letters; or more severe FDA actions including significant civil penalties, an import ban on our products into the United States, an injunction, seizures of our products or a consent decree. Related developments could increase our legal, compliance and reporting costs, cause reputational harm, lead to customer and distributor losses, and result in litigation. Also, if we incur FDA fines or penalties or we are unable to obtain clearances or approvals needed to market existing or new products in a timely fashion or at all, our business would be significantly disrupted, and our sales and profitability could be materially and adversely affected.

Failure to comply with applicable import and export related laws, rules and regulations for our products could have a material and adverse effect on our reputation, business, financial condition, results of operations and prospects.

We primarily manufacture our products in China and then sell our products through different distribution channels in different geographies. We must comply with import and export related laws, rules and regulations in every region we do business in. Import and export related laws, rules and regulations differ from region to region and our inability to

comply with them may delay or prolong the regulatory clearance or approval for our existing or new products and could have a material and adverse effect on our reputation, business, financial condition, results of operations and prospects.

We are subject to product liability exposure and have limited insurance coverage. Any product liability claims or regulatory actions could be costly and time-consuming to defend, damage our reputation and materially and adversely affect our business, financial condition and results of operations.

Our main products are medical devices used in diagnosing and monitoring patients, exposing us to potential product liability claims if their use causes or results in, or is alleged to have caused or resulted in, in each case either directly or indirectly, personal injuries or other adverse effects. Any product liability claims or regulatory actions could be costly and time-consuming to defend. If successful, product liability claims may require us to pay substantial damages. We maintain limited product liability insurance to cover potential product liability arising from the use of our products. As a result, future liability claims could be excluded or could exceed the coverage limits of our policy. As we expand our sales internationally and increase our exposure to these risks in many countries, we may be unable to maintain sufficient product liability insurance coverage on commercially reasonable terms, or at all. A product liability claim or potential safety-related regulatory action, with or without merit, could result in significant negative publicity and materially and adversely affect the marketability of our products and our reputation, as well as our business, financial condition and results of operations.

Moreover, a material design, manufacturing or quality failure or defect in our products, other safety issues or heightened regulatory scrutiny could each warrant a product recall by us and result in increased product liability claims. For example, in August 2012, we initiated a voluntary recall in the United States, Latin America and Australia to repair our A3/A5 Anesthesia Delivery System when we detected the possibility of a system leak. We subsequently advised the FDA of this recall and repaired 100% of affected machines in the United States, with no reports of associated injuries. However, if authorities in the countries where we sell our products decide that any of our products fail to conform to applicable quality and safety requirements, we could be subject to regulatory action. In China, violation of PRC product quality and safety requirements may subject us to confiscation of related earnings, penalties, an order to cease sales of the violating product or to cease operations pending rectification. Furthermore, if the violation is determined to be serious, our business license to manufacture or sell violating and other products could be suspended or revoked.

Government tender sales in China have and will likely continue to be a small portion of our revenues.

We have historically generated certain portions of our China revenues from government tenders sales. Tender sales in China are a discretionary decision driven by government policies and can vary in terms of magnitude and timing of sales. Due to lack of government spending on tender sales and shift from government tender sales to hospitals' direct purchases, our revenues from government tender sales in China remained flat and accounted for 1.1% and 0.7% of our net revenues in 2013 and 2014, respectively. We expect our revenues from government tenders to remain relatively stable as a percentage of our net revenues the near future. Our inability to accurately predict trends in government tender sales in China could cause us to underestimate demand and prevent us from timely meeting demand for our products, which in turn could materially and adversely affect our financial conditions and results of operations.

The global economic downturn adversely affected, and could continue adversely affecting, our business, financial condition and results of operations.

We experienced a global economic downturn affecting all areas of business, including healthcare. Disruptions in orderly financial and commodities markets resulting from, among other factors, government instability, diminished liquidity and credit availability plus volatile valuations of securities, other investments and commodities prices caused business and consumer confidence to ebb, business activities to slow down, and unemployment to increase. For example, uncertainties surrounding European sovereign debt could affect our direct sales and distribution networks in Europe, political instability in countries in the Middle East could disrupt our distribution networks in such countries, and reduced oil prices in many of our emerging market countries could reduce government expenditures in healthcare and in turn reduce the ability for healthcare providers to purchase our products.

We are unable to predict global economic conditions. The economic downturn adversely affected and could continue adversely affecting our business in several ways, including:

Reduced demand for our products. Customers may adopt a strategy of deferring purchases to upgrade existing equipment or deploy new equipment until later periods when visibility of their cash flows becomes more assured. In addition, customers who must finance their capital expenditures through various forms of debt may find financing unavailable to them.

Increased pricing pressure and lower margins. Our competitors include several global enterprises with relatively greater size in terms of revenues, working capital, financial resources and number of employees, and some of our end-users are healthcare service providers who are typically owned, controlled, or sponsored by governments. Competition for available sales may become more intense, which could require us to offer or accept pricing, payment, or local content terms which are less favorable to remain competitive. In some cases we might be unwilling or unable to compete for business where competitive pressures make a potential opportunity unprofitable to us.

Greater difficulty in collecting accounts receivable. Many of our end-users are either owned or controlled by governments; any changes in such governments' policies concerning the authorization or funding of payments for capital expenditures could lengthen the cash collection cycle of our distributors, which could cause our liquidity to deteriorate if our distributors are unable to pay us on time. Additionally, sales made to our distributors or other customers whose financial resources may be subject to rapid decline, has caused and could continue to cause us to lose sales, delaying revenue recognition or causing greater collection risks due to credit quality issues.

Greater difficulty in obtaining supplies, components and related services. Some suppliers or vendors could choose to provide supplies or services to us on more stringent payment terms than those currently in place, such as by requiring advance payment or payment upon delivery of such supplies or services. Additionally, some suppliers might experience a worsening financial condition causing them to either withdraw from the market or be unable to meet our expected timing for the receipt of goods ordered from them, either of which condition could adversely affect our ability to serve our customers and lengthen the cycle time for transforming customer orders into cash receipts. Additionally, if it is necessary to seek alternative sources of supply, the effects on our costs, cycle time for cash collections, and customer satisfaction with us are uncertain.

Restructuring and impairment charges. If we are unable to generate the level of revenues, profits, and cash flow contemplated by our business plan, management may be forced to take further action to focus our business activities and align our cost structure with anticipated revenues. These actions, if necessary could result in restructuring charges and/or asset impairment charges being recognized.

The economic downturn has affected, among others, China, the United States, Europe, the Middle East and North Africa, which we believe has affected medical product purchasing in these regions. The economic downturn could continue adversely affecting our business and could materially affect our financial condition and results of operations.

Our quarterly revenues and operating results are difficult to predict and could fall below investor expectations, which could cause the market price of our ADSs to decline.

Our quarterly revenues and operating results have fluctuated and may continue to fluctuate significantly depending upon numerous factors. In particular, the first and third quarters of each year historically have lower, and the fourth quarter historically has higher revenues and operating results than the other quarters of the year. We believe that our weaker first quarter performance has been largely due to the Chinese Lunar New Year holiday and that our weaker third quarter performance has largely been due to summer holidays. We believe our stronger fourth quarter

performance has been largely due to our customers spending their remaining annual budget amounts. Other factors that may affect our quarterly results include:

• global economic conditions;

• our ability to attract and retain distributors and key customers;

• changes in pricing policies by us or our competitors;

• fluctuations in PRC government spending on healthcare and stimulus programs;

- healthcare reform in the United States, Europe, the PRC and certain emerging markets;
- variations in customer purchasing cycles;
- our sales and delivery cycle length;
- the timing and market acceptance of new product introductions by us or our competitors;
- our ability to expand into and further penetrate international markets;
- the timing of receipt of government incentives;
- inventory value readjustments due to year-end supplier pricing renegotiation;
- changes in the industry operating environment;
- changes in government policies or regulations, including new product approval procedures, or their enforcement; and
- availability of financing for healthcare facilities.

Many of these factors are beyond our control, making our quarterly results difficult to predict, which could cause the market price of our ADSs to decline below investor expectations. You should not rely on our results of operations for prior quarters as an indication of our future results.

Fluctuations in exchange rates could result in foreign currency exchange losses.

As of December 31, 2014, our cash and cash equivalents were mainly denominated in Renminbi and U.S. dollars. As a result, exchange rate fluctuations between the Renminbi and the U.S. dollar affect our relative purchasing power, revenue, expenses and earnings per share in U.S. dollars. In addition, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar could affect our financial results prepared and reported in U.S. dollar terms without giving effect to any underlying change in our business, financial condition or results of operations. The Renminbi is pegged against the U.S. dollar in a manner determined by the People's Bank of China. Daily fluctuations of the Renminbi against the U.S. dollar can rise or fall within a determined band (from April 2012 until March 2014 the band was 1% and in March 2014 was increased to 2%). The Renminbi may appreciate or depreciate significantly

in value against the U.S. dollar in the long term, depending on the fluctuation of the basket of currencies against which it is currently valued, or it may be permitted to enter into a full float, which may also result in a significant appreciation or depreciation of the Renminbi against the U.S. dollar. Fluctuations in exchange rates will also affect the relative value of any dividends we issue, which will be exchanged into U.S. dollars and earnings from and the value of any U.S. dollar-denominated investments we make. Appreciation of the Renminbi relative to other foreign currencies could decrease the per unit revenues generated from international sales. If we increased our international pricing to compensate for the reduced purchasing power of foreign currencies, we would decrease the market competitiveness, on a price basis, of our products. This could result in a decrease in our international sales volumes. As we continue to expand our international presence, in particular in emerging markets and the European Union, sometimes through establishing local offices, we may be exposed to greater foreign currency risks as such operations are incurred in the local currency. Very limited hedging instruments are available in China to reduce our exposure to Renminbi exchange rate fluctuations. We have entered into certain forward contracts to reduce our exposure to several foreign currencies. However, the effectiveness of these forward contracts may be limited and we may not be able to successfully reduce our exposure. In addition, PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currencies could magnify our currency exchange risks. See Item 11, “Quantitative and Qualitative Disclosures about Market Risk — Foreign Currency Risk.”

Warranty claims could substantially increase our costs and harm our reputation and brand, and materially affect our business, financial condition, results of operations and prospects.

We typically sell our main products with warranties against technical defects at terms covering 12-24 months and related accessories with warranties against technical defects at terms covering six months. Our product warranties require us to repair all malfunctions and, if necessary, replace defective components. We accrue liability for potential warranty claims at the time of sale. If we experience an increase in warranty claims or if our repair and replacement costs associated with warranty claims increase significantly, we may have to accrue a greater liability for potential warranty claims. Moreover, an increase in the frequency of warranty claims could substantially increase our costs, harm our reputation and brand, and materially affect our business, financial condition, results of operations and prospects.

Our principal shareholders substantially control our corporate actions. Our dual-class ordinary share structure with different voting rights could discourage others from pursuing any change of control transactions that our shareholders may view as beneficial.

Our ordinary shares are divided into Class A ordinary shares and Class B ordinary shares. Holders of Class A ordinary shares are entitled to one vote per share, while holders of Class B ordinary shares are entitled to five votes per share.

As of March 31, 2015, three of our shareholders and their affiliated entities beneficially owned approximately 27.7% of our outstanding ordinary shares, representing approximately 63.5% of our voting power due to our dual-class ordinary share structure. Mr. Xu Hang, our Chairman of the Board of Directors, Mr. Li Xiting, our Executive Chairman of the Board of Directors, President and Co-CEO, and Mr. Cheng Minghe, our Co-CEO and Chief Strategic Officer, through their respective affiliates, hold all of our Class B ordinary shares. These shareholders will continue to exert control over all matters subject to shareholder vote until the total number of Class B ordinary shares they own is collectively less than 20% of the total number of issued and outstanding ordinary shares. This concentration of voting power may discourage, delay or prevent a change in control or other business combination, which could deprive you of an opportunity to receive a premium for your securities as part of a sale of our company and might reduce the market price of our securities. The interests of Messrs. Xu, Li and Cheng as directors, officers and employees of our company may differ from their interests as shareholders of our company or from your interests as a shareholder.

Anti-takeover provisions in our charter documents may discourage our acquisition by a third party, which could limit your opportunity to sell your shares, including Class A ordinary shares represented by our ADSs, at a premium.

Our amended and restated memorandum and articles of association include provisions that could limit the ability of others to acquire control of us, modify our structure or cause us to engage in change of control transactions. These provisions could have the effect of depriving you of an opportunity to sell your shares, including Class A ordinary shares represented by ADSs, at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of us in a tender offer or similar transaction.

For example, our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix the powers and rights of these shares, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our Class A ordinary shares. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control or make removal of management more difficult. In addition, if our board of directors authorizes the issuance of preferred shares, the market price of our ADSs may fall and the voting and other rights of the holders of our Class A ordinary shares may be materially and adversely affected.

Certain actions require the approval of at least two-thirds of our board of directors present at the relevant board meeting which, among other things, would allow our non-independent directors to block a variety of actions or transactions, such as a merger, asset sale or other change of control, thereby further depriving our shareholders of an opportunity to sell their shares at a premium. In addition, our directors serve staggered terms of three years each, which means that shareholders can elect or remove only a limited number of our directors in any given year. The length of these terms could present an additional obstacle against the taking of action, such as a merger or other change of control, which could be in the interest of our shareholders.

We may become a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. holders.

Depending upon the value of our ordinary shares and ADSs and the nature of our assets and income over time, we could be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes.

We will be classified as a PFIC in any taxable year if either: (1) at least 50% of the value of our assets, based on an average of the quarterly values of the assets during a taxable year, is attributable to assets that produce passive income or are held for the production of passive income or (2) at least 75% of our gross income for the taxable year is passive income. According to these technical rules, we would likely become a PFIC if the value of our outstanding ordinary shares and ADSs were to decrease significantly while we hold substantial cash and cash equivalents.

We believe we were not a PFIC for U.S. federal income tax purposes for our taxable year ended December 31, 2014. Although we intend to conduct our business activities in a manner to reduce the risk of our classification as a PFIC in the future, we currently hold, and expect to continue to hold, a substantial amount of cash and other passive assets, and, because the value of our assets is likely to be determined in large part by reference to the market prices of our ordinary shares and ADSs, which are likely to fluctuate, there can be no assurance that we will not be classified as a PFIC for 2015 or any future taxable year. If we are a PFIC for any taxable year during which a U.S. investor holds our ordinary shares or ADSs, certain adverse U.S. federal income tax consequences would apply to the U.S. investor. For details, please refer to Item 4.C, “Information on the Company — Taxation.”

We may be unable to maintain an effective system of internal control over financial reporting, and as a result we may be unable to accurately report our financial results or prevent fraud.

We are subject to provisions of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act, or Section 404, requires that we include a report from management on our internal control over financial reporting in our annual reports on Form 20-F. In addition, our independent registered public accounting firm and our management concluded that our internal control over financial reporting is effective as of December 31, 2014. Our management’s or our independent public accounting firm’s failure to conclude that our internal control over financial reporting is effective could result in a loss of investor confidence in the reliability of our reporting processes, which could materially and adversely affect the market price of our ADSs.

Our reporting obligations as a public company will continue to place a significant strain on our management, operational and financial resources and systems for the foreseeable future. Our failure to maintain effective internal control over financial reporting could result in the loss of investor confidence in the reliability of our financial reporting processes, which in turn could harm our business and negatively impact the market price of our ADSs.

The trading prices of our ADSs have been, and are likely to continue to be, volatile, which could result in substantial losses to investors.

Between September 26, 2006 and April 13, 2015, the trading price of our ADSs on the NYSE ranged from \$12.31 to \$45.19 per ADS, and the last reported sale price on April 13, 2015 was \$29.90 per ADS. The trading prices of our ADSs could fluctuate widely in response to factors beyond our control. Broad market and industry factors may significantly affect the market price and volatility of our ADSs, regardless of our actual operating performance, including the following:

- actual or anticipated fluctuations in our quarterly operating results and changes or revisions of our expected results;

- changes in financial estimates by securities research analysts;

- changes in the economic performance or market valuations of other IT services companies;

- announcements by our competitors of new services, acquisitions, strategic partnerships, joint ventures or capital commitments;

- rumors in the market about us or our industry, regardless of merit;

- technological breakthroughs in the services outsourcing industry;

fluctuations of exchange rates between the Renminbi and U.S. dollar or other foreign currencies;

release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares or ADSs;

sales or perceived sales of additional ordinary shares or ADSs; and

general market conditions or other developments affecting us, our industry or the global economy.

In addition, the performance, and fluctuation in market prices, of other companies with business operations located mainly in China that have listed their securities in the United States may affect the volatility in the price of and trading volumes of our ADSs. Volatility in global capital and commodity markets, such as the global financial crisis, the European debt crisis and the recent drop in oil prices, could also have an adverse effect on the market price of our ADSs. Furthermore, short sellers and other funds may take a short position or positions in our ADSs for the specific purpose of driving down market price for our ADSs. Short sellers may also publish articles or other allegations in conjunction with such attacks. Even when there is no truth to their claims and we rebut their allegations, such attacks can have a material impact on the market price of our ADSs and divert management resources and attention. The securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also have a material adverse effect on the market price of our ADSs.

In addition to market and industry factors, the price and trading volume for our ADSs may also be highly volatile for specific business reasons including variations in our revenues, earnings and cash flow, announcements of new products, acquisitions, strategic partnerships, joint ventures or capital commitments, addition or departure of our senior management and other key personnel and potential litigation or administrative investigations. Any of these factors may result in large and sudden changes in the volume and trading price of our ADSs. If we were involved in a class action suit or other securities litigation or investigation relating to such volatility, our senior management and resources would be diverted and we would incur significant expenses. Whether or not adversely determined, any litigation or investigation could have a material adverse effect on our business, financial condition, results of operations and prospects.

RISKS RELATED TO DOING BUSINESS IN CHINA

Changes in China's economic, political and social conditions could adversely affect our financial condition and results of operations.

We conduct a substantial portion of our business operations in China and derived 45.9% of our 2014 revenues from sales in China. Accordingly, our business, financial condition, results of operations and prospects are affected to a significant degree by economic, political and social conditions in China. For example, China's recent anti-corruption campaign targeted at corruption among public officials and executives of state-owned enterprises, including public hospital administrators, has caused many public hospitals to be more cautious in making purchasing decisions for medical devices and other investments. Such shifts in purchasing patterns may adversely affect our business. The PRC economy differs from the economies of most developed countries in many respects, including the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. The PRC government has implemented various measures to encourage, but also to control, economic growth and guide the allocation of resources. Some of these measures benefit the overall PRC economy, but may also have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by changes in tax regulations applicable to us. Although the PRC economy has grown significantly in the past decade, that growth may not continue and any slow-down may have a negative effect on our business. Since 2012, the growth of the PRC economy has slowed. The slowdown in the economic growth of China could lead to reduced consumable income of our customers and reduced demand for our products, which could materially and adversely affect our business, financial condition, results of operations and prospects.

The PRC legal system embodies uncertainties that could limit the legal protections available to you and us.

The PRC legal system is a civil law system based on written statutes. Unlike common law systems, it is a system in which decided legal cases have limited precedential value. In 1979, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation over the past three decades has significantly increased the protections afforded to various forms of foreign investment in China. Our PRC operating subsidiaries are foreign-invested enterprises and are subject to laws and regulations applicable to foreign investment in China as well as laws and regulations applicable to foreign-invested enterprises. These laws and regulations change frequently, and their interpretation and enforcement involve uncertainties. For example, under the Guiding Catalogue of Industries for Foreign Investment (2011 Amendment), promulgated on December 24, 2011 by the National Development and Reform Commission (“NDRC”) and Ministry of Commerce (“MOFCOM”) and effective from January 30, 2012, manufacturing of medical equipment, such as composite materials products for medical treatment and recuperation, manufacturing of key components of medical imaging equipment and (3D) ultrasonic transducers for medical use fall within the categories of industries in which foreign investments are encouraged. While the Guiding Catalogue of Industries for Foreign Investment is subject to the amendments by NDRC and MOFCOM from time to time, manufacturing of medical equipment and devices may fall into the categories of industries in which foreign investments are restricted and prohibited, which could adversely affect our business and operation in China. In addition, we may have to resort to administrative and court proceedings to enforce the legal protections that we enjoy either by law or contract. However, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties may also impede our ability to enforce the contracts we have entered into. As a result, these uncertainties could materially and adversely affect our business and operations.

PRC regulations relating to offshore investment activities by PRC residents may increase the administrative burden we face and create regulatory uncertainties that could restrict our overseas and cross-border investment activity, and failure by our shareholders who are PRC residents to make any required applications and filings pursuant to such regulations may prevent us from distributing profits and could expose us and our PRC resident shareholders to liability under PRC law.

China’s State Administration of Foreign Exchange (“SAFE”) promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents’ Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37, on July 4, 2014, which replaced its predecessor rule issued in 2005. SAFE Circular 37 requires PRC residents to register, with a local branch of SAFE, their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, using such PRC residents’ legally owned assets or equity interests in domestic enterprises or offshore assets or interests. This offshore entity is referred to in SAFE Circular 37 as a “Special Purpose Vehicle” (“SPV”). SAFE Circular 37 further requires amendment to the registration in the event of any significant changes to the SPV, such as increase or decrease of capital contributed by PRC individuals, share transfer or exchange, merger, division or other material event. In the event that a PRC shareholder holding interests in a SPV fails to fulfill the required SAFE registration, the PRC subsidiaries of that SPV may be prohibited from distributing their profits and proceeds from any reduction in capital, share transfer or

liquidation to the offshore parent, and the SPV may be restricted in its ability to contribute additional capital into its PRC subsidiaries. Moreover, failure to comply with the various SAFE registration requirements described above could result in fines and/or legal sanctions under PRC law for evasion of foreign exchange controls.

SAFE issued the Notice on Further Simplified and Improved Direct Investment Foreign Exchange Management Measures, or SAFE Notice 13, on February 28, 2015, which will be effective from June 1, 2015. Pursuant to SAFE Notice 13, there is no need for foreign exchange registration approval for both onshore and offshore direct investment (“Direct Investment Foreign Exchange Registration”), and banks shall be able to review and register direct investment foreign exchange in accordance with the newly released Guidelines for Direct Investment Foreign Exchange Registration. SAFE and its local branches shall supervise Direct Investment Foreign Exchange Registration indirectly through the banks.

We have notified and urged our shareholders, and the shareholders of the offshore entities in our corporate group, who are PRC residents to make the necessary SAFE registrations, including the amended registration, as required under this regulation for our initial public offering and our subsequent secondary offerings. However, different local SAFE offices may have different views on application and implementation of the SAFE regulations in practice, and it is unclear how these SAFE regulations and any future legislation concerning offshore or cross-border transactions will be interpreted, amended and implemented by the relevant government authorities. While we believe that these shareholders submitted applications with local SAFE offices, some of our shareholders may not comply with our request to make or obtain any applicable registrations or approvals required by the regulation or other related legislation. The failure or inability of our PRC resident shareholders to obtain any required approvals or make any required registrations may subject us to fines and legal sanctions, prevent us from being able to make distributions or pay dividends, as a result of which our business operations and our ability to distribute profits to you could be materially and adversely affected.

We may rely on dividends and other distributions on equity paid by our operating subsidiaries to fund cash and financing requirements, and limitations on the ability of our operating subsidiaries to pay dividends to us may have a material adverse effect on our ability to conduct our business.

We are a holding company, and we may rely on dividends and other distributions on equity paid by our operating subsidiaries, primarily Shenzhen Mindray, for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders, service any debt we may incur and pay our operating expenses. If Shenzhen Mindray incurs debt on its own behalf, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Furthermore, relevant PRC laws and regulations permit payments of dividends by Shenzhen Mindray and our other PRC subsidiaries only out of their respective retained earnings, if any, determined in accordance with PRC accounting standards and regulations.

Under PRC laws and regulations, our PRC subsidiaries are required to set aside a portion of their respective net income each year to fund certain statutory surplus reserve funds. These reserves are not distributable as cash dividends. As of December 31, 2014, the amount of these restricted portions of our PRC subsidiaries was approximately \$40.0 million. As a result of these PRC laws and regulations, our PRC subsidiaries are restricted in their abilities to transfer a portion of their respective net reserves to us whether in the form of dividends, loans or advances. Limitations on the ability of our PRC subsidiaries to pay dividends to us may adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends, or otherwise fund and conduct our business.

Restrictions on currency exchange may limit our ability to utilize our capital effectively.

A significant portion of our revenues and a majority of our operating expenses are denominated in Renminbi. The Renminbi is currently convertible under the “current account,” which includes dividends, trade and service-related

foreign exchange transactions. Currently, Shenzhen Mindray and Nanjing Mindray may purchase foreign exchange for settlement of “current account transactions,” including payment of dividends to us, without the approval of SAFE. Pursuant to the relevant regulations, a company applying for the remittance of dividends should provide to the bank handling the remittance: (i) board resolutions on the distribution of profits and dividends, (ii) the latest capital verification report issued by an accounting firm, and (iii) an audit report on the company’s financial condition during the current year. These procedural requirements generally do not pose any risk to a wholly foreign-owned company’s ability to remit dividends to its offshore parent. Although the Renminbi has been fully convertible for current account transaction since 1996, we cannot assure you that the PRC government will not take measures in the future to restrict access to foreign currencies for current account transactions.

Conversion of Renminbi into foreign currencies, and of foreign currencies into Renminbi, for payments relating to “capital account transactions,” which include among other things investments, loans and acquisitions of land and other fixed assets overseas, generally requires the approval of SAFE and other relevant PRC governmental authorities. Restrictions on the convertibility of the Renminbi for capital account transactions could affect the ability of our PRC subsidiaries to make investments overseas or to obtain foreign currency through debt or equity financing, including by means of loans or capital contributions from us. In particular, if Shenzhen Mindray or Nanjing Mindray borrows foreign currency from us or other foreign lenders, it must do so within approved limits that satisfy their approval documentation and PRC debt to equity ratio requirements. Further, such loans must be registered with SAFE or its local counterpart. We cannot assure you that the registration process will not delay or prevent our conversion of Renminbi for use outside of China. We are exploring new means of transferring funds within our corporate group under a SAFE Circular on Further Improving and Adjusting Foreign Exchange Policies on Direct Investment, or Circular 59, including a three-year cross-border Renminbi intra-group loan facility. However, we cannot assure you that the PRC government will not implement new restrictions in the future.

The discontinuation of any of the preferential tax treatments or the financial incentives currently available to us in China could adversely affect our financial condition and results of operations.

The China Enterprise Income Tax Law, or the EIT Law, and its implementing rules became effective on January 1, 2008. The EIT Law significantly curtails tax incentives granted to foreign-invested enterprises, or FIEs, under the previous tax law. The EIT Law, however, (i) reduces the top EIT rate from 33% to 25%, permits companies to continue to enjoy their existing tax incentives, subject to certain transitional phase-out rules, and (ii) introduces new tax incentives, subject to various qualification criteria. The EIT Law and its implementing rules permit qualified “New and Hi-Tech Enterprises” to enjoy a reduced 15% EIT rate. Nanjing Mindray had obtained a qualification certificate of New and Hi-Tech Enterprises status on December 13, 2010 with a valid period of three years, hence was entitled to a reduced 15% EIT rate for the years 2010 through 2012. The status was renewed in September 2013 for another three years and Nanjing Mindray will be entitled to a reduced 15% EIT rate for the years 2013 through 2015. Shenzhen Mindray had obtained a qualification certificate of New and Hi-Tech Enterprise status on December 16, 2008 with a valid period of three years, hence was entitled to a reduced 15% EIT rate for the years 2008 through 2010, and the status was subsequently renewed in October 2011 and successfully re-applied in September 2014 respectively, each time for another three years; therefore Shenzhen Mindray will be entitled to a reduced 15% EIT rate for the years 2011 through 2016. Beijing Mindray had obtained a qualification certificate of New and Hi-Tech Enterprises status on December 24, 2008 with a valid period of three years, hence Beijing Mindray was entitled to a reduced 15% EIT rate for the years 2008 through 2010, and the status was subsequently renewed in October 2011 and successfully re-applied in October 2014 respectively, each time for another three years; therefore Beijing Mindray will be entitled to a reduced 15% EIT rate for the years 2011 through 2016. Additionally, Shenzhen Mindray Software had obtained a qualification certificate of New and Hi-Tech Enterprise status on November 11, 2013 with a valid period of three years, hence Shenzhen Mindray Software will be entitled to a reduced 15% EIT rate for the years 2013 through 2015. However, the continued qualification for New and Hi-Tech Enterprise Status will still be subject to evaluation by the relevant government authority in China. In addition, Nanjing Mindray, Shenzhen Mindray, Beijing Mindray and Shenzhen Mindray Software will need to apply for an additional three-year extension upon the expiration of the current qualification if they desire to continue to enjoy the 15% reduced rate.

Shenzhen Mindray was also awarded “Nationwide Key Software Enterprise” status for the calendar years 2009 through 2014, which allows Shenzhen Mindray to enjoy a unified 10% EIT rate for these years under the tax policies for software and integrated circuit industries. Currently, the Nationwide Key Software Enterprise status is granted every two years by the relevant government authority in China. Shenzhen Mindray may not be granted this status for any future years.

Under the phase-out rules of EIT Law, enterprises established before the promulgation date of the EIT Law and which were granted preferential EIT treatment under the then effective tax laws or regulations may continue to enjoy their preferential tax treatments until their expiration. Accordingly, Beijing Mindray, an enterprise established before the promulgation date of the EIT Law, was entitled to a preferential treatment under the phase-out rules, under which it enjoyed a 50% reduction to the EIT for the taxable years 2008 to 2010. Nanjing Mindray, was entitled to an EIT exemption from 2008 to 2009 and a 50% tax reduction from 2010 to 2012. Additionally, Shenzhen Mindray Software is entitled to the tax exemption in 2013 and 2014, and a 50% tax reduction from 2015 through 2017.

The PRC tax policies, interpretations and practices regarding preferential treatments is subject to continuous change and uncertainty and we cannot assure you that Shenzhen Mindray, Beijing Mindray, Nanjing Mindray and Shenzhen Mindray Software will continue to qualify as New and Hi-Tech Enterprises under the EIT Law, enjoy the preferential treatments, not encounter any challenges regarding past application of such treatments, or that the local tax authorities will not, in the future, change their position and revoke any of our past preferential tax treatments. The discontinuation of any of our preferential tax treatments could materially increase our tax obligations.

Pursuant to a PRC tax policy intended to encourage the development of software and integrated circuit industries, our primary operating subsidiary in China, Shenzhen Mindray, has been entitled to a refund of VAT at a maximum rate of 14% of the sale value of self-developed software that is embedded in our products since 2001. In addition, this VAT refund policy is extended after its expiration at end of 2010 by the State Council on January 28, 2011 by promulgation of the Notice on Printing and Distribution of Several Policies to Further Stimulate the Development of Software and Integrate Circuit Industries, without a specific term for the extension however. The amount of VAT refunds included in revenue in 2012, 2013 and 2014 was \$26.9 million, \$28.4 million and \$31.9 million, respectively. While Shenzhen Mindray and certain of our PRC subsidiaries expect to continue to qualify for the VAT refund, we cannot assure you that they will not encounter any challenges regarding such VAT refund from local tax authorities in the future.

We typically receive government subsidies for the development of new high technology medical products and purchase of export credit insurance as well as PRC government incentives for making high technology investments in their region, filing patent applications for new inventions and optimizing their foreign trade structure on an irregular basis, and amounts received tend to fluctuate significantly. While we intend to continue applying for government subsidies and government incentives, we may not receive any in the future.

Any increase in the EIT rate applicable to us or discontinuation or reduction of any of the preferential tax treatments or financial incentives currently enjoyed by our PRC subsidiaries could adversely affect our business, operating results and financial condition.

We may be classified as a “resident enterprise” for PRC enterprise income tax purposes. This classification could result in unfavorable tax consequences to us and our non-PRC shareholders.

The EIT Law provides that enterprises established outside of China whose “de facto management bodies” are located in China are considered “resident enterprises” and are generally subject to the uniform 25% EIT rate on their worldwide income. A tax circular issued by the PRC State Administration of Taxation on April 22, 2009, or Circular 82 regarding the standards used to classify certain PRC-controlled enterprises registered outside of China as “resident enterprises” states that dividends paid by such “resident enterprises” and other income paid by such “resident enterprises” will be considered to be PRC source income, subject to PRC withholding tax, currently at a rate of 10%, when received or recognized by non-PRC resident enterprise shareholders. This circular also subjects such “resident enterprises” to various reporting requirements with the PRC tax authorities. Under the implementation rules to the EIT Law, a “de facto management body” is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and assets of an enterprise. In addition, Circular 82 mentioned above specifies that certain PRC-controlled enterprises will be classified as “resident enterprises” if the following are located or resident in China: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision-making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders’ meetings; and half or more of senior management or directors having voting rights. The State Administration of Taxation issued the Announcement of the State Administration of Taxation on Issues concerning the Recognition of Resident Enterprises Based on the Place of Effective Management Criteria on January 29, 2014, which made several amendments to

Circular 82, while the standards used to classify certain PRC-controlled enterprises registered outside of China as “resident enterprises” remain unchanged.

Currently, there is no specific regulation determining that offshore companies controlled by PRC individuals or foreign corporations like us are PRC resident enterprises. Circular 82 applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreign corporations like us, therefore Circular 82 does not apply to us directly. However, the State Administration of Taxation may take the view that the determining criteria set forth in Circular 82 reflects general position on how the “de facto management body” test should be applied in determining the tax resident status of all offshore enterprises. Currently, a substantial majority of the members of our management team as well as the management team of some of our offshore holding companies are located in China. However, there are some criteria by reference to Circular 82 which we do not clearly fall into. Therefore, in the absence of detailed implementing regulations or other guidance determining that offshore companies controlled by PRC individuals or foreign corporations like us are PRC resident enterprises, we do not currently consider our Cayman Islands company or any of our overseas subsidiaries to be a PRC resident enterprise. Additional implementing regulations or guidance may be issued determining that our Cayman Islands company is a “resident enterprise” for PRC enterprise income tax purposes. If the PRC tax authorities determine that we are a “resident enterprise,” a number of unfavorable PRC tax consequences could follow. First, we will be subject to income tax at the rate of 25% on our worldwide income and reporting obligations. Second, although under the EIT Law and its implementing rules, dividends paid to our Hong Kong company and ultimately to our Cayman Islands company from our PRC subsidiaries would qualify as “tax-exempted income,” we cannot assure you that such dividends will not be subject to a 10% withholding tax, as the PRC foreign exchange control authorities, which enforce the withholding tax, have not yet issued guidance with respect to the processing of outbound remittances to entities that are treated as “resident enterprises” for PRC EIT purposes. Finally, a withholding tax of 10% for our non-PRC enterprise investors or potentially an individual income tax of 20% for individual investors will be imposed on dividends we pay to them and with respect to gains derived by such investors from transferring our shares or ADSs. In addition to the uncertainty in how the new “resident enterprise” classification could apply, it is also possible that the rules may change in the future, possibly with retroactive effect. If we are required under the EIT Law to withhold PRC income tax on our dividends payable to our foreign shareholders and ADS holders who are “non-resident enterprises,” or if you are required to pay PRC income tax on the transfer of our shares or ADSs under the circumstances mentioned above, the value of your investment in our shares or ADSs may be materially and adversely affected. It is unclear whether, if we are considered a PRC “resident enterprise,” holders of our shares or ADSs would be able to claim the benefit of income tax treaties or agreements entered into between China and other countries or areas.

We may be unable to enjoy the favorable 5% treaty-based rate of income tax withholding for any dividends our PRC subsidiaries pay to us through our Hong Kong holding companies.

Prior to January 1, 2008, dividends derived by foreign enterprises from business operations in China were not subject to the PRC enterprise income tax. However, such tax exemption ceased after January 1, 2008 with the effectiveness of the EIT Law and a withholding tax rate of 10% will apply on such dividends (subject to reductions by the relevant tax treaties, if applicable).

According to the Notice of the State Administration of Taxation on Summary Table of Treaty Rates for Dividends, or Circular 112, which was issued on January 29, 2008 and the Arrangement between the PRC and the Hong Kong Special Administrative Region on the Avoidance of Double Taxation and Prevention of Tax Evasion, or the Double Taxation Arrangement (Hong Kong), which became effective on December 8, 2006, dividends from our PRC

subsidiaries paid to us through our Hong Kong subsidiaries may be subject to a withholding tax at a reduced rate of 5% if such Hong Kong entity owns at least 25% of the equity interest of the PRC company. In addition, the PRC State Administration of Taxation promulgated a tax notice on October 27, 2009, or Circular 601, which provides that tax treaty benefits will be denied to “conduit” or shell companies without business substance, and a beneficial ownership analysis with the unfavorable factor tests will be used based on a “substance-over-form” principle to determine whether or not to grant tax treaty benefits. On June 29, 2012, the State Administration of Taxation further issued the Announcement regarding Recognition of “Beneficial Owner” under Tax Treaties, or Announcement 30, which provides that a comprehensive analysis should be made when determining the beneficial owner status based on various factors that supported by various types of documents including the articles of association, financial statements, records of cash movements, board meeting minutes, board resolutions, staffing and materials, relevant expenditures, functions and risk assumption as well as relevant contracts and other information. On April 12, 2013, the State Administration of Taxation further issued an opinion, or Circular 165, which explains how to apply the unfavorable factor test described in Circular 601, as well as provides relevant interpretations on Announcement 30 in beneficial ownership analysis. As a result, although our PRC subsidiaries are currently wholly-owned by our Hong Kong subsidiaries, we cannot assure you that we would be entitled to the tax treaty benefits and enjoy the favorable 5% rate applicable under the Double Taxation Arrangement (Hong Kong) on dividends. If our Hong Kong subsidiaries would not be considered to be the beneficial owners of any such dividends or the shareholding is less than 25%, such dividends would as a result be subject to income tax withholding at the rate of 10% rather than the favorable 5% rate applicable under the tax treaty between mainland China and Hong Kong.

If additional remedial measures are imposed on the Big Four PRC-based accounting firms, including an affiliate of our independent registered public accounting firm, associated with administrative proceedings brought by the SEC alleging the firms' failure to meet specific criteria set by the SEC, we could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act.

In December 2012, the SEC instituted administrative proceedings against the Big Four PRC-based accounting firms, including an affiliate of our independent registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC's rules and regulations thereunder by failing to provide to the SEC the firms' work papers related to their audits of certain PRC-based companies that are publicly traded in the United States. On January 22, 2014, an initial administrative law decision was issued, sanctioning these accounting firms and suspending them from practicing before the SEC for a period of six months. The sanction will not take effect until there is an order of effectiveness issued by the SEC. Any Commission endorsement or other determination itself could be appealed by the accounting firms in the U.S. court system. On February 12, 2014, the Big Four PRC-based accounting firms initiated a review of the initial administrative law decision to the SEC. We were not and are not involved in the proceedings brought by the SEC against these accounting firms. On February 6, 2015, the Big Four PRC-based accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and audit US-listed companies. The settlement required the Big Four PRC-based accounting firms to follow the SEC's specified procedures and to seek to provide the SEC with access to the Big Four PRC-based accounting firms' audit documents via the China Securities Regulatory Commission. If potential document productions depart from the criteria pursuant to the SEC's specified procedures, the SEC retains authority to impose a variety of additional remedial measures on the Big Four PRC-based accounting firms, depending on the nature of such departure. While we cannot predict whether the SEC will further review the Big Four PRC-based accounting firms' compliance with the SEC specified criteria or whether the results of such a review would result in the SEC imposing penalties such as suspensions or reinitiating administrative proceedings, if the Big Four PRC-based accounting firms are subject to the additional remedial measures, because our auditor having its PRC-based affiliate carrying out audit procedures on our Mainland China operations, our ability to file our financial statements in compliance with SEC requirements could be impacted.

Our independent registered public accounting firm's audit documentation related to their audit report included in this annual report may be located in the People's Republic of China. The Public Company Accounting Oversight Board currently cannot inspect audit documentation located in China and, as such, you may be deprived of the benefits of such inspection.

Auditors of companies that are registered with the United States Securities and Exchange Commission and traded publicly in the United States, including our independent registered public accounting firm, must be registered with the U.S. Public Company Accounting Oversight Board (United States) ("the "PCAOB") and are required by the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United States and professional standards. Because we have substantial operations within the People's Republic of China and the PCAOB is currently unable to conduct inspections of the work of our auditors as it relates to those operations without the approval of the PRC authorities, our auditor's work related to our operations in China is not currently inspected by the PCAOB. In May 2013, PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the China Securities Regulatory Commission ("the CSRC") and the PRC Ministry of

Finance, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by PCAOB, the CSRC or the PRC Ministry of Finance in the United States and the PRC, respectively. PCAOB continues to be in discussions with the CSRC and the PRC Ministry of Finance to permit joint inspections in the PRC of audit firms that are registered with PCAOB and audit PRC companies that trade on the U.S. exchanges.

This lack of PCAOB inspections of audit work performed in China prevents the PCAOB from regularly evaluating audit work of any auditors that was performed in China including that performed by our auditors. As a result, investors may be deprived of the full benefits of PCAOB inspections.

The inability of the PCAOB to conduct inspections of audit work performed in China makes it more difficult to evaluate the effectiveness of our auditor's audit procedures as compared to auditors in other jurisdictions that are subject to PCAOB inspections on all of their work.

ITEM 4. INFORMATION ON THE COMPANY

A. History and Development of the Company.

We are a Cayman Islands holding company. Our operations began in China and date back to 1991. In advance of our initial public offering in 2006, we established our current holding company structure. Our holding company, Mindray International, is an exempted company with limited liability under the Companies Law of the Cayman Islands, or the Companies Law.

We conduct a substantial majority of our business through our consolidated operating subsidiary, Shenzhen Mindray. Additionally, our other primary operating subsidiary is Mindray DS USA. In 2013, we acquired ZONARE, a U.S. ultrasound technology company in the high-end radiology market. For additional information on our organizational structure, see Item 4.C, "Information on the Company — Organizational Structure."

Our principal executive offices are located at Mindray Building, Keji 12th Road South, Hi-tech Industrial Park, Nanshan, Shenzhen, 518057, People's Republic of China, and our telephone number is (86-755) 8188-8666. Our website address is <http://www.mindray.com>. The information on our website does not form a part of this annual report.

B. Business overview.

Overview

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global operational headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey, and multiple sales offices in major domestic and international markets. From our main engineering and manufacturing base in China and through our worldwide distribution network, we supply globally a broad range of products across three primary business segments, comprising patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems.

We sell our products through different distribution channels in different geographies. In China and emerging markets, we sell our products primarily to third-party distributors. We believe we have one of the largest distribution, sales, marketing and service networks for medical devices in China with over 1,600 distributors. As of December 31, 2014, we had more than 2,100 sales, marketing and services personnel managing our distribution network and covering the direct sales activities in the China region. In the United States, the United Kingdom, France, Germany and the Netherlands, we sell our products primarily through a direct-sales model. To the extent we complement our direct sales model with independent distribution network, our direct sales force in a country also manages the distributors in such country. We also work with over 1,700 third-party distributors and have more than 1,100 sales, marketing and services personnel managing our distribution network and covering regions outside of China as of December 31, 2014. We additionally provide after-sales services to our direct-sales customers and through our distribution channels.

We employ a vertically integrated operating model that enables us to efficiently develop, manufacture and market quality products at competitive prices. Our research and development team and our manufacturing department work closely together to optimize manufacturing processes and develop commercially viable products. In addition, they incorporate regular feedback from our sales and marketing personnel, enabling us to timely and cost-effectively introduce products fit for end-user needs. Furthermore, our research and development and manufacturing operations, which are based primarily in China, provide us with a distinct competitive advantage in international markets by enabling us to leverage low-cost technical expertise, labor, raw materials, and facilities.

We have made and expect to continue making substantial investments in research and development activities, investing approximately 10% of our net revenues, in research and development in 2012, 2013 and 2014. We currently have research and development centers located in Shenzhen, Beijing, Nanjing, Xi'an, Chengdu and Shanghai in China. We also maintain research and development centers in Mahwah, New Jersey; Mountain View, California; Seattle, Washington; Miami, Florida; and Stockholm, Sweden. We believe that our emphasis on research and development investment is the most important core competency we have to achieve our historic growth and maintain growth potential going forward. We maintain what we believe is the largest research and development team of any medical device manufacturer based in China. As of December 31, 2014, we had more than 2,000 engineers and other research and development personnel in multiple research and development centers in China, the United States and Sweden. Our research and development facility in Shenzhen coordinates our global research and development efforts, leveraging the core competencies of each of our centers.

Products

We have three primary product business segments — patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems. In past years, we expanded our product offerings through acquisitions and some of these acquisitions are in high-value consumables, such as in the orthopedic and endoscope businesses.

In 2014, our products were sold in more than 190 countries and regions, and international sales accounted for 54.1% of our net revenues in 2014.

We typically obtain a CE mark and FDA 510(k) clearance for the products we intend to market internationally. A CE mark certifies full compliance with the Medical Device Directives of the European Union and enables us to market the products in any member state of the European Union. We declare the CE mark ourselves for a majority of in-vitro diagnostic products pursuant to the relevant regulation of European Union, internal defibrillation paddles are issued by SGS and the remaining are issued by TUV. The CE mark issued by SGS or TUV demonstrates that not only has a representative sample of the product been evaluated, tested, and approved for safety, but also that the production line has been inspected on an annual basis. FDA 510(k) clearance from the U.S. Food and Drug Administration, or FDA, is required to market any of the medical devices in our current product portfolio in the United States. We also obtain CFDA Registration Certificate for products that market in China, as well as certifications and registrations as required

according to local regulation in the other markets where we sell our products.

The chart below provides selected summary information about the products that we introduced in 2014:

Business Segment	Products	Description
Patient Monitoring and Life Support Products	The SV-300 ventilator	A state-of-the-art ventilator equipped with extensive ventilation modes that can treat pediatric and adult patients of all acuity levels at ICUs and Intermediate Care
	The HyBase 8500 operating table	An operating table that guarantees the highest safety and stability in any position and the modularized tabletop can be tailored to various surgical disciplines
	The BeneFusion DS5 bedside work station	An advanced bedside work station based on intravenous infusion workflow management with modern electronics, IT and state-of-the-art manufacturing technology
	The BeneFusion CS5 central infusion supervision system	An intelligent central infusion supervision system with real-time patients' infusion status

In-vitro Diagnostic Products	The CAL 8000 cellular analysis line	A cellular analysis line that integrates high performance five-part hematology analyzer/body fluid analyzer, highly reliable automated slide maker and stainer and modularized track system
	The BriCyte E6 flow cytometer	A dual-laser flow cytometer which can perform quantitative analysis of both biochemical and biophysical characteristics of cells
Medical Imaging Systems	The M9 portable ultrasound system	A premium hand-carried color Doppler ultrasound system with logical and efficient workflow
	The DC-70 ultrasound system	An efficient workhorse in the mid-range segment which combines powerful and versatile diagnostic tools with perfect user experience by touch gesture operations

We plan to introduce an additional seven to ten new products in 2015.

Patient Monitoring and Life Support Products

Patient monitoring devices. Our patient monitoring devices track the physiological parameters of patients, such as heart rate, blood pressure, respiration and temperature. We currently offer patient monitoring devices that are suitable for adult, pediatric and neonatal patients and are used principally in hospital intensive care units, operating rooms and emergency rooms. Our product line offers customers a broad range of functionality, such as single- and multiple-parameter monitors, mobile and portable multifunction monitors, central stations that can collect and display multiple patient data on a single screen, and an electro-cardiogram monitoring device. Our multi-parameter monitoring devices can be networked, allowing hospitals to remotely gather patient data from patient rooms and centralize that data in a single location. Our patient monitoring devices also have built-in recorders and have batteries for portability in most models, as well as power backup in the event of power failure in mobile models. We also offer a line of veterinary monitoring devices.

Life support products. We are also actively expanding the range of our life support products to provide operation room or intensive care unit solutions for the end-users in the operating room. We currently offer anesthesia machines, defibrillators, surgical equipment (including surgical beds and surgical lights ceiling pendants), syringes and infusion pumps, as well as ventilators.

Patient monitoring and life support products accounted for 42.4%, 38.7% and 36.7% of our total net revenues in 2012, 2013 and 2014, respectively.

In-vitro Diagnostic Products

Our in-vitro diagnostic products provide data and analysis on blood, urine and other bodily fluid samples for clinical diagnosis and treatment. We offer a range of semi-automated and fully-automated in-vitro diagnostic products for laboratories, clinics and hospitals to perform analysis to detect and quantify various substances in the patient samples. Our current product portfolio consists of in-vitro diagnostic products in seven product categories: hematology analysis, biochemistry analysis, immunoassay analysis, flow cytometric analysis, coagulation analysis, urine sediment analysis and microbiology analysis. Urinalysis, together with hematology and biochemistry analysis, are the three most common methods used in in-vitro diagnostic market.

Hematology analyzers. Our hematology analyzers test blood samples to detect abnormalities or foreign substances. For example, our hematology analyzers can be used to detect blood diseases, such as anemia, and to screen to differentiate between illnesses caused by viruses from those caused by bacteria. We currently offer semi-automated and fully-automated three-part differential analyzers and fully-automated five-part differential analyzers (analyzers of three or five different types of white blood cells) with the ability to analyze a broad range of parameters through the use of reagents.

Biochemistry analyzers. Our biochemistry analyzers measure the concentration or activity of substances such as enzymes, proteins and substrates. These analyzers may be used as therapeutic drug monitors or to check for drug abuse.

Immunoassay analyzers. Our immunoassay analyzers measure the concentration of protein such as hormone, tumor marker and virus protein. These hormone measurements can monitor the functioning of glands such as the thyroid gland. Tumor marker measurement can be used on cancer diagnostics and cancer treatment monitoring. Virus protein measurement can be used on infection disease diagnostics and monitor of antiviral therapy such as hepatitis B.

Flow Cytometers. Our flow cytometers use a laser-based flowing system to simultaneously measure physical and chemical characteristics of thousands of cells per second. They can assist the diagnosis of a wide range of health disorders, especially leukemia, lymphoma and immunodeficiency diseases. Besides clinical purposes, there are many other applications for our flow cytometers in basic research and in the pharmaceutical industry.

Coagulation analyzers. Our coagulation analyzers are used to measure activated partial thromboplastin time (APPT), prothrombin time (PT), thrombin time (TT), fibrinogen (FIB), D-Dimer and clotting factor. They are mainly applied for examination before operation, cardiovascular and blood coagulation diseases detection.

Urine sediment analyzers and consumables. Our urine sediment analysis can detect kidney and urinary tract diseases by analyzing blood cells, bacteria, urinary casts, etc., in urine samples. Urinalysis includes urine sediment and dry chemistry analysis.

Microbiology analyzers. Our microbiology analyzers are used in clinical laboratories by using the microbial identification and antibiotic susceptibility testing (ID/AST) system to identify microbes and perform antibiotic susceptibility testing, while they use the blood culture system to recover pathological organisms.

Reagents. We also offer reagents for use with our in-vitro diagnostic products. A reagent is a substance used in the chemical reactions analyzed by our in-vitro diagnostic products. As of December 31, 2014, we offered more than 90 reagents for hematology analyzers, 120 reagents for biochemistry analyzers and 27 reagents for immunoassay analyzers. We also offer reagents that can be used in diagnostic laboratory instruments produced by other international and China-based manufacturers. This ongoing consumption and resulting need to order additional reagents creates a recurring revenue stream for us. As we expand our line of reagents available for sale in China and globally and continue to grow our installed base of in-vitro diagnostic products and offer products with the ability to run more tests per hour, we anticipate that the recurring revenue stream from reagent sales will likewise grow. Reagent sales accounted for 35.3%, 38.8% and 43.8% of our in-vitro diagnostic products segment revenues in 2012, 2013 and 2014, respectively.

In-vitro diagnostic products, including reagents, accounted for 27.0%, 27.6% and 27.8% of our total net revenues in 2012, 2013 and 2014, respectively.

Medical Imaging Systems

Our medical imaging systems segment includes ultrasound systems, digital radiography systems and a magnetic resonance imaging system.

Our ultrasound systems use computer-managed sound waves to produce real time images of anatomical movement and blood flow. Ultrasound systems are commonly employed in medical fields such as urology, gynecology, obstetrics and cardiology. We currently offer black and white and color ultrasound systems, with a broad range of transducers to enhance the adaptability of these products for a variety of applications. We believe this variety and adaptability increases customer appeal and broadens our potential client base. Our digital radiography systems use flat-panel detectors to capture images. Digital radiography systems shorten x-ray exposure time compared to traditional film-based radiography systems. The detector design of our digital radiology systems eliminates manual activities, hastens treatment, improves patient comfort and provides greater cost efficiency. Our magnetic resonance imaging system uses permanent magnetic field and in-scan technology to record the image of the scanned area of the body.

Our medical imaging systems segment accounted for 23.9%, 25.0% and 26.0% of our total net revenues in 2012, 2013 and 2014, respectively.

Other products

Our other products segment mainly includes orthopedic products, endoscope devices and healthcare IT solutions products.

We have a range of orthopedic products including trauma, spine and joint. Trauma products are used to restore function of fractured extremities. Spine products are mainly applied in vertebral body damage and spine chronic diseases while joint products are applied in damaged or disabled joint replacement. Currently we have both rigid and flexible endoscope products. Both types of endoscope products can be used to examine the interior of a hollow organ or body cavity. Compared to traditional open surgery, minimally invasive surgery using a rigid or flexible endoscope is generally considered safer and quicker, typically resulting in less pain and shorter rehabilitation time for patients. Our healthcare IT solutions mainly include PACS (Picture Archiving and Communication System) and RIS (Radiology Information System). PACS is a medical imaging technology that provides economical storage of and convenient access to images from multiple modalities. RIS is a computerized database used by radiology departments to store, manage and distribute patient radiological data and imagery. The RIS system generally consists of patient tracking and scheduling, result reporting and image tracking capabilities, and is critical to the efficient workflow of radiology practices. The PACS and RIS systems are used in hospitals' radiology, ultrasound, endoscopy and pathology

departments as digital picture archiving and communication management solutions.

China Distribution, Direct and Tender Sales

Our products are sold in China primarily through our nationwide distribution and sales network. As of December 31, 2014, we had over 1,600 distributors. As of December 31, 2014, we had more than 2,100 sales, marketing and services personnel managing our distribution network and covering the direct sales activities in the China region, located in 32 offices in China. Our distribution network broadens our customer reach and enhances our ability to further penetrate the market in China within a short period of time. Exclusive distributors have the exclusive right to sell one or more of our products in a defined territory. We grant the majority of our distributors in China an exclusive right to sell a particular product or set of products within a specified territory. In any given territory we may have several distributors selling different products on an exclusive basis if their customers or use-fields are specified differently. We often select exclusive distributors from our pool of non-exclusive distributors based on their prior sales performance for us. We also make selections based on factors such as sales experience, knowledge of medical equipment, contacts in the medical community, reputation and market coverage. We actively manage our distribution network, regularly reviewing distributor performance and terminating underperforming distributors. We typically negotiate and enter into annual framework distribution agreements with a majority of our distributors and sell on a purchase-order basis. However, for certain of our distributors, we enter into long-term distribution agreements to enable such distributors to invest more resources in promoting our products. None of our distributors accounted for more than 2% of our net revenues in any of the past three years. Prior to shipment, our exclusive distributors in China typically pay at least 50% of the purchase price.

In China, we also sell our products directly to hospitals, clinics and government health bureaus.

We define government tender sales as organized medical equipment purchasing activities from central or provincial governments in China for multiple hospitals, clinics and other healthcare facilities. Tender sales are a facilitated government-run tender process, and can involve both direct sales by us to end users and sales through a distributor. Government tender sales are based on government budget, policies and directives. There is no certainty of the nature of such policies from period to period. We generally enter into China-based tender sales contracts with tender organizers such as government healthcare entities or provincial health departments. The terms of these contracts generally provide that following product delivery, the tender organizer has seven product inspection days, after which the products will be deemed accepted, and a one to three year warranty period will commence. Upon acceptance, the tender organizer will prepare an application for payment and an acceptance report to the relevant government body, such as a provincial finance bureau or procurement center, for approval and payment. The relevant government body will generally pay 95% of our invoice within 30 to 60 days after the acceptance date. The remaining invoice balance is typically payable one year following the acceptance date. Due to changes in government funding allocation, primarily the shift from government tender sales to hospitals' direct purchases in China, our revenues generated from China-based tender sales provided to government agency customers accounted for 4.7%, 2.3% and 1.5% of our net domestic revenues in 2012, 2013 and 2014, respectively.

International Distribution and Direct Sales

We maintain both distribution networks and direct sales channels in our international markets. As of December 31, 2014, our international distribution and sales network consisted of over 1,700 distributors and more than 1,100 sales, marketing and service personnel covering more than 190 countries and regions. We grant a minority of our international distributors an exclusive right to sell a particular product or set of products within a specified territory or country.

As we expand our international sales, we sometimes provide qualified distributors with credit terms that we believe are consistent with prevailing market practices in their distribution areas. Most of our credit extended to international distributors is covered by our export credit insurance. See Item 5, "Operating and Financial Review and Prospects — Critical Accounting Policies — Allowance for Doubtful Accounts."

In the United States, United Kingdom, France, Germany and the Netherlands, we maintain direct sales channels primarily and employ sales teams in these regions with direct sales experience with hospitals, medical clinics and doctors. For certain direct sales in the United States and France, we have also utilized third-party equipment leasing agents. Such leasing companies perform credit assessments and provide payment and interest terms to customers, thereby assuming all risk of customer nonpayment, with no contractual recourse against us. We in turn are paid by the leasing company upon product delivery. For the period from 2012 to 2014, these arrangements represented an immaterial percentage of our total net revenues.

Marketing

We focus our marketing efforts on establishing and strengthening business relationships and growing our brand recognition, which primarily involves attending and sponsoring exhibitions and seminars pertaining to our product offerings. In 2014, we attended and sponsored over 170 medical exhibitions in China and internationally. We also conduct on-site demonstrations of our products at hospitals, and we often offer new customers one of our products at a discounted rate. In addition, we advertise in industry publications that cater to distributors of medical devices, industry experts or doctors.

Customers

We primarily sell to two categories of customers: distributors, who sell through our distribution and sales network, and hospitals and government agencies to whom we sell directly. Our customer base is widely dispersed both on a revenues and geographic basis. Our ten largest customers based on net revenues collectively accounted for 5.2%, 4.8% and 5.1% of our net revenues in 2012, 2013 and 2014, respectively.

Our distributors. Sales to our distributors make up the substantial majority of our revenues, both on a segment by segment basis and in the aggregate. As of December 31, 2014, we have over 1,600 distributors in China and over 1,700 additional distributors outside China.

Hospital and government agency customers. In China, our hospital and government agency customers primarily include hospitals, as well as central and provincial level public health bureaus and population and family planning bureaus. These customers typically place, through state-owned bidding agents, large volume orders that are awarded based on bids submitted by competing medical equipment companies, and we count them as government tender sales. In some cases, these customers do not engage a bidding agent to solicit competitive bids from different vendors, and we are allowed to negotiate directly with them, in which case we count these sales as direct sales.

Internationally, our direct sales forces in the United States, United Kingdom, France, Germany and the Netherlands sell primarily to hospitals with 500 or fewer beds, as well as to surgery centers, private clinics and veterinary clinics.

Customer Support and Service

China

We believe that we have the largest customer support and service team for medical devices in China, with more than 600 employees located in our main facility in Shenzhen and our 32 local sales, marketing and services offices in China as of December 31, 2014. This enables us to provide domestic training, technical support, and warranty, maintenance and repair services to end-users of our products, as well as distributor support and service.

Customer Support and Service. In 2014, we conducted over 170 training sessions at our main facility in Shenzhen and over 120 training sessions at our other offices in China. We also conducted over 170 training sessions in hospitals and

other venues throughout China. We maintain a customer service center in Shenzhen to address our customers' needs, including basic technical support and product repair. For more complex issues, our customer service center connects our customers with the appropriate personnel from our research and development team. For support issues that require a site visit or for maintenance and repair requests, we maintain maintenance and repair personnel as well as supplies of parts and components at our China offices. We believe our domestic support and service capabilities give us a significant advantage over our competitors, as they enable us to respond timely to requests for support, maintenance, and repair, which in turn creates and reinforces positive impressions of our brand.

Distributor Support and Service. In addition to ensuring that our brand is associated with high quality products and responsive service, our customer support and service employees work with our distributors in a wide range of areas to help them become more effective. In particular, we can assist our distributors in establishing a series of best practices in their approach to sales and marketing management, helping them identify market opportunities, and providing feedback on their sales performance and customer relations.

- *Extended Warranty Service.* We provide extended warranty services, typically under one-year contracts, for a separate fee to both our end users and our distributors.

We also provide our distributors with technical support, including training in the basic technologies of the products they sell, participating in presentations to potential customers, and assisting in preparing bidding documents for large volume purchase contracts awarded through competitive bidding and tenders. By working closely with our domestic distributors, our customer support and service employees are able to provide us valuable insights into the operations of each local distributor, which help us ensure that each distributor is able to operate effectively for us.

International

In several of the countries where we have direct sales, particularly the United States, United Kingdom, France, Germany and the Netherlands, we provide substantial after-sales services including extended warranty services, sales of accessories and repair-services for post warranty period. The product warranty terms that vary by sales region but typically range from one year (most typical) to five years. Our service solutions business provides support with an array of integrated solutions, from project management and network installations, to comprehensive technology maintenance programs. The dedicated service offers clinical engineering partnership programs and rapid emergency service response, optimizing product performance and clinical results.

In our other international markets, we rely on our distributors to provide after-sales services, and provide extended warranty services for certain components of our products. We provide technical support and training to our international distributors on an ongoing basis. When we conduct our training and technical support visits to the locations of our international distributors, we also take the opportunity to meet with a sample of end-users in that market to gather feedback on our products as well as market information such as levels of satisfaction, price information and specific functions desired from end-users serviced by our distributors.

We also maintain international sales, marketing and service offices. As our international markets mature, we will consider adding offices to assist with sales and support.

Manufacturing and Assembly

We manufacture, assemble and store a substantial majority of our products at our facilities located in Shenzhen and Nanjing, China. We outsource a small minority of our products, mostly products produced by ZONARE, to third-party manufacturers.

All of our China-based facilities are ISO 9001 and ISO 13485 certified. We manufacture and assemble our patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems primarily in four facilities across China, comprising approximately 163,900 square meters in size. See Item 4.D., “Information on the Company—Property, Plant and Equipment” for a schedule and description of our facilities.

As part of our overall strategy to lower production costs, we have made substantial investments in our in-house manufacturing infrastructure to complement our research and development and product design activities. In particular, we seek to achieve the following objectives:

Increase use of common resources within and across products. By identifying resources that can be commonly applied within and across products, we are able to purchase raw materials and components in greater quantities, which often results in reduced material and component costs. As we improve existing products and develop new products, we look to carry over common resources. The cost of the new or improved products can be reduced as a result of the lower costs already in place from volume purchases. As more products utilize common resources, the resulting increased purchases of common resources further reduce costs, with benefits across a range of products.

Increase use of in-house manufactured facilities. To better optimize the benefit of our use of common resources across business segments and increasing sales levels, we produce the majority of the components that go into our products.

Increase use of common manufacturing and assembly practices within and across business segments. We continually seek to identify common manufacturing and assembly practices both within and across business segments. By identifying common manufacturing and assembly practices for new products, we seek to reduce capital outlays for new manufacturing equipment. This also allows us to spread our manufacturing team across fewer manufacturing and assembly stations, creating a streamlined manufacturing and assembly workflow. We believe this increases employee efficiency, with employees required to learn to manufacture or assemble fewer components, and reduces our training costs.

We believe that by increasingly using common resources, manufacturing components in-house and using common manufacturing and assembly practices, we will be able to maintain or improve our competitive cost structure.

Our manufacturing strategy also incorporates strategic outsourcing. In particular, we outsource components that we believe can more efficiently and cost-effectively be produced by third-party providers. Major outsourced components include integrated circuits, electronic components, raw materials and chemicals for reagents, and valves. Other components outsourced in the manufacturing process include various types of other electrical and plastic parts that are generally readily available in sufficient quantities from our local suppliers.

Consistent with our overall strategy of maintaining a China-based manufacturing infrastructure and leveraging our vertically integrated operating model, we have transferred, as practicable, substantially all outsourced manufacturing contracts entered into by our acquired Datascope's patient monitoring business to our in-house manufacturing infrastructure in China. Currently, the manufacturing process of the recently acquired ZONARE is outsourced to third-party manufacturers. However, as we integrate ZONARE into our overall company structure and strategy, we are continuously assessing the cost efficiency and manufacturing margins of bringing some or all of ZONARE's products in-house. We intend to transfer the manufacturing of substantially all of ZONARE's products in-house in the near future. We purchase components for our products from approximately 500 suppliers, most of whom have long-term business relationships with us. No single supplier accounted for more than 3% of our supply purchase expenditures in 2013 or 2014. Since we have multiple suppliers for most of our components, we believe it is beneficial not to have long-term supply contracts with our suppliers; accordingly, we generally enter into annual contracts. In particular, having the ability to negotiate price reductions on a periodic basis has allowed us to reduce our component costs and to maintain our profit margins.

We have our own independent quality control system, and devote significant attention to quality control for the designing, manufacturing, assembly, and testing of our products. In particular, we have established a quality control system in accordance with CFDA regulations in China. In addition, we obtained ISO 9001 certification and ISO 13485 certification issued by both TUV and Beijing Hua Guang Certification of Medical Devices Co., Ltd. We have received international certifications for various products including FDA clearance letters, Canadian Medical Device Licenses and CE marks. We inspect components prior to assembly, and inspect and test our products both during and after their manufacture and assembly. See Item 3.D., "Key Information — Risk Factors — Risks Relating to Our Business and Industry — If we fail to obtain or maintain applicable regulatory clearances or approvals for our products, or if such clearances or approvals are delayed, we will be unable to commercially distribute and market our products at all or in a timely manner, which could significantly disrupt our business and materially and adversely affect our sales and profitability."

We typically sell our main products with warranties against technical defects at terms covering 12-24 months and related accessories with warranties against technical defects at terms covering six months. If necessary, we will exchange a defective product. However, we do not typically accept any returns for a refund of the purchase price. The

costs associated with our warranty claims have historically been low, although we do accrue a liability for potential warranty costs at the time of sale based on historical rate of warranty services rendered and estimated associated costs. Unlike the warranties on most of our products, certain ZONARE products are covered under various warranties that range between one to five years with the option to purchase additional coverage.

Intellectual Property

We have developed a valuable portfolio of intellectual property rights to protect the technologies, inventions and improvements that we believe are significant to our business, which includes issued patents in China and the United States, as well as pending patent applications in China, the United States, Europe and India. Moreover, we possess proprietary technology and know-how in manufacturing processes, design, and engineering. We are expanding our portfolio of intellectual property rights in overseas markets as we increase our sales in those markets.

Our success in the medical equipment industry requires effective management of both intellectual property assets and infringement risks. In particular, we must be able to protect our own intellectual property as well as minimize the risk that any of our products infringes on the intellectual property rights of others.

We enter into agreements with all our employees involved in research and development, under which all intellectual property during their employment belongs to us, and they waive all relevant rights or claims to such intellectual property. All our employees involved in research and development are also bound by a confidentiality obligation, and have agreed to disclose and assign to us all inventions conceived by them during their term of employment. Despite measures we take to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or our proprietary technology or to obtain and use information that we regard as proprietary. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — If we fail to protect our intellectual property rights, it could harm our business and competitive position.”

We often purchase components that incorporate the supplier’s intellectual property, especially with respect to components with advanced technologies that we are currently not capable of producing ourselves. With respect to computer software we develop for use in our products, we actively apply for copyright registration in China in order to maximize our ability to enforce our copyrights.

We have registered trademarks in China and in the United States and in other countries for the “Mindray” name and associated marks used on our own-brand products. In December 2013, the Trademark Office of the SAIC recognized our “Mindray” name as a Well-Known Trademark in medical analysis instruments, medical devices and instruments, and medical diagnostic equipment. We also have registered trademark rights for the use of the Datascope trademarks in our patient monitoring devices. In 2011, we also granted certain Datascope entities a 20-year exclusive license for certain Datascope related trademarks for use in certain circumstances. We have filed for trademark protection for the “Mindray” name and associated marks in the North American, Central American, South American, European, Asian, African and Oceanian countries where we market our products, and will continue to follow our brand management policy to build brand name recognition of “Mindray” and associated marks in these countries. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — Disputes over use of our brand names or the brand names we license, the expenses incurred in developing and preserving the value of our brand name, and any loss of rights to use our brand names or the brand names we license as a result of challenge, may adversely affect our business.”

Competition

The medical equipment and healthcare industries are characterized by rapid product development, technological advances, intense competition and a strong emphasis on proprietary products. Across all product lines and product tiers, we face direct competition both domestically in China and internationally. We compete based on factors such as price, value, customer support, brand recognition, reputation, and product functionality, reliability and compatibility.

For domestic sales, our competitors include multinational companies and domestic PRC companies. We believe that we can continue to compete successfully in China because our established domestic distribution network and customer support and service network allows us significantly better access to China's small- and medium-sized hospitals. In addition, our strong investment in research and development, coupled with our low-cost operating model, allows us to compete effectively for our sales to large-sized hospitals. We are facing increasing competition within the domestic markets, mainly attributable to the increasing entry of multinational companies into the domestic markets through acquisitions of established PRC companies.

In international markets, our competitors include publicly traded and privately held multinational companies. These companies typically focus on the premium segments of the market. We believe we can successfully penetrate certain international markets by offering products of comparable quality at substantially lower prices. We also face competition in international sales from companies that have local operations in the markets in which we sell our products. We believe that we can compete successfully with these companies by offering products of substantially better quality at comparable prices.

Set forth below is a summary of our primary competitors by business segment. We expect to increasingly compete against multinational companies, both domestically and internationally, as we continue to manufacture more advanced products.

Patient Monitoring and Life Support Products. In both domestic and international sales of patient monitoring and life support products, our primary competitors are Philips Healthcare, GE Healthcare and Draeger Medical.

In-vitro Diagnostic Products. For both domestic and international sales of hematology analyzers, our primary competitors are Sysmex Corporation, Danaher Corporation and ABX. For domestic sales of biochemistry analyzers, our primary competitors are Danaher Corporation, Hitachi and Roche Diagnostics. For international sales of biochemistry analyzers, our primary competitors are Danaher Corporation, Abbott Laboratories and Roche Diagnostics.

Medical Imaging Systems. For domestic sales of medical imaging systems, our primary competitors are GE Healthcare, Philips Healthcare and Siemens Medical. For international sales of medical imaging systems, our primary competitors are GE Healthcare, Philips Healthcare and Hitachi.

These and other of our existing and potential competitors may have substantially greater financial, research and development, sales and marketing, personnel and other resources than we do and may have more experience in developing, manufacturing, marketing and supporting new products. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — Our business faces intense competition, which may reduce demand for our products and materially and adversely affect our business, financial condition, results of operations and prospects.”

We must also compete for distributors, particularly international distributors, with other medical equipment companies. Our competitors will often prohibit their distributors from selling products that compete with their own. These and other potential competitors may have higher visibility, greater name recognition and greater financial resources than we do. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — We depend on distributors for a substantial portion of our revenues. Failure to establish and maintain relationships with distributors would materially and adversely affect our business, financial condition and results of operations.”

Seasonality

Our revenues are subject to seasonal fluctuations due to our customers' budgetary cycles and holiday schedules in markets where we sell our products. The first quarter is typically the lowest quarter for our sales due to the Chinese Lunar New Year holidays when our sales force works fewer days during the quarter, affecting both international and domestic sales revenues and lengthening accounts receivable turnover days. In addition, hospitals in China typically have their budgets approved and begin spending only after the Chinese Lunar New Year holiday. In the second quarter revenues from sales are typically sequentially higher due to spending and settling of payment associated with newly approved customer budgets in China, and spending in the United States to fulfill budgetary requirements as many hospitals in the United States have a June 30 fiscal year end. In the third quarter, our revenues are typically flat in our China, U.S., and European markets as customers reduce their commercial activity during summer holidays and, with respect to the United States, certain hospitals' new budgetary cycles begin. There is a similar but less pronounced effect on domestic revenue growth trends during the summer months due to a slight slowdown in overall commercial activity in China. The fourth quarter is typically the strongest quarter for our China, U.S., and European sales, as many customers seek to allocate all funds remaining in their annual purchasing budgets before the end of the fiscal and calendar year. Our past experience indicates that our revenues tend to be lower in the first quarter and higher in the fourth quarter of each year, assuming other factors remain constant.

Our accounts receivables balances and receivable turnover days are, in turn, impacted by seasonality in revenues. Our accounts receivable balances are typically the lowest in the first quarter in connection with lower first quarter sales due to the Chinese Lunar New Year holiday, and typically the highest at year-end, as the fourth quarter is traditionally our strongest sales quarter. Receivables turnover days for any period are calculated by using accounts receivable net balances at the beginning and end of the period compared to net revenues for the period. Demonstrating the impact of seasonality, our receivable turnover days for the first quarter of 2014 was 69 days (reflecting higher accounts receivable balances at the beginning of the first quarter and lower first quarter sales) compared to 62 days for calendar year 2014.

Insurance

We maintain various insurance policies in connection with the operation of our business. For example, we maintain liability insurance to cover product liability claims arising from the use of our products sold outside of China, comprehensive property insurance to recover loss and damage of certain of our fixed assets. We maintain cargo insurance coverage to recover loss and damage to our products during transportation. Our various insurance coverages, however, may not be sufficient to cover any claim for product liability, advertising or promotional liability, damage to our fixed assets or damage to our products during transit or litigation or related indemnity costs. Insurance companies in China offer limited business insurance products and do not, to our knowledge, offer business liability insurance. While business disruption insurance is available to a limited extent in China, we have determined that the risks of disruption, cost of such insurance and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance in China. As a result, we do not have any business liability, disruption or litigation insurance coverage for our operations in China. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — We are subject to product liability exposure and have limited insurance coverage. Any product liability claims or regulatory actions could be costly and time-consuming to defend, damage our reputation and materially and adversely affect our business, financial condition and results of operations.”

We provide credit terms to qualified international distributors, typically located in North America and Western Europe. To date, most of our credit extended to international distributors has been covered by our export credit insurance. See Item 5, “Operating and Financial Review and Prospects — Critical Accounting Policies — Allowance for Doubtful Accounts.”

Facilities

See Item 4.D, “Information on the Company — Property, Plant and Equipment.”

Legal Proceedings

From time to time, we may bring against others or be subject to various claims and legal actions arising in the ordinary course of business, including businesses we may acquire.

On December 21, 2012, Masimo Corporation brought an action in the United States District Court for the Central District of California against Mindray DS USA and Shenzhen Mindray. Masimo alleges that Shenzhen Mindray's pulse oximeters and sensors infringe nine Masimo patents relating to pulse oximeters and sensors, and that Shenzhen Mindray breached its Purchase and License Agreement with Masimo dated November 13, 2002, as amended, by failing to use best efforts to promote adoption of Masimo's oximeter technology outside the United States. Shenzhen Mindray's Purchase and License Agreement with Masimo expired on December 31, 2012. The District Court dismissed Mindray DS USA from the litigation on February 28, 2013. Masimo filed a First Amended Complaint against Shenzhen Mindray alone on August 5, 2013 and a Second Amended Complaint against Shenzhen Mindray alone, but adding Masimo International SARL as co-plaintiff, on July 7, 2014. Shenzhen Mindray is vigorously defending itself against Masimo's claims; has asserted counterclaims for declarations of non-infringement and invalidity of all nine asserted patents, and has asserted numerous counterclaims against Masimo, including for antitrust violations and for infringement of two United States patents. Trial has been scheduled for December 1, 2015.

In addition, on December 11, 2013, Masimo Corporation brought an action in New Jersey Superior Court, Bergen County, against Mindray DS USA, Shenzhen Mindray, and its holding company, Mindray International. Masimo alleges that Mindray DS USA, Shenzhen Mindray and Mindray International are alter-egos of each other, and that Mindray DS USA has breached its Restated Purchasing and Licensing Agreement with Masimo dated August 17, 1997, as amended (“the DS Agreement”), acquired by Mindray DS USA in 2008 in connection with its acquisition of the Datascope’s patient monitoring business. Masimo further alleges that Shenzhen Mindray and Mindray International have conspired with Mindray DS USA to breach the DS Agreement by failing to integrate Masimo SET® technology into all of Mindray DS USA’s future pulse oximetry products and by continuing to market Mindray pulse oximetry technology. Mindray DS USA removed the originally filed state court action to the United States District Court for the District of New Jersey on January 17, 2014, and on January 24, 2014, filed a motion asking the New Jersey District Court to stay or dismiss the case. Masimo filed a motion asking the New Jersey District Court to remand the case to the Superior Court. The District Court granted the Masimo’s motion to remand on January 7, 2015 without ruling on Mindray DS USA’s motion to dismiss. Mindray DS USA again removed the remanded state court action to the United States District Court for the District of New Jersey, and refiled its motion to stay or dismiss the case. On January 29, 2015, Mindray International and Shenzhen Mindray each moved to have the Complaint against them dismissed. Briefing on those motions is completed, and motions are awaiting to be taken up by the District Court.

We acquired ZONARE in July 2013. On November 1, 2013, HDX Corporation, or HDX, filed a complaint against ZONARE in the Northern District of California, alleging that ZONARE was in breach of a December 11, 2009 Manufacturing Rights Agreement between ZONARE and HDX. HDX’s complaint also named three former or current employees of ZONARE as individual defendants. In the complaint, HDX also alleged that ZONARE and the individual defendants engaged in promissory fraud and asserted that the defendants’ alleged misrepresentations in connection with the 2009 agreement induced HDX invest in ZONARE. Specifically, HDX asserted claims for breach of contract, intentional fraud, fraudulent concealment and violations of California statutory provisions, and sought both monetary damages and injunctive relief. In January 2014, ZONARE and the individual defendants filed motions with the court to compel arbitration and dismiss HDX fraud-based claims. Subsequently, HDX agreed to refer the matter to arbitration, the court stayed the action pending arbitration and, in February 2014, HDX filed a demand for arbitration with the American Arbitration Association. ZONARE and the individual defendants and HDX have recently agreed to settle and dismiss the arbitration and all claims with prejudice.

On November 11, 2013, Shenzhen Mindray entered into a \$14.8 million settlement agreement with an OEM manufacturing customer, Beckman Coulter, Inc. The dispute was an ordinary course commercial dispute that did not involve intellectual property or product liability matters. We have since terminated the OEM arrangement with Beckman Coulter, Inc. and do not consider this termination to be material to our business or operations.

Regulation

Our patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems are medical devices and are subject to regulatory controls governing medical devices in the countries where we manufacture and sell our products. As a manufacturer of medical equipment and supplies we are subject to regulation

and oversight by different levels of the food and drug administration in China, in particular the CFDA, as well as the FDA in the U.S. and various regulatory agencies in Europe and other countries in which we sell our products. We are also subject to other PRC government laws and regulations which are applicable to manufacturers in general. CFDA requirements include obtaining production certifications, medical device manufacturing licenses, medical device distribution licenses, compliance with clinical testing standards, quality standards, applicable industry standards and adverse event reporting, and advertising and packaging standards.

China

Classification of Medical Devices

In China, medical devices are classified into three different categories, Class I, Class II and Class III, depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. Classification of a medical device is important because the class to which a medical device is assigned determines, among other things, whether a manufacturer needs to obtain a Medical Device Manufacturing License and the level of regulatory authority involved in obtaining such license. Classification of a device also determines the types of registration required and the level of regulatory authority involved in effecting the product registration.

Class I devices require product certification and are those with low risk to the human body and are subject to “general controls.” Class I devices are regulated by the municipal level food and drug administration where the manufacturer is located. Class II devices are those with medium risk to the human body and are subject to “strict controls.” Class II devices require product certification, usually through a quality system assessment, and are regulated by the provincial level food and drug administration where the manufacturer is located. Class III devices are those with high risk to the human body, such as life-sustaining, life-supporting or implantable devices. Class III devices also require product certification and are regulated by the CFDA under the strictest regulatory control.

The majority of our products manufactured in China are classified as Class II or Class III devices. The majority of our in-vitro diagnostic products are Class II medical devices and the remainder are Class III medical devices. Beneview series, PM series and MEC series patient monitors, TMS-6016 telemetry monitoring system, WATO and A series anesthesia machines, E5/E3 ventilator, are classified as Class III medical devices, while the remainder of our patient monitors and operating tables and surgical lights are classified as Class II medical devices. Our MRI system is classified as a Class III medical device, our DR is classified as Class II medical device, and our Color Doppler Ultrasound Device consists of products classified both as Class II medical devices and as Class III medical devices. The remainder of our medical imaging systems are classified as Class II medical devices. Our various reagents are classified as either Class II or Class III devices. We produce a small number of Class I products, such as cables for cardiographs, diluent and lead wires.

In China, our reagents used with our in-vitro diagnostic products are divided into the categories of hematology reagents, flow cytometer reagents, immunology reagents and clinical chemistry reagents. While a part of biological reagents are subject to regulatory controls similar to those governing pharmaceutical products, all the reagents manufactured by us are subject to regulatory controls similar to those governing medical devices; i.e. in order to engage in the manufacture of IVD reagents, a manufacturer must have a medical device manufacturing license specifically covering IVD reagents, in order to engage in the distribution of IVD reagents, a distributor must have a medical device distribution license specifically covering IVD reagents and each reagent product must be registered before it can be manufactured for commercial distribution.

Medical Device and IVD Reagent Manufacturing License

A manufacturer must obtain a manufacturing license from the provincial level food and drug administration before commencing the manufacture of Class II and Class III medical devices or IVD reagents. No manufacturing license is required for the manufacture of Class I devices, but the manufacturer must notify the municipal level food and drug administration where the manufacturer is located and file for record with it.

Our manufacturing license covers the manufacture of our patient monitoring and life support products, in-vitro diagnostic products (including IVD reagents) and medical imaging systems.

A manufacturing license, once obtained, is valid for five years and is renewable upon expiration. To renew a manufacturing license, a manufacturer needs to submit to the original level food and drug administration that issued the license an application to renew the license, along with required information six months before the expiration date of the license. Our manufacturing licenses for Shenzhen Mindray and Nanjing Mindray will expire on June 3, 2019 and July 19, 2018, respectively.

Medical Device Distribution License and IVD Reagent Distribution License

A manufacturer or distributor must obtain a distribution license in order to engage in sales and distribution of Class II and Class III medical devices or IVD reagents in China. A distribution license is valid for five years and is renewable upon expiration. To renew a distribution license, a manufacturer or distributor needs to submit to original level food and drug administration that issued the license an application to renew the license, along with required information six months before the expiration date of the license. We have a medical device distribution license covering the distribution of Class II and Class III medical devices which will expire on March 30, 2016 and a medical device distribution license covering the distribution of IVD reagents which will expire on September 24, 2019.

Registration Requirement

On March 7, 2014, the State Council promulgated the Regulations for Supervision and Administration of Medical Devices, which took effect on June 1, 2014. CFDA also promulgated the Measures for the Administration of Registration of Medical Devices, Measures on the Supervision and Administration of the Business Operations of Medical Devices and Measures for the Supervision and Administration of Medical Device Production on July 30, 2014, all of which have come into effective on October 1, 2014. Before a medical device can be manufactured for commercial distribution, a manufacturer must affect medical device registration by proving the safety and effectiveness of the medical device to the satisfaction of respective levels of the food and drug administration. In order to conduct a clinical trial on a Class II or Class III medical device, the CFDA requires manufacturers to apply for and obtain in advance a favorable inspection result for the device from an inspection center jointly recognized by the CFDA and the Administration of Quality Supervision, Inspection and Quarantine. The application to the inspection center must be supported by appropriate data, such as animal and laboratory testing results. If the Ethics Committee in the institutions recognized by the food and drug administration approves the application for clinical trial and the clinical trial has been filed to the provincial food and drug administration for record, the qualified clinical trial institution may begin the clinical trial. Clinical trials for some particular high risk devices need approval from the food and drug administration in advance. A registration application for a Class II or Class III device must provide required pre-clinical and clinical trial data and information about the device and its components regarding, among other things, device design, manufacturing and labeling. The food and drug administration, after receiving an application for the registration, will review the application package and notify the applicant whether the application for registration is approved. The application materials shall be submitted to the technology review organization within three days after the relevant food and drug administration receives the application for registration. The technology review organization shall complete the technology review in 60 business days for Class II device and in 90 business days for Class III device. In practice, however, this review process for Class III devices could take up to eight months or even longer. If approved, a registration certificate will be issued within ten days after written approval. If the food and drug administration requires supplemental information, the approval process may take much longer. The registration is currently valid for five years.

Pursuant to the Measures for the Administration of Registration of In-Vitro Diagnostic Reagents enacted by the CFDA on July 30, 2014 and which became effective on October 1, 2014, all of our IVD reagents products are subject

to registration requirements similar to medical devices. To date, approximately 300 IVD reagents which are manufactured and sold by Shenzhen Mindray have obtained required medical device registration certificates from respective levels of food and drug administration.

The CFDA may change its policies, adopt additional regulations, revise existing regulations or tighten enforcement, each of which could block or delay the approval process for a medical device or an IVD reagent.

Continuing CFDA Regulation

We are subject to continuing regulation by the CFDA. In the event of significant modification to an approved medical device, its labeling or its manufacturing process, a new premarket approval or premarket approval supplement may be required. Our products are subject to, among others, the following regulations:

• CFDA's quality system regulations which require manufacturers to create, implement and follow certain design, testing, control, documentation and other quality assurance procedures;

• medical device reporting regulations, which require that manufacturers report to the CFDA certain types of adverse reaction and other events involving their products; and

• CFDA's general prohibition against promoting products for unapproved uses.

Class II and III devices may also be subject to special controls applicable to them, such as supply purchase information, performance standards, quality inspection procedures and product testing devices which may not be required for Class I devices. We believe we are in compliance with the applicable CFDA guidelines, but we could be required to change our compliance activities or be subject to other special controls if the CFDA changes or modifies its existing regulations or adopts new requirements.

We are also subject to inspection and market surveillance by the CFDA to determine compliance with regulatory requirements. If the CFDA decides to enforce its regulations and rules, the agency can institute a wide variety of enforcement actions such as:

- fines, injunctions and civil penalties;
- recall or seizure of our products; confiscation of illegal revenue;
- the imposition of operating restrictions, partial suspension or complete shutdown of production; or
- withdraw the Registration Certificate for Medical Device.

Radio Transmission Equipment Type Approval Certificate

As we produce multi-parameter monitoring devices that can share data remotely through network connections, we are required to obtain a Radio Transmission Equipment Type Approval Certificate issued by the PRC Ministry of Industry and Information Technology. Our certificate will expire on June 9, 2019.

United States

For any of our products that we distribute in the United States, the labeling, distribution and marketing are subject to regulation by the FDA and other regulatory bodies. The FDA regulates our currently marketed products as medical devices and we are required to obtain review and clearance or approval from the FDA prior to commercial sales of our devices. As a publicly-listed company, we are also subject to rules promulgated by the Securities Exchange Commission, or SEC.

FDA Premarket Clearance and Approval Requirements

Unless an exemption applies, each medical device we wish to commercially distribute in the United States will require either prior 510(k) clearance or prior premarket approval from the FDA. The FDA classifies medical devices into one of three classes depending on the degree of risk posed to patients by the medical device. Devices deemed to pose lower risk are placed in either Class I or II, which requires the manufacturer to obtain 510(k) clearance from the FDA prior to marketing such devices. Some low-risk Class I devices are exempt from the 510(k) requirement altogether. Devices deemed by the FDA to pose greater risk, or devices deemed not substantially equivalent to a previously cleared 510(k) device are placed in Class III, most of which require premarket approval. Both premarket clearance and premarket approval applications are subject to the payment of user fees, to be paid at the time of submission for FDA review.

510(k) Clearance Pathway

To obtain 510(k) clearance, a premarket notification must be submitted, demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications. The FDA's 510(k) clearance process usually takes from two to eight months from the date the application is submitted, but it can take significantly longer.

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new 510(k) clearance or could require premarket approval. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer's determination. If the FDA disagrees with a manufacturer's determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or premarket approval is obtained. If the FDA requires us to seek 510(k) clearance or premarket approval for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device until we obtain this clearance or approval. Also, in these circumstances, we may be subject to significant regulatory fines or penalties.

All products that we currently distribute in the United States have been cleared through the 510(k) clearance pathway.

Premarket Approval Pathway

To obtain premarket approval, a premarket approval application must be submitted if the device cannot be cleared through the 510(k) process, and is usually utilized for Class III medical devices, or devices that pose a significant safety risk, including unknown risks related to the novelty of the device.

A premarket approval application must be supported by extensive data including, but not limited to, technical, preclinical, clinical trials, manufacturing data and labeling information to demonstrate to the FDA's satisfaction the safety and effectiveness of the device for its intended use. Technical performance data required for diagnostic laboratory instrument premarket approval applications may include validation of the performance of hardware and software under repeat testing, calibration of mechanical components and stability of reagents and other products used in specimen collection, storage and testing. Preclinical trial data may include results from tests to determine product stability and biocompatibility, among other features.

Continuing FDA Regulation

After a device is placed on the market, numerous regulatory requirements apply. These include:

quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the manufacturing process, otherwise known as Good Manufacturing Practices, or GMPs;

labeling regulations, which prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling; and

medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if it were to recur.

Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:

- fines, injunctions, and civil penalties;
- recall or seizure of our products;
- operating restrictions, partial suspension or total shutdown of production;
- refusal of our request for 510(k) clearance or premarket approval of new products;
- withdrawal of 510(k) clearance or premarket approvals that are already granted; and
 - criminal prosecution.

Conflict Minerals

In 2012 pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC introduced a special disclosure rule that requires us to conduct due diligence on and disclose if we are able to determine whether certain materials (including tantalum, tin, gold and tungsten), known as conflict minerals, that originate from mines in the Democratic Republic of Congo or certain adjoining countries, or DRC, are used in our products. The DRC minerals report is due annually on May 31 for the prior calendar year and we are conducting appropriate diligence measures to comply with such requirements.

European Union

The European Union has promulgated rules that require commercial medical products to bear the CE mark. The CE mark is recognized by the European Union as a symbol of compliance with 93/42/EEC, the Medical Device Directives of the European Union. The CE mark allows us to market our products throughout the European Economic Area. Our manufacturing facilities received the most updated ISO 9001/ISO 13485 Quality Systems certification in December 2008. These certifications and repeated inspections are required in order to continue to affix the CE Mark to our approved products in Europe. Failure to receive regulatory approval to affix the CE mark would prohibit us from selling these products in member countries of the European Union.

We declare the CE mark ourselves for a majority of our in-vitro diagnostic products pursuant to the European Union Directive 98/79/EC, internal defibrillation paddles are issued by SGS and the remaining are issued by TUV. The CE mark issued by SGS or TUV demonstrates that not only has a representative sample of the product been evaluated, tested, and approved for safety, but also that the production line has been inspected on an annual basis.

In September 2012, the European Commission adopted proposals for amendment of the Medical Device Directives (93/42/EEC) and the Regulation on In-vitro Diagnostic Medical Devices (98/79/EC) in order to enhance the current legal regime on medical devices and strive for more uniform implementation of rules throughout European Union. Both proposals have been submitted to the European Parliament and the Council and are targeted to be adopted in 2015. If adopted, these amendments would gradually come into effect from 2015 to 2019. Upon the effectiveness of the amendments, medical device manufacturers like us would be subject to more scrutiny, including a more thorough testing system on device manufacturing, more stringent traceability on safety responsibilities and stricter requirements for clinical assessment, among others.

In July of 2011, the European Union issued directive RoHS 2.0, which now includes medical devices in its scope. Previously, the RoHs directive did not require any specific labeling to prove compliance. Beginning July 22, 2014, however, all medical devices covered under this new directive will be restricted from the use of six substances, and

only compliant products can be labeled with the CE mark. To meet the requirements of this directive, we have established the Hazardous Substance Process Management according to IECQ QC 080000:2012 and Directive RoHS 2.0 to effectively safeguard the designing, manufacturing and assembly of our products to demonstrate our compliance. We received the IECQ QC 080000 certificate issued by SGS. Working together with our suppliers, our medical equipment released in EU have complied with RoHS 2.0 from July 22, 2014. We plan to ensure that IVD products and veterinary equipment will meet compliance of this directive by July 2016 and July 2019, respectively.

The third edition of IEC60601-1 standard, a globally recognized standard for electro-medical equipment safety, was published in 2005. Both the European Union and Canada required that all products launched in the market after June 1, 2012 comply with this standard and existing products already tested to second edition standards be reevaluated to the third edition. According to the relevant enforcement schedules, products with a particular standard are controlled by such standard, and both that standard and the second edition will continue to be used together until a new particular standard is published that aligns with the third edition. Working with a third-party test lab, all of our medical products marketed in the European Union currently comply with the third edition of IEC 60601-1 standard.

Other National and Provincial Level Laws and Regulations in China

We are subject to evolving regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are, or may be, applicable to our business. Our hospital customers are also subject to a wide variety of laws and regulations that could affect the nature and scope of their relationships with us.

Laws regulating medical device manufacturers and hospitals cover a broad array of subjects. We must comply with numerous additional state and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection and fire hazard control. We believe we are currently in compliance with these laws and regulations in all material respects. We may be required to incur significant costs to comply with these laws and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could have a material adverse effect on our business, financial condition and results of operations.

Anti-Corruption Laws

We are subject to China's anti-corruption laws, the U.S. Foreign Corrupt Practices Act, or FCPA, the Bribery Act 2010 of England and Wales, or the UK Bribery Act, and applicable anti-corruption and anti-bribery laws of other jurisdictions in which we do business, in connection with the marketing and distribution of our products. Due to the conditions of competition in the markets for medical devices in China and other emerging markets, we believe that corrupt practices may still occur within our industry. Such practices in China may involve inappropriate and unlawful payments or favors to influence procurement decision of customers, regulatory approval decisions of the CFDA and clinical trials conducted by PRC hospitals and medical institutions. Many of the individuals involved in these processes would qualify as "foreign government officials" under the FCPA, and improper payments to such recipients may violate the anti-bribery provisions of the FCPA and other applicable anti-corruption laws. Additionally, as we have sales offices in the United Kingdom and employ UK citizens, we may be subject to the commercial bribery provisions of the UK Bribery Act, which applies to non-government officials. There have been numerous enforcement actions by government authorities in the United States, China and other jurisdictions that have involved corruption in the medical device industry. In January 2013, we updated our anti-corruption policies and procedures to ensure compliance with applicable laws concerning corrupt practices. We also hired a dedicated compliance officer and established the Compliance Office to monitor the implementation of such policies and procedures together with our Supervision Department and Internal Audit Department.

Foreign Exchange Control and Administration

Foreign exchange in China is primarily regulated by:

- The Foreign Currency Administration Rules (1996), as amended in 2008; and
- The Administration Rules of the Settlement, Sale and Payment of Foreign Exchange (1996), or the Administration Rules.

Under the Foreign Currency Administration Rules, the Renminbi is convertible for current account items, including the distribution of dividends, interest payments, and trade and service-related foreign exchange transactions. Conversion of Renminbi into foreign currency for capital account items, such as direct investment, loans, investment

in securities and repatriation of funds, however, is still subject to the supervision of SAFE. Under the Administration Rules, foreign-invested enterprises may only buy, sell and remit foreign currencies at banks authorized to conduct foreign exchange transactions after providing valid commercial documents and, in the case of capital account item transactions, only after obtaining approval from SAFE.

Capital investments directed outside of China by foreign-invested enterprises are also subject to restrictions, which include approvals by the PRC Ministry of Commerce, SAFE and the PRC National Reform and Development Commission. We receive a portion of our revenues in Renminbi, which is currently not a freely convertible currency. We may also rely on dividends and other distributions on equity paid to our operating subsidiaries in China to fund cash and financing requirements. On November 19, 2012, SAFE issued a Circular on Further Improving and Adjusting Foreign Exchange Policies on Direct Investment, or Circular 59. Circular 59 allows foreign-invested enterprises to make loans to their overseas parent companies provided that such loan amount does not exceed the sum of distributed but un-repatriated profits of the foreign investor and its share of undistributed profits in the enterprise. This development will enable us to explore other means of transferring funds within our corporate group.

The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in China's political and economic conditions. The conversion of Renminbi into foreign currencies, including U.S. dollars, has been based on rates set by the People's Bank of China. On July 21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar. Under the new policy, the Renminbi will be permitted to fluctuate within a band against a basket of certain foreign currencies. There remains significant international pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi against the U.S. dollar.

Regulation of Foreign Exchange in Certain Onshore and Offshore Transactions

On July 4, 2014, SAFE issued a Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 superseded SAFE's Circular on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Financing and Round Trip Investment via Overseas Special Purpose Companies and its subsequent amendments, supplements or implementation rules, or SAFE Circular 75, issued on October 21, 2005. According to SAFE Circular 37, a PRC resident (whether a natural person or legal persons) shall register with the local branch of the SAFE before it establishes or controls an overseas SPV, with assets or equity interests in a PRC company, for purposes of overseas equity financing. The PRC resident shall apply for SAFE registration for overseas investment before paying capital to the SPV by using his, her or its legally owned assets, whether overseas or domestic. The SPV is defined as "offshore enterprise directly established or indirectly controlled by the domestic residents (including domestic institutions and individuals) with their legally owned assets and equity of the domestic enterprise, or legally owned offshore assets or equity, for the purpose of offshore investment and financing." In addition, SAFE Circular 37 requires amendment to the registration in the event of any significant changes to the SPV, such as increase or decrease of capital contributed by PRC individuals, share transfer or exchange, merger, division or other material event.

According to SAFE Circular 37, if the registered or beneficial shareholders of the offshore holding company who are PRC residents do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from distributing their profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore company, and the SPV may be restricted in its ability to contribute additional capital to its PRC subsidiaries. Failure to make the required registration or truthfully disclose actual controllers of the round-trip enterprises may subject PRC residents to fines up to RMB300,000 in case of domestic institutions or RMB50,000 in case of domestic individuals. Moreover, failure to comply with SAFE registration and amendment requirements described above could result in additional liability under PRC law for violating applicable foreign exchange restrictions.

As a Cayman Islands company holding our operating subsidiaries in China, we are considered a SPV under SAFE Circular 37. PRC residents who are beneficial holders of our shares are required to register with SAFE in connection with their investment in us. We have requested our shareholders, and the shareholders of the offshore entities in our corporate group, who are PRC residents to make the necessary SAFE registrations. See "Risk Factors—Risks Related to

Doing Business in China—PRC regulations relating to offshore investment activities by PRC residents may increase the administrative burden we face and create regulatory uncertainties that could restrict our overseas and cross-border investment activity, and failure by our shareholders who are PRC residents to make any required applications and filings pursuant to such regulations may prevent us from distributing profits and could expose us and our PRC resident shareholders to liability under PRC law.”

SAFE issued the Notice on Further Simplified and Improved Direct Investment Foreign Exchange Management Measures, or SAFE Notice 13, on February 28, 2015, which will be effective from June 1, 2015. Pursuant to SAFE Notice 13, there is no longer a need for Direct Investment Foreign Exchange Registration and banks shall be able to review and register direct investment foreign exchange in accordance with the newly released Guidelines for Direct Investment Foreign Exchange Registration. SAFE and its local branches shall supervise Direct Investment Foreign Exchange Registration indirectly through the banks.

Dividend Distributions

Pursuant to the Foreign Currency Administration Rules promulgated in 1996 and amended in 2008 and various regulations issued by SAFE, and other relevant PRC government authorities, the PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China.

Our PRC subsidiaries are regulated under the revised PRC Company Law which was amended on December 28, 2013. Accordingly, they shall allocate 10% of after-tax profits to a statutory surplus reserve fund until the balance of their statutory surplus reserve fund reaches 50% of their respective registered capital. As of December 31, 2014, the amount of these restricted portions of our PRC subsidiaries was approximately \$40.0 million. These funds, however, may not be distributed to equity owners except in accordance with PRC laws and regulations.

C. Organizational Structure.

We are a Cayman Islands holding company and conduct a substantial majority of our business through our consolidated subsidiaries Shenzhen Mindray and Mindray DS USA. We own approximately 99.9% of the equity of Shenzhen Mindray through two Hong Kong holding companies, MR Holdings (HK) Limited and MR Investments (HK) Limited. We own 100% of Mindray DS USA through our consolidated subsidiary Mindray Medical Netherlands B.V. Our corporate structure reflects common practice for companies with operations in several different countries where separate legal entities are often required or advisable for purposes of obtaining relevant operating licenses in such jurisdictions.

The diagram below illustrates our current corporate structure and the place of incorporation and affiliation of our principal subsidiaries as of March 31, 2015:

For the complete list of our subsidiaries with their country of incorporation, shareholding structure and principal activities, please refer to Exhibit 8.1 of this annual report.

D. Property, Plant and Equipment.

We currently maintain our global operational headquarters at Mindray Building, Keji 12th Road South, Hi-tech Industrial Park, Nanshan, Shenzhen, 518057, People’s Republic of China. Pursuant to an agreement with the Government of the Nanjing Jiangning Development Zone, we have established a research and development center in Nanjing, on which we are presently operating approximately 51,000 square meters of research and development, manufacturing and sales and administrative office facilities. In China, we additionally operate research and development centers in Beijing, Xi’an, Chengdu and Shanghai. All capital expenditures are funded by internally generated operating cash flow. See Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry — We currently principally rely on four facilities for manufacturing, product assembly and storage and to conduct research and development activities. Any disruption to the use or development of our current manufacturing facilities could reduce or restrict our sales, harm our reputation and have a material adverse effect on our business, financial condition, results of operations and prospects.”

We maintain our U.S. operational headquarters in Mahwah, New Jersey, which occupies approximately 12,000 square meters and is used as a Patient Monitoring and Technology Services headquarters and the research and development and warehousing of patient monitoring devices.

We also maintain research and development centers in Mountain View, California; Seattle, Washington; Miami, Florida; and Stockholm, Sweden. We have 32 local sales, marketing and services offices in China and more than 30 international sales, marketing and service offices.

Our primary production facilities, BaiWang and XiLi, are developed on parcels of land leased through October 31, 2017 and June 30, 2016, respectively. In April 2009, we secured property rights to a location in GuangMing, Shenzhen with a 50-year lease and land use rights. We are currently developing our own facilities on this land to replace our current leased production facilities in Shenzhen.

The following table contains information concerning our significant real property that we own or lease:

No.	Location	General Character and Use of Property
1	High-Tech Park of NanShan District, Shenzhen, China	Owned, approximately 107,000 square meters, used for research and development center and operational headquarters
2	(XiLi) Shenzhen, China	Leased, approximately 20,700 square meters, used for manufacturing, assembly, testing and research and development
3	(BaiWang) Shenzhen, China	Leased, approximately 87,000 square meters, used for manufacturing, assembly, testing and research and development
4	(GongMing) Shenzhen, China	

Edgar Filing: Mindray Medical International LTD - Form 20-F

		Leased, approximately 5,200 square meters, used for manufacturing, assembly, testing and research and development
5	(GuangMing) Shenzhen, China	Owned, approximately 104,000 square meters of land, being developed to substitute our current manufacturing, assembly, testing and research development facility leased in Shenzhen
6	HaiDian District, Beijing, China	Owned, approximately 2,200 square meters, used for research and development center
7	ChaoYang District, Beijing, China	Owned, approximately 1,900 square meters, used for sales, marketing and administration
8	(Zhongguancun International Life Science Park) ChangPing District, Beijing, China	Owned, approximately 48,000 square meters of land, in process of constructing a research and development center
9	Nanjing, China	Owned, approximately 207,700 square meters of land; approximately 51,000 square meters of floor area are currently used for manufacturing, research and development, sales and other daily operations; approximately 43,000 square meters of floor area is reserved for further development
10	Chengdu, China	Leased, approximately 1,400 square meters, used for research and development
11	Xi'an, China	Owned, approximately 16,800 square meters of land, in process of constructing a research and development center
12	Xi'an, China	Leased, approximately 1,300 square meters, used for research and development
13	Shanghai, China	Leased, approximately 1,500 square meters, used as a research and development center and a service support office
14	Wuhan, China	Owned, approximately 18,170 square meters of land; approximately 17,000 square meters of floor area is used for research and development, manufacturing and office space for Wuhan Dragonbio Surgical Implant Co., Ltd.
15	Seattle, Washington, USA	Leased, approximately 1,750 square meters, used for research and development, sales support and other daily operations
16	Mahwah, New Jersey, USA	Owned, approximately 12,000 square meters, used as a Patient Monitoring and Technology Services headquarters and the research and development and warehousing of patient monitoring devices
17	Hoevelaken, Netherlands	Owned, approximately 3,080 square meters, used for office; leased, approximately 1,380 square meters, used for warehousing
18	Sundbyberg, Stockholm, Sweden	Leased, approximately 1,000 square meters, used for research and development, sales storage and other daily operations
19	Miami, Florida, USA	Owned, approximately 1,200 square meters, used for research and development, sales support and client training
20	Mountain View, CA, USA	Leased, approximately 2,880 square meters, used for research and development, sales, service and support, and final quality control

We believe that our facilities and equipment are in good working condition.

ITEM 4A. UNRESOLVED STAFF COMMENTS

Not applicable.

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

The following discussion of our financial condition and results of operations is based upon and should be read in conjunction with our consolidated financial statements and their related notes included in this annual report. This annual report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. See “Introduction — Forward- Looking Statements.” In evaluating our business, you should carefully consider the information provided under Item 3.D, “Key Information — Risk Factors.” We caution you that our businesses and financial performance are subject to substantial risks and uncertainties.

A. Operating Results.

Overview

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global operational headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey, and multiple sales offices in major domestic and international markets. From our main engineering and manufacturing base in China and through our worldwide distributor and direct sales networks, we supply internationally a broad range of products across our three primary business segments: patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems.

Our overall net revenues increased from \$1,060.1 million in 2012 to \$1,214.0 million in 2013 and to \$1,322.8 million in 2014. Our net income increased from \$180.2 million in 2012 to \$224.8 million in 2013 and decreased to \$193.3 million in 2014.

Geographically, our net revenues generated from China markets increased from \$473.0 million in 2012 to \$551.2 million in 2013 and to \$606.7 million in 2014. Our net revenues generated from international markets increased from \$587.1 million in 2012 to \$662.8 million in 2013 and to \$716.1 million in 2014.

We sell our products through different distribution channels in different geographies. In China, primarily due to geographic size and the costs that would be associated with maintaining a nationwide sales force, we sell our products primarily to third-party distributors. We also sell our products directly to hospitals, clinics, government health bureaus in China. We believe we have one of the largest distribution, sales, marketing and service networks for medical devices in China. As of December 31, 2014, we had over 1,600 distributors and more than 2,100 sales, marketing and services personnel managing our distribution network and covering the China region. In 2014, to better address the market for our high-end medical devices in China we increased the number of our related sales force personnel. To better address the market for our mid- and low-end medical devices markets, we focused on expanding the number of and nationwide reach of our distributors.

For international markets, we have more than 1,100 sales, marketing and services personnel and work with over 1,700 third-party distributors as of December 31, 2014. In reaching our international direct sales customers, we sell products either through our international sales team stationed in China or through our overseas subsidiaries. Although profits on products sold directly by our PRC subsidiaries tend to be higher (because our PRC subsidiaries do not bear additional or higher costs borne by our overseas subsidiaries), we intend to continue to strengthen our on-the-ground sales, marketing and service support in international markets. We believe that increased local sales, marketing and service support in international markets improves our net revenues growth prospects, and helps us gain improved market information that we use when developing new or enhanced products. The expansion of our on-the-ground sales offices and services support allows us to better understand customer needs, provide customer service and build our brand.

We have made and expect to continue making substantial investments in research and development activities, investing approximately 10% of our net revenues in research and development in 2012, 2013 and 2014. We currently have research and development facilities located in Shenzhen, Beijing, Nanjing, Xi'an, Chengdu, and Shanghai in China. We also maintain research and development centers in Mahwah, New Jersey; Mountain View, California; Seattle, Washington; Miami, Florida; and Stockholm, Sweden. We believe that our emphasis on research and development is a core competency that has allowed us to grow and provides us with ongoing growth possibilities. We maintain what we believe is the largest research and development team of any medical device manufacturer based in China. As of December 31, 2014, the total number of our engineers and other research and development personnel in multiple research and development centers in China, the United States and Sweden increased to more than 2,000. Our research and development headquarters in Shenzhen coordinates our global research and development efforts, leveraging the core competencies of each of our centers.

Pricing

We sell our products both to distributors and through our direct sales force. In markets where we rely on distributors, we price our products at levels that we believe offer attractive economic returns to distributors, taking into account the prices of competing products and our gross margins. Where we rely on direct sales, we price our products based primarily on market conditions. We believe that we offer value-based products with a more favorable ratio of functionality to cost than our competitors. For our low- to mid-end markets, we deploy a more competitive pricing structure to better meet our customers' needs and capture market share.

The average selling prices of our products typically decrease over time due to natural price erosion. With the current global market competition, we are facing more pricing pressures including pressures to provide or assist in arranging third-party financing which we anticipate will continue in the near term. In China and the international markets, we anticipate declines in the average selling price. In China, we expect these declines particularly in hospitals at and below the county level in China, with these hospitals being typically more price sensitive. We may also face some pricing uncertainty related to foreign currency fluctuations, which can affect purchasing power in international markets. In international markets, we offer competitive, value-based products. However, we also experience pricing pressure from competitors that offer a wider variety of products or are more established in those markets. Moreover, the consolidation of healthcare providers and the formation of group purchasing organizations in the United States further increase our pricing pressures as sales are made to fewer customers who prefer purchasing under bulk discounts.

Our current selling prices are mainly denominated in U.S. dollars and Renminbi, while a significant portion of our costs are currently denominated in Renminbi. Since June 2010, the Renminbi has appreciated slowly against the U.S. dollar, though there have been periods recently when the U.S. dollar appreciated against the Renminbi. Such exchange rate fluctuations have not had a material impact on our overall pricing. However, it is difficult to predict how long the current situation may last and when and how the relationship between the Renminbi and U.S. dollar will change again. Fluctuations in the exchange rates between Renminbi and U.S. dollars could have a material impact on our overall future pricing and results of operations.

Revenue

Our customer base is widely dispersed on a geographic basis, with sales into more than 190 countries and regions in 2014. China is our largest market by a significant margin. In the near term, we anticipate revenues from sales in China will increase as a percentage of our total revenues due primarily to: (i) anticipated increases in government healthcare spending, particularly directed at county-level hospitals (although spending by hospitals in China may be tempered by a recent reduction in China's projected economic growth rate and increasing governmental scrutiny over public hospital spending); (ii) the growing private market for healthcare, driven by increasing personal wealth; (iii) the increasing availability of health insurance and medical insurance reimbursement due to government initiatives; and (iv) government efforts to encourage hospitals to purchase products from domestic manufacturers. In recent periods, China's economy generally fared better compared to most developed markets where we sell our products. However, in the long-term, we anticipate that net revenues from sales outside of China will increase as a percentage of our total net revenues because the addressable medical device market outside of China is substantially larger than the China market. In the near-term, we anticipate that our growth rates experienced outside of China will be slower. Factors impacting growth in North America include a hospital consolidation trend and uncertainties in healthcare reform. Europe may be impacted by increasing uncertainties in various Western European economies and the recent weakening of the Euro. Emerging markets are subject to uncertainties as a result of tightened foreign exchange, decrease in oil prices and import policies and political instabilities.

For our sales in China, we record revenues net of value-added tax, or VAT. The VAT represents a 17% tax collected from customers on behalf of the tax authority, which were \$78.0 million, \$100.3 million and \$127.3 million in 2012, 2013 and 2014, respectively, offset by a VAT refund. Pursuant to a PRC government policy, “Certain Policies to Encourage the Development of Software and Integrated Circuit Industries as New and Hi-Tech Enterprises,” we receive a VAT refund arising from the sale of embedded self-developed software in our devices. Although there has been no indication of an intention on the part of the PRC government to discontinue this policy, the PRC government could choose to do so. VAT refunds included in net revenues were \$26.9 million, \$28.4 million and \$31.9 million in 2012, 2013 and 2014, respectively.

Our customer base is also widely dispersed on a net revenues basis. In each of 2012, 2013 and 2014, no single customer, including our distributors, accounted for not more than 2% of our total net revenues. We primarily derive revenues from three business segments: patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. Our patient monitoring and life support products business segment accounted for 42.4%, 38.7% and 36.7% of our total net revenues in 2012, 2013 and 2014, respectively. Our in-vitro diagnostic products business segment accounted for 27.0%, 27.6% and 27.8% of our total net revenues in 2012, 2013 and 2014, respectively. Our medical imaging systems business segment accounted for 23.9%, 25.0% and 26.0% of our total net revenues in 2012, 2013 and 2014, respectively. Our services revenues, revenues from other products that were outside our three business segments, are grouped into business segment called “others,” which accounted for 6.7%, 8.7% and 9.5% of our total net revenues in 2012, 2013 and 2014, respectively.

Patient Monitoring and Life Support Products. We derive revenues for our patient monitoring and life support products segment from the sale of patient monitoring devices, anesthesia machines, defibrillators, surgical equipment, syringes and pumps, and ventilators. Our patient monitoring and life support products segment is our largest business segment and our patient monitoring products has the most extensive market penetration of our three segments both domestically and internationally. We expect to continue building market share with large hospitals within China and international markets with recently introduced products offering increased functionality and more comprehensive features, as well as those in our near-term product pipeline. As our product offerings continue to grow through both self-development and acquisitions, we are able to provide more comprehensive solutions to hospitals. Over the last two decades, we have gradually transformed from a product provider to a solution provider for clinicians from critical care to sub-acute settings across the emergency room, operating room, intensive care unit, or ICU, and coronary care unit, or CCU.

In-vitro Diagnostic Products. We derive revenues for our in-vitro diagnostic, or IVD, products segment from diagnostic laboratory instruments and related reagents sales. Our current IVD products portfolio consists of seven product categories: hematology analysis, biochemistry analysis, immunoassay analysis, flow cytometric analysis, coagulation analysis, urine sediment analysis and microbiology analysis. We plan to continue investing significantly in, and further penetrate, this market by introducing products with more comprehensive features from developing more products in-house and also through acquisitions. We also sell reagents for use with our products in in-vitro diagnostic products. Reagents typically have a higher gross margin compared to our other IVD products and provide a recurring revenue stream; for example, consumable liquid reagents are used each time an analysis is performed and the same unit of the consumable liquid reagent cannot be reused. Our reagent net revenues accounted for 9.5%, 10.7% and 12.2% of our total net revenues in 2012, 2013 and 2014. We expect reagent sales to increase in both dollar terms

and percentage terms as we increase our installed base of analyzers, develop more effective reagent marketing methods, and increase of focus on the manufacture and sale of reagents. To increase our IVD product manufacturing capacity, particularly for reagents, we have expanded or are in the process of expanding our manufacturing facilities in Shenzhen and Nanjing.

Medical Imaging Systems. We derive medical imaging systems segment revenues from sales of our ultrasound systems, digital radiography systems, magnetic resonance imaging system and related accessories. We have successfully penetrated the ultrasound market in China and emerging markets. We believe that near- and long-term growth in this segment will be driven, in part, by our ability to further penetrate the China market and additional emerging country markets and to develop and market products offering more advanced ultrasound and other imaging modalities. In July 2013, we acquired ZONARE, an ultrasound technology U.S. company in the high-end radiology market. The ZONARE acquisition has further strengthened our high-end ultrasound research and development and U.S. sales capabilities.

Others. Others revenues are primarily derived from provision of extended warranty services, accessory sales, and repair services for post-warranty periods. This segment also includes revenues derived from other products, such as orthopedic products, endoscope devices and healthcare IT solutions products which mainly include PACS and RIS products, which are outside the three business segments as described above. We expect our others segment may not follow the same net revenues growth rate as our primary segments.

Our ability to increase our revenues depends in large part on our ability to increase the market penetration of our existing products and successfully identify, develop, introduce and commercialize, in a timely and cost-effective manner, new and upgraded products. We devote resources to product development efforts that we believe are commercially feasible, can generate significant revenues and margins and can be introduced into the market in the near term.

In any period, several factors will impact our net revenues, including:

- global economic conditions;
- new and potentially increased competition;
- the level of acceptance of our products among hospitals and other healthcare facilities;
- pricing pressures and our ability to price our products at levels that provide favorable margins;
- our ability to attract and retain distributors, key customers and our direct sales force;
- new product introductions by us and our competitors;
- component and raw material costs and our resulting manufacturing efficiency;
- foreign currency fluctuations;
- our ability to expand into and further penetrate international markets;
- the availability of credit and financing for our customers;

- sales seasonality;

• key governments and major group purchasing organizations tender criteria changes, policy changes, review process changes, and execution timing changes;

- government tax policy changes;

• healthcare-related policies and healthcare reform that could lead to curtailed capital investments, or changes in healthcare insurance policies, particularly in China and the United States;

• regulatory actions, such as those approving or denying the sale or importation of our products or product lines; and

- government tender sales in China.

For a detailed discussion of some of the factors that may cause our net revenues to fluctuate, see Item 3.D, “Key Information — Risk Factors — Risks Relating to Our Business and Industry.”

Cost of Revenues

Cost of revenues includes our costs incurred directly related to revenue-generating activities, including component and material costs, salaries and related personnel expenses, depreciation of fixed assets incurred directly related to revenue-generating activities, shipping and handling costs, provisional costs of warranty-based maintenance, costs of repair and after-sales services, costs of providing sales incentives, an urban construction and maintenance tax and education surcharge and other related surcharges imposed by the PRC government, and our other direct costs incurred to manufacture our products or for revenue-generating activities. Beginning in January 2013, our cost of revenues also included a 2.3% medical excise tax on certain U.S. medical device sales. In 2013 and 2014, we recorded \$1.9 million and \$2.0 million in excise taxes, respectively.

Our cost of revenues as a percentage of our net revenues is driven by product mix, distribution channel, material costs, our pricing strategies, manufacturing efficiencies, utilization of fixed costs for our after-sales services and sales incentive program.

Enhanced products. When we introduce a new product that improves upon an existing product, our cost of revenues is typically lower than for existing products in that category, as we take advantage of previously achieved manufacturing efficiencies from the outset.

New product types and lines. Cost of revenues tends to be higher for new product types or lines. Therefore, when we introduce a greater than average number of new product types or lines, our cost of revenues as a percentage of net revenues tends to be higher. This is due primarily to start-up costs and generally higher raw material and component costs when the initial production volumes are low. As production volumes increase, we typically improve our manufacturing efficiencies and are able to strengthen our purchasing power by buying raw materials and components in greater quantities. Furthermore, when production volumes become sufficiently large, we often gain further cost efficiencies by producing additional components in-house.

Over time, production costs for our products typically decrease due to our:

• leveraging our understanding of component performance by identifying more suitable and cost-effective components;

- standardizing components across product models and product lines;
- seeking to use adaptable and cost-effective software instead of hardware where possible;
- actively managing our supply chain; and

• use of in-house and external suppliers to achieve a competitive cost structure while maintaining the same quality standards for our products.

We currently have a relatively low cost base compared to medical device companies in more developed countries because we source a significant portion of our raw materials and components and manufacture a significant portion of our products in China. Furthermore, we continually seek to improve cost of revenues by:

leveraging our research and development capacities to improve manufacturing efficiencies and product design, thereby reducing production costs;

as appropriate, vertically integrating our manufacturing operations and realigning manufacturing facilities, allowing us to increasingly produce product components in-house;

strategically moving to China certain component and raw material production and product assembly for our U.S. and Sweden operations;

generating economies of scale through increased purchase volumes and using more common resources across product lines; and

- realigning our employees to leverage their core competencies and to reduce redundancies.

Historically, these efforts have typically enabled us to reduce our per unit cost of revenues on a year-over-year basis. These positive effects have helped us maintain or improve gross margins while facing pricing pressures and wage increases in China. We may continue facing each of these issues going forward.

Gross Profit and Gross Margin

Gross profit is equal to net revenues less cost of revenues. Gross margin is equal to gross profit divided by net revenues. Between 2012 and 2014, we were able to maintain overall gross margins between approximately 50% and 60%. In the near term, we anticipate that our overall gross margin will remain within this range. While we will continue to develop high gross margin products, we are also developing or acquiring complementary products that can boost our total net revenues but may have lower gross margins. However, because these are complementary products, we believe the overall impact to net revenues and net income is positive, as we can leverage our existing sales infrastructure. In addition to product mix, our gross margin may also be affected by currency exchange rate as our current selling prices are mainly denominated in U.S. dollars and Renminbi, while a significant portion of our cost of revenues are currently denominated in Renminbi.

Although the average selling prices of each of our products generally decreases over time, these decreases have generally not had an adverse impact on our gross margins because in most instances they result from or can be offset by our ability to reduce our cost of revenues, new product introductions, product mix change and improvement on manufacturing and services efficiency. However, we expect pricing pressure will have a more significant impact in 2015 as we strengthen and increase our market share in markets covering hospitals at the county level or below in China, with these hospitals typically being more price-sensitive.

Operating Expenses

Our operating expenses consist of selling expenses, general and administrative expenses, research and development expenses, and employee share-based compensation expenses.

Selling Expenses

Selling expenses consist primarily of compensation and benefits for our sales and marketing staff, expenses for promotional, advertising, travel and entertainment activities, project tendering fees, lease payments for our sales and marketing offices, depreciation expenses related to equipment used for sales and marketing activities and other expenses incurred in connection with selling and marketing purposes.

In China, we primarily sell our products to distributors. We believe our China sales and marketing expenses as a percentage of net revenues are significantly lower than medical device manufacturers that primarily sell their products directly to end-users. While we intend to continue selling our products in China primarily to distributors, we are also seeking to expand our geographic coverage both domestically and internationally and build brand recognition. In connection with these efforts, we expect that certain components of our selling expenses as a percentage of total net revenues will increase.

General and Administrative Expenses

General and administrative expenses consist primarily of compensation and benefits for our general management, finance, information systems, administrative staff, depreciation and amortization with respect to equipment used for general corporate purposes, professional and legal advisor fees for compliance and merger and acquisition activities, IT development and maintenance fees, foreign exchange gain (loss), allowance (recovery) for doubtful accounts, lease payments, dispute charges relating to certain disputes occurred in the ordinary course of business and other expenses incurred in connection with general corporate purposes. As we leverage our existing operating structure, excluding the

impact of dispute charges or non-recurring expenses, we anticipate that general and administrative expenses as a percentage of net revenues will remain stable.

Research and Development Expenses

Research and development expenses consist primarily of costs associated with product design, development, prototyping, manufacturing and testing. Among other things, these costs include compensation and benefits for our research and development staff, expenditures for supplies and machinery, depreciation expenses related to equipment used for research and development activities, and other relevant costs incurred in connection with research and development purposes. We are committed to maintaining what we believe is the largest research and development team of any medical device manufacturer in China, and developing and commercializing new and more advanced products. We intend to continue investing approximately 10% of our net revenues in research and development efforts on technology and product development.

Employee Share-Based Compensation Expenses

We award share options or restricted shares under our Amended and Restated 2006 Employee Share Incentive Plan to our employees from time to time as a reward to our employees usually based on their achievement in prior year. Such options and restricted shares granted generally do not vest unless the grantee remains under our employment or in service with us on the given vesting date. We account for employee share-based compensation expenses based on the fair value of share option or restricted share grants at the date of grant. We incurred \$14.0 million, \$14.7 million and \$19.9 million in employee share-based compensation expenses in 2012, 2013 and 2014, respectively. Higher share-based compensation in 2014 reflects additional equity grants following the ZONARE acquisition and additional key employee retention grants.

The table below shows the effect of the 2012, 2013 and 2014 share-based compensation charges on our operating expense line items:

	Year Ended December 31,		
	2012	2013	2014
	(In thousands)		
Cost of revenues	\$ 811	\$ 752	\$ 1,120
Selling expenses	4,457	4,345	6,420
General and administrative expenses	4,409	4,819	7,616
Research and development expenses	4,307	4,767	4,714

Other Income, Net

Other income, net, consists primarily of cash subsidies, and incentives received from the PRC government as well as non-operating income or expenses. They are generally provided in relation new high-technology medical product development and export credit insurance purchases as well as PRC State and/or local government incentives which aim to encourage capital investment in high-technology industries in China, to file patent applications for new inventions, to optimize foreign trade structure, and other projects that were encouraged by the government from time to time. We receive government subsidies or government incentives on an irregular basis and in amounts that vary significantly. While we intend to continue applying for government subsidies and incentives, the PRC government may choose to reduce or eliminate them.

Interest Income

Interest income represents interest income derived from cash deposits, deposits on restricted cash excluding restricted cash in respect of acquisition consideration held in escrow, and short-term investments.

Interest Expense

Interest expense represents primarily interest expense charged on our loan facilities and amortization of related bank loan arrangement fees.

Taxes and Incentives

We are an exempted company incorporated in the Cayman Islands and are not subject to taxation under the current Cayman Islands law. Our subsidiaries operating in China are subject to PRC taxes as described below and the subsidiaries incorporated in the BVI are not subject to taxation.

Under the PRC EIT Law effective on January 1, 2008, China has adopted a uniform enterprise income tax rate of 25% for all PRC enterprises (including foreign-invested enterprises) and revoked the previous tax exemption, reduction and preferential treatments applicable to foreign-invested enterprises. However, the EIT Law also permits enterprises to continue to enjoy their existing tax incentives, adjusted by certain transitional phase-out rules, under which enterprises established before the promulgation date of the EIT Law that were granted tax holidays under the then effective tax laws or regulations may continue to enjoy their tax holidays until their expiration. Beijing Mindray, an enterprise established before the promulgation date of the EIT Law, was entitled to a preferential treatment under the phase-out rules, under which it enjoyed a 50% reduction to the enterprise income tax for the taxable years 2008 to 2010. Nanjing Mindray was entitled to tax exemption from 2008 to 2009 and a 50% tax reduction from 2010 to 2012. Additionally, Shenzhen Mindray Software is entitled to the tax exemption in 2013 and 2014, and a 50% tax reduction from 2015 through 2017.

In addition, the EIT Law also introduces new tax incentives, subject to various qualification criteria. The EIT Law permits qualified “New and Hi-Tech Enterprises” to enjoy a reduced 15% enterprise income tax rate and qualified “Nationwide Key Software Enterprises” to enjoy a preferential tax rate of 10%. Nanjing Mindray and Shenzhen Mindray Software are qualified as “New and Hi-Tech Enterprises” and are entitled to a reduced 15% EIT rate for the years 2010 through 2015 and 2013 through 2015, respectively. In addition, Shenzhen Mindray and Beijing Mindray are each qualified as “New and Hi-Tech Enterprises” and are each entitled to a reduced 15% EIT rate for the years 2008 through 2016. The continued qualification for a “New and Hi-Tech Enterprises” is still subject to review by the relevant government authority in China. In addition, Shenzhen Mindray also obtained “Nationwide Key Software Enterprise” status for the calendar years 2009 through 2014. The qualification for “Nationwide Key Software Enterprise” is granted on a two-year basis by the relevant government authority in China. Although we intend to apply for “Nationwide Key Software Enterprise” status for qualifying entities in respect of 2015 and later periods, we may not successfully meet or maintain the required qualifications.

As a result of above mentioned tax incentives, the applicable enterprise income tax rates for our major PRC subsidiaries were as follows:

	2012	2013	2014
Nanjing Mindray	12.5 %	15 %	15 %
Shenzhen Mindray	10 %	10 %	10 %
Beijing Mindray	15 %	15 %	15 %
Shenzhen Mindray Software*	*	0 %	0 %

* Shenzhen Mindray Software was established in 2011 and was loss making in 2011 and 2012. It became profitable in 2013 and therefore became eligible for a tax-holiday starting in 2013.

Our subsidiaries in China are required to withhold income tax for their immediate parent holding companies in connection with dividends payable out of post-January 1, 2008 undistributed earnings (dividends paid out of pre-January 1, 2008 undistributed earnings are not subject to withholding taxes). The applicable tax rate for dividends is generally 10% subject to reduction by the tax treaties in China. Shenzhen Mindray and Nanjing Mindray are wholly owned by our Hong Kong subsidiaries and therefore our Hong Kong subsidiaries may be able to enjoy a favorable tax rate of 5% applicable under the Double Taxation Arrangement (Hong Kong) on dividends paid by our PRC subsidiaries to our Hong Kong subsidiaries if our Hong Kong subsidiaries would be considered to be the beneficial owners of any such dividends or the shareholding is not less than 25%. These withholding taxes and related deferred tax obligations apply only once amounts are determined to be available for distribution. As of December 31, 2013 and 2014, our PRC subsidiaries had \$1.2 billion and \$1.6 billion, respectively of undistributed earnings (all related to post-January 1, 2008 earnings). Of this total, we expect \$1.2 billion and \$1.2 billion, respectively will be permanently reinvested in China and, therefore, we recorded a deferred tax obligations of \$3.0 million and \$23.6 million as of December 31, 2013 and 2014, respectively in relation to undistributed earnings that may be distributed by our PRC subsidiaries. However, to the extent that, due to unforeseen circumstances, there may be a reduction in the amount expected to be permanently reinvested in China, we would incur withholding tax and deferred tax obligation in connection with undistributed earnings designated or otherwise available for dividend distributions. See Item 3.D, “Key Information — Risk Factors — Risks Related to Doing Business in China — We may be unable to enjoy the favorable 5% treaty-based rate of income tax withholding for any dividends our PRC subsidiaries pay to us through our Hong Kong holding companies.”

Certain of our PRC Subsidiaries, in particular Shenzhen Mindray and Shenzhen Mindray Software, are entitled to VAT refunds, at a maximum rate of 14% of the sale value of self-developed software that is embedded in our products. The total amount of VAT refunds for all our PRC subsidiaries included in net revenue in 2012, 2013 and 2014 were \$26.9 million, \$28.4 million and \$31.9 million, respectively.

Our PRC subsidiaries are subject to urban construction and maintenance tax, or UCMT, as well as educational surcharge, or ES. The applicable UCMT rate is 7% and ES rate is 3% for all of our PRC subsidiaries. Since January 1,

2011, an additional 2% local ES has been imposed by the PRC government. We recorded UCMT and ES tax in an aggregate amount of \$9.8 million, \$12.6 million and \$11.9 million in our cost of revenues in 2012, 2013 and 2014, respectively.

On March 23, 2010, the United States passed the Patient Protection and Affordable Care Act, shortly thereafter amended by the Health Care and Education Reconciliation Act of 2010, or the Reconciliation Act, on March 30, 2010. The Reconciliation Act added section 4191 to the U.S. Internal Revenue Code of 1986, as amended, which imposed an excise tax, effective as of January 1, 2013, on the sale of non-retail medical devices by the manufacturer, producer or importer in the amount equal to 2.3% of the sale price. Accordingly, Mindray DS USA and ZONARE have been subject to this excise tax since January 1, 2013. We recorded excise tax in an aggregate amount of \$1.9 million and \$2.0 million in our cost of revenues in 2013 and 2014, respectively.

Due to the pending or potential expiration of preferential tax treatments and financial incentives currently available to us, our historic operating results may not be indicative of our operating results for future periods. See Item 3.D, “Key Information — Risk Factors — Risks Related to Doing Business in China — The discontinuation of any of the preferential tax treatments or the financial incentives currently available to us in China could adversely affect our financial condition and results of operations.”

Acquisitions

Our growth strategy involves acquisitions of new technologies, businesses, products or services or establishing strategic alliances in areas in which we do not currently operate or areas in which we seek to further expand. Since 2011, we have made 11 acquisitions, including nine domestic medical devices companies and two foreign medical devices companies. Our most significant recent acquisition is our 2013 acquisition of ZONARE, a U.S. ultrasound technology company in the high-end radiology market for \$101.1 million in cash. This acquisition strengthened our high-end ultrasound research and development ability in order to generate the next generation of high-end products and our direct- sales capabilities in the United States.

Acquired businesses complementary to our existing business are grouped under our three primary business segments. Other acquired businesses, such as our medical orthopedic products, endoscopes businesses and healthcare IT solutions, are included in our “others” segment. For more details, please see the notes to our consolidated financial statements appearing elsewhere in this annual report.

Results of Operations

The following table sets forth our consolidated statements of operations by amount for the indicated periods:

	Year Ended December 31,					
	2012		2013		2014	
	(In thousands, except percentages)					
Net revenues	\$1,060,054	100.0%	\$1,213,987	100.0%	\$1,322,814	100.0%
Cost of revenues(a)	(459,389)	43.3	(527,402)	43.4	(584,310)	44.2
Gross profit	600,665	56.7	686,585	56.6	738,504	55.8
Operating expenses:						
Selling expenses(a)	(188,804)	17.8	(220,589)	18.2	(261,965)	19.8
General and administrative expenses(a)	(116,228)	10.9	(128,308)	10.6	(137,016)	10.4
Research and development expenses(a)	(104,302)	9.8	(127,464)	10.5	(146,997)	11.1
Income from operations	191,331	18.0	210,224	17.3	192,526	14.6
Other income, net	1,619	0.2	3,881	0.3	9,363	0.7
Interest income	30,794	2.9	37,047	3.1	38,985	2.9
Interest expense	(4,093)	0.4	(6,345)	0.5	(6,400)	0.5
Income before income taxes and non-controlling interests	219,651	20.7	244,807	20.2	234,474	17.7
Provision for income taxes	(37,369)	3.5	(14,260)	1.2	(35,485)	2.7
Net income	\$182,282	17.2	\$230,547	19.0	\$198,989	15.0
Less: Net income attributable to non-controlling interests	(2,073)	0.2	(5,793)	0.5	(5,697)	0.4
Net income attributable to Mindray shareholders	\$180,209	17.0 %	\$224,754	18.5 %	\$193,292	14.6 %

Note (a):

	Year Ended December 31,		
	2012	2013	2014
	(In thousands)		
Share-based compensation charges incurred during the years related to:			
Cost of revenues	\$811	\$752	\$1,120
Selling expenses	4,457	4,345	6,420
General and administrative expenses	4,409	4,819	7,616
Research and development expenses	4,307	4,767	4,714

Comparison of Years Ended December 31, 2013 and December 31, 2014

Net Revenues

	Year Ended December 31, 2013		2014		
	Net Revenues as % of Total		Net Revenues as % of Total		
(in thousands, except percentages)					
Geographic Data:					
China	\$551,155	45.4	% \$606,745	45.9	%
Other Asia	93,777	7.7	114,521	8.7	
Europe	121,262	10.0	137,133	10.4	
North America	162,453	13.4	187,778	14.2	
Latin America	125,038	10.3	107,758	8.1	
Others	160,302	13.2	168,879	12.7	
Total net revenues	\$1,213,987	100.0	% \$1,322,814	100.0	%
Segment Data:					
Patient monitoring and life support products	\$469,689	38.7	% \$485,103	36.7	%
In-vitro diagnostic products	335,511	27.6	367,148	27.8	
Medical imaging systems	303,416	25.0	343,285	26.0	
Others	105,371	8.7	127,278	9.5	
Total net revenues	\$1,213,987	100.0	% \$1,322,814	100.0	%

Our total net revenues increased by \$108.8 million, or 9.0%, from \$1,214.0 million in 2013 to \$1,322.8 million in 2014. The increase primarily reflected the continuing growth in our sales volume in both China and international markets offset by a general decline in the selling price of our products.

Geographically, our net revenues generated from the China market increased from \$551.2 million in 2013 to \$606.7 million in 2014. Our net revenues from the China market, as a percentage of total net revenues, increased from 45.4% in 2013 to 45.9% in 2014. The increase in our China net revenues was primarily attributable to the positive healthcare spending environment in China, with increased funding to, and related purchases by, our county-level hospital customers, continued strong growth in our in-vitro diagnostic products and medical imaging systems segments, and favorable net revenue contributions from PRC businesses acquired in 2013 and 2014. Net revenues growth from the China market decreased from 16.5% in 2013 to 10.1% in 2014 as a result of more cautious hospital spending in China starting in the second half of 2013 as induced by PRC regulatory authority's increased scrutiny over spending by public hospitals.

Our net revenues generated from international markets increased from \$662.8 million in 2013 to \$716.1 million in 2014. Our net revenues from international markets, as a percentage of total net revenues, were 54.6% and 54.1% in 2013 and 2014, respectively. The increase in our international revenues reflects the positive sales volume growth in Western Europe, Asia (other than China) and Africa and the full-year effect of net revenues contribution from our ZONARE (acquired in July 2013). International sales, as a percentage of total net revenues, have continued to decline slightly since 2012. Net revenues growth from international markets decreased from 12.9% in 2013 to 8.0% in 2014 due to negative net revenues growth in the Commonwealth of Independent States, or CIS, regions, Latin America and Middle East as a result of tightened foreign exchange and import policies, decrease in oil price and political instabilities.

Each of our business segments experienced net revenues growth in 2014. Net revenues in our patient monitoring and life support products segment increased by \$15.4 million, or 3.3%, from \$469.7 million in 2013 to \$485.1 million in 2014. Despite strong sales growth for our anesthesia, defibrillator and surgical equipment products, segment growth was impacted by a modest decline in unit sales volumes for our patient monitoring devices in China and emerging market.

Net revenues in our in-vitro diagnostic products segment increased by \$31.6 million, or 9.4%, from \$335.5 million in 2013 to \$367.1 million in 2014. The increase in net revenues in our in-vitro diagnostic products segment primarily reflects the expansion of our installed equipment base, which provides a platform for recurring reagent sales. As a percentage of total in-vitro diagnostic product segment net revenues, reagent net revenues increased from 38.8% in 2013 to 43.8% in 2014.

Net revenues in our medical imaging systems segment increased by \$39.9 million, or 13.1%, from \$303.4 million in 2013 to \$343.3 million in 2014. The increase in net revenues in our medical imaging systems segment primarily resulted from increased medical imaging systems sales volumes, particularly in China and European markets, which recorded higher than average segment growth rates, and the full-year effect of net revenue contribution from ZONARE (acquired in July 2013).

Net revenues from our others segment increased by \$21.9 million, or 20.8%, from \$105.4 million in 2013 to \$127.3 million in 2014. The increase is primarily attributable to increase in net revenues derived from extended warranty service, accessory sales and repair services for post-warranty period resulting from increased medical device sales volumes, which increased demand for after-sales services.

Cost of Revenues

Total cost of revenues as a percentage of total net revenues increased from 43.4% in 2013 to 44.2% in 2014. The increase in cost of revenues as a percentage of total net revenues in 2014 compared to 2013 was primarily attributable to a general decline in our selling price and the dilutive effect from our ZONARE acquisition, offset by improved utilization of manufacturing facilities, due to increased sales volumes, lowered materials costs, changed sales mix, and by improved utilization of fixed costs for our after-sales services.

Patient Monitoring and Life Support Devices

Patient monitoring and life support devices segment cost of revenues as a percentage of patient monitoring and life support devices segment net revenues increased from 42.5% in 2013 to 45.2% in 2014. The increase from 2013 was primarily attributable to the general decline in selling price and changed sales mix, offset by lowered material costs as a result of attaining more favorable terms with suppliers.

In-vitro Diagnostic Products

In-vitro diagnostic products segment cost of revenues as a percentage of in-vitro diagnostic products segment net revenues decreased from 42.1% in 2013 to 41.5% in 2014, as a result of our increased reagent sales. Reagent products typically have lower overall cost of revenues compared to equipment and device products. Net revenues generated from reagent sales, as a percentage of total in-vitro diagnostic products segment net revenues, increased from 38.8% in 2013 to 43.8% in 2014.

Medical Imaging Systems

Medical imaging systems segment cost of revenues as a percentage of medical imaging systems segment net revenues increased from 37.1% in 2013 to 39.2% in 2014. The increase in 2014 was mainly attributable to the full-year effect of ZONARE (acquired in July 2013), with product gross margins that tend to be lower than our other medical imaging systems products; partially offset by improved utilization of manufacturing facilities caused by increased sales volumes and lowered materials costs from attaining more favorable terms with suppliers.

Others

Other cost of revenues as a percentage of other net revenues decreased from 70.1% in 2013 to 61.2% in 2014. The decrease in 2014 was primarily due to improved utilization of fixed costs on after-sales services following an increase in services sales volume.

Gross Profit and Gross Margin

Total gross profit increased by \$51.9 million, or 7.6%, from \$686.6 million in 2013 to \$738.5 million in 2014. Our consolidated gross margin was 56.6% in 2013 and 55.8% in 2014 due to the foregoing.

Operating Expenses

Our operating expenses primarily consist of selling expenses, general and administrative expenses and research and development expenses. Operating expenses, as a percentage of total net revenues, increased from 39.2% in 2013 to 41.3% in 2014. Our operating expenses were \$546.0 million in 2014, an increase of 14.6% compared to \$476.4 million in 2013. The increase in operating expenses is analyzed below:

Selling Expenses

Our selling expenses, as a percentage of total net revenues, increased from 18.2% in 2013 to 19.8% in 2014. The increase was primarily attributable to our business expansions in the international markets, which have relatively higher selling expenses as a percentage of net revenues compared to that for our China markets and our increased spending on sales and marketing support to introduce our high-end products. Our selling expenses were \$262.0 million in 2014, an increase of 18.8% from \$220.6 million in 2013. The increase is mainly driven by: (1) a general increase in employee compensation for sales and marketing staff; (2) increased travel, marketing and training expenses; (3) increased advertising and promotion expenses as a result of our increased marketing activities; and (4) the full-year effect of consolidating ZONARE (acquired in July 2013), including expenses related to ZONARE's direct sales force.

General and Administrative Expenses

Our general and administrative expenses, as a percentage of total net revenues, decreased from 10.6% in 2013 to 10.4% in 2014. Our general and administrative expenses were \$137.0 million in 2014, an increase of 6.8% compared to \$128.3 million in 2013. The increase in general and administrative expenses was driven primarily by (1) a general increase in employee compensation for general and administrative staff; (2) a \$2.0 million allowance for doubtful accounts (related to accounts receivable from international markets) versus a \$0.9 million reversal was recorded in 2013; and (3) the full-year effect of consolidating ZONARE (acquired in July 2013), offset by a \$14.8 million charge taken in 2013 in connection with our dispute with Beckman Coulter, Inc.

Research and Development Expenses

Our research and development expenses, as a percentage of total net revenues, increased from 10.5% in 2013 to 11.1% in 2014. The increase in research and development expenses as a percentage of total net revenues was primarily attributable to the increase in our investment in product innovations in 2014 and the full-year effect of consolidating ZONARE (acquired in July 2013) (which has, as a percentage of net revenues, relatively higher research and development expenses than our group average). Our research and development expenses were \$147.0 million in 2014, an increase of 15.3% compared to \$127.5 million in 2013. The increase in research and development expenses was primarily due to (1) increased employee compensation for research and development staff and research and development material costs and (2) full-year effect of including ZONARE's research and development expenses.

Other Income, Net

Our other income, net, was \$9.4 million in 2014, an increase of 141.3% compared to \$3.9 million in 2013. Other income, net, in 2013 and 2014 included \$4.0 million and \$7.2 million, respectively, related to cash subsidies and incentives received from the PRC government. These subsidies and incentives are granted by the PRC government on an irregular basis and amounts received tend to vary significantly. In 2014, other income, net, also benefited from payment of a \$2.7 million indemnification claim from escrow account established in connection with our ZONARE's acquisition, of which \$1.4 million was recognized as other income in 2014.

Interest Income

Our interest income was \$39.0 million in 2014, an increase of 5.2% compared to \$37.0 million in 2013. The increase in interest income was caused by increase in our overall average interest rate earned from short-term investments.

Interest Expense

Our interest expense was \$6.4 million in 2014, an increase of 0.9% compared to \$6.3 million in 2013. The increase was mainly due to the relatively higher weighted average of loan amount outstanding during 2014 as compared to 2013, offset by a general decrease in the weighted average of interest rates for our bank borrowings during 2014 compared with that in 2013.

Provision for Income Tax

Provision for income taxes increased from \$14.3 million in 2013 to \$35.5 million in 2014. These provisions reflect (i) in 2013 cumulative tax benefits of \$26.8 million recognized in 2013 in relation to "Nationwide Key Software Enterprise" status for the calendar years 2011, 2012 and 2013 (favorable tax status in respect of calendar 2011 and 2012 was not secured until 2013) and (ii) tax benefits of \$5.9 million recognized in 2014 in relation to "Nationwide Key Software Enterprise" status for the calendar year 2014. The 2013 provision for income tax includes a \$12 million tax provision in relation to VAT refund income recognized from 2009 to 2013 in connection with the sale of embedded software in our products (these refund amounts became taxable in 2013 as a result of emerging tax practice in the China market).

The provisions for income tax in 2013 and 2014 also include a deferred income tax liability provision of \$3.0 million and \$20.6 million in 2013 and 2014, respectively in relation to the undistributed earnings of our PRC subsidiaries as of December 31, 2013 and 2014 which may be distributed to the respective immediate parent companies in the future.

Our overall effective tax rate was 5.8% and 15.1% in 2013 and 2014, respectively, primarily related to tax benefits from obtaining “Nationwide Key Software Enterprise” status from 2009 to 2014 for Shenzhen Mindray. Excluding the impact of this factor, our effective tax rate would have been 16.8% and 17.7% in 2013 and 2014, respectively.

Net Income

As a result of the foregoing, net income decreased from \$224.8 million in 2013 to \$193.3 million in 2014, and net margin decreased from 18.5% in 2013 to 14.6% in 2014.

Comparison of Years Ended December 31, 2012 and December 31, 2013

Net Revenues

The following table sets forth net revenues by geography and the percentage of our total net revenues and net revenues by business segment for the years ended December 31, 2012 and 2013:

	Year Ended December 31,		2013	Net Revenues % of Total	
	2012	Net Revenues % of Total			
	Net Revenues	Net Revenues % of Total	Net Revenues	Net Revenues % of Total	
(In thousands, except percentages)					
Geographic Data:					
China	\$472,991	44.6	% \$551,155	45.4	%
Other Asia	78,574	7.4	93,777	7.7	
Europe	100,985	9.5	121,262	10.0	
North America	144,283	13.7	162,453	13.4	
Latin America	116,036	10.9	125,038	10.3	
Others	147,185	13.9	160,302	13.2	

Edgar Filing: Mindray Medical International LTD - Form 20-F

Total net revenues	\$1,060,054	100.0	%	\$1,213,987	100.0	%
Segment Data:						
Patient monitoring and life support products	\$449,131	42.4	%	\$469,689	38.7	%
In-vitro diagnostic products	286,075	27.0		335,511	27.6	
Medical imaging systems	253,234	23.9		303,416	25.0	
Others	71,614	6.7		105,371	8.7	
Total net revenues	\$1,060,054	100.0	%	\$1,213,987	100.0	%

Our total net revenues increased by \$153.9 million, or 14.5%, from \$1,060.1 million in 2012 to \$1,214.0 million in 2013. The increase primarily reflected the continuing growth in our sales volume in both China and international markets.

Geographically, our net revenues generated from China markets increased from \$473.0 million in 2012 to \$551.2 million in 2013. Our net revenues from China markets, as a percentage of total net revenues, increased from 44.6% in 2012 to 45.4% in 2013. The increase in our China net revenues was primarily attributable to the positive healthcare spending environment in China, particularly spending directed at county-level hospitals, the strong performance of our IVD sales, net revenues contribution from acquired China businesses in 2012 and 2013 and appreciation of the Renminbi against the U.S. dollar in 2013. Net revenues growth rate from the China market decreased from 26.4% in 2012 to 16.5% in 2013 as a result of spending by hospitals in China being more cautious since the second half of 2013, as induced by China's increased scrutiny over spending by public hospitals. Hospitals have been more cautious in their purchasing decisions and, in some cases, have delayed their orders.

Our net revenues generated from international markets increased from \$587.1 million in 2012 to \$662.8 million in 2013. Our net revenues from international markets, as a percentage of total net revenues, were 55.4% and 54.6% in 2012 and 2013, respectively. The increase in our international revenues reflects the sales growth in emerging markets and net revenues contribution from acquired international businesses in 2013. International sales, as a percentage of total net revenues, continued to decline slightly in 2012 and 2013. In 2012, our net revenues growth in North America and Europe slowed due to weaker hospital demand and economic uncertainties. In 2013, net revenues growth in Latin American and the Commonwealth of Independent States, or CIS, regions, particularly in Venezuela and Russia, slowed due to tightened foreign exchange and import policies and political instabilities.

Each of our business segments experienced net revenues growth in 2013. Net revenues in our patient monitoring and life support products segment increased by \$20.6 million, or 4.6%, from \$449.1 million in 2012 to \$469.7 million in 2013. All sub-segments under patient monitoring and life support products segment recorded growth in net revenues in 2013 as a result of increased sales volume in 2013. We recorded a higher than average segment growth rate in our defibrillators and surgical equipment in 2013. The slower net revenues growth rate in our patient monitoring devices and anesthesia products, in 2013 was mainly due to weak performance in net revenues in China and in the United States as a result of the increased caution in hospital spending in China since the second half of 2013.

Net revenues in our in-vitro diagnostic products segment increased by \$49.4 million, or 17.3%, from \$286.1 million in 2012 to \$335.5 million in 2013. The increase in net revenues in our in-vitro diagnostic products segment primarily reflects the expansion of our installed equipment base, which provides a platform for recurring reagent sales. As a percentage of total in-vitro diagnostic products segment net revenues, reagent net revenues increased from 35.3% in 2012 to 38.8% in 2013.

Net revenues in our medical imaging systems segment increased by \$50.2 million, or 19.8%, from \$253.2 million in 2012 to \$303.4 million in 2013. The increase in net revenues in our medical imaging systems business segment primarily resulted from increased medical imaging systems sales volumes, particularly in China and European markets which recorded a higher than average segment growth rate, and net revenue contribution from ZONARE beginning in July 2013. Our DC-8 diagnostic ultrasound system was a key driver for net revenues growth of this segment in 2013.

Net revenues from our others segment increased by \$33.8 million, or 47.1% from \$71.6 million in 2012 to \$105.4 million in 2013. The increase in net revenues from others segment is primarily attributable to increase in net revenues derived from extended warranty service, accessory sales and repair services for post-warranty period resulting from increased medical device sales volumes, which increased demand for after-sales services, and net revenue contribution from new businesses acquired in 2012.

Cost of Revenues

Total cost of revenues as a percentage of total net revenues increased from 43.3% in 2012 to 43.4% in 2013. The stability in cost of revenues as a percentage of total net revenues in 2013 compared to 2012 was primarily attributable to improved utilization of manufacturing facilities driven by increased sales volumes, lowered materials costs, changed sales mix, and improved utilization of fixed costs for our after-sales services; offset by the dilutive effect from our ZONARE acquisition, which has product gross margins that tend to be lower than our other medical imaging systems products, appreciation of the Renminbi against the U.S. dollar and increased equipment costs from our in-vitro diagnostic business expansion.

Patient Monitoring and Life Support Devices

Patient monitoring and life support devices segment cost of revenues as a percentage of patient monitoring and life support devices segment net revenues decreased from 43.5% in 2012 to 42.5% in 2013. The decrease in 2013 was primarily attributable to improved manufacturing facilities utilization driven by increased sales volumes and lowered material costs as a result of attaining more favorable terms with suppliers.

In-vitro Diagnostic Products

In-vitro diagnostic products segment cost of revenues as a percentage of in-vitro diagnostic products segment net revenues increased slightly from 41.7% in 2012 to 42.1% in 2013, as a result of our increased equipment costs for our in-vitro diagnostic business expansion, offset by the increase in the proportion of net revenues from reagent sales, which typically have lower overall cost of revenues compared to equipment sales, increased from 35.3% of total in-vitro diagnostic net revenues in 2012 to 38.8% in 2013.

Medical Imaging Systems

Medical imaging systems segment cost of revenues as a percentage of medical imaging systems segment net revenues increased from 34.7% in 2012 to 37.1% in 2013. The increase in 2013 was mainly attributable to dilutive effect of our ZONARE acquisition partially offset by improved manufacturing facilities utilization driven by increased sales volumes and lowered materials costs from attaining more favorable terms with suppliers.

Others

Other cost of revenues as a percentage of other net revenues decreased from 79.1% in 2012 to 70.1% in 2013. The decrease in 2013 was primarily due to the addition of our product portfolio of orthopedic products, endoscope devices and healthcare IT solution products, whose gross margins are generally higher than those for our after-sales services and the improved utilization of fixed costs on after-sales services following an increase in services sales volume.

Gross Profit and Gross Margin

Total gross profit increased by \$85.9 million, or 14.3%, from \$600.7 million in 2012 to \$686.6 million in 2013. Our consolidated gross margin was 56.7% in 2012 and 56.6% in 2013 as a result of the foregoing.

Operating Expenses

Our operating expenses primarily consist of selling expenses, general and administrative expenses and research and development expenses. Operating expenses, as a percentage of total net revenues, increased from 38.6% in 2012 to 39.2% in 2013. Our operating expenses in 2013 were \$476.4 million, an increase of 16.4% compared to \$409.3 million in 2012.

Selling Expenses

Our selling expenses, as a percentage of total net revenues, increased from 17.8% in 2012 to 18.2% in 2013. The increase as a percentage of total net revenues was primarily attributable to our business expansions in the United States, which has selling expenses, as a percentage of net revenues, relatively higher than that for our other regions. Our selling expenses in 2013 were \$220.6 million, an increase of 16.8% compared to \$188.8 million in 2012. The increase is mainly driven by: (1) a general increase in employee compensation for sales and marketing staff; (2) increased travel, marketing and training expenses; (3) increased advertising and promotion expenses as a result of our increasing marketing activities; and (4) consolidating ZONARE's business since July 2013, including the expenses related to the direct sales force of ZONARE.

General and Administrative Expenses

Our general and administrative expenses, as a percentage of total net revenues, decreased from 10.9% in 2012 to 10.6% in 2013. Our general and administrative expenses in 2013 were \$128.3 million, an increase of 10.4% compared to \$116.2 million in 2012. The increase in general and administrative expenses was driven primarily by: (1) a \$14.8 million charge taken in 2013 in connection with our dispute with Beckman Coulter, Inc. compared to a \$9.7 million charge taken in 2012 related to our Masimo dispute; (2) an increase in foreign exchange loss from \$1.0 million in 2012 to \$8.9 million in 2013, primarily attributable to the Renminbi appreciating against the U.S. dollar throughout 2013; (3) increased professional and legal fees for our mergers and inclusion of ZONARE's general and administrative expenses since July 2013; and (5) a general increase in employee compensation for general and administrative staff, offset by a decrease in our allowance for doubtful accounts, to which a reversal of \$0.9 million was recorded in our allowance for doubtful accounts in 2013 as a result of accounts receivable collections improvements while a provision of \$9.6 million for doubtful accounts was recorded in 2012, of which \$4.0 million resulted from change in estimate for providing allowance for doubtful accounts against accounts receivable related to international sales in 2012.

Research and Development Expenses

Our research and development expenses, as a percentage of total net revenues, increased from 9.8% in 2012 to 10.5% in 2013. The increase in research and development expenses as a percentage of total net revenues was primarily attributable to consolidating ZONARE's business since July 2013 (whose research and development expense as a percentage of net revenues were relatively higher than our group average). Our research and development expenses in 2013 were \$127.5 million, an increase of 22.2% compared to \$104.3 million in 2012. The increase in research and development expenses was primarily due to increased employee compensation for research and development staff and research and development material costs.

Other Income, Net

Our other income, net, was \$3.9 million in 2013, an increase of 139.7% compared to \$1.6 million in 2012. Other income, net, in 2013 and 2012 included \$4.0 million and \$1.7 million, respectively, of cash subsidies and incentives received from the PRC government. These subsidies and incentives are granted by the PRC government on an irregular basis and amounts received tend to vary significantly.

Interest Income

Our interest income was \$37.0 million in 2013, an increase of 20.3% compared to \$30.8 million in 2012. The increase in interest income was driven by our increased cash and cash equivalents and short term investments in China, partially offset by a decrease in our overall interest rate earned from short-term investments.

Interest Expense

Our interest expense was \$6.3 million in 2013, an increase of 55.0% compared to \$4.1 million in 2012. The increase was mainly attributable to an increase in our bank borrowings used for paying dividends, financing acquisitions outside China and short-term financing for our share repurchase program, offset by a general decrease in average interest rates for our bank borrowings.

Provision for Income Tax

Provision for income taxes decreased from \$37.4 million in 2012 to \$14.3 million in 2013, primarily caused by: (1) tax benefits of \$26.8 million recognized in 2013 in relation to “Nationwide Key Software Enterprise” status for the calendar years 2012, 2013 and 2014, and (2) the favorable impact of Shenzhen Mindray Software which enjoyed tax holiday in 2013, offset by (1) an accrual of income tax provision of \$12 million recorded in 2013 in relation to VAT refund income recognized for the period from 2009 to 2013 which is arisen from the sale of embedded software in our devices and become taxable in later of 2013 as a result of emerging tax practice in the China market and (2) a provision of deferred tax liability for income taxes of \$3 million recorded in 2013 in relation to approximately \$52.7 million of the undistributed earnings of our PRC subsidiaries which may be distributed to its immediate parent companies in the future.

Our overall effective tax rate was 17.0% and 5.8% in 2012 and 2013, respectively. The decrease in our effective tax rate was primarily attributable to tax benefits resulted from our receiving “Nationwide Key Software Enterprise” status in 2013 for calendar years 2012, 2013 and 2014. Excluding the impact of this factor, our effective tax rate would have been 16.8%.

Net Income

As a result of the foregoing, net income increased from \$180.2 million in 2012 to \$224.8 million in 2013, and net margin increased from 17.0% in 2012 to 18.5% in 2013.

Critical Accounting Policies

We prepare our financial statements in conformity with U.S. GAAP, which requires us to make estimates and assumptions that affect our reporting of, among other things, assets and liabilities, contingent assets and liabilities and net revenues and expenses. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences and other factors that we believe to be relevant under the circumstances. Since our financial reporting process inherently relies on the use of estimates and assumptions, our actual results could differ from what we expect. This is especially true with some accounting policies that require higher degrees of judgment than others in their application. We consider the policies discussed below to be critical to an understanding of our audited consolidated financial statements because they involve the greatest reliance on our management’s judgment.

Allowance for Doubtful Accounts

We sell our products domestically in China primarily through distributors. We generally require both our distributors and direct domestic customers to make advance payments or payments upon product delivery. However, from time to time, we extend credit to domestic distributors in the ordinary course of business, with payment in full typically due within 30 or 60 days of product delivery based on factors such as a satisfactory business history with us. Internationally, we sell our products through distributors and our direct sales force. We generally require distributors in developing markets to pre-pay for products in cash or with letters of credit, and generally require advance payments as a deposit. From time to time, we may allow distributors with a satisfactory business history with us to purchase products on different payment terms.

For international distributors, primarily located in North America and Western Europe, we frequently provide different payment terms that we believe are consistent with prevailing market practices in such areas. Payment in full is typically due within a negotiated period after product delivery. We typically extend credit to most of our international direct customers, primarily located in the U.S. and Western Europe, with payment in full typically within a negotiated period after product delivery, which we believe is consistent with prevailing market practices in such areas. As of December 31, 2013 and 2014, our accounts receivable balances totaled \$221.6 million and \$225.9 million, respectively, net of an allowance for doubtful accounts of \$14.6 million and \$15.1 million. The allowance for doubtful account reflects estimated losses resulting from the inability of our customers to make required payments. The allowance is determined by (i) analyzing specific customer accounts that have known or potential collection issues, and (ii) applying historical loss rates to the remaining accounts receivable balances based on aging. For purposes of analyzing specific accounts receivable with known or potential collection issues, we consider factors such as the background of the customer and its current affairs, on-going or historical disputes, litigation and customer going concern considerations.

As of December 31, 2013 and 2014, the \$14.6 million and \$15.1 million allowance for doubtful account balances represented 6.2% and 6.3% of the then-outstanding gross accounts receivable balances, respectively.

As of December 31, 2013 and 2014, our accounts receivable balances aged over one year but less than two years totaled \$5.5 million and \$4.3 million, respectively, net of allowance for doubtful accounts of \$3.3 million and \$2.6 million, respectively. As of December 31, 2013 and 2014, gross accounts receivable balances aged two years or more totalled \$6.1 million and \$6.9 million, respectively, net of allowance for doubtful accounts of \$5.3 million and \$6.2 million, respectively. Of these long outstanding receivable balances aged over one year but less than two years and aged over two years as of December 31, 2014, 12.7% and 1.3% had been collected as of March 31, 2015, respectively.

We purchase export credit insurance to mitigate the risk of loss and accounts receivable impairment on sales to most of our international distributors purchasing our products under credit terms. Under these arrangements, our insurer reviews the relevant customer contract and sales invoice and establishes a specified insurable amount (generally ranging from 80-90% of the outstanding invoice amount) based on the insurer's assessment of collectability. We record provisions for estimated losses on receivable balances covered by export credit insurance based on specific identification. Such provision is made on 100% of the accounts receivable in question. After the provision is made, we consider if an insurance receivable should be recorded. We record an insurance receivable only when recoveries are probable, which is when we have submitted a claim with all necessary information, on the basis that there is a legally enforceable contract, for the insurable amounts. We have historically received related insurance claims payment within 12-18 months of filing the claim. The total amount of insurance claims that we received was immaterial to our accounts receivable balance during the years ended December 31, 2012, 2013 and 2014.

Additional allowances may be required (i) as we extend additional credit to domestic distributors and direct customers, and to qualified international direct customers and international distributors, (ii) if we change our credit policies, (iii) as our customer base expands and further diversifies, or (iv) if the financial conditions of our customers deteriorate.

Write Down of Inventories

We value inventories, which include material, labor and manufacturing overhead, at the lower of cost or net realizable value using the standard cost basis that approximates the weighted average cost method. Management evaluates inventory from time to time for obsolete or slow-moving inventory and we base our provisions on our estimates of forecasted net revenue levels, economic market conditions and quantity on hand. A significant change in the timing or level of demand for our products as compared to forecasted amounts may result in recording additional write downs for obsolete or slow-moving inventory. We record such adjustments to cost of revenues in the period the condition exists.

Warranty Provision

We record a warranty provision at the time product revenues are recorded based on our historical experience and review the provision during the year and if necessary, adjusting the provision to reflect new product offerings or changes in claims, which we track by product line.

Impairment of Goodwill and Indefinite-lived Intangible Assets

We review our goodwill and indefinite-lived intangible assets for potential impairment at least annually or in circumstances where indicators of impairment exist. The evaluation of goodwill for impairment involves two steps: (1) identification of potential impairment by comparing the fair value of the reporting unit with its carrying value, including goodwill and (2) comparing the implied fair value of the goodwill with its carrying value. For indefinite-lived intangible assets, the evaluation for its impairment also involves two steps: (1) identification of potential impairment by comparing its fair value with its carrying value and (2) comparing its implied fair value with its carrying value. The estimates of fair values involve significant judgment by management.

Impairment of Long-lived Assets

We review our long-lived assets and finite-lived intangible assets for potential impairment in circumstances where the carrying amount of the assets may not be recoverable. If the sum of the projected undiscounted cash flows is less than the carrying amount of the assets, the carrying value is reduced to the estimated fair value as measured by the discounted cash flows. Management judgment is required in the area of asset impairment, particularly in assessing whether: (1) an event has occurred that indicates potential impairment and (2) the carrying value of an asset can be supported by the future cash flows from the asset using estimated cash flow projections.

Provisions for Income Taxes

We record liabilities for probable income tax assessments based on our estimate of potential tax-related exposures. Estimating these assessments requires significant judgment as uncertainties often exist in respect to new laws, new interpretations of existing laws and rulings by taxing authorities. Differences between actual results and our assumptions are recorded in the period they become known. Our accruals represent accounting estimates that are subject to the inherent uncertainties associated with the tax audit process, and therefore include certain contingencies. We believe that any potential tax assessments from the various tax authorities that are not covered by our income tax provision will not have a material adverse impact on our consolidated financial position or cash flows. However, they may be material to our consolidated earnings of a future period. Our overall effective tax rate was 17.0%, 5.8% and 15.1% for 2012, 2013 and 2014, respectively.

Revenue Recognition

We generate revenues from medical device sales. The medical devices that we sell include a software element that is essential to their functionality of the tangible medical devices. Therefore, revenues from the sale of medical devices are recognized when all of the following conditions have been satisfied:

- there is persuasive evidence of an arrangement;
- delivery has occurred (e.g., an exchange has taken place);
- the sales price is fixed or determinable; and
- collectability is reasonably assured.

All sales are based on firm customer orders with fixed terms and conditions. We do not provide our customers with general right of return (except for certain direct customers, which were required by applicable law and regulations), price protection or cash rebates. The sales arrangements do not include any significant post customer support services in warranty period and do not provide customers with upgrades. Accordingly, revenues from the sale of products are typically recognized upon shipment, when the terms are free-on-board shipping point, or upon delivery; for certain China-based tender sales, where customers have inspection and acceptance rights, we recognize revenue upon acceptance. China-based tender sales accounted for 2.1%, 1.1% and 0.7% of our consolidated sales in 2012, 2013 and 2014, respectively. For products sold with installation service, revenue is allocated between the product and installation service if the product has standalone value to the customer, and based on the price at which the product and installation service are expected to be sold on a standalone basis. Revenue for service repairs of equipment is

recognized after service has been completed, and service revenue for extended warranty is recognized ratably over the term of the contract.

We offer sales incentives to certain customers in the form of free products if they meet a certain level of items purchased. The costs of these sales incentives are estimated and accrued as a cost of revenues with a corresponding increase in current liability at the time of revenue recognition based on our past experience and our customers' purchase history, which involves significant judgment by management.

Valuation of Share-Based Compensation

We account for share-based compensation to our employees based on the fair value of the share options and restricted shares at grant date. We elected to use the Black-Scholes Option Pricing Model to determine the fair value of share options on the date of grant. We are required to make assumptions on variables such as share price volatility, expected terms of options and discount rates. Our share-based compensation arrangement includes a performance condition that affects vesting. We estimate the probability of the employees meeting the performance condition that affect the vesting amount. Changes in these assumptions and our estimates of the probability could significantly affect the amount of employee share-based compensation expense we recognize in our consolidated financial statements.

Recent Accounting Pronouncements

In July 2013, the Financial Accounting Standards Board issued an Accounting Standard Update (ASU 2013-11) which requires unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This Update applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. We adopted the ASU 2013-11 in fiscal year 2014. The adoption does not have a significant impact on our consolidated financial statements.

In May 2014, the Financial Accounting Standards Board and International Accounting Standards Board have issued a converged standard on revenue recognition, ASC 606 (the “ASC 606”) and International Financial Reporting Standards 15, Revenue from Contracts with Customers, respectively. The objective of the converged revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. The ASC 606 contains principles that an entity will apply using a new five-step model to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Almost all entities will be affected to some extent by the significant increase in required disclosures. But the changes extend beyond disclosures, and the effect on entities will vary depending on industry and current accounting practices. For U.S. GAAP public reporting entities, the ASC 606 is effective for the first interim period within annual reporting periods beginning after 15 December 2016. Early adoption is not permitted. We are currently evaluating financial and operational effects, if any, that the adoption of the ASC 606 will have on our consolidated financial statements.

B. Liquidity and Capital Resources.

Overview

Our principal sources of liquidity are our cash and cash equivalents, short-term investments, and cash flow generated from our operations. We anticipate that we will continue to generate sufficient operating cash flows to satisfy our currently anticipated cash requirements through at least the next 12 months. We believe we have adequate liquidity reasonably available to meet the requirements of our currently anticipated operational circumstances, and do not have

the need to utilize non-operational cash sources to meet our current operational cash needs.

Overseas Funding Arrangement

We generally have substantial cash in accounts located in China. In light of, among other things, PRC governmental restrictions on currency exchange and remittances outside of China, favorable borrowing conditions outside of China and higher investment returns in China, we determined that it was more cost efficient to use offshore third-party borrowings to fund our offshore cash needs, including funds required for international acquisitions and dividend payments. Accordingly, we entered into various financing arrangement with the banks from time to time in past few years.

In the third quarter of 2013, our primary operating subsidiary, Shenzhen Mindray, declared an intra-group dividend to initiate a one-time fund transfer out of China given concerns that offshore borrowing rates would increase and we recorded a related \$20.8 million withholding tax obligation. In the fourth quarter of 2013, we reversed the \$20.8 million withholding tax charge when we elected to unwind the proposed intra-group dividend from the distribution of earnings from 2008 and thereafter. We did so based on changed near-term expectations for offshore borrowing rates and to provide us additional opportunities to explore other tax-efficient means to transfer funds within our corporate group (including possible cross-border Renminbi inter-group loans from Shenzhen Mindray directly to our Hong Kong subsidiaries). In the fourth quarter of 2013, Shenzhen Mindray entered into a three-year cross-border Renminbi intra-group loan facility with one of our Hong Kong subsidiaries with up to RMB2.0 billion (equivalent to \$326.9 million) available under this facility. As of December 31, 2014, RMB1.0 billion (equivalent to \$163.4 million) of the intra-group facility had been utilized. For details, please refer to below section “– Cash Flows—Dividend Distributions”.

Cash and Short-term Investments Balances

The following table sets forth a summary of our unrestricted cash and cash equivalents and unrestricted short-term investments, net of our outstanding borrowings as of the dates indicated.

	December 31,	
	2013	2014
	(In thousands)	
Cash and cash equivalents	\$385,224	\$276,598
Short-term investments	847,041	816,394
Total ⁽¹⁾	1,232,265	1,092,992
Less: Total borrowings ⁽²⁾	(475,703)	(257,210)
Total	\$756,562	\$835,782

(1) Excludes restricted cash and restricted investments of \$18.2 million and \$12.5 million as of December 31, 2013 and 2014 in respect of (i) acquisition consideration held in escrow and payable to the sellers under the terms of the related acquisition agreements and (ii) cash held as collateral for letters of credit issued for normal business operation.

(2) Represents primarily bank borrowings to facilitate funding of operations outside of China, for payment of annual dividends in U.S. dollars, to finance our 2013 overseas acquisition and repurchases of our equity securities. All of our bank loans were initially denominated in U.S. dollars. In 2013 and 2014, we converted a portion of our outstanding loans into Euro-denominated debt for foreign currency hedging purposes. As of December 31, 2013 and 2014, total borrowings included €25.0 million and €35.0 million in borrowings, respectively.

Cash and cash equivalents consist of cash on hand and short-term deposits that are unrestricted as to withdrawal and use, and which have original maturities less than three months. Our cash and cash equivalents are usually held in U.S.

dollars and Renminbi.

Our investment policy and strategy is focused on principal protection and meeting company liquidity needs. Short-term investments consist of liquid investments with maturities greater than 90 days and less than one year at the date of purchase. As of December 31, 2013 and 2014, short-term investments mainly consisted of investments in Renminbi denominated financial products in an aggregate principal amount of \$823.2 million and \$797.0 million. We primarily invest in the financial products offered through high-credit quality financial institutions in China including the Bank of China. These financial products consist of a pool of assets selected and managed by the banks and/or its custodian. As of December 31, 2013 and 2014, the accrued interest rate of the Company's Renminbi denominated financial products ranged from 4.5% to 5.7% per annum and from 3.7% to 5.6% per annum, respectively. Our financial products that we have invested in are primarily principal protected.

Cash Flows

The following table sets forth a summary of our cash flows for the periods indicated:

	Year Ended December 31,		
	2012	2013	2014
	(In thousands)		
Cash and cash equivalents	\$247,859	\$385,224	\$276,598
Net cash provided by operating activities	325,666	307,918	330,454
Net cash used in investing activities	(232,545)	(424,541)	(92,838)
Net cash provided by (used in) financing activities	28,223	251,367	(342,997)

Operating Activities

Net cash provided by operating activities in 2012, 2013 and 2014 were \$325.7 million, \$307.9 million and \$330.5 million, respectively.

The change in 2013 as compared to 2012 was mainly attributable to our improved cash collection of our accounts receivable, offset by the effect of payment of the Beckman Coulter, Inc. dispute charges of \$14.8 million in 2013 and consolidating ZONARE's net operating cash outflow (acquired in July 2013).

The increase in 2014 compared to 2013 was mainly attributable to the effect of the payment of \$14.8 million in 2013 relating to the Beckman Coulter, Inc. dispute and increase in software value-added tax refund received from the PRC tax authorities by \$16.0 million in 2014, offset by the full-year effect consolidation of ZONARE's net operating cash outflow (acquired in July 2013).

In managing our operations and evaluating our financial results, we consider and report various operating metrics such as accounts receivable turnover days, inventory turnover days and accounts payable turnover days. When publicly announcing quarterly financial results, we provide these operating metrics calculated on a quarterly basis. Commencing with our 2012 Annual Reports on Form 20-F, we reported those operating metrics for both the fourth quarter of the relevant prior years (i.e., in our 2013 Form 20-F, for the fourth quarter of 2011, 2012 and 2013) and the relevant full years. Our operating metrics vary from period to period and are impacted by seasonality and other events.

Accounts receivable turnover days, inventory turnover days and accounts payable turnover days are provided below for both the year and the fourth quarter ended December 31, 2012, 2013 and 2014, calculated as follows:

accounts receivable turnover days is the average of the beginning and ending net accounts receivable balance for the relevant period divided by net revenues for such period, multiplied by 91 days (quarterly calculation) or 365 days (annual calculation) as applicable; and

inventory turnover days is the average of the beginning and ending inventory balance for the relevant period divided by cost of revenues for such period multiplied by 91 days or 365 days, as applicable; and

accounts payable turnover days is the average of the beginning and ending accounts payable balance for the relevant period divided by cost of revenues for such period, multiplied by 91 days or 365 days, as applicable.

Our accounts receivable turnover days for the fiscal years 2012, 2013 and 2014 were 67, 62 and 62, respectively. Accounts receivable turnover days for the fourth quarter ended December 31, 2012, 2013 and 2014 were 53, 50 and 48, respectively. The general decrease throughout 2012 to and 2014 reflects the impact of our improved cash collections efforts beginning in 2012. Efforts to improve cash collections, and in turn accounts receivable turnover days, included strengthening our credit control by more closely monitoring customers to ensure timely payment and withholding additional orders until prior outstanding invoices are paid. We have also on a limited basis utilized third party equipment leasing agents, or Leasing Companies, primarily in relation to certain direct sales in the United States. These Leasing Companies perform credit assessments and provide payment and interest terms to customers, thereby assuming all risk of customer nonpayment, with no contractual recourse against us. We in turn are paid by the Leasing Companies upon product delivery.

Demonstrating the impact of seasonality on our receivables turnover days, for the first quarter of 2014, receivable turnover days were 69 days (reflecting high accounts receivable balances at the beginning of the first quarter and lower first quarter sales) compared to 62 days for the fiscal year 2014. Our accounts receivable balances are typically lowest at first quarter end in connection with lower first quarter sales due to the Chinese Lunar New Year holiday and typically highest at year-end, as the fourth quarter is traditionally our strongest sales quarter.

The carrying value of our inventories has generally increased as a result of growth in our business and operations. Our inventory turnover days for fiscal 2012, 2013 and 2014 were 81, 86 and 90, respectively. The increase in inventory turnover days resulted from slow movement in our inventory as a result of our actual net revenues growth being slower than our expectations.

Inventory turnover days for the fourth quarter ended December 31, 2012, 2013 and 2014 were 83, 79 and 82, respectively. We recorded a decrease in our quarterly inventory turnover days in 2013 compared with respective quarter in 2012 driven by improvements in inventory management in Shenzhen Mindray and Mindray DS USA implemented in the third quarter of 2013. However, in 2014, we recorded a general increase in our quarterly inventory turnover days compared with respective quarter in 2013 because our actual 2014 net revenues growth was slower than our expectations.

Our accounts payable turnover days for fiscal 2012, 2013 and 2014 were 47, 58 and 65, respectively. Accounts payable turnover days for the fourth quarters ended December 31, 2012, 2013 and 2014 were 47, 54 and 54, respectively. The increase was due to attaining more favorable terms with our suppliers.

Investing Activities

Net cash used in investing activities in 2012, 2013 and 2014 were \$232.5 million, \$424.5 million and \$92.8 million, respectively.

In 2012, the investing activities represent mainly capital expenditures related to the construction for new manufacturing plants, research and development facilities and replacement of normal capital expenditures totaling \$65.6 million, payments for the purchase of medical device companies totaling \$34.6 million, restricted cash and restricted investment held in escrow totaling \$21.5 million in connection with those acquisitions and a \$112.6 million net increase in short-term investments.

In 2013, the investing activities represent mainly a net increase in short-term investments of approximately \$210.1 million, capital expenditures related to the construction for new manufacturing plants, research and development facilities and replacement of normal capital expenditures totaling \$109.1 million, payments for the purchase of medical device companies totaling \$109.4 million (of which \$83.2 million related to ZONARE), and a net of cash inflow of restricted cash and restricted investment amounted to \$3.3 million net of the release of restricted cash and restricted investment as recorded in 2012 and the increase of restricted cash in 2013 related to our acquisitions in 2013.

In 2014, the investing activities represent mainly a net increase in short-term investments of approximately \$20.7 million, capital expenditures related to the construction of new manufacturing plants, research and development facilities and replacement of normal capital expenditures of \$107.1 million, payments for the purchase of medical device companies of \$11.8 million, and a net of cash inflow of restricted cash of \$4.4 million primarily as a result of the release of restricted cash related to our acquisitions as recorded in 2013.

Financing Activities

In 2012 and 2013, net cash provided by financing activities totaled \$28.2 million and \$251.4 million, respectively. In 2014, net cash used in financing activities totaled \$343.0 million.

In 2012, financing activities represent mainly the net result of proceeds from bank loans of \$52 million and proceeds from option exercises of \$24.6 million, offset by dividend payments of \$46.4 million and repayment of bank loans of \$2.5 million.

In 2013, financing activities represent mainly the net result of proceeds from bank loans, net of costs, of \$371.7 million and proceeds from option exercises of \$16.1 million, offset by dividend payments of \$59.1 million, repayment of bank loans of \$35.0 million and \$42.4 million to repurchase our equity securities.

In 2014, financing activities represent mainly the net result of repayment of bank loans of \$214.4 million, dividend payments of \$58.7 million, cash used in repurchasing our equity securities of \$68.1 million and purchasing non-controlling interest shares of acquired companies of \$5.8 million, offset by proceeds from option exercises of \$3.3 million.

As of December 31, 2013 and 2014, we had outstanding bank borrowings of \$475.7 million and \$257.2 million, respectively of which \$260.0 million and \$59.6 million were current. A significant portion of our bank borrowings were used to pay annual dividends in U.S. dollars, finance our overseas acquisition of ZONARE, fund ZONARE working capital and repurchase our equity securities. To pay our fiscal year 2012 dividend, we entered into a three-year \$60.0 million loan in March 2013, a portion of which was subsequently converted into an Euro-denominated term loan in various periods in 2013 and 2014 with the same maturity date. In June 2013, we took out three-year term loans in an aggregate amount of \$120.0 million to finance our acquisition of ZONARE. In October 2013, we entered into a six-month term loan agreement with the Hongkong and Shanghai Banking Corporation Limited in an aggregate principal amount of \$160.0 million to finance our share repurchase program launched in November 2013 (fully repaid in the second quarter of 2014). For details of our share repurchase program, please refer to below "Share Repurchase Program." For more details about our bank loans, please see note 10 to our consolidated financial statements appearing elsewhere in this annual report. The interest rate charged on bank borrowings is determined based on a fixed margin plus LIBOR or EURIBOR. As of December 31, 2013 and 2014, the weighted average interest rate for borrowings outstanding was 1.86% and 1.64%, respectively. These financings did not require pledging any of our assets. However, in connection with our bank loans outstanding under Bank of China (Hong Kong) Limited and Nanyang Commercial Bank, Ltd, we are required to maintain Renminbi denominated deposits/ Renminbi denominated financial products equal to 105% of the borrowed amounts with a PRC affiliate of these two banks.

We maintain banking facilities with various banks in China, Hong Kong and the United States. We have aggregate available banking facilities of \$607.5 million and \$581.5 million with various banks for short-term and long-term borrowings, bills, letters of guarantee/credits and standby letter of credits facilities, of which \$57.0 million and \$244.3 million were unutilized as of December 31, 2013 and 2014, respectively. Some of these facilities were secured by our corporate guarantees. In addition, we are required to comply with certain financial covenants imposed by these financial institutions. As of December 31, 2013 and 2014, we are in compliance with the financial covenants imposed by the banks.

Share Repurchase Program

Our Board of Directors approved a share repurchase program under which we were authorized to repurchase up to \$300 million of our issued and outstanding ADSs on the NYSE Euronext at prevailing market prices from time to time between November 2013 and March 31, 2015 in trades pursuant to a Rule 10b5-1 repurchase plan, or otherwise, in accordance with applicable U.S. federal securities laws, including the anti-manipulation provisions of Rule 10b-18, promulgated under the U.S. Securities Exchange Act of 1934, as amended. Repurchases were to be made at management's discretion, subject to restrictions on price, volume, and timing. In 2013 and 2014, we repurchased approximately 1.1 million ADSs and 2.0 million ADSs, respectively, for an aggregate purchase price of \$42.4 million and \$68.1 million, respectively. The share repurchase program lapsed on March 31, 2015 with no additional purchases thereunder in 2015.

Dividend Distributions

In addition to offshore borrowings, we may rely on dividends and other distributions on equity paid by our operating subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends to our shareholders. Pursuant to relevant PRC laws and regulations applicable to our subsidiaries in China, each of our PRC subsidiaries is required to provide 10% of its after-tax profits to statutory surplus reserve fund. When the aggregate balance in the statutory surplus reserve fund is 50% or more of the subsidiaries' registered capital, our subsidiaries need not make any further allocations to the fund. Currently, Shenzhen Mindray, Shenzhen Mindray Software and Wuhan Dragonbio Surgical Implant Co., Ltd. have contributed over 50% of its registered capital to its statutory surplus reserve fund and are no longer allocating net income to the fund. Furthermore, if any of our PRC subsidiaries incur debt on its own behalf, the instruments governing the debt may restrict its ability to pay dividends or make other payments to us. As a result of PRC laws and regulations, our PRC operating subsidiaries are restricted in their ability to transfer a portion of their net assets to us whether in the form of dividends, loans or advances. As of December 31, 2013 and 2014, the amount of these restricted portions was approximately \$35.4 million and \$40.0 million, respectively. See Item 5, "Taxes and Incentives" for discussion on our intention to permanently reinvest the undistributed earnings of our PRC subsidiaries as of December 31, 2014.

We may require additional cash resources if we wish to pursue opportunities for investment, acquisition, strategic cooperation, cross-border funding or other similar opportunities. We are also exploring other alternatives to fund our business activities and development overseas. In the fourth quarter of 2013, Shenzhen Mindray entered into a three-year cross-border Renminbi intra-group loan facility providing for loans aggregating up to RMB2.0 billion (equivalent to \$326.9 million) with one of our Hong Kong subsidiaries. The interest rate is 5% and the facility can be extended at Shenzhen Mindray's discretion. As of December 31, 2013 and 2014, we utilized RMB1.0 million (equivalent to \$0.2 million) and RMB1.0 billion (equivalent to \$163.4 million) of the loan facility, respectively. For risks associated with this arrangement and dividend distributions, see "Risk Factors—Risks Related to Doing Business in China—We may rely on dividends and other distributions on equity paid by our operating subsidiaries to fund cash and financing requirements, and limitations on the ability of our operating subsidiaries to pay dividends to us may have a material adverse effect on our ability to conduct our business," and "—Restrictions on currency exchange may limit our ability to utilize our capital effectively." If we determine that our cash requirements exceed our aggregate amounts of cash and cash equivalents on hand and short-term investments, we may seek to issue debt or equity securities or obtain a credit facility. Any issuance of equity securities would cause shareholder dilution. Any incurrence of indebtedness would increase our debt service obligations and could subject us to restrictive operating and finance covenants. It is possible that, when we need additional cash resources, financing will only be available to us in amounts or on terms that would not be acceptable to us or financing will not be available at all.

Capital Expenditures

Our capital expenditures totaled \$65.6 million, \$109.1 million and \$107.1 million in 2012, 2013 and 2014, respectively. Our capital expenditures primarily related to construction of our manufacturing and assembly plants, research and development facilities, purchase of land use rights, machineries, electronic equipment, furniture and

fixture and intangible assets such as patents and trademarks. Our capital expenditures are primarily funded by net cash provided by operating activities. As of December 31, 2014, our capital commitment for property, plant and equipment totaled \$75.7 million, which will also be funded by net cash provided by operating activities.

We expect our capital expenditures in 2015 to be approximately \$150.0 million, which will be utilized primarily for construction for manufacturing facilities in Shenzhen and dedicated research and development facilities in Beijing and Xi'an, China, as well as our recurring capital expenditures.

C. Research and Development.

Our success to date has in part resulted from our strong research and development capabilities, which allow us to regularly introduce new and more advanced products at competitive prices within a relatively short period of time. Between 2012 and 2014, our spending on research and development activities remained relatively steady at approximately 10% of net revenues. We believe our current spending level, as a percentage of net revenues, is comparable to many of our international competitors and higher than most of our domestic competitors. As of December 31, 2014, our research and development team consisted of more than 2,000 engineers and other research and development personnel, representing approximately one-fourth of our employees worldwide.

In 2015, we expect to add to our research and development team to focus, in particular, on the development of high-end medical devices. As the average cost of a research and development engineer in China is significantly lower than in the United States or Western Europe, we have been able to build a research and development team that we believe is much larger, as a percentage of total employees, than most of our international competitors, and the largest of any domestic manufacturer of medical devices in China. Due to our strong brand reputation we have been able to recruit a strong research and development team.

We employ project selection procedures that focus on projects that we believe are commercially and technologically feasible, can generate significant revenue and future profits, have distinctive channel and market advantages and can be introduced into the market. Prior to developing improvements to an existing product or a new product, we consult our sales, marketing and service representatives and review end-user feedback to better identify the changing needs and demands of medical service providers. We also engage outside consultants to assist us in identifying trends in the medical device market. We believe this increases the likelihood of developing commercially viable products. Once we identify a product opportunity, our sales, marketing and service, research and development, and manufacturing teams work closely together to determine potential market demand for a product and how it fits with our current design and manufacturing capabilities. We organize regular meetings in which our sales, marketing and service, research and development, and manufacturing teams review progress and, if necessary, adjust the emphases of our research and development projects.

If we deem a new product to be commercially feasible, our research and development team will work closely with our manufacturing team to move production forward. This integrated approach allows us to identify potential difficulties in commercializing our product or product improvement. Furthermore, it also enables us to make adjustments as necessary and develop cost-efficient manufacturing processes prior to mass production. We believe these abilities can significantly shorten the time it takes to launch a commercialized product.

In addition to new product development and improvements to existing products, our research and development team focuses on manufacturing and assembly process improvements to control and reduce costs.

We currently have research and development centers located in Shenzhen, Beijing, Nanjing, Xi'an, Chengdu and Shanghai in China. We also maintain research and development centers in Mahwah, New Jersey; Mountain View, California; Seattle, Washington; Miami, Florida; and Stockholm, Sweden. The location of our research and development centers in China allows us to compete for skilled research and development technicians and managers across the country. The research and development centers in Mahwah and Stockholm were acquired through the acquisition of Datascope's patient monitoring business, and the research and development center in Mountain View was acquired through the acquisition of ZONARE.

D. Trend Information.

Other than as disclosed elsewhere in this annual report, we are not aware of any significant trends, uncertainties, demands, commitments or events for the period from January 1, 2012 to December 31, 2014 that are reasonably likely to have a material adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the reported financial information not necessarily to be indicative of future operating results or financial conditions.

E. Off-Balance Sheet Arrangements.

Other than as disclosed elsewhere in this annual report, we are not party to any off-balance sheet arrangements, including guarantee contracts, retained or contingent interest, certain derivative instruments and variable interest entities, that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, changes in consolidated financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

F. Tabular Disclosure of Contractual Obligations.

The following table sets forth our contractual obligations and commitments with definitive payment terms on a consolidated basis which will require significant cash outlays in the future as of December 31, 2014:

	Payments due by period				Total
	Less than 1 Year	1-3 Years	3-5 Years	More than 5 Years	
Debt repayment obligations(a)	\$59,625	\$197,585	\$ —	\$ —	\$257,210
Operating leases obligations(b)	12,673	16,021	1,938	66	30,698
Consideration obligations(c)	17,173	—	—	—	17,173
Notes payable obligations(d)	9,234	—	—	—	9,234
Purchase obligations(e)	75,714	—	—	—	75,714
Total	\$174,419	\$213,606	\$ 1,938	\$ 66	\$390,029

Debt repayment obligations: We are obligated to repay our bank borrowings throughout different periods. The amounts do not include interest payments because the interest rate for our bank borrowings is subject to either (a) LIBOR or EURIBOR fluctuations. For more details, please see the notes to our consolidated financial statements appearing elsewhere in this annual report

Operating leases obligations: We have entered into various non-cancelable operating lease agreements for our (b) offices premises and our assembly and manufacturing facility. Such operating leases do not contain significant restrictive provisions.

Consideration obligations: We are obligated to make consideration payments under purchase and sale agreements (c) associated with our acquisition of certain medical device companies in 2013 and 2014. For more details, please refer to the notes to our consolidated financial statements appearing elsewhere in this annual report.

Notes payable: We are obligated to repay bills issued by various banks in favor of our vendors and suppliers as (d) payments for our purchased goods and services

Purchase obligations: We are obligated to make payments under non-cancellable contractual arrangements with our (e) vendors, principally for our property, plant and equipment.

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

A. Directors and Senior Management.

The following table sets forth certain information relating to our directors and executive officers as of March 31, 2015:

Name	Age	Position
Xu Hang	52	Chairman
Li Xiting	63	Executive Chairman, President and Co-Chief Executive Officer
Cheng Minghe(1)	53	Co-Chief Executive Officer and Chief Strategic Officer
Wang Jianxin(2)	53	Chief Operating Officer
Alex Lung	43	Chief Financial Officer
Fannie Lin Fan	42	Group General Counsel; Secretary of Board of Directors
Ronald Ede	56	Director
Joyce I-Yin Hsu	40	Director
Kern Lim	44	Director
Wu Qiyao	78	Director

Audit Committee:	Compensation Committee:	Corporate Governance and Nominations Committee:	Transactions Committee
Ronald Ede Kern Lim*	Joyce I-Yin Hsu Kern Lim*	Xu Hang* Joyce I-Yin Hsu Kern Lim	Xu Hang Li Xiting Ronald Ede Cheng Minghe Joyce I-Yin Hsu*

(1) Mr. Cheng Minghe assumed the position of co-chief executive officer in June 2013. Prior to this, he served as our chief strategic officer and maintains this role.

(2) Mr. Wang Jianxin assumed the position of chief operating officer in May 2014. He previously served as our chief administrative officer and has been with our company since 2006.

* Chairman

Xu Hang is one of our founders and has served as the chairman of our board of directors since 1991. Mr. Xu was our co-chief executive officer from 1991 to 2012. Mr. Xu received a bachelor's degree from Tsinghua University Department of Computer Science and Technology, a master's degree in biomedical engineering from Tsinghua University Department of Electrical Engineering and an EMBA degree from China-Europe International Business School.

Li Xiting is one of our founders, and has served as our executive chairman of our board of directors since March 2015, and co-chief executive officer, director and president since 1991. Mr. Li was our chief executive officer in 2012. Mr. Li is the core managerial personnel of our business and is responsible for our business operations and management. Mr. Li received a bachelor's degree from University of Science and Technology of China.

Cheng Minghe has served as our co-chief executive officer since June 2013 and as our chief strategic officer since September 2010. From 2007 to September 2010, Mr. Cheng served as executive vice president of strategic development. Previously, Mr. Cheng served as the executive vice president of sales and marketing since 2004 and vice president of sales and marketing from 2000 to 2003. Prior to that, from 1998 to 2000, he served as a vice president for Rayto Life and Analytical Sciences Limited. From 1991 to 1998, Mr. Cheng served as vice president of our sales department. Mr. Cheng received his bachelor's degree and master's degree in biomedical engineering from Shanghai Jiaotong University.

Wang Jianxin joined us as a vice president in 2006, served as our chief administrative officer between June 2013 and May 2014, and began serving as our chief operating officer in May 2014. He is also the vice president of China Chamber of Commerce for Import and Export of Medicines and Health Products and the vice president of the China Association for Medical Devices Industry. Mr. Wang started his career in 1983 and has held various executive roles in the private and public sectors. Between 2001 and 2006, Mr. Wang served as the vice president of Shenzhen Huaqiang

Group, the chairman of Shenzhen Sanyo Huaqiang Electronics, the chairman of Tsinghua University's Shenzhen Graduate School Lihe Digital Electronics Company, and the general manager of Shanghai Feile Acoustics Co., Ltd., where he was primarily responsible for each company's investment strategies, sales and marketing, and overall management. He received his master's degree in Management Science and Engineering from Harbin University of Science and Technology, and his bachelor's degree in Automation from the University of Shanghai for Science and Technology.

Alex Lung has served as our chief financial officer since August 2011 and as our deputy chief financial officer from March 2011 to August 2011. From June 2009 to March 2011, he served as our group finance director. Previously, he served as a corporate controller of ASAT Holdings Limited and as a finance manager of Clipsal Asia Holdings Limited, a subsidiary of Schneider Electric. Mr. Lung has 10 years of professional experience at KPMG engaged in auditing, corporate finance and management consulting. Mr. Lung received his bachelor's degree in Mechanical Engineering from Imperial College, London, United Kingdom. He is also an associate member of City & Guilds and a fellow member of the UK Association of Chartered Certified Accountants.

Fannie Lin Fan has served as our group general counsel and secretary of board of directors since June 2011. From 2007 to 2011, she worked for Jones Day and Sidley Austin in Hong Kong. From 2005 to 2007, she practiced at Bernstein, Shur, Sawyer & Nelson in the United States. She also completed a judicial internship for the Honorable Judge Donald C. Pogue at the United States Court of International Trade in 2003 and a summer law clerkship at Vermont Department of Banking, Insurance, Securities and Healthcare Administration in 2004. Ms. Fan obtained her Juris Doctor degree from the University of Connecticut School of Law, her Master of Business Administration degree from Arizona State University and her Bachelor of Arts degree from Shanghai Maritime University.

Ronald Ede has served as our director since September 2006. He has served as the chief financial officer of Biosensors International Group, a listed company on the Singapore Exchange, since May 2011. From June 2008 to April 2011, he held various senior management positions at Mindray, including chief financial officer from May 2009 to April 2011 and group vice president of international operations from June 2008 to April 2011. From September 2006 to June 2008, he served as our independent director and chairman of the audit committee. Prior to joining Mindray, from 2004 until June 2008, he served as the chief financial officer of Asia Pacific for JDSU Corp. From 2003 to 2004 he served as director of Grandfield Consultancy Ltd. From 2002 to 2003 he served as a marketing director and consultant to Ernst & Young. From 1998 to 2002 he served as the managing director in Asia for SonoSite Inc. From 1992 to 1998 he was the director of international finance for ATL Ultrasound Inc. Mr. Ede received his bachelor of business administration degree from University of Hawaii and a master of business administration degree from the University of Washington.

Joyce I-Yin Hsu has served as our director since 2006. Ms. Hsu also served as our chief financial officer from February 2006 to April 2009. From 2000 to February 2006, Ms. Hsu was an executive director at Goldman Sachs (Asia) L.L.C. with its Principal Investment Area. From 1998 to 2000, Ms. Hsu worked as an investment banker at Goldman Sachs where she divided her responsibilities between the equity capital markets group and corporate finance. Ms. Hsu has also served on the boards of Focus Media Holding Limited, China Yurun Food Group Limited and China Haisheng Juice Holdings Company Limited. Ms. Hsu received her bachelor of science degree in business administration from the University of California at Berkeley.

Kern Lim has served as our director since September 2008. Mr. Lim currently serves as the president and chief executive officer of Asia Strategic Consulting. From 2008 to 2009, Mr. Lim was vice president of finance of the Venetian Macao-Resort-Hotel, and from 2006 to 2008, he was the global chief financial officer of Asimco Technologies Limited, a Cayman Islands company with operations in China. From 2003 to 2006, Mr. Lim was the

chief financial officer of Eastman Kodak for the Asia Pacific region. Mr. Lim also served as a director and member of the audit committee of RDA Microelectronics Ltd, a NASDAQ listed company, as a director and member of the audit committee of China Auto Electronics Group Ltd, a Singapore public company, and as a director and member of the audit committee of Dapai International, a Singapore public company. Mr. Lim is a Singapore certified public accountant and also holds a Certification in Risk Management Assurance (CRMA) with the II A (USA). In 2010, Mr. Lim was accepted as Fellow Member of the Hong Kong Institute of Directors and also as Full Member of the Singapore Institute of Directors. He has also been a member of the National Association of Corporate Directors (USA) since 2012. Mr. Lim is GreenBelt Certified and BlackBelt Trained in 6 Sigma Discipline and graduated from the GE Experienced Finance Leadership Program in the General Electric Company. Mr. Lim received his bachelor's degree in financial and management accounting from the Nanyang Technological University in Singapore.

Wu Qiyao has served as our director since 2006. Mr. Wu has been a professor in Beijing Institute of Technology since 1985. Mr. Wu has served as an evaluation committee member of medical device registration of the CFDA since 1993. From 1996 to 2002, he served as a deputy director of State Medical Equipment Evaluation Expert Committee. Since 1998, Mr. Wu has served as a director general of the Chinese Institute of Electronics and a director general of the China Instrument and Control Society. From 2000 to 2007, Mr. Wu served as one of the experts on the National Population and Family Planning Committee. In May 2013, Mr. Wu was appointed as a director of Zhuhai Hokai Medical Instruments Co., Ltd., a Shenzhen Stock Exchange listed company. Mr. Wu received his bachelor's degree in wireless electricity from Beijing Institute of Technology.

The business address of our directors and executive officers is Mindray Building, Keji 12th Road South, Hi-tech Industrial Park, Nanshan, Shenzhen, 518057, People's Republic of China.

Our Insider Trading Policy allows directors, officers and other employees covered under the policy to establish, under limited circumstances contemplated by Rule 10b5-1 under the Securities Exchange Act of 1934, written programs that permit automatic trading of our stock or trading of our stock by an independent person who is not aware of material nonpublic information at the time of the trade. From time to time, certain of our directors, executive officers, and employees have adopted Rule 10b5-1 trading plans.

B. Compensation.

Remuneration and Borrowing

The directors may determine remuneration to be paid to the directors. The compensation committee assists the directors in reviewing and approving the compensation structure for the directors. The directors may exercise all the powers of our company to borrow money and to mortgage or charge its undertaking, property and uncalled capital, and to issue debentures or other securities whether outright or as security for any debt obligations of our company or of any third party.

Compensation of Directors and Executive Officers

In 2014, we paid aggregate cash compensation of approximately \$8.6 million to our directors and executive officers as a group. We do not pay or set aside any amounts for pension, retirement or similar benefits for our officers and directors.

2006 Employee Share Incentive Plan

Our 2006 Employee Share Incentive Plan was adopted by our board of directors at a meeting in February 2006 and was subsequently amended by our Amended and Restated 2006 Share Incentive Plan by shareholders resolution on September 1, 2006. The Amended and Restated 2006 Employee Share Incentive Plan was amended on November 6, 2009, to increase the amount of awards authorized to be issued to 21,000,000 Class A ordinary shares. The plan was subsequently amended on June 10, 2010 to allow awards of restricted shares or restricted share units. The Amended and Restated 2006 Employee Share Incentive Plan is intended to promote our success and to increase shareholder value by providing an additional means to attract, motivate, retain and reward selected directors, officers, employees.

Options and restricted shares granted under the plan generally do not vest unless the grantee remains under our employment or in service with us on the given vesting date. However, in circumstances where there is a death or disability of the grantee, or, for certain option or restricted shareholders, a change in the control of our company, the vesting of options or restricted shares will be accelerated to permit immediate exercise of all options or restricted shares granted to a grantee.

Our compensation committee, which administers our plan, has wide discretion to make awards of options or restricted shares. Subject to the provisions of our plan, our compensation committee determines who will receive grants, the type and timing of grants, vesting schedules and other terms and conditions of grants, including the exercise price of options. Any of our employees is eligible to receive grants. The number of options or restricted shares awarded to a person, if any, is based on the person's past performance, potential ability to contribute to our success, the person's position with us and other factors chosen by our board of directors. In some cases, the number of options or restricted shares that vest for an employee in any given year is subject to the length of service and/or performance evaluation.

Generally, to the extent an outstanding option or restricted share granted under our plan has not vested on the date the grantee's employment by or service with us terminates, the unvested portion of the option or restricted share will terminate and become unexercisable.

Our board of directors may amend, alter, suspend, or terminate our plan at any time, provided, however, that in order to increase the current limit of 21,000,000 Class A ordinary shares available for grants under our plan, our board of directors must first seek the approval of our shareholders and, if such amendment, alteration, suspension or termination would adversely affect the rights of a recipient of any grant made prior to that date, the approval of such grantee. Without further action by our board of directors, the Amended and Restated 2006 Employee Share Incentive Plan will terminate in 2016.

As approved on our annual general meeting of shareholders held on December 15, 2009, the number of shares that may be delivered pursuant to awards granted under the Amended and Restated 2006 Employee Share Incentive Plan is 21,000,000 Class A ordinary shares. As of March 31, 2015, options to purchase 1,543,048 Class A ordinary shares were outstanding. The table below sets forth the option and RSU grants made to our directors and executive officers pursuant to the Amended and Restated 2006 Employee Share Incentive Plan as of March 31, 2015.

* The aggregate number of ordinary shares underlying the options and RSUs of the corresponding directors and executive officers granted is less than 1% of our total outstanding ordinary shares as of March 31, 2015.

† Options reissued on March 16, 2009 in connection with our option exchange program. See note 15 to our consolidated financial statements included elsewhere in this annual report.

Name	Number of Ordinary Shares to be Issued Upon Exercise of Options	Exercise Price per Ordinary Share	Date of Grant	Date of Expiration
		(In \$)		
Xu Hang	600,000	11.00	September 8, 2006	September 8, 2016
Li Xiting	600,000	11.00	September 8, 2006	September 8, 2016

Edgar Filing: Mindray Medical International LTD - Form 20-F

Cheng Minghe	200,000	5.00	February 22, 2006	February 22, 2016
	*	0.00	(RSU) May 9, 2012	
	*	0.00	(RSU) January 26, 2014	
Wang Jianxin	*	20.50	January 23, 2007†	January 21, 2015
	*	0.00	(RSU) August 17, 2010	
	*	0.00	(RSU) February 15, 2011	
	*	0.00	(RSU) May 9, 2012	
	*	0.00	(RSU) February 25, 2013	
	*	0.00	(RSU) January 26, 2014	
Alex Lung	*	29.30	August 6, 2009	August 6, 2017
	*	0.00	(RSU) August 17, 2010	
	*	0.00	(RSU) February 15, 2011	
	*	0.00	(RSU) September 9, 2011	
	*	0.00	(RSU) May 9, 2012	
	*	0.00	(RSU) February 25, 2013	
	*	0.00	(RSU) January 24, 2014	
Fannie Lin Fan	*	0.00	(RSU) September 9, 2011	
Ronald Ede	*	11.00	September 8, 2006	September 8, 2016
	*	20.50	May 15, 2008†	May 15, 2016
	*	0.00	(RSU) February 25, 2013	
Joyce I-Yin Hsu	*	5.00	February 22, 2006	February 22, 2016
	*	29.30	August 6, 2009	August 6, 2017
	*	0.00	(RSU) February 25, 2013	
Wu Qiyao	*	11.00	September 8, 2006	September 8, 2016
	*	0.00	(RSU) February 25, 2013	
Kern Lim	*	0.00	(RS) March 6, 2009	
	*	0.00	(RSU) February 25, 2013	

Employment Agreements

We have entered into employment agreements with some of our executive officers. We may terminate their employment for cause at any time, without notice or remuneration, for certain acts by an executive officer, including but not limited to acts of personal dishonesty in connection with an executive officer's employment by us which are intended to result in the executive officer's substantial personal enrichment or reasonably likely to materially harm us, any conviction of a crime which our board of directors reasonably believes has had or will have a material detrimental effect on our reputation or business, willful misconduct that is materially injurious to us, or continued violations of an executive officer's obligations to us after we have delivered a written demand for performance. An executive officer may terminate employment upon the occurrence of certain events, including but not limited to a material reduction of or removal from his or her duties, position or responsibilities without the executive officer's express written consent and a material reduction of the executive officer's compensation or benefits and if we fail to cure these issues within reasonable time. Upon the occurrence of any of these events, or in the case of termination without cause, the departing executive officer will be entitled to receive a severance payment equal to six months to one year of his or her annualized base salary. An executive officer may also terminate his or her employment for other reasons or no reason at all after providing prior written notice of at least 30 days or 60 days. We may terminate the employment of any of our executive officers without cause by giving him or her prior written notice of at least 30 days or 60 days.

Each executive officer that has executed an employment agreement with us has agreed to hold, both during and after his employment agreement expires or is terminated, in strict confidence and not to use, except for our benefit (including our affiliated entities and our subsidiaries), any proprietary or confidential information, including technical data and trade secrets of our company or the confidential information of any third party, including our affiliated entities and our subsidiaries, that we receive. Typically, an executive officer that has executed an employment agreement with us has also agreed to disclose to us and hold in trust for us all of the inventions, ideas, designs and trade secrets conceived of by him or her during the period that he or she is employed by us, and to assign all of his or her interests in them to us.

C. Board Practices.

Duties of Directors

Under Cayman Islands law, our directors have a duty of loyalty to act honestly in good faith with a view to our best interest. Our directors also have a duty to exercise the care, diligence and skills that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duty of care to us, our directors must ensure compliance with our amended and restated memorandum and articles of association. A shareholder has the right to seek remedies on behalf of the company if one of the above duties owed to us by our directors is breached.

The functions and powers of our board of directors include, among others:

- convening shareholders' annual general meetings and reporting its work to shareholders at such meetings;
- issuing authorized but unissued shares and redeeming or purchasing outstanding shares of our company;
- declaring dividends and distributions;
- appointing officers and determining the term of office and compensation of officers;
- exercising the borrowing powers of our company and mortgaging the property of our company; and
- approving the transfer of shares of our company, including the registering of such shares in our share register.

Terms of Directors and Executive Officers

We have a classified board, which means the terms of office of a portion of our board will expire every year, upon which the directors whose terms have expired will be subject to reelection. The terms of office of Messrs. Xu and Ede will expire at the 2015 annual general meeting of our shareholders; the terms of office of Ms. Hsu and Mr. Wu will expire at the 2016 annual general meeting of our shareholders; and the terms of office of Messrs. Li and Lim will expire at the 2017 annual general meeting of our shareholders.

Our directors are subject to a three-year term of office and hold office until their term of office expires or until such time as they are removed from office by resolution of our shareholders. A director will be removed from office automatically if, among other things, the director (i) becomes bankrupt or makes any arrangement or composition with his creditor, (ii) dies, or (iii) is found by our company to be or becomes of unsound mind. Our executive officers are elected by and serve at the discretion of our board of directors.

Qualification

There is no shareholding qualification for directors.

Board Committees

Our board of directors has established an audit committee, a compensation committee, a corporate governance and nominations committee and a transactions committee.

Audit Committee

Our audit committee consists of Messrs. Lim and Ede, each of whom satisfies the requirements of New York Stock Exchange Listed Company Manual, or NYSE Manual, Section 303A. Mr. Lim is the chairman of our audit committee and meets the criteria of an audit committee financial expert as set forth under the applicable rules of the SEC.

Our board of directors has determined that each of our audit committee members is an “independent director” within the meaning of NYSE Manual Section 303A and meets the criteria for independence set forth in Section 10A(m)(3) of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10A-3 under the Exchange Act.

Our audit committee is responsible for, among other things:

recommending to our shareholders, if appropriate, the annual re-appointment of our independent auditors and pre-approving all auditing and non-auditing services permitted to be performed by the independent auditors;

annually reviewing an independent auditors’ report describing the auditing firm’s internal quality control procedures, any material issues raised by the most recent internal quality control review, or peer review of the independent auditors and all relationships between the independent auditors and our company;

- setting clear hiring policies for employees or former employees of the independent auditors;
- reviewing with the independent auditors any audit problems or difficulties and management’s response;

reviewing and approving all proposed related-party transactions, as defined in Item 404 of Regulation S-K promulgated by the SEC;

- discussing the annual audited financial statements with management and the independent auditors;

discussing with management and the independent auditors major issues regarding accounting principles and financial statement presentations;

reviewing reports prepared by management or the independent auditors relating to significant financial reporting issues and judgments;

- reviewing with management and the independent auditors the effect of regulatory and accounting initiatives, as well as off-balance sheet structures, if any, on our financial statements;
- discussing policies with respect to risk assessment and risk management;

reviewing major issues as to the adequacy of our internal controls and any special audit steps adopted in light of material control deficiencies;

timely reviewing reports from the independent auditors regarding all critical accounting policies and practices to be used by our company, all alternative treatments of financial information within U.S. GAAP that have been discussed with management and all other material written communications between the independent auditors and management;

establishing procedures for the receipt, retention and treatment of complaints received from our employees regarding accounting, internal accounting controls or auditing matters and the confidential anonymous submission by our employees of concerns regarding questionable accounting or auditing matters;

- annually reviewing and reassessing the adequacy of our audit committee charter;

such other matters that are specifically delegated to our audit committee by our board of directors from time to time;

- meeting separately and periodically with management, the internal auditors and the independent auditors; and
- reporting regularly to the full board of directors.

Compensation Committee

Our compensation committee consists of Mr. Lim and Ms. Hsu. Mr. Lim is the chairman of our compensation committee. Our board of directors has determined that Mr. Lim is an “independent director” within the meaning of NYSE Manual Section 303A.

Our compensation committee is responsible for, among other things:

reviewing and approving corporate goals and objectives relevant to the compensation of our co-chief executive officers, evaluating the performance of our co-chief executive officers in light of those goals and objectives, and setting the compensation level of our co-chief executive officers based on this evaluation;

reviewing and making recommendations to our board of directors regarding our compensation policies and forms of compensation provided to our directors and officers;

reviewing and making recommendations to our co-chief executive officers regarding the compensation level, share-based compensation and bonuses for our officers other than our co-chief executive officers;

- reviewing and determining cash and share-based compensation for our directors;
- administering our equity incentive plans in accordance with the terms thereof; and

such other matters that are specifically delegated to the compensation committee by our board of directors from time to time.

Corporate Governance and Nominations Committee

Our corporate governance and nominations committee consists of Mr. Xu, Mr. Lim and Ms. Hsu.

Mr. Xu is the chairman of our corporate governance and nominations committee. Our board of directors has determined that Mr. Lim is an “independent director” within the meaning of NYSE Manual Section 303A.

Our corporate governance and nominations committee is responsible for, among other things, selecting and recommending the appointment of new directors to our board of directors.

Transactions Committee

Our transactions committee consists of Mr. Xu, Mr. Li, Mr. Ede, Mr. Cheng and Ms. Hsu. Ms. Hsu is the chairperson of our transactions committee.

Our transactions committee is responsible for, among other things:

• reviewing, and providing guidance to management and advising our board of directors on acquisition, investment, financing, joint venture and divestiture strategies;

• assisting management and advising our board of directors on the identification of acquisition, investment, financing, joint venture and divestiture opportunities;

• overseeing management and, as applicable, our board of directors’ due diligence process with respect to proposed acquisitions, investments, financings, joint ventures and divestitures;

• reviewing acquisition, investment, financing, joint venture and divestiture candidates with management, when and as appropriate; and

• such other matters that are specifically delegated to the transactions committee by our board of directors from time to time.

Corporate Governance

Our board of directors has adopted a code of ethics that is applicable to our senior executive and financial officers. In addition, our board of directors adopted a code of conduct that is applicable to all of our directors, officers and employees. Our code of ethics and our code of conduct are publicly available on our website.

In addition, our board of directors has adopted a set of corporate governance guidelines. These guidelines reflect certain guiding principles with respect to the structure of our board of directors, procedures and committees. They are not intended to change or interpret any law, or our amended and restated memorandum and articles of association.

Differences in Corporate Law

Mindray Medical International Limited was incorporated as an exempted company with limited liability in the Cayman Islands on June 10, 2005 under the Companies Law of the Cayman Islands. Our corporate affairs are governed by our amended and restated memorandum and articles of association, the Cayman Islands Companies Law and the common law of the Cayman Islands. A summary of the significant differences between the provisions of Cayman Law applicable to us and the laws applicable to companies incorporated in the State of Delaware is available on our website at <http://www.mindray.com>.

Interested Transactions

A director may vote with respect to any contract or transaction in which he or she is interested, provided that the nature of the interest of any director in such contract or transaction is disclosed by him or her at or prior to its consideration and any vote in that matter.

D. Employees.

We had approximately 7,500, 7,900 and 8,300 employees worldwide as of December 31, 2012, 2013 and 2014, respectively. The following table sets forth the number of employees categorized by function as of December 31, 2014:

	As of December 31, 2014
Manufacturing	1,983
Research and development	2,088
General and administration	875
Marketing and sales (including customer support and service)	3,331
Total	8,277

As required by PRC regulations, we participate in various employee benefit plans that are organized by municipal and provincial governments, including pension, work-related injury benefits, maternity insurance, medical and unemployment benefit plans. We are required under PRC law to make contributions to the employee benefit plans at specified percentages of the salaries, bonuses, housing funds and certain allowances of our employees, up to a maximum amount specified by the local government from time to time. Members of the retirement plan are entitled to a pension equal to a fixed proportion of the salary prevailing at the member's retirement date. In our U.S. and European operations we participate in various employee benefit plans to comply with relevant regulations and market conditions. Beginning in 2011, we have begun to pay a housing allowance for all employees of our PRC subsidiaries. For Shenzhen Mindray and Nanjing Mindray, the housing allowance is equivalent to 5% of each employee's base salary.

Generally, in our China-based operations, we enter into a five-year standard employment contract with our officers and managers and a five-year standard employment contract with other employees. According to these contracts, all of our employees are prohibited from engaging in any activities that compete with our business during the period of their employment with us. Furthermore, the employment contracts with certain officers or managers generally include a covenant that prohibits officers or managers from engaging in any activities that compete with our business for two years after the period of their employment with us. It may be difficult or expensive for us to seek to enforce the provisions of these agreements.

In addition, we provide a 401(k) plan to our employees in the U.S. which covers all employees with six months or more of service. Employees who participate in the plan may contribute a portion of their salaries up to a limit specified by law. Our contribution to the plan is based on the percentage of contribution by the employee of the individual employee's monthly base salary.

E. Share Ownership.

The following table sets forth information with respect to the beneficial ownership, within the meaning of Rule 13d-3 under the Exchange Act, of our ordinary shares, as of March 31, 2015, the latest practicable date by:

- each of our directors and executive officers who beneficially own our ordinary shares; and

- each person known to us to own beneficially more than 5% of our ordinary shares.

Beneficial ownership includes voting or investment power with respect to the securities. Except as indicated below, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all ordinary shares shown as beneficially owned by them. Percentage of beneficial ownership is based on 117,817,168 ordinary shares outstanding as of March 31, 2015, and taking into consideration options exercisable by such person within 60 days of March 31, 2015.

Name	Ordinary Shares		Percentage of		
	Beneficially Owned Number	Percent	Votes Held Percent		
Directors and Executive Officers					
Xu Hang(1)**	15,047,476	12.7 %	28.9	%	
Li Xiting(2)**	15,500,163	13.1 %	30.6	%	
Cheng Minghe(3)**	2,188,288	1.9 %	4.0	%	
Wang Jianxin	*	*	*		
Alex Lung	*	*	*		
Fannie Lin Fan	*	*	*		
Ronald Ede	*	*	*		
Joyce I-Yin Hsu	*	*	*		
Kern Lim	*	*	*		
Wu Qiyao	*	*	*		
Principal Shareholders					
Commonwealth Bank of Australia(4)	6,564,372	5.6 %	2.8	%	
Mondrian Investment Partners Limited(5)	11,167,500	9.5 %	4.8	%	
Baillie Gifford & Co(6)	9,630,815	8.2 %	4.1	%	
EARNEST Partners, LLC(7)	4,646,166	3.9 %	2.0	%	
Schroder Investment Management North America Inc(8)	12,447,811	10.6 %	5.3	%	
M&G Investment Management Limited(9)	4,711,809	4.0 %	2.0	%	

* Upon exercise of all options currently exercisable or vesting within 60 days of the date of this annual report, would beneficially own less than 1% of our ordinary shares.

** Mr. Xu Hang, Mr. Li Xiting, and Mr. Cheng Minghe hold all of our Class B ordinary shares.

- Holdings include (i) 201,742 Class A ordinary shares held by New Dragon (No. 12) Investments Limited (“New Dragon”), of which Mr. Xu Hang is the sole owner; (ii) 9,229,755 Class B ordinary shares held by New Dragon; (iii) 515,979 American Depositary Shares, each representing one Class A ordinary share, held by Credit Suisse AG for the benefit of New Dragon; (iv) 4,000,000 Class B ordinary shares held by New Phoenix Limited (“New Phoenix”), over which Mr. Xu Hang exercises voting and investment control; (v) American Depositary Shares representing 500,000 Class A ordinary shares, held by Credit Suisse AG for the benefit of New Phoenix; and (vi) (1) 600,000 Class A ordinary shares issuable upon the exercise of stock options held by Mr. Xu Hang, which includes stock options vesting within 60 days of March 31, 2015. 6,206,896 of the Class B ordinary shares are pledged pursuant to a Collateral Agreement as security for a credit facility made available by Credit Suisse AG to New Dragon (the “Credit Facility”). New Dragon and New Phoenix each have the address of Uglan House, P.O. Box 309, George Town, Grand Cayman, Cayman Islands. 6,206,896 of the Class B ordinary shares held by Mr. Xu are pledged as collateral pursuant to a collateral agreement as security for a credit facility made available by Credit Suisse AG to New Dragon.
- (2) Holdings include (x)(i) 193,258 Class A ordinary shares; (ii) 14,080,214 Class B ordinary shares; and (iii) 626,691 American Depositary Shares (ADSs), each representing one Class A ordinary share, and (y) 600,000 Class A ordinary shares issuable upon the exercise of stock options held by Mr. Li, which includes stock options that vest within 60 days of March 31, 2015. The outstanding ordinary shares and ADSs referenced in clause (x) are held through UBS Trustees (BVI) Limited, as Trustee of the Magic Bell Trust. The assets of this family trust include all outstanding shares of Magic Bell Limited, a BVI company (“Magic Bell”), and Quiet Well Limited, a BVI Company

("Quiet Well"). Magic Bell is the sole owner of Quiet Well which in turn holds those ordinary shares and ADSs. Mr. Li retains sole voting and disposition power over all Mindray securities held through the trust. Quiet Well's address is Tropic Isle Building, P.O. Box 438, Road Town Tortola, BVI. Magic Bell's address is Romasco Place, Wichkhams Cay 1, PO Box 3140, Road Town, Tortola, BVI.

- Holdings include 1,809,938 Class B ordinary shares and 378,350 ADSs, which are held by City Legend Limited, or
- (3) City Legend. Mr. Cheng is the controlling shareholder and exercises investment and voting power over the shares held by City Legend. City Legend is a BVI company and its address is P.O. Box 3152, Road Town, Tortola, BVI. Represents the ADSs that may be deemed beneficially owned with shared voting power and dispositive power by Commonwealth Bank of Australia, Colonial Holding Company Limited, Commonwealth Insurance Holdings Limited, Colonial First State Group Limited and First State Investments (Hong Kong) Limited. The address of
- (4) Commonwealth Bank of Australia is Ground Floor, Tower 1, 201 Sussex Street, Sydney, New South Wales, 2000, Commonwealth of Australia. The number of shares and the information provided in this footnote is as of December 31, 2014 and is based on a Schedule 13G filed with the SEC on February 12, 2015.

- Represents the sponsored ADRs held by Mondrian Investment Partners Limited. Mondrian Investment Partners Limited is an investment adviser with the business address of Fifth Floor, 10 Gresham Street, London EC2V 7JD, United Kingdom. The number of shares held is as of December 31, 2014 and is based on a Schedule 13G filed with the SEC on January 29, 2015.
- (5) Represents the ADSs held by Baillie Gifford & Co, an investment advisor with the business address of Calton Square, 1 Greenside Row, Edinburgh EH1 3AN, Scotland, United Kingdom. The number of shares and the information provided in this footnote is as of December 31, 2014 and is based on a Schedule 13G/A filed with the SEC on January 21, 2015.
- (6) Represents the ADSs that may be deemed beneficially owned with share voting power and sole dispositive power by EARNEST Partners, LLC. EARNEST Partners, LLC is an investment adviser with the business address of 1180 Peachtree Street NE, Suite 2300, Atlanta, Georgia 30309, U.S.A. The number of shares and the information provided in this footnote is as of December 31, 2014 and is based on a Schedule 13G filed with the SEC by EARNEST Partners, LLC on February 11, 2015.
- (7) Represents the ADRs that may be deemed beneficially owned with shared voting power and dispositive power by Schroder Investment Management North America Inc, Schroder Investment Management North America Ltd, Schroder Investment Management Ltd, Schroder Investment Management Hong Kong Ltd and Schroder Investment Management Singapore Ltd. Schroder Investment Management North America Inc is an investment adviser with the business address of 875 Third Ave, 22nd Floor, New York, NY 10022, U.S.A. The number of shares and the information provided in this footnote is as of December 31, 2014 and is based on a Schedule 13G filed with the SEC by Schroder Investment Management North America Inc on February 6, 2015.
- (8) Represents the ADSs that may be deemed beneficially owned with shared voting power and dispositive power by M&G Investment Management Limited. M&G Investment Management Limited is an investment adviser with the business address of Governor's House, Laurence Pountney Hill, London, EC4R OHH, United Kingdom. The number of shares and the information provided in this footnote is as of December 31, 2014 and is based on a Schedule 13G filed with the SEC by M&G Investment Management Limited on February 5, 2015.
- (9)

Our ordinary shares are divided into Class A ordinary shares and Class B ordinary shares. Holders of Class A ordinary shares are entitled to one vote per share, while holders of Class B ordinary shares are entitled to five votes per share. Mr. Xu Hang, our Chairman of the Board of Directors, Mr. Li Xiting, our Executive Chairman of the Board of Directors, President and Co-CEO, and Mr. Cheng Minghe, our Co-CEO and Chief Strategic Officer, through their respective affiliates, hold all of our Class B ordinary shares. These shareholders will continue to exert control over all matters subject to shareholder vote until the total number of Class B ordinary shares they own is collectively less than 20% of the total number of issued and outstanding ordinary shares. None of our other shareholders own Class B ordinary shares or have different voting rights.

Our ordinary shares underlying the ADSs listed on the New York Stock Exchange are held in Hong Kong by our custodian, the Hong Kong Shanghai Banking Corporation, on behalf of the Bank of New York Mellon, the depository.

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

A.

Major Shareholders.

See Item 6.E, “Directors, Senior Management and Employees — Share Ownership.”

B. Related Party Transactions.

None.

C. Interests of Experts and Counsel.

Not applicable.

ITEM 8. FINANCIAL INFORMATION

A. Consolidated statements and other financial information.

We have appended consolidated financial statements filed as part of this annual report. See Item 18, “Financial Statements.”

Legal Proceedings

See Item 4.B, “Business Overview — Legal Proceedings.”

Dividend Policy

We intend to pay annual cash dividends to our shareholders, while maintaining a balance between shareholder returns and investment in our business and capital structure. Payment of cash dividends, if any, will be at the sole discretion of our board of directors. In April 2012, our board of directors authorized, but did not obligate, us to pay an annual dividend to our shareholders for the next three years, effective as of fiscal year 2012, at a payout ratio of up to 20% to 25% of our annual net income. In determining whether to pay cash dividends, if any, under this policy, our board of directors will consider numerous factors, including our future operations and earnings, capital requirements and surplus, general financial conditions, shareholders’ interests, contractual restrictions and other factors as our board of directors may deem relevant. Our board of directors may periodically review and modify our dividend policy without prior notice. You are cautioned that our current policy to declare dividends at up to 20-25% of our annual net income is subject to the ultimate discretion of our board of directors, and we give no assurance that we will declare dividends at this ratio, or at all. We can only pay dividends out of profits or other distributable reserves.

In addition, our ability to pay dividends may depend on the profitability generated by our overseas subsidiaries, our ability to finance through third-party borrowing or the payment of dividends to us by our primary operating subsidiary, Shenzhen Mindray. Shenzhen Mindray may pay dividends only out of its accumulated distributable profits, if any, determined in accordance with its articles of association, and the accounting standards and regulations in China. Moreover, pursuant to relevant PRC laws and regulations applicable to our subsidiaries in China, each of our PRC subsidiaries are required to provide 10% of its after-tax profits to a statutory surplus reserve fund. When the aggregate balance in the statutory surplus reserve fund is 50% or more of the subsidiaries’ registered capital, our subsidiaries need not make any further allocations to the fund. Shenzhen Mindray had previously contributed over 50% of its registered capital to its statutory surplus reserve, and is no longer allocating after-tax profits to the fund.

Allocations to these statutory surplus reserve funds can only be used to offset extraordinary losses and are not distributable to us in the form of loans, advances or cash dividends. Furthermore, if any of our PRC subsidiaries incur debt on its own behalf, the instruments governing the debt may restrict its ability to pay dividends or make other payments to us. Any limitation on the above could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our businesses, pay dividends and otherwise fund and conduct our businesses.

Other than the above, pursuant to certain provisions as specified in the bank loan agreements as entered into by us, there is a loan covenant which restricts us from declaring dividend over 40% of its net profit.

We paid cash dividends of \$46.4 million, \$59.1 million and \$58.7 million in 2012, 2013 and 2014, respectively. On March 9, 2015, we declared a cash dividend of \$0.40 per ordinary share and the cash dividends of approximately \$47.1 million were payable to shareholders of record as of March 19, 2015.

Holders of ADSs will be entitled to receive dividends, subject to the terms of the deposit agreement, to the same extent as holders of our Class A ordinary shares, less the fees and expenses payable under the deposit agreement. Cash dividends will be paid by the depository to holders of ADSs in US dollars. Other distributions, if any, will be paid by the depository to holders of our ADSs in any means it deems legal, fair and practical.

B. Significant Changes.

Not applicable.

ITEM 9. THE OFFER AND LISTING

A. Offering and listing details.

Price Range of Our ADSs

Our ADSs are listed for trading on the New York Stock Exchange under the symbol “MR”. The following table sets forth the monthly high and low market prices of our ADSs on the New York Stock Exchange for the periods indicated:

Annual Highs and Lows	High	Low
2010	\$40.35	\$25.52
2011	31.21	21.25
2012	36.36	25.77
2013	43.81	28.65
2014	40.89	26.20
Quarterly Highs and Lows		
First Quarter 2013	40.50	28.65
Second Quarter 2013	42.40	36.30
Third Quarter 2013	43.81	36.13
Fourth Quarter 2013	42.11	33.88
First Quarter 2014	40.89	30.03
Second Quarter 2014	34.54	29.94
Third Quarter 2014	32.99	28.54
Fourth Quarter 2014	31.84	26.20
First Quarter 2015	33.83	25.90
Monthly Highs and Lows		
September 2014	31.89	29.78
October 2014	31.36	28.43
November 2014	31.84	27.52
December 2014	31.01	26.20
January 2015	27.87	25.90
February 2015	28.99	26.83
March 2015	33.83	26.62

April 2015 (through April 13, 2015) 30.32 27.21

On April 13, 2015, the closing sale price of our ADSs as reported on the New York Stock Exchange was \$29.90 per ADS.

B. Plan of Distribution.

Not applicable.

C. Markets.

See Item 9.A above.

D. Selling Shareholders.

Not applicable.

E. Dilution.

Not applicable.

F. Expenses of the Issue.

Not applicable.

ITEM 10. ADDITIONAL INFORMATION

A. Share capital.

Not applicable.

B. Memorandum and Articles of Association.

We incorporate by reference into this annual report the text of our amended and restated memorandum of association previously filed with the SEC with our Report on Form 6-K (File No. 001-33036) on November 10, 2008, as amended. Our shareholders adopted our amended and restated memorandum and articles of association by a special resolution on October 17, 2008.

C. Material Contracts.

We have not entered into any material contracts other than in the ordinary course of business and other than those described in Item 4, "Information on the Company" and in Item 7, "Major Shareholders and Related Party Transactions" or elsewhere in this annual report.

D. Exchange Controls.

Foreign exchange in China is primarily regulated by:

- The Foreign Currency Administration Rules (1996), as amended; and

•

The Administration Rules of the Settlement, Sale and Payment of Foreign Exchange (1996), or the Administration Rules.

Under the Foreign Currency Administration Rules, the Renminbi is convertible for current account items, including the distribution of dividends, interest payments, and trade and service-related foreign exchange transactions. Conversion of Renminbi into foreign currency for capital account items, such as direct investment, loans, investment in securities and repatriation of funds, however, is still subject to the approval of SAFE. Under the Administration Rules, foreign-invested enterprises may only buy, sell, and remit foreign currencies at banks authorized to conduct foreign exchange transactions after providing valid commercial documents and, in the case of capital account item transactions, only after obtaining approval from SAFE.

Capital investments directed outside of China by foreign-invested enterprises are also subject to restrictions, which include approvals by the PRC Ministry of Commerce, SAFE and the PRC National Reform and Development Commission. We receive a portion of our revenues in Renminbi, which is currently not a freely convertible currency. Under our current structure, our income will be primarily derived from dividend payments from our subsidiaries in China.

The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in China's political and economic conditions. The conversion of Renminbi into foreign currencies, including U.S. dollars, has been based on rates set by the People's Bank of China. On July 21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar. Under the new policy, the Renminbi will be permitted to fluctuate within a band against a basket of certain foreign currencies. There remains significant international pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi against the U.S. dollar.

Regulation of Foreign Exchange in Certain Onshore and Offshore Transactions

On July 4, 2014, SAFE issued a Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents' Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 superseded SAFE's Circular on Relevant Issues Concerning Foreign Exchange Administration for PRC Residents to Engage in Financing and Round Trip Investment via Overseas Special Purpose Companies and its subsequent amendments, supplements or implementation rules, or SAFE Circular 75, issued on October 21, 2005. According to SAFE Circular 37, a PRC resident (whether a natural person or legal persons) shall register with the local branch of the SAFE before it establishes or controls an overseas Special Purpose Vehicles ("SPV"), with assets or equity interests in a PRC company, for purposes of overseas equity financing. The PRC resident shall apply for SAFE registration for overseas investment before paying capital to the SPV by using his, her or its legally owned assets, whether overseas or domestic. The SPV is defined as "offshore enterprise directly established or indirectly controlled by the domestic residents (including domestic institutions and individuals) with their legally owned assets and equity of the domestic enterprise, or legally owned offshore assets or equity, for the purpose of offshore investment and financing." In addition, SAFE Circular 37 requires amendment to the registration in the event of any significant changes to the SPV, such as increase or decrease of capital contributed by PRC individuals, share transfer or exchange, merger, division or other material event.

According to SAFE Circular 37, if the registered or beneficial shareholders of the offshore holding company who are PRC residents do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from distributing their profits and proceeds from any reduction in capital, share transfer or liquidation to the offshore company, and the SPV may be restricted in its ability to contribute additional capital to its PRC subsidiaries. Failure to make the required registration or truthfully disclose actual controllers of the round-trip enterprises may subject PRC residents to fines up to RMB300,000 in case of domestic institutions or RMB50,000 in case of domestic individuals. Moreover, failure to comply with SAFE registration and amendment requirements described above could result in additional liability under PRC law for violating applicable foreign exchange restrictions.

As a Cayman Islands company holding our operating subsidiaries in China, we are considered a SPV under SAFE Circular 37. PRC residents who are beneficial holders of our shares are required to register with SAFE in connection with their investment in us. We have requested our shareholders, and the shareholders of the offshore entities in our corporate group, who are PRC residents to make the necessary SAFE registrations. See "Risk Factors—Risks Related to Doing Business in China—PRC regulations relating to offshore investment activities by PRC residents may increase the administrative burden we face and create regulatory uncertainties that could restrict our overseas and cross-border investment activity, and failure by our shareholders who are PRC residents to make any required applications and filings pursuant to such regulations may prevent us from distributing profits and could expose us and our PRC resident shareholders to liability under PRC law."

SAFE issued the Notice on Further Simplified and Improved Direct Investment Foreign Exchange Management Measures, or SAFE Notice 13, on February 28, 2015, which will be effective from June 1, 2015. Pursuant to SAFE

Notice 13, there is no longer a need for Direct Investment Foreign Exchange Registration and banks shall be able to review and register direct investment foreign exchange in accordance with the newly released Guidelines for Direct Investment Foreign Exchange Registration. SAFE and its local branches shall supervise Direct Investment Foreign Exchange Registration indirectly through the banks.

We believe that these foreign exchange restrictions may reduce the amount of funds that would be otherwise available to us to capitalize overseas subsidiaries or expand our international operations. Our international cost allocation scheme shifts a majority of any startup capital and working capital costs to our international distributors. We anticipate that as we expand internationally, we will only need to provide limited funding, if any. We therefore do not anticipate that the restrictions set forth in the SAFE regulations will have a material adverse effect on our ability to capitalize foreign subsidiaries or expand our international operations.

E. Taxation.

The following is a general summary of the material Cayman Islands, PRC and U.S. federal income tax consequences relevant to an investment in our ADSs or ordinary shares. The discussion is not intended to be, nor should it be construed as, legal or tax advice to any particular prospective purchaser or current holder of our ADSs or ordinary shares. The discussion is based on laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change or different interpretations, possibly with retroactive effect. The discussion does not address U.S. state or local tax laws, or tax laws of jurisdictions other than the Cayman Islands, PRC and the United States. You should consult your own tax advisors with respect to the consequences of acquisition, ownership and disposition of our ADSs or ordinary shares.

Cayman Islands Taxation

The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or brought within the jurisdiction of, the Cayman Islands. The Cayman Islands is a party to a double tax treaty entered into with the United Kingdom in 2010 but otherwise is not party to any double tax treaties. There are no exchange control regulations or currency restrictions in the Cayman Islands.

We have, pursuant to Section 6 of the Tax Concessions Law (1999 Revision) of the Cayman Islands, obtained an undertaking from the Governor-in-Council that:

no law which is enacted in the Cayman Islands imposing any tax to be levied on profits or income or gains or appreciation applies to us or our operations; and

the aforesaid tax or any tax in the nature of estate duty or inheritance tax are not payable on our ordinary shares, debentures or other obligations.

The undertaking that we have obtained is for a period of 20 years from June 28, 2005.

U.S. Federal Income Taxation

Edgar Filing: Mindray Medical International LTD - Form 20-F

The following is a general summary of the material U.S. federal income tax considerations related to the acquisition, ownership and disposition of our ADSs or ordinary shares. This summary deals only with persons or entities that are “U.S. Holders” (as defined below) who hold our ADSs or ordinary shares as capital assets within the meaning of section 1221 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”). This summary does not address all aspects of U.S. federal income taxation that may be applicable to U.S. Holders in the light of their particular circumstances or to shareholders subject to special treatment under U.S. federal income tax law, such as (without limitation):

- banks, insurance companies, and other financial institutions;
 - dealers in securities or foreign currencies;
 - regulated investment companies;
 - traders in securities that mark to market;
 - U.S. expatriates;
 - non-U.S. persons and entities;
 - tax-exempt entities;
 - persons liable for alternative minimum tax;

• persons holding an ADS or ordinary share as part of a straddle, appreciated financial position, synthetic security, hedge, conversion transaction or other integrated investment;

- persons holding an ADS or ordinary share as a result of a constructive sale;
- persons holding an ADS or ordinary share whose functional currency is not the US dollar;
- U.S. persons who own or are deemed to own 10% or more of the total combined voting power of all classes of shares entitled to vote of Mindray or any of our non-U.S. subsidiaries; or

entities that acquire an ADS or ordinary share that are treated as partnerships for U.S. federal income tax purposes and investors (i.e., partners) in such partnerships.

Furthermore, this summary does not address any aspect of U.S. federal gift or estate tax, state, local or non-U.S. taxes, the Medicare tax or the alternative minimum tax provisions of the Code.

If an entity treated as a partnership holds our ADSs or ordinary shares, the tax treatment of the partners will generally depend on the status of the partner and the activities of the partnership. If you are a partner of a partnership holding our ADSs or ordinary shares, you should consult your tax advisor.

PROSPECTIVE PURCHASERS ARE STRONGLY URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR ADSs OR ORDINARY SHARES TO THEM, INCLUDING THE APPLICABLE U.S. FEDERAL, STATE AND LOCAL AND NON-US TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF ADSs OR ORDINARY SHARES TO THEM AND THE EFFECT OF POSSIBLE CHANGES IN TAX LAWS.

The discussion below of the U.S. federal income tax consequences to “U.S. Holders” will apply if you are the beneficial owner of ADSs or ordinary shares and you are, for U.S. federal income tax purposes:

- an individual who is a citizen or resident of the United States;
- a corporation (or other entity taxable as a corporation) organized under the laws of the United States, any State thereof or the District of Columbia;
- an estate whose income is subject to U.S. federal income taxation regardless of its source; or

a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.

The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit agreement and any related agreement will be complied with in accordance with the terms.

Taxation of Dividends and Other Distributions on the ADSs or Ordinary Shares

Subject to the “passive foreign investment company,” or PFIC, rules discussed below under “Passive Foreign Investment Company,” the gross amount of distributions made by us with respect to the ADSs or ordinary shares generally will be included in your gross income in the year received as ordinary dividend income, but only to the extent that the distribution is treated as paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Such dividends would generally not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations.

To the extent that the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), it will be treated first as a tax-free return of your tax basis in your ADSs or ordinary shares, and to the extent the amount of the distribution exceeds your tax basis, the excess will be taxed as capital gain. However, we do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that a distribution will generally be treated as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.

Under current law and with respect to non-corporate U.S. Holders, including individual U.S. Holders, dividends may be “qualified dividend income” that is taxed at a reduced capital gains rate, provided that certain conditions are satisfied, including: (1) the ADSs or ordinary shares are readily tradable on an established securities market in the United States, (2) we are not a PFIC for both our taxable year in which the dividend is paid and the preceding taxable year, and (3) certain holding period requirements are met. The Internal Revenue Service has indicated that common or ordinary stock, or an ADR in respect of such stock, is considered for purposes of clause (1) above to be readily tradable on an established securities market in the United States when it is listed on the New York Stock Exchange.

There is no assurance, however, that any dividends paid on our ADSs or ordinary shares will be eligible for the reduced capital gains tax rate. Any dividends paid by us that are not eligible for the preferential rate will be taxed as ordinary income to a non-corporate U.S. Holder. You should consult your tax advisors regarding the availability of the qualified dividend income rate with respect to our ADSs or ordinary shares, including the effects of any change in law after the date of this annual report.

Taxation of a Disposition of ADSs or Ordinary Shares

Subject to the PFIC rules discussed below under “Passive Foreign Investment Company,” you will recognize taxable gain or loss on any sale, exchange or other taxable disposition of an ADS or ordinary share equal to the difference between the amount realized (in U.S. dollars) for the ADS or ordinary share and your tax basis (in U.S. dollars) in the ADS or ordinary share. The gain or loss generally will be capital gain or loss. If you are a non-corporate U.S. Holder, including an individual U.S. Holder, who has held the ADS or ordinary share for more than one year, you will be eligible for reduced long-term capital gains tax rates. The deductibility of capital losses is subject to limitations. Any such gain or loss that you recognize will generally be treated as U.S. source gain or loss for foreign tax credit limitation purposes.

Passive Foreign Investment Company

We do not believe that we were a PFIC for U.S. federal income tax purposes for the taxable year ended December 31, 2014, and we do not expect to be considered a PFIC for U.S. federal income tax purposes for the taxable year ending December 31, 2015. However, we cannot assure you that we will not be a PFIC for 2015 or any future taxable year.

A non-U.S. corporation is considered a PFIC for any taxable year if either:

- at least 75% of its gross income is passive income (the “Income Test”), or

at least 50% of the value of its assets (based on an average of the quarterly values of the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income (the “Asset Test”).

We will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other corporation in which we own, directly or indirectly, 25% or more (by value) of the stock.

We must make a separate determination each year as to whether we are a PFIC. As a result, it is possible that our PFIC status will change. In particular, our PFIC status under the Asset Test will generally be determined by using the market price of our ADSs and ordinary shares, which is likely to fluctuate over time, to calculate the total value of our assets. Accordingly, fluctuations in the market price of the ADSs or ordinary shares may result in our being a PFIC. In addition, the application of the PFIC rules is subject to uncertainty in several respects (such as the determination of goodwill) and the composition of our income and assets will be affected by how, and how quickly, we spend the substantial amount of cash that we currently have on hand. If we are classified as a PFIC for any year during which you hold ADSs or ordinary shares, we will generally continue to be treated as a PFIC for all succeeding years during which you hold ADSs or ordinary shares.

If we are a PFIC for any taxable year during which you hold ADSs or ordinary shares, you will be subject to special tax rules (“PFIC rules”) with respect to any “excess distribution” that you receive and any gain you realize from a sale or other disposition (including a pledge) of the ADSs or ordinary shares, unless you make a “mark-to-market” election. The amount of the total distributions you receive in a taxable year that is greater than 125% of the average annual distributions you received during the shortest of the three preceding taxable years or the portion of your holding period for the ADSs or ordinary shares before the particular taxable year will be treated as an excess distribution. Under the PFIC rules:

- the excess distribution or gain will be allocated ratably over your holding period for the ADSs or ordinary shares,
 - the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we were a PFIC, will be treated as ordinary income, and

the amount allocated to each other year will be subject to the highest tax rate in effect for that year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year.

The tax liability for amounts allocated to years prior to the year of disposition or an “excess distribution” cannot be offset by any net operating losses for such years, and gains (but not losses) realized on the sale of the ADSs or ordinary shares cannot be treated as capital, even if you hold the ADSs or ordinary shares as capital assets.

Alternatively, a U.S. Holder of “marketable stock” (as defined below) in a PFIC may make a mark-to-market election for such stock of a PFIC to elect out of the tax treatment discussed in the two preceding paragraphs. If you make a mark-to-market election for the ADSs or ordinary shares, you will include in income each year an amount equal to the excess, if any, of the fair market value of the ADSs or ordinary shares as of the close of your taxable year over your adjusted basis in such ADSs or ordinary shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of the ADSs or ordinary shares over their fair market value as of the close of the taxable year. However, deductions are allowable only to the extent of any net mark-to-market gains on the ADSs or ordinary shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of the ADSs or ordinary shares, are treated as ordinary income. Ordinary loss treatment also applies to the deductible portion of any mark-to-market loss on the ADSs or ordinary shares, as well as to any loss realized on the actual sale or disposition of the ADSs or ordinary shares, to the extent that the amount of such loss does not exceed the net mark-to-market gains previously included for such ADSs or ordinary shares. Your basis in the ADSs or ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a valid mark-to-market election, the tax rules that apply to distributions by corporations which are not PFICs would apply to distributions by us, except that the lower applicable capital gains rate for qualified dividend income discussed above under “— Taxation of Dividends and Other Distributions on the ADSs or Ordinary Shares” would not apply.

The mark-to-market election is available only for “marketable stock,” which is stock that is traded in other than *de minimis* quantities on at least 15 days during each calendar quarter (“regularly traded”) on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. We have listed our ADSs on the New York Stock Exchange and, consequently, provided the ADSs continue to be regularly traded thereon, if you are a holder of ADSs, the mark-to-market election would be available to you were we to be or become a PFIC. Because a mark-to-market election cannot be made for equity interests in any lower-tier PFICs that we own, a U.S. Holder may continue to be subject to the PFIC rules with respect to its indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes.

If a non-U.S. corporation is a PFIC, a holder of shares in that corporation may elect out of the PFIC rules discussed above by making a “qualified electing fund” election to include its pro rata share of the corporation’s income on a current basis. However, you may make a qualified electing fund election with respect to our company only if we agree to furnish you annually with certain tax information, and we do not presently intend to prepare or provide such information.

If you hold ADSs or ordinary shares in any year in which we are a PFIC, you are required to file an annual report containing such information as the United States Treasury Department may require and may be required to file Internal Revenue Service Form 8621 regarding distributions received on the ADSs or ordinary shares and any gain

realized on the disposition of the ADSs or ordinary shares.

If we are treated as a PFIC with respect to you for any taxable year, to the extent any of our subsidiaries are also PFICs, you may be deemed to own shares in such lower-tier PFICs in the proportion which the value of the ADSs or ordinary shares you own bears to the value of all of our ADSs or ordinary shares, and you may be subject to the adverse tax consequences described in the preceding paragraph with respect to the shares of such lower-tier PFICs that you would be deemed to own. The mark-to-market election is not available for stock of any such subsidiaries. We do not presently intend to prepare or provide information required for you to make a qualified electing fund election with respect to any such subsidiaries.

You are urged to consult your tax advisor regarding the application of the PFIC rules to your investment in ADSs or ordinary shares.

Information Reporting and Backup Withholding

Dividend payments with respect to ADSs or ordinary shares and proceeds from the sale, exchange or redemption of ADSs or ordinary shares may be subject to information reporting to the Internal Revenue Service and possible U.S. backup withholding at a current rate of 28%, unless the conditions of an applicable exception are satisfied. Backup withholding will not apply to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on Internal Revenue Service Form W-9. U.S. Holders should consult their tax advisors regarding the application of the U.S. information reporting and backup withholding rules.

Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by timely filing the appropriate claim for refund with the Internal Revenue Service and furnishing any required information. Certain U.S. Holders who hold “specified foreign financial assets”, including stock of a non-U.S. corporation that is not held in an account maintained by a U.S. “financial institution”, whose aggregate value exceeds \$50,000 during the tax year, may be required to attach to their tax returns for the year certain specified information. A U.S. Holder who fails to timely furnish the required information may be subject to a penalty. Each U.S. Holder is advised to consult with its tax advisor regarding the application of the U.S. information reporting rules to their particular circumstances.

People’s Republic of China Taxation

In 2007 China passed the Enterprise Income Tax Law, or the EIT Law, and its implementing rules, both of which became effective on January 1, 2008. The EIT Law created a new “resident enterprise” classification, which, if applied to us, would impose a PRC enterprise income tax on our worldwide income at a tax rate of 25% and result in a situation in which a withholding tax of 10% for our non-PRC enterprise investors or a potential 20% individual income tax for individual investors is imposed on dividends we pay to them, and on gains derived by our non-PRC shareholders from disposition of our shares or ADSs, if such dividends or gains are determined to have been derived from sources within China. It is unclear whether, if we are considered a PRC “resident enterprise,” our non-PRC enterprise shareholders or ADS holders would be able to claim the benefit of income tax treaties or arrangements entered into between China and other countries or areas. The EIT Law and its implementing rules are unclear as to how to determine the sources of such dividends or gains for non-PRC enterprises or group enterprise controlled entities.

If we are not deemed a resident enterprise, then dividends payable to our non-PRC shareholders and gains from disposition of our shares of ADSs by our non-PRC shareholders will not be subject to PRC income tax withholding. See Item 3.D, “Key Information — Risk Factors — Risks Related to Doing Business in China — We may be classified as a

‘resident enterprise’ for PRC enterprise income tax purposes. This classification could result in unfavorable tax consequences to us and our non-PRC shareholders.”

F. Dividends and Paying Agents.

Not applicable.

G. Statement by Experts.

Not applicable.

H. Documents on Display.

We previously filed with the Securities and Exchange Commission our registration statement on Form F-1 as amended.

We have filed this annual report on Form 20-F with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Statements made in this annual report as to the contents of any document referred to are not necessarily complete. With respect to each such document filed as an exhibit to this annual report, reference is made to the exhibit for a more complete description of the matter involved, and each such statement shall be deemed qualified in its entirety by such reference.

We are subject to the informational requirements of the Exchange Act and file reports and other information with the Securities and Exchange Commission. Reports and other information which the Company filed with the Securities and Exchange Commission, including this annual report on Form 20-F, may be inspected and copied at the Public Reference Room of the Securities and Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549.

The Public can also obtain copies of this annual report on Form 20-F by mail from the Public Reference Section of the Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549, at prescribed rates. The public may obtain information on the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

I. Subsidiaries Information

Not applicable.

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Quantitative and Qualitative Disclosures about Market Risk

Foreign Currency Risk

Although exchange of the Renminbi for foreign currency is highly regulated in China, the value of the Renminbi against the value of the U.S. dollar, Euro, or any other currency nonetheless may fluctuate and be affected by, among other things, changes in China's political and economic conditions. Under the currency policy in effect in China today, the value of the Renminbi fluctuates within a narrow band against a basket of foreign currencies. China is currently under significant international pressures to liberalize its currency policy, and if such liberalization were to occur, the value of the Renminbi could appreciate or depreciate against the U.S. dollar, the Euro, or any other currency.

We use U.S. dollars as the reporting currency for our financial statements. All transactions in currencies other than U.S. dollar during the year are re-measured at the exchange rates prevailing on the respective relevant dates of such transactions. Monetary assets and liabilities existing at the balance sheet date denominated in currencies other than U.S. dollar are re-measured at the exchange rates prevailing on such date. Exchange differences are recorded in our consolidated statement of operations.

Fluctuations in exchange rates may affect our net revenues, costs, operating margins and net income. For example, in 2014, over 50% of our net revenues were generated from sales denominated in currencies other than U.S. dollar, and over 50% of our operating expenses were denominated in currencies other than U.S. dollars. The fluctuations in the exchange rates between the U.S. dollar and the Renminbi and other foreign currencies resulted in a decrease of \$8.6 million in operating income in 2014.

Fluctuations in exchange rates may also affect our balance sheet. For example, to the extent that we need to convert U.S. dollars or Euro into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar or Euro would have an adverse effect on the Renminbi amount that we receive from the conversion. Conversely, if we decide to convert our Renminbi or Euro into U.S. dollars for the purpose of paying dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the Renminbi or the Euro against the U.S. dollar would have a positive effect on the corresponding U.S. dollar amount available to us. Considering the amount of our cash and cash equivalents, short-term investments and accounts receivables as of December 31, 2014, a 1.0% change in the exchange rates between the U.S. dollar and the Renminbi would result in an increase or decrease of \$1.7 million to our total cash and cash equivalents, \$8.1 million to our short term investments and \$0.6 million to our accounts receivable.

In the fourth quarter of 2013 and during 2014, we entered into forward contracts to reduce our foreign currency exposure against the U.S. dollar. In 2013 and 2014, we also converted \$33.7 million and \$12.3 million of U.S. dollar denominated loan into Euro denominated loan in order to hedge against foreign currency exposure of our receivables denominated in Euro.

Interest Rate Risk

Our exposure to interest rate risk primarily relates to our interest income generated by our excess cash, which is mostly held in interest-bearing bank deposits and short-term investments as well as interest expenses under our short-term and long-term bank loans. Our future interest income from our cash deposited in bank and short-term investments may fall short of expectations due to changes in interest rates. As of December 31, 2014, our outstanding short-term and long-term borrowings were \$59.6 million and \$197.6 million, respectively. The decrease in our borrowings in 2014 was as a result of our entering into a three-year cross-border Renminbi intra-group loan facility between our subsidiaries in Hong Kong and China in 2013. The interest rate of our borrowings is the aggregate of a fixed margin and LIBOR or EURIBOR. We are therefore exposed to interest rate risk related to potential fluctuations in the LIBOR and EURIBOR. A hypothetical 100 basis point increase in LIBOR and EURIBOR would result in an increase of \$2.1 million and €0.4 million, respectively in our interest expenses incurred by the respective outstanding loans as of December 31, 2014 in 2015.

Inflation Risk

In recent years, China has not experienced significant inflation, and thus inflation has not had a material impact on our results of operations. According to the National Bureau of Statistics of China, the year-on-year change in the consumer price index in China was 2.6%, 2.5% and 1.5% in 2012, 2013 and 2014, respectively.

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

A. Debt securities

Not applicable.

B. Warrants and Rights

Not applicable.

C. Other securities

Not applicable.

D. American Depositary Shares.

Our depositary is the Bank of New York Mellon, or the Depositary, with principle executive office located in One Wall Street, New York, N.Y. 10286. It collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary services by deductions from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The Depositary may refuse to provide delivery of ADSs or deposited shares or provide any distributions until its fees for those services are paid.

As provided in the deposit agreement among us, the Depositary, and owners and holders of our ADSs, owners and/or holders of our ADSs may have to pay the following service fees to the Depositary:

Fees and Expenses

- \$5.00 (or less) per 100 ADSs (or portion thereof)
- \$0.02 (or less) per ADS (or portion thereof)
- A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
- \$0.02 (or less) per ADS (or portion thereof) per calendar year
- Registration or Transfer fees
- Expenses of Depositary
- Taxes and other governmental charges the depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes
- Any charges incurred by the depositary or its agents for servicing the deposited securities

Service

- Each issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
- Each cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
- Any cash distributed to ADS holders
- Distribution of securities distributed to holders of deposited securities which are distributed by the depositary to ADS holders
- Depositary services
- Transfer and registration of shares on our share register to or from the name of the depositary or its agent when ADS holders deposit or withdraw shares
- Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement)
- Converting foreign currency to U.S. dollars
- As necessary
- As necessary

The depositary has agreed to reimburse us for expenses we incur that are related to the establishment and maintenance of the ADR program, including investor relations expenses and the New York Stock Exchange application and listing fees. There are limits on the amount of expenses for which the depositary will reimburse us, but the amount of reimbursement available to us is not related to the amounts of fees the depositary collects from investors under the ADR program.

In addition, as part of its service to us, the depositary has agreed to waive fees for the standard costs associated with the maintenance and administration of the ADR program amounting to \$0.1 million. The depositary has also reimbursed us approximately \$1.2 million for expenses incurred by us from various third party service providers for the year ended December 31, 2014, as follows:

Category of Expenses	Amount paid (in thousands)
Legal Advisory	\$ 257
Current Auditor	953
Total	\$ 1,210

PART II.

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

The rights of securities holders have not been materially modified.

ITEM 15. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our Co-Chief Executive Officers and Chief Financial Officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this annual report (the “Evaluation Date”), have concluded that as of the Evaluation Date our disclosure controls and procedures were effective and designed to ensure that all material information required to be included in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended, for our company. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements in accordance with generally accepted accounting principles and includes those policies and procedures that pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of a company’s assets; provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that a company’s receipts and expenditures are being made only in accordance with authorizations of a company’s management and directors; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of a company’s assets that could have a material effect on the consolidated financial statements.

Because of its inherent limitations, a system of internal control over financial reporting can provide only reasonable assurance with respect to consolidated financial statement preparation and presentation and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As required by Section 404 and related rules as promulgated by the Securities and Exchange Commission, management assessed the effectiveness of the our internal control over financial reporting as of December 31, 2014

using criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2014 based on the criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 2013.

Report of the Independent Registered Public Accounting Firm

The effectiveness of our internal control over financial reporting as of December 31, 2014 has been audited by PricewaterhouseCoopers, an independent registered public accounting firm as stated in their report, which appears on page F-2 of this annual report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting that occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

ITEM 16A. *AUDIT COMMITTEE FINANCIAL EXPERT*

Our audit committee consists of Messrs. Lim and Ede, each of whom satisfies the requirements of New York Stock Exchange Listed Company Manual, or NYSE Manual, Section 303A. Mr. Lim is the chairman of our audit committee and meets the criteria of an audit committee financial expert as set forth under the applicable rules of the SEC.

Our board of directors has determined that each of our audit committee members is an “independent director” within the meaning of NYSE Manual Section 303A and meets the criteria for independence set forth in Section 10A(m)(3) of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10A-3 under the Exchange Act.

ITEM 16B. CODE OF ETHICS

Our board of directors has adopted a code of ethics that is applicable to our senior executive and financial officers. In addition, our board of directors adopted a code of business conduct and ethics that is applicable to all of our directors, officers and employees. Our code of ethics and our code of business conduct and ethics are publicly available on our website: <http://www.mindray.com>

ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table sets forth the aggregate fees by category specified below in connection with certain professional services rendered by PricewaterhouseCoopers, our principal external auditor, for the periods indicated.

	Year Ended December 31,	
	2013	2014
	(in thousands)	
Audit fees (1)	\$ 2,580	\$ 2,708
Audit-related fees (2)	347	663
Advisory fees (3)	609	220
Tax fees (4)	215	262
Total	\$ 3,751	\$ 3,853

(1) “Audit fees” means the aggregate fees billed in each of the fiscal years listed for professional services rendered by our principal external auditor for the integrated audit of our annual financial statements, including audit of internal control over financial reporting in accordance with Sarbanes-Oxley Act, and review of our quarterly consolidated financial information.

(2) “Audit-related fees” means the aggregate fees billed in each of the fiscal years listed for professional services rendered by our principal external auditor primarily for performing statutory audits for certain of our subsidiaries and other miscellaneous audit-related services.

(3) “Advisory fees” means the aggregate fees billed in each of the fiscal years listed for professional services rendered by our principal external auditor, other than service reported under “audit fees,” “audit-related fees” and “tax fees.” “Advisory fees” in 2013 and 2014 mainly represent consulting fees for our product development management project and other miscellaneous business process projects.

(4)

“Tax fees” means the aggregate fees billed in each of the fiscal years listed primarily for tax compliance services rendered by our principal external auditor.

The audit committee or our board of directors is to pre-approve all auditing services and permitted non-audit services to be performed for us by our principal external auditor, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described in Section 10A(i)(1)(B) of the Exchange Act which are approved by the audit committee or our board of directors prior to the completion of the audit). The auditors are not permitted to provide non audit services that would compromise their independence or violate any laws or regulations that would affect their appointment as auditors. They are eligible for selection to provide non audit services only to the extent that their skills and experience make them a logical supplier of the services.

All of the audit and non-audit services carried out in the years ended December 31, 2013 and 2014 were pre-approved by audit committee.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

None.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

On November 4, 2013, our board of directors approved a share repurchase program, authorizing us to repurchase up to \$200.0 million worth of our ADSs on the NYSE Euronext at prevailing market prices from time to time until July 2014 in trades pursuant to a Rule 10b5-1 repurchase plan or in accordance with applicable federal securities laws. The repurchase program was amended in March 2014 to authorize us to repurchase up to \$300.0 million worth of our ADSs. The share repurchase program lapsed on March 31, 2015 with no additional purchases thereunder in 2015. The table below sets forth certain information relating to our repurchases of ADSs under such program.

Period	Total Number of Shares (or Units) Purchased	Average Price Paid per Share (or Units)	Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2013 to October 30, 2013	—	—	—	—
November 1, 2013 to November 30, 2013	439,124	\$ 39.24	439,124	\$ 282.8 million ¹
December 1, 2013 to December 31, 2013	672,540	\$ 37.31	672,540	\$ 257.7 million ¹
January 1, 2014 to January 31, 2014	1,284,378	\$ 35.66	1,284,378	\$ 211.9 million ¹
February 1, 2014 to February 28, 2014	83,502	\$ 35.30	83,502	\$ 208.9 million ¹
March 1, 2014 to March 31, 2014	591,796	\$ 32.04	591,796	\$ 190.0 million ¹
Total	3,071,340	\$ 35.83	3,071,340	

¹ Such maximum dollar value is calculated based on \$300.0 million, the amended share repurchase program.

ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT

None.

ITEM 16G. CORPORATE GOVERNANCE

Differences between Cayman Islands and NYSE Corporate Governance Practices

We are incorporated in the Cayman Islands. Under Section 303A of the NYSE Manual, NYSE-listed non-companies may, in general, follow their home country corporate governance practices in lieu of some of the NYSE corporate governance requirements. We are committed to a high standard of corporate governance. As such, we endeavor to comply with most of the NYSE corporate governance practices. However, the following are the ways in which our current corporate governance practices differ from NYSE corporate governance requirements as the laws of the Cayman Islands do not require such compliance:

As of the date of this annual report, 50% of our directors are independent. As a result, we would not otherwise meet the requirement that a majority of our board be independent;

- We do not have a minimum of three members on our audit committee;

Our corporate governance and nominations committee of our board of directors is not comprised entirely of independent directors;

- Our compensation committee is not comprised entirely of independent directors; and
- We do not hold regular executive session meetings of non-management directors.

ITEM 16H. *MINE SAFETY DISCLOSURE*

Not applicable.

ITEM 17. *FINANCIAL STATEMENTS*

We have elected to provide our financial statements pursuant to Item 18.

ITEM 18. *FINANCIAL STATEMENTS*

Our consolidated financial statements are included at the end of this annual report.

ITEM 19. *EXHIBITS*

The following exhibits are filed as part of this annual report.

Index to Exhibits

Exhibit Number	Description
1.1	Amended and Restated Memorandum and Articles of Association of Mindray Medical International Limited (incorporated by reference from Exhibit 99.2 to the Registrant's Form 6-K filed with the Securities and Exchange Commission on November 10, 2008).
2.1	Form of American Depositary Receipt (incorporated by reference from Exhibit 4.1 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
2.2	Specimen Certificate for Class A Ordinary Shares (incorporated by reference from Exhibit 4.2 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 22, 2006).
2.3	Form of Deposit Agreement among Mindray Medical International Limited, The Bank of New York and owners and holders of the American Depositary Shares (incorporated by reference from Exhibit 4.3 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
2.4	Form of Indenture (incorporated by reference from Exhibit 4.4 to the Registrant's Form F-3 filed with the Securities and Exchange Commission on March 3, 2010).
4.1	Shareholders' Agreement between Mindray International Holdings Ltd., Shenzhen Mindray Bio- Medical Electronics Co., Ltd., the several shareholders named therein, and the several investors named therein, dated September 26, 2005 (incorporated by reference from Exhibit 4.4 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
4.2	Registration Rights Agreement between Mindray Medical International Limited and the several investors named therein, dated September 5, 2006 (incorporated by reference from Exhibit 4.5 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
4.3	Mindray DS USA, Inc. 401(k) Savings Plan (incorporated by reference from Exhibit 4.3 to the Registrant's Form S-8 filed with the Securities and Exchange Commission on September 16, 2010).
4.4	Employee Share Incentive Plan and form of Option Agreement (incorporated by reference from Exhibit 10.1 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
4.5	Amended and Restated Limited Share Incentive Plan (incorporated by reference from Exhibit 4 to the Registrant's Form S-8 filed with the Securities and Exchange Commission on January 5, 2012).
4.6	Form of Indemnification Agreement with the officers and directors of Mindray Medical International Limited (incorporated by reference from Exhibit 10.2 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
4.7	

Edgar Filing: Mindray Medical International LTD - Form 20-F

Form of Employment Agreement of Mindray Medical International Limited (incorporated by reference from Exhibit 10.3 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).

4.8 Grant Contract of Use Right of State-owned Land of Mindray headquarters building between Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Shenzhen Planning and State-owned Land Bureau, dated July 18, 2001 (incorporated by reference from Exhibit 10.4 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).

109

- 4.9 Agreement for Assignment of Trademark between Chang Run Da Electronic (Shenzhen) Co., Ltd. and Shenzhen Mindray Bio-Medical Electronics Co., Ltd., dated November 20, 2002 (incorporated by reference from Exhibit 10.5 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.10 Purchase Agreement of New Energy Building between Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Shenzhen Mindray Electronic Co., Ltd., dated April 9, 2002 (incorporated by reference from Exhibit 10.6 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.11 Lease Agreement of Reagent and Manufacturing building between Shenzhen Mindray Bio- Medical Electronics Co., Ltd. and Shenzhen Zhongguan Company Limited, dated June 28, 2004 (incorporated by reference from Exhibit 10.7 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.12 Lease Agreement of Manufacturing Building between Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Shenzhen Zhongguan Company Limited, dated July 27, 2005 (incorporated by reference from Exhibit 10.8 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.13 Subscription and Share Purchase Agreement dated July 6, 2005 and Subscription and Share Purchase Amendment Agreement dated August 22, 2005 (incorporated by reference from Exhibit 10.9 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.14 Form of Agreement on Transfer of Shares of Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (incorporated by reference from Exhibit 10.10 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.15 Form of Equity Transfer Agreement (incorporated by reference from Exhibit 10.11 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on September 6, 2006).
- 4.16 Investment Cooperation Agreement between Mindray Medical International Limited and the Management Committee of the Nanjing Jiangning Economic and Technological Development Zone, dated December 27, 2006 (incorporated by reference from Exhibit 10.12 to the Registrant's Form F-1 filed with the Securities and Exchange Commission on January 24, 2007).
- 4.17 Asset Purchase Agreement by and between Datascope Corp. and Mindray Medical International Limited, dated as of March 10, 2008 (incorporated by reference from Exhibit 10.1 to the Registrant's Form 6-K filed with the Securities and Exchange Commission on May 15, 2008).
- 4.18 Loan Agreement by and among MR Holdings (HK) Limited, MR Investments (HK) Limited, Mindray Medical International Limited and Bank of China (HK) Limited, dated as of April 23, 2008 (incorporated by reference from Exhibit 10.2 to the Registrant's Form 6-K filed with the Securities and Exchange Commission on May 15, 2008).
- 8.1* List of subsidiaries.
- 11.1 Code of Ethics (incorporated by reference from Exhibit 11.1 to the Registrant's Form 20-F filed with the Securities and Exchange Commission on June 30, 2008).

Edgar Filing: Mindray Medical International LTD - Form 20-F

- 12.1* Certification of Co-Chief Executive Officer pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a)).
- 12.2* Certification of Co-Chief Executive Officer pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-14(a) (17 CFR 240.15d-14(a)).
- 12.3* Certification of Chief Financial Officer pursuant to Rule 13a-14(a) (17 CFR 240.13a-14(a)) or Rule 15d-1(a) (17 CFR 240.15d-1(a)).
- 13.1* Certification pursuant to Rule 13a-14(b) (17 CFR 240.13a-14(b)) or Rule 15d-14(b)(17 CFR 240.15d-14(b)) and 18 U.S.C. Section 1350.

110

23.1* Consent of PricewaterhouseCoopers, Independent Registered Public Accounting Firm.

101.INS* XBRL Instance Document

101.SCH* XBRL Taxonomy Extension Schema Document

101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* Taxonomy Extension Definition Linkbase Document

101.LAB* Taxonomy Extension Label Linkbase Document

101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

* Filed with this Annual Report.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

Mindray Medical International Limited

/s/ Alex Lung
Alex Lung
Chief Financial Officer

Date: April 16, 2015

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, 2012, 2013 and 2014

Table of Contents

MINDRAY MEDICAL INTERNATIONAL LIMITED

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS

Contents	Pages
<u>Report of Independent Registered Public Accounting Firm</u>	F-2
<u>Consolidated Balance Sheets as of December 31, 2013 and 2014</u>	F-3
<u>Consolidated Statements of Operations for the years ended December 31, 2012, 2013 and 2014</u>	F-4
<u>Consolidated Statements of Comprehensive Income for the years ended December 31, 2012, 2013 and 2014</u>	F-5
<u>Consolidated Statements of Shareholders' Equity for the years ended December 31, 2012, 2013 and 2014</u>	F-6
<u>Consolidated Statements of Cash Flows for the years ended December 31, 2012, 2013 and 2014</u>	F-7 – F-8
<u>Notes to the Consolidated Financial Statements for the years ended December 31, 2012, 2013 and 2014</u>	F-9 – F-39

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of Mindray Medical International Limited:

In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, comprehensive income, shareholders' equity and cash flows present fairly, in all material respects, the financial position of Mindray Medical International Limited and its subsidiaries at December 31, 2014 and December 31, 2013, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2014 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2014, based on criteria established in *Internal Control — Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in Management's Report on Internal Control over Financial Reporting appearing under Item 15. Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers

Hong Kong

April 16, 2015

F-2

MINDRAY MEDICAL INTERNATIONAL LIMITED**CONSOLIDATED BALANCE SHEETS****(In thousands of US dollars, except share and per share amounts)**

	As of December 31,	
	2013	2014
ASSETS		
Current assets:		
Cash and cash equivalents	\$385,224	\$276,598
Restricted cash	759	7,422
Short-term investments	847,041	816,394
Accounts receivable, net of allowance of \$14,571 and \$15,076	220,228	222,522
Inventories	138,808	150,642
Value added tax receivables	10,225	3,432
Other receivables	21,512	23,316
Prepayments and deposits	14,310	16,481
Deferred tax assets, net	9,585	14,802
Total current assets	1,647,692	1,531,609
Restricted cash, non-current	17,453	5,061
Other assets	10,755	9,666
Accounts receivable-non-current, net of allowance of \$nil and \$nil	1,389	3,350
Advances for purchase of property, plant and equipment	18,919	21,840
Property, plant and equipment, net	324,710	412,733
Land use rights, net	59,463	59,057
Intangible assets, net	181,077	175,451
Goodwill	242,476	254,435
Total assets	\$2,503,934	\$2,473,202
LIABILITIES AND EQUITY		
Current liabilities:		
Short-term bank loans	\$260,000	\$59,625
Notes payable	10,945	9,234
Accounts payable	93,673	93,523
Advances from customers	28,240	31,396
Salaries payable	91,220	114,583
Other payables and current liabilities	118,951	168,139
Purchase consideration payable	20,457	17,173
Income taxes payable	20,721	20,415
Other taxes payable	12,832	10,342
Total current liabilities	657,039	524,430

Edgar Filing: Mindray Medical International LTD - Form 20-F

Long-term bank loans	215,703	197,585
Other long-term liabilities	7,222	10,670
Deferred tax liabilities, net	45,812	69,233
Total liabilities	925,776	801,918
Commitments and contingencies (Note 22)		
Mindray shareholders' equity:		
Ordinary shares ^(a) (HK\$0.001 par value, 5,000,000,000 shares authorized, 118,328,437 shares and 117,301,753 shares issued and outstanding, respectively)	15	15
Additional paid-in capital	521,617	453,564
Retained earnings	865,676	1,000,257
Accumulated other comprehensive income	150,432	144,120
Treasury stock at cost, 506,543 shares and nil shares, respectively	(18,792)	-
Total Mindray shareholders' equity	1,518,948	1,597,956
Non-controlling interests	59,210	73,328
Total equity	1,578,158	1,671,284
Total liabilities and equity	\$2,503,934	\$2,473,202

Note (a) Ordinary shares of the Company consists of Class A and Class B ordinary shares as follows:

¹ Class A ordinary shares, HK\$0.001 par value per share, 4,000,000,000 shares authorized, 89,208,530 shares and 88,181,846 shares issued and outstanding as of December 31, 2013 and 2014, respectively.

² Class B ordinary shares, HK\$0.001 par value per share, 1,000,000,000 shares authorized, 29,119,907 shares and 29,119,907 shares issued and outstanding as of December 31, 2013 and 2014, respectively.

The accompanying notes are an integral part of these consolidated financial statements.

MINDRAY MEDICAL INTERNATIONAL LIMITED**CONSOLIDATED STATEMENTS OF OPERATIONS****(In thousands of US dollars, except share and per share amounts)**

	Years Ended December 31,		
	2012	2013	2014
Net revenues	\$1,060,054	\$1,213,987	\$1,322,814
Cost of revenues ^(a)	(459,389)	(527,402)	(584,310)
Gross profit	600,665	686,585	738,504
Operating expenses:			
Selling expenses ^(a)	(188,804)	(220,589)	(261,965)
General and administrative expenses ^(a)	(116,228)	(128,308)	(137,016)
Research and development expenses ^(a)	(104,302)	(127,464)	(146,997)
Income from operations	191,331	210,224	192,526
Other income, net	1,619	3,881	9,363
Interest income	30,794	37,047	38,985
Interest expense	(4,093)	(6,345)	(6,400)
Income before income taxes and non-controlling interests	219,651	244,807	234,474
Provision for income taxes	(37,369)	(14,260)	(35,485)
Net income	\$182,282	\$230,547	\$198,989
Less: Net income attributable to non-controlling interests	(2,073)	(5,793)	(5,697)
Net income attributable to Mindray shareholders	\$180,209	\$224,754	\$193,292
Net income attributable to Mindray shareholders per share - basic	\$1.54	\$1.91	\$1.65
Net income attributable to Mindray shareholders per share - diluted	\$1.50	\$1.87	\$1.63
Shares used in per share calculation - basic	116,749,213	117,705,414	117,057,116
Shares used in per share calculation - diluted	119,815,004	120,051,635	118,412,460

Note (a):

Years Ended December 31,
2012 2013 2014

Share-based compensation charged during the years related to:

Cost of revenues	\$ 811	\$ 752	\$ 1,120
Selling expenses	4,457	4,345	6,420

Edgar Filing: Mindray Medical International LTD - Form 20-F

General and administrative expenses	4,409	4,819	7,616
Research and development expenses	4,307	4,767	4,714

The accompanying notes are an integral part of these consolidated financial statements.

F-4

MINDRAY MEDICAL INTERNATIONAL LIMITED**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME****(In thousands of US dollars)**

	Years Ended December 31,		
	2012	2013	2014
Net income	\$ 182,282	\$ 230,547	\$ 198,989
Other comprehensive income			
Foreign currency translation adjustments	16,417	33,876	(6,312)
Comprehensive income	198,699	264,423	192,677
Less: Comprehensive income attributable to non-controlling interests	(2,073)	(5,793)	(5,697)
Comprehensive income attributable to Mindray shareholders	\$ 196,626	\$ 258,630	\$ 186,980

The accompanying notes are an integral part of these consolidated financial statements.

MINDRAY MEDICAL INTERNATIONAL LIMITED

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(In thousands of US dollars, except share and per share amounts)

	Ordinary Shares	Additional Paid-in Capital		Retained Earnings	Accumulated Other Comprehensive Income	Treasury Stock	Total Mindray Shareholders' Equity	Non-controlling Interests	Total Equity
	Number	Amount	Amount						
As of December 31, 2011	115,341,581	\$15	\$486,314	\$566,184	\$100,139	\$(10,160)	\$1,142,492	\$8,943	\$1,151,435
Net income	-	-	-	180,209	-	-	180,209	2,073	182,282
Non-controlling interests arising from acquisition of subsidiaries	-	-	-	-	-	-	-	34,124	34,124
Dividends declared, \$0.40 per share ^(a)	-	-	-	(46,401)	-	-	(46,401)	-	(46,401)
Issuance of ordinary shares in relation to exercise of options/issuance of restricted shares	2,092,950	-	24,593	-	-	-	24,593	-	24,593
Share-based compensation	-	-	14,156	-	-	-	14,156	-	14,156
Foreign currency translation adjustments	-	-	-	-	16,417	-	16,417	3	16,420
Reissuance of treasury stock in relation to exercise of options/issuance of restricted shares	-	-	(10,160)	-	-	10,160	-	-	-
Others	-	-	(623)	-	-	-	(623)	1,129	506
As of December 31, 2012	117,434,531	\$15	\$514,280	\$699,992	\$116,556	\$-	\$1,330,843	\$46,272	\$1,377,115

Edgar Filing: Mindray Medical International LTD - Form 20-F

Net income	-	-	-	224,754	-	-	224,754	5,793	230,547
Non-controlling interests arising from acquisition of subsidiaries	-	-	-	-	-	-	-	7,083	7,083
Dividends declared, \$0.50 per share ^(a)	-	-	-	(59,070)	-	-	(59,070)	-	(59,070)
Issuance of ordinary shares in relation to exercise of options/issuance of restricted shares	2,005,570	-	16,091	-	-	-	16,091	-	16,091
Share-based compensation	-	-	14,823	-	-	-	14,823	-	14,823
Foreign currency translation adjustments	-	-	-	-	33,876	-	33,876	62	33,938
Purchase of treasury stock	(1,111,664)	-	-	-	-	(42,369)	(42,369)	-	(42,369)
Retirement of treasury stock	-	-	(23,577)	-	-	23,577	-	-	-
As of December 31, 2013	118,328,437	\$ 15	\$ 521,617	\$ 865,676	\$ 150,432	\$(18,792)	\$ 1,518,948	\$ 59,210	\$ 1,578,158
Net income	-	-	-	193,292	-	-	193,292	5,697	198,989
Non-controlling interest arising from acquisition of a subsidiary	-	-	-	-	-	-	-	8,915	8,915
Dividends declared, \$0.50 per share ^(a)	-	-	-	(58,711)	-	-	(58,711)	-	(58,711)
Issuance of ordinary shares in relation to exercise of options/issuance of restricted shares	932,992	-	3,324	-	-	-	3,324	-	3,324
Share-based compensation	-	-	20,131	-	-	-	20,131	-	20,131
Foreign currency translation adjustments	-	-	-	-	(6,312)	-	(6,312)	25	(6,287)
Purchase of treasury stock	(1,959,676)	-	-	-	-	(68,080)	(68,080)	-	(68,080)

Edgar Filing: Mindray Medical International LTD - Form 20-F

Retirement of treasury stock	-	-	(86,872)	-	-	-	86,872	-	-	-
Cash contribution from a non-controlling interest	-	-	-	-	-	-	-	-	655	655
Cash paid to acquire non-controlling interests	-	-	(4,636)	-	-	-	-	(4,636)	(1,174)	(5,810)
As of December 31, 2014	117,301,753	\$15	\$453,564	\$1,000,257	\$144,120	\$-	\$1,597,956	\$73,328	\$1,671,284	

Note (a) The Company declared a cash dividend of \$0.4, \$0.5 and \$0.5 per each Class A ordinary share and each Class B ordinary share for the years ended December 31, 2012, 2013 and 2014, respectively.

The accompanying notes are an integral part of these consolidated financial statements.

MINDRAY MEDICAL INTERNATIONAL LIMITED**CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands of US dollars)**

	Years Ended December 31,		
	2012	2013	2014
Cash flows from operating activities:			
Net income	\$ 182,282	\$ 230,547	\$ 198,989
Adjustments to reconcile net income to net cash provided by operating activities:			
Amortization of land use rights	1,246	1,338	1,369
Depreciation of property, plant and equipment	28,043	33,499	36,017
Non-cash impairment charges on intangible asset	308	-	-
Amortization of intangible assets	13,115	19,741	21,278
Inventories write-down	2,609	2,154	1,633
Allowance (recovery) for doubtful accounts	9,572	(940)	2,002
Amortization of bank loan costs	-	893	1,205
Loss (gain) on disposal of property, plant and equipment	39	10	(80)
Loss (gain) on fair value change of derivative instruments	835	(101)	157
Share-based compensation expenses	13,984	14,683	19,870
Deferred income taxes	(27)	1,016	15,629
Changes in assets and liabilities, net of effects of acquisitions:			
Accounts receivable	7,308	(15,002)	(7,103)
Inventories	(11,185)	(18,984)	(14,635)
Value added tax receivables	3,505	(2,608)	6,753
Other receivables	(13,646)	(5,177)	3,773
Prepayments and deposits	(1,108)	(3,087)	(1,993)
Other assets	(3,324)	486	1,050
Notes payable	1,568	2,023	(1,654)
Accounts payable	5,965	27,663	(504)
Advances from customers	(3,352)	3,608	2,178
Salaries payable	29,597	17,120	23,727
Other payables and current liabilities	42,914	4,805	20,256
Income taxes payable	12,701	(9,942)	(245)
Other taxes payable	1,068	3,515	(2,666)
Other long-term liabilities	1,649	658	3,448
Net cash provided by operating activities	325,666	307,918	330,454
Cash flows from investing activities:			
Acquisition cost of subsidiaries, net of cash received	(34,552)	(109,376)	(11,764)
Purchase of property, plant and equipment and intangible assets	(54,132)	(83,739)	(82,541)
Purchase of land use rights	(660)	(2,602)	(1,179)

Edgar Filing: Mindray Medical International LTD - Form 20-F

Advances for purchase of property, plant and equipment	(10,813)	(22,739)	(23,404)
Proceeds from disposal of property, plant and equipment	1,766	741	981
(Increase) decrease in restricted cash	(7,246)	(10,966)	4,370
(Increase) decrease in restricted investment	(14,282)	14,282	-
Proceeds from sale of short-term investments	144,395	652,896	825,839
Increase in short-term investments	(257,021)	(863,038)	(805,140)
Net cash used in investing activities	(232,545)	(424,541)	(92,838)

F-7

MINDRAY MEDICAL INTERNATIONAL LIMITED**CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued)****(In thousands of US dollars)**

	Years Ended December 31,		
	2012	2013	2014
Cash flows from financing activities:			
Repayment of bank loans	(2,475)	(35,000)	(214,375)
Proceeds from bank loans, net of costs	52,000	371,715	-
Dividends paid	(46,401)	(59,070)	(58,711)
Proceeds from exercise of options	24,593	16,091	3,324
Repurchase of ordinary American depository shares	-	(42,369)	(68,080)
Cash contribution from a non-controlling interest	506	-	655
Cash paid to acquire non-controlling interests	-	-	(5,810)
Net cash provided by (used in) financing activities	28,223	251,367	(342,997)
Net increase (decrease) in cash and cash equivalents	121,344	134,744	(105,381)
Cash and cash equivalents, beginning of year	124,311	247,859	385,224
Effect of exchange rate changes on cash and cash equivalents	2,204	2,621	(3,245)
Cash and cash equivalents, end of year	\$247,859	\$385,224	\$276,598
Supplemental disclosure for cash flows information:			
Income taxes paid, net of tax benefits received	\$27,372	\$24,152	\$21,083
Interest paid	3,619	5,528	6,068
Supplemental disclosure for non-cash activities:			
Capital expenditures incurred but not yet paid	\$11,093	\$11,710	\$38,422
Purchase consideration payable	20,354	20,457	17,173

The accompanying notes are an integral part of these consolidated financial statements.

MINDRAY MEDICAL INTERNATIONAL LIMITED

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(In thousands of US dollars, except share and per share amounts)

1 Organization and principal activities

Mindray Medical International Limited (“Mindray”, “Mindray International” or the “Company”) was incorporated as an exempted company with limited liability in the Cayman Islands on June 10, 2005 under the Companies Law of the Cayman Islands.

The Company is a leading developer, manufacturer and marketer of medical devices worldwide. The Company maintains its global operational headquarters in Shenzhen, the People’s Republic of China (“PRC”), U.S. headquarters in Mahwah, New Jersey, and multiple sales offices in domestic and major international markets. From its main manufacturing and engineering base in the PRC and through the worldwide distributor and direct sales networks, the Company supplies internationally a broad range of products across three primary business segments: patient monitoring and life support products, in-vitro diagnostic products, and medical imaging systems.

2 Summary of significant accounting policies

(a) Basis of presentation and principles of consolidation

The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).

The consolidated financial statements include the financial statements of the Company and all its majority-owned and controlled subsidiaries. The Company does not have interests in any variable interest entities. All significant intercompany balances and transactions have been eliminated upon consolidation. The Company has included the results of operations of acquired companies from the date of acquisition.

(b) Use of estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenues and expenses in the financial statements and accompanying notes. The accounting estimates which have had an impact on the Company's financial statements include but not limited to share-based compensation, impairment of intangible assets including goodwill, impairment of long-lived assets, purchase price allocation, fair value of derivative instruments, allowance for sales returns, allowance for doubtful accounts, inventories write-down, cost of sales incentives, provision for warranty expenses, economic useful lives of property, plant and equipment and intangible assets, accrued liabilities, income taxes and tax valuation allowances. Actual results could differ from those estimates.

(c) Cash and cash equivalents

Cash and cash equivalents consist of cash on hand and highly liquid short-term deposits which are unrestricted as to withdrawal and use, and which have original maturities less than three months.

An amount of \$82,337 and \$126,795 as of December 31, 2013 and 2014, respectively included in cash and cash equivalents are compensating balance arrangement in relation to bank loans (see Note 10 for details).

(d) Restricted cash and restricted investment

Restricted cash and restricted investment are cash and investment that are restricted as to withdrawal or usage. For restriction which is not expected to be released within one year of the balance sheet date, restricted cash and restricted investment are classified as non-current.

Restricted cash as of December 31, 2013 and 2014 was primarily (1) purchase consideration in connection with the Company's acquisition of certain of its subsidiaries held in escrow accounts which were opened by escrow agents for the Company and payable to the sellers according to the terms set forth in the Company's acquisition agreements and (2) cash held as collateral for letters of credit issued for normal business operation.

As of December 31, 2013 and 2014, there is no restricted investment.

(e) Short-term investments

Short-term investments primarily consist of highly liquid investments with maturities greater than 90 days and less than one year at the date of purchase.

As of December 31, 2013 and 2014, short-term investments mainly consisted of investments in RMB denominated financial products in an aggregate amount of \$823,172 and \$797,039, respectively. The Company primarily invests in RMB denominated financial products offered through high-credit quality financial institutions in the PRC, including Bank of China. These financial products consist of a pool of assets selected and managed by the banks and/or its custodian. They are contractually mature at various periods throughout 2014 and 2015, respectively. The Company's investments in RMB denominated financial products are primarily with 100% capital protection from the banks. As of December 31, 2013 and 2014, the accrued interest rate of the Company's RMB denominated financial products ranged from 4.5% to 5.7% per annum and from 3.7% to 5.6% per annum, respectively.

Investments in RMB denominated financial products are stated in the consolidated balance sheets at the principal amount plus accrued interest income. Interest income is calculated at the specified interest rate and is recognized as interest income on the consolidated statements of operations.

An amount of \$159,163 and \$62,205 as of December 31, 2013 and 2014, respectively in RMB denominated financial products placed with Bank of China are compensating balance arrangement in relation to bank loans (see Note 10 for details).

The fair values of forward foreign exchange contract were recorded in short-term investments on the consolidated balance sheets. (See Note 2(x) for details)

(f) Accounts receivable, net

Receivables on the consolidated balance sheets are stated net of allowance for doubtful accounts. Receivables with original maturities dated more than one year from the balance sheet date are classified as non-current. The Company maintains allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The allowance is determined by (i) analyzing specific customer accounts that have known or potential collection issues, and (ii) then applying historical loss rates to the remaining accounts receivable balances based on aging. For purposes of analyzing specific accounts receivable with known or potential collection issues, the Company considers factors such as the background of the customer and its current affairs, on-going or historical disputes, litigation and going concerns.

The Company purchases export credit insurance to mitigate the risk of loss and accounts receivable impairment on sales to most of its international distributors who have purchased its products under credit terms. Under these arrangements, the Company's insurer reviews the relevant customer contract and sales invoice and establishes a specified insurable amount (generally ranging from 80-90% of the outstanding invoice amount) based on the insurer's assessment of collectability. The Company records provisions for estimated losses on receivable balances covered by export credit insurance based on specific identification. Such provision is made on 100% of the accounts receivable in question. After provision is made, the Company considers if an insurance receivable should be recorded. The Company records an insurance receivable only when recoveries are probable, which is when the Company has submitted a claim with all necessary information, on the basis that there is a legally enforceable contract, for the insurable amounts. The Company has historically received related insurance claims payment within 12-18 months of filing the claim.

(g) Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is calculated using the standard costing, which approximates average costing. Write downs of potentially obsolete or slow-moving inventories are recorded based on the management's specific analysis of future sales forecasts and economic conditions.

(h) Property, plant and equipment, net

Property, plant and equipment are carried at cost less accumulated depreciation and impairment loss, if any. Assets under construction are not depreciated until construction is completed and the assets are ready for their intended use. Gains and losses from the disposal of property, plant and equipment are included in income from operations. Repairs and maintenance costs are expensed as incurred.

Depreciation is computed on a straight-line basis over the estimated useful lives of assets as follows:

Classification	Years
Land	Indefinite
Buildings and leasehold improvements	Shorter of lease term or 20 to 50 years
Plant and machinery	3 to 10 years
Electronic equipment, furniture and fixtures	2 to 10 years
Motor vehicles	3 to 5 years

(i) Land use rights, net

Land use rights represent fees paid to acquire the right to use the land in the PRC for a specified period of time and are stated at cost less accumulated amortization and impairment loss, if any. Amortization is computed using straight-line basis over their respective lease periods, ranging from 20 to 50 years.

(j) Intangible assets, net

Intangible assets with finite useful lives consist of tradenames, technologies, core technologies, customer relationships and lease agreement. They are carried at cost less accumulated amortization and impairment loss, if any. Amortization is computed using straight-line basis over their estimated useful lives, ranging from 1 to 20 years.

Intangible assets with infinite lives, excluding goodwill, are carried at cost and are not subject to amortization. It primarily consists of tradenames. It is tested for impairment at the reporting unit level on at least an annual basis or when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount in accordance with ASC 350, "Intangibles - Goodwill and Other" ("ASC 350"). The evaluation of indefinite-lived intangible assets for impairment involves two steps. The first step is to compare the fair value of the reporting unit with its carrying amount. If the fair value of the reporting unit is less than the carrying value, a second step is performed to determine the implied fair value of indefinite-lived intangible assets. If the implied fair value of indefinite-lived intangible assets is lower than its carrying value, an impairment charge equal to the difference is recorded. No impairments of indefinite-lived intangible assets were identified during any of the years presented.

(k) Goodwill

Goodwill represents the excess of the purchase price plus fair value of non-controlling interests over the fair value of identifiable assets and liabilities acquired. Goodwill is not amortized, but is tested for impairment at the reporting unit level on at least an annual basis or when an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount in accordance with ASC 350. The evaluation of goodwill for impairment involves two steps. The first step is to compare the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit is less than the carrying value, a second step is performed to determine the implied fair value of goodwill. If the implied fair value of goodwill is lower than its carrying value, an impairment charge equal to the difference is recorded. No impairments of goodwill were identified during any of the years presented.

(l) Impairment of long-lived assets

In accordance with ASC 360, "Impairment or Disposal of Long-Lived Assets", the Company evaluates the carrying value of its long-lived assets such as intangible assets subject to amortization, property, plant and equipment and land use rights whenever events or changes in circumstance indicate that the carrying amount of the assets may not be recoverable. If the sum of the projected undiscounted cash flows expected to be generated from the asset's use and eventual disposition is less than the carrying amount of the long-lived assets, the Company would recognize an impairment loss based on the difference between the estimated fair values of the assets calculated using a discounted cash flow and the carrying amount. A non-cash impairment loss of \$308, \$nil and \$nil were recorded for intangible assets with finite useful lives during the years ended December 31, 2012, 2013 and 2014, respectively.

Management judgment is required in the area of asset impairment, particularly in assessing whether an event has occurred that indicates potential impairment. The estimation of future cash flows attributable to assets require significant judgment based on the Company's historical and anticipated results and are subject to many factors. Different assumptions and judgments could materially affect estimated future cash flows relating to assets which could trigger impairment.

(m) Treasury stock

The Company accounted for treasury stock under the cost method. At retirement, excess of the cost of treasury stock over its par value was charged entirely to additional paid-in capital. As of December 31, 2013 and 2014, the amount of treasury stock was \$18,792 and \$nil, respectively. (See Note 13 for details).

(n) Revenue recognition

The Company generates revenue from sale of medical devices. The medical devices that the Company sells include a software element which is essential to the functionality of the tangible medical devices. Therefore, revenues from the sale of medical devices are recognized when all of the following conditions have been satisfied:

- There is persuasive evidence of an arrangement;
- Delivery has occurred (e.g., an exchange has taken place);
- The sales price is fixed or determinable; and
- Collectability is reasonably assured.

All sales are based on firm customer orders with fixed terms and conditions. The Company does not provide its customers with general right of return (except for certain direct customers which were required by applicable law and regulations), price protection or cash rebates. The sales arrangements generally do not include any significant post customer support services and does not provide customers with upgrades. Accordingly, revenue from the sale of products is typically recognized upon shipment, when the terms are free-on-board shipping point, or upon delivery. For products sold with installation service, revenue is allocated to the products and installation service elements if the products delivered have standalone value to the customer, and based on the price at which the product and installation service are expected to be sold on a standalone basis. For sales of services, revenue is recognized in period in which the services were rendered.

The Company offers sales incentives to certain customers in the form of free products if they meet certain level of purchases. The costs of these sales incentives are estimated and accrued as cost of revenues with a corresponding increase in current liability at the time of revenue recognition based on the Company's past experience and its customers' purchase history.

The Company presents revenues net of value-added tax ("VAT"). In China, the VAT represents a 17% tax collected from customers on behalf of the tax authority, which amounted to \$78,024, \$100,311 and \$127,295 for the years ended December 31, 2012, 2013 and 2014, respectively, offset by a 14% VAT refund which the Company is entitled to for sales of products with embedded self-developed software of \$26,898, \$28,406 and \$31,869, respectively for the years ended December 31, 2012, 2013 and 2014. The VAT refunds are recognized on an accrual basis.

(o) Warranty provision

The Company provides a warranty provision at the time product revenue is recognized based on the historical rate of warranty services rendered. Such provision is included in cost of revenues on the consolidated statements of operations. The provision is reviewed during the year and is adjusted, if appropriate, to reflect new product offerings or changes in experience. Actual warranty claims are tracked by product line. Movements in accrued warranty provision which was included in other payables on the consolidated balance sheets as of December 31, 2012, 2013 and 2014 were as follows:

	December 31,		
	2012	2013	2014
Balance, beginning of year	\$9,342	\$11,417	\$13,583
Warranty liabilities assumed in connection with acquisitions	-	765	-
Provision made during the year	12,714	12,958	21,534
Settlement made during the year	(10,789)	(11,775)	(18,233)
Foreign currency translation adjustments	150	218	(60)
Balance, end of year	\$11,417	\$13,583	\$16,824

(p) Shipping and handling costs

Shipping and handling costs are included in cost of revenues on the consolidated statements of operations. For the years ended December 31, 2012, 2013 and 2014, shipping and handling costs were \$21,230, \$24,003 and \$26,775, respectively.

(q) Government subsidies

Government subsidies include cash subsidies and incentives received from the PRC government as recorded by the PRC subsidiaries of the Company. Such subsidies are generally provided in relation to the development of new high-technology medical products, purchase of export credit insurance as well as State and/or local government incentives which aim to encourage capital investment in high-technology industry in China, to file patent applications for new invention, to optimize their foreign trade structure and other projects that was encouraged by government from time to time. Subsidies are recognized as deferred income when received and recognized as other income when all the conditions for their entitlement have been satisfied. Subsidies recognized as other income on the consolidated statements of operations were \$1,725, \$3,972 and \$7,154 for the years ended December 31, 2012, 2013 and 2014, respectively.

(r) Software development costs

The Company capitalizes software development costs in accordance with ASC 985-20, "Costs of Software to be Sold, Leased or Marketed". Software development costs are capitalized after technological feasibility is established upon completion of a working model or detailed software design specification. Once the software products become available for general releases to the public, the Company amortizes costs over the related product's estimated economic useful life to cost of revenues ranging from 3 to 7 years. Net capitalized software development costs were included in intangible assets on the consolidated balance sheets as core technologies.

Net capitalized software development costs as of December 31, 2013 and 2014 consisted of the following:

	December 31,		
	2012	2013	2014
Capitalized software development costs			
Balance at beginning of year	\$33,046	\$45,203	\$54,548
Capitalization made during the year	12,073	8,230	5,777
Foreign currency translation adjustments	84	1,115	(242)
Balance at end of year	45,203	54,548	60,083
Less: Accumulated amortization			
Balance at beginning of year	(2,779)	(7,055)	(13,386)
Amortization made during the year	(4,189)	(6,077)	(6,802)
Foreign currency translation adjustments	(87)	(254)	22
Balance at end of year	(7,055)	(13,386)	(20,166)
Total net capitalized software development costs	\$38,148	\$41,162	\$39,917

(s) Research and development costs

Research and development costs are incurred in the development of the new products and processes, including significant improvements and refinements to existing products. Research and development costs are expensed as incurred, except for software development costs as disclosed in Note 2(r).

(t) Advertising expenses

Advertising costs are expensed as incurred. Advertising expenses were \$1,921, \$2,403 and \$2,017 for the years ended December 31, 2012, 2013 and 2014, respectively, and were included in selling expenses on the consolidated statements of operations.

(u) Staff retirement plan costs

The Company's costs related to its defined contribution staff retirement plans are expensed as incurred (See Note 18).

(v) Share-based compensation

The Company accounts for share-based compensation to employees of the Company based on the fair value of the share options or restricted shares at grant date. The Company elected to use the Black-Scholes Option Pricing Model to determine the fair value of share options on the dates of grant. Restricted shares are measured based on the fair market values of the underlying stock on the dates of grant. Share-based compensation expense is recognized in accordance with ASC 718, "Compensation - Stock compensation", using the graded vesting attribution over the vesting period when it is probable that the performance condition will be achieved.

In December 2013, the Company extended the expiration dates of certain batch of fully vested options that have not been exercised by the employees for another two years. The difference between the fair value of the modified award and the fair value of the original award (immediately before it was modified) amounted to \$670 was fully charged to consolidated statements of operations at the date of modification.

(w) Operating leases

Leases where substantially all the rewards and risks of ownership of assets remain with the leasing company are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease period.

(x) Derivative instruments

ASC 815, "Accounting for Derivative Instruments and Hedging Activities" ("ASC 815") requires every derivative instrument (including certain derivative instruments embedded in other contracts) to be recorded on the balance sheet at fair value as either an asset or a liability. ASC 815 also requires that changes in the fair value of recorded derivatives be recognized currently in earnings unless specific hedge accounting criteria are met.

The Company entered into various forward foreign exchange contracts to limit its exposure to fluctuation in foreign currency exchange rates during the years ended December 31, 2012, 2013 and 2014. According to ASC 815, all these forward foreign exchange contracts are not accounted for under hedge accounting. The notional amounts of these forward foreign exchange contracts were \$8,451, \$33,957 and \$nil as of December 31, 2012, 2013 and 2014, respectively. These instruments are recorded at their fair value amounting to \$56, \$157 and \$nil as of December 31, 2012, 2013 and 2014, respectively and were all included in short-term investments on the consolidated balance sheets. The Company recorded a loss on derivative instruments of \$835, a gain on derivative instruments of \$101 and a loss on derivative instruments of \$157 during the years ended December 31, 2012, 2013 and 2014, respectively. Such gain/(loss) on derivative instruments was included in general and administrative expenses on the consolidated statements of operations.

(y) Income taxes

The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets, including those related to tax loss carry-forwards and credits, and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using the enacted tax rates in effect for the year in which differences are expected to reverse. A valuation allowance is recorded to reduce deferred tax assets when it is more likely than not that the net deferred tax asset will not be realized.

The Company accounts for a tax benefit from an uncertain position in the financial statements only if it is more-likely-than-not that the position is sustainable, based solely on its technical merits and consideration of the relevant taxing authority's widely understood administrative practices and precedents. If the recognition threshold for the tax position is met, the Company records only the portion of the tax benefit that is greater than 50 percent likely to be realized.

(z) Basic and diluted earnings per share

Basic earnings per share is computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period.

Diluted earnings per share give effect to all dilutive potential ordinary shares outstanding during the period. The weighted average number of ordinary shares outstanding is adjusted to include the number of additional ordinary shares that would have been outstanding if the dilutive potential ordinary shares had been issued. Potential ordinary shares are calculated using the treasury stock method and consist of unvested restricted stock and the incremental common shares issuable upon the exercise of share options.

(aa) Foreign currency transactions

The functional currency of the Company is the U.S. dollar ("USD"). The functional currency of the Company's foreign subsidiaries and branches primarily is the applicable local currency. All transactions in currencies other than functional currencies during the year are remeasured at the exchange rates prevailing on the respective transaction dates. Monetary assets and liabilities existing at the balance sheet date denominated in currencies other than functional currencies are remeasured at the exchange rates existing on that date. For the years ended December 31, 2012, 2013 and 2014, the total foreign currency exchange differences of \$976, \$8,863 and \$8,627, respectively was included in the general and administrative expenses on the consolidated statements of operations.

Assets and liabilities of non-US dollar functional currency entities are translated into U.S. dollars using the applicable exchange rates at the balance sheet date. Items in the statements of operations are translated into U.S. dollars using the average exchange rate during the period. Equity accounts were translated at their historical exchange rates. The resulting translation adjustments are accumulated as a component of accumulated other comprehensive income on the consolidated statements of shareholders' equity.

(bb) Comprehensive income

Comprehensive income refers to the change in equity of the Company during the year from transactions and other events and circumstances from non-owner sources. Comprehensive income comprises net income and other comprehensive income. Other comprehensive income refers to revenues, expenses, gains, and losses that under U.S. GAAP are included in statements of shareholders' equity but excluded from net income. During the years presented, the Company's comprehensive income includes its net income and foreign currency translation adjustments. Comprehensive income is presented on the consolidated statements of comprehensive income.

(cc) Fair value disclosures

The fair value of a financial instrument is the amount at which the financial instrument would be exchanged in a current transaction between willing parties. The carrying amounts of cash and cash equivalents, restricted cash, restricted investments, short-term investments, accounts receivable, value added tax receivables, other receivables, prepayments and deposits, short-term bank loans, notes payable, accounts payable, advances from customers, salaries payable, other payables and current liabilities, purchase consideration payable, income tax payable and other taxes payable approximate their fair values due to the short-term nature of these instruments. The carrying amounts of long-term bank loans also approximate their fair value as the interest rate on the debt is close to prevailing market rate as of December 31, 2013 and 2014.

(dd) Fair value measurement

Fair value reflects the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability.

The Company applies a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value:

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

F-14

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The estimated fair values of the Company's financial assets and liabilities classified under the appropriate level of the fair value hierarchy as described above was as follows:

	Fair Value Measurements Using			
	Total Fair Value	Quoted Prices in Active Market for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
As of December 31, 2013				
Cash and cash equivalents	\$385,224	\$ 385,224	\$ -	\$ -
Restricted cash	759	759	-	-
Restricted cash, non-current	17,453	17,453	-	-
Short-term investments	847,041	-	847,041	-
Short-term bank loans	260,000	-	260,000	-
Long-term bank loans	215,703	-	215,703	-
Forward foreign exchange contracts	157	-	157	-
As of December 31, 2014				
Cash and cash equivalents	\$276,598	\$ 276,598	\$ -	\$ -
Restricted cash	7,422	7,422	-	-
Restricted cash, non-current	5,061	5,061	-	-
Short-term investments	816,394	-	816,394	-
Short-term bank loans	59,625	-	59,625	-
Long-term bank loans	197,585	-	197,585	-

(ee) Concentration of credit risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and restricted investments, short-term investments, derivative instruments and accounts receivable.

The Company places its cash and cash equivalents and restricted cash with high-credit quality financial institutions and a significant portion of them is placed with financial institutions in the PRC, Hong Kong and Singapore. The Company's short-term investments and restricted investment of the Company are primarily with 100% capital protection by high-credit quality financial institutions in the PRC.

The derivative instruments expose the Company to credit risk to the extent that its counterparties may be unable to meet the terms of the agreements. The Company seeks to mitigate this risk by limiting its counterparties to high-credit quality financial institutions in the PRC, Hong Kong and Singapore. Although there is no official deposit insurance program or any agency similar to the Federal Deposit Insurance Corporation (FDIC) in the PRC, the Company believes that the risk of failure of any of these PRC banks, Hong Kong banks and Singapore bank is remote and no significant credit risks exist.

Accounts receivable are typically unsecured and are derived from revenues earned from customers. The Company generally requires upfront payment or a significant installment prior to delivery of their products and performs ongoing credit evaluation of its customers. The Company purchases export credit insurance to mitigate the risk of loss and accounts receivable impairment on shipments to its international distributors as disclosed in Note 2 (f). In addition, no single customer accounts for 2% or more of the Company's total net revenues during the years presented. The Company believes that no significant credit risk exists as credit loss.

(ff) Recently issued accounting standards

In July 2013, the Financial Accounting Standards Board issued an Accounting Standard Update ("ASU 2013-11") which requires unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This Update applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments in this Update are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The Company adopted ASU 2013-11 in fiscal year 2014. The adoption does not have a significant impact on its consolidated financial statements.

In May 2014, the Financial Accounting Standards Board and International Accounting Standards Board have issued a converged standard on revenue recognition, ASC 606 ("ASC 606") and International Financial Reporting Standards 15, Revenue from Contracts with Customers, respectively. The objective of the converged revenue standard is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. ASC 606 contains principles that an entity will apply using a new five-step model to determine the measurement of revenue and timing of when it is recognized. The underlying principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Almost all entities will be affected to some extent by the significant increase in required disclosures. But the changes extend beyond disclosures, and the effect on entities will vary depending on industry and current accounting practices. For U.S. GAAP public reporting entities, ASC 606 is effective for the first interim period within annual reporting periods beginning after 15 December 2016. Early adoption is not permitted. The Company is currently evaluating financial and operational effects, if any, that the adoption of ASC 606 will have on the Company's consolidated financial statements.

3 Subsidiaries

Details of the Company's principal consolidated subsidiaries as of December 31, 2014 were as follows:

Name of Company	Place of Establishment and Operation	Percentage of Ordinary share/ Registered Capital Held by the Company	Principal Activities
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.	PRC	99.99%	Manufacturing and sales of medical equipment, research and development of related products and investment holding
Shenzhen Mindray Investment & Development Co., Ltd.	PRC	100%	Investment holding
Nanjing Mindray Bio-Medical Electronics Co., Ltd.	PRC	100%	Manufacturing and sales of medical equipment, research and development of related products and investment holding
Mindray (Nanjing) Bio-Technology Co., Ltd. *	PRC	100%	Manufacturing and sales of medical equipment
Shenzhen Mindray Software Technology Co., Ltd.	PRC	100%	Development and sale of software applications
Shen Mindray (Beijing) Medical Technology Co., Ltd.	PRC	100%	Research and development of medical equipment and related products
Xi'an Shen Mindray Medical Electronics Technology Research Institute Co., Ltd.	PRC	100%	Research and development of medical equipment and related products
	PRC	100%	

Edgar Filing: Mindray Medical International LTD - Form 20-F

Chengdu Shen Mindray Medical Electronics Technology Research Institute Co., Ltd.			Research and development of medical equipment and related products
Shanghai Medical Optical Instruments Factory Co., Ltd	PRC	100%	Manufacturing and sales of medical equipment and research and development of related products
Beijing Shen Mindray Medical Electronics Technology Research Institute Co., Ltd.	PRC	99.9%	Research and development of medical equipment and related products
Zhejiang Greenlander Information Technology Co., Ltd	PRC	60%	Development and sales of software applications
Hangzhou Optela Medical Instrument Co., Ltd	PRC	85%	Manufacturing and sales of medical equipment and research and development of related products
Shenzhen Shenke Medical Instrument Technical Development Co., Ltd	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products
Suzhou Hyssen Electronic Technology Ltd	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products

Hunan Changsha Tiandiren Biotech Co., Ltd	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products
Wuhan Dragonbio Surgical Implant Co., Ltd	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products
Beijing Precil Instrument Co., Ltd.	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products
Shanghai Long Island Biotec. Co., Ltd.*	PRC	51%	Manufacturing and sales of medical equipment and research and development of related products
MR Holdings (HK) Limited	Hong Kong	100%	Investment holding
MR Investments (HK) Limited	Hong Kong	100%	Sales and marketing of medical equipment and investment holding
Mindray Global Limited	BVI	100%	Investment holding
Mindray Research and Development Limited	BVI	100%	Investment holding
Surgical Global Limited*	BVI	100%	Dormant
MR Surgical Investments Limited*	BVI	100%	Dormant
MR Surgical International Limited*	Cayman Islands	100%	Dormant
Mindray Investments Singapore Pte. Ltd.	Singapore	100%	Investment holding
Mindray DS USA Inc.	United States	100%	Sales and marketing of medical equipment and research and development of related products
ZONARE Medical Systems, Inc.	United States	100%	Manufacturing and sales of medical equipment, research and development of related products and investment holding
Zenith Medical Systems Canada Ltd.	Canada	100%	Sales and marketing of medical equipment
Zenith Medical Systems Brazil	Brazil	100%	Sales and marketing of medical equipment
Zenith Medical Systems UK Ltd.	United Kingdom	100%	Sales and marketing of medical equipment
Zenith Medicinska Systems, AB	Sweden	100%	Sales and marketing of medical equipment
Zenith Medical Systems, GMBH	Germany	100%	Sales and marketing of medical equipment
Mindray Medical Canada Limited	Canada	100%	Marketing of medical equipment
Mindray Medical Sweden AB	Sweden	100%	Sales of medical equipment and research and development of related products
Mindray (UK) Limited	United Kingdom	100%	Sales and marketing of medical equipment and investment holding
Mindray Medical France SARL	France	100%	Sales and marketing of medical equipment and investment holding
Facai Immobilier	France	100%	Property holding
Mindray Medical Germany GmbH	Germany	100%	Sales and marketing of medical equipment
Mindray Medical Italy S.r.l.	Italy	100%	Sales and marketing of medical equipment

Edgar Filing: Mindray Medical International LTD - Form 20-F

Mindray Medical Netherlands B.V.	The Netherlands	100%	Sales and marketing of medical equipment and investment holding
Mindray Medical Espana S.L.	Spain	100%	Sales and marketing of medical equipment
Mindray Medical Mexico S de R.L. de C.V.	Mexico	100%	Sales and marketing of medical equipment
Mindray - Distribution and Commercialization of Medical Equipment Brazil Ltda.	Brazil	100%	Sales and marketing of medical equipment
Mindray Medical Colombia S.A.S	Colombia	100%	Sales and marketing of medical equipment
Mindray Medical Rus Limited	Russia	100%	Sales and marketing of medical equipment
Mindray Medical India Private Limited	India	100%	Sales and marketing of medical equipment

F-17

Edgar Filing: Mindray Medical International LTD - Form 20-F

PT Mindray Medical Indonesia	Indonesia	100%	Sales and marketing of medical equipment
Mindray Medical Thailand Limited	Thailand	100%	Sales and marketing of medical equipment
Mindray Medical Vietnam Company Limited	Vietnam	100%	Sales and marketing of medical equipment
Mindray Medical Technology Istanbul Limited Liability Company	Turkey	100%	Sales and marketing of medical equipment
Mindray Medical Egypt Limited	Egypt	100%	Marketing of medical equipment
Mindray Medical (M) Sdn. Bhd.	Malaysia	100%	Marketing of medical equipment
Mindray Medical Peru, SAC	Peru	100%	Marketing of medical equipment
Mindray Bio-Medical Electronics Nigeria Limited	Nigeria	100%	Marketing of medical equipment
Mindray Bio-Medical Venezuela C.A.	Venezuela	100%	Marketing of medical equipment
Mindray Medical Panama S.DE R.L.	Panama	100%	Marketing of medical equipment
Mindray Medical Australia (Holdings) Pty Ltd.	Australia	100%	Investment holding
Mindray Medical Australia Pty Ltd.	Australia	100%	Sales and marketing of medical equipment
Mindray Medical Korea Co., Ltd.*	Republic of Korea	100%	Marketing of medical equipment
Mindray Medical Poland sp. Z o.o. *	Poland	100%	Marketing of medical equipment
Mindray Medical Kenya Limited*	Kenya	100%	Marketing of medical equipment
Mindray Argentina S.R.L. *	Argentina	100%	Marketing of medical equipment
Mindray Medical South Africa (Pty) Ltd*	South Africa	100%	Marketing of medical equipment
Mindray Medical Philippines Inc. *	Philippines	100%	Marketing of medical equipment

Remarks*: Subsidiaries that were acquired or set up in 2014.

4 Accounts receivable, net

Accounts receivable, net consisted of the following:

	December 31,	
	2013	2014
Accounts receivable	\$236,188	\$240,948
Less: Allowance for doubtful debts	(14,571)	(15,076)
Total accounts receivable, net	221,617	225,872
Less: Non-current portion	(1,389)	(3,350)
Current portion	\$220,228	\$222,522

Movements in allowance for doubtful accounts were as follows:

	December 31,		
	2012	2013	2014
Balance at beginning of year	\$7,787	\$16,034	\$14,571
Allowance (recovery) made during the year	9,572	(940)	2,002
Foreign currency translation adjustments	(1,325)	(523)	(1,497)
Balance at end of year	\$16,034	\$14,571	\$15,076

5 Inventories

Inventories consisted of the following:

	December 31,	
	2013	2014
Raw materials	\$51,762	\$58,071
Work-in-progress	35,821	30,089
Finished goods	51,225	62,482
Total inventories	\$138,808	\$150,642

During the years ended December 31, 2012, 2013, and 2014, the Company recorded inventories write-down of \$2,609, \$2,154 and \$1,633, respectively, to their net realizable values.

6Property, plant and equipment, net

Property, plant and equipment, net consisted of the following:

	December 31,	
	2013	2014
Land	\$4,550	\$4,413
Buildings and leasehold improvements	238,227	277,324
Plant and machinery	55,123	65,903
Electronic equipment, furniture and fixtures	124,378	144,234
Motor vehicles	2,795	2,679
Total cost	425,073	494,553
Less: Accumulated depreciation	(161,516)	(191,629)
	263,557	302,924
Construction in progress	61,153	109,809
Total property, plant and equipment, net	\$324,710	\$412,733

Depreciation expenses were \$28,043, \$33,499 and \$36,017 for the years ended December 31, 2012, 2013, and 2014, respectively.

7 Land use rights, net

The Company's interests in land use rights represent prepaid operating lease payments and their net book values were analyzed as follows:

	December 31,	
	2013	2014
Land use rights	\$65,038	\$65,987
Less: Accumulated amortization	(5,575)	(6,930)
Total land use rights, net	\$59,463	\$59,057

Amortization expenses were \$1,246, \$1,338 and \$1,369 for the years ended December 31, 2012, 2013 and 2014, respectively.

8 Intangible assets, net

Intangible assets, net consisted of the following:

		December 31, 2013				December 31, 2014			
	Range of Useful Lives	Gross Carrying Amount	Accumulated Amortization	Provision for Impairment	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Provision for Impairment	Net Carrying Amount
Tradenames	5-20 years	\$17,598	\$(2,029)	\$ -	\$15,569	\$18,420	\$(3,089)	\$ -	\$15,331
Technologies	1-15 years	100,872	(29,568)	(311)	70,993	104,766	(36,532)	(256)	67,978
Core technologies	3-7 years	54,548	(13,386)	-	41,162	60,083	(20,166)	-	39,917
Customer relationships	3-13 years	63,800	(18,552)	-	45,248	69,118	(24,817)	-	44,301
Lease agreement	5 years	283	(57)	-	226	282	(113)	-	169
Other intangible assets	Indefinite	7,879	-	-	7,879	7,755	-	-	7,755
Total		\$244,980	\$(63,592)	\$(311)	\$181,077	\$260,424	\$(84,717)	\$(256)	\$175,451

Amortization expense was \$13,115, \$19,741 and \$21,278 for the years ended December 31, 2012, 2013 and 2014, respectively.

As of December 31, 2014, estimated aggregate amortization expense for each of the next five years ending December 31, is as follows:

2015	\$26,376
2016	24,368
2017	22,717
2018	15,504
2019	13,978
2020 and thereafter	64,753
Total	\$167,696

F-20

9 Goodwill

Movements in goodwill were as follows:

	Patient Monitoring and Life Support Devices	In-vitro Diagnostic Products	Medical Imaging Systems	Others	Total
Balance as of December 31, 2012	\$ 112,075	\$ 11,969	\$ 5,585	\$33,387	\$163,016
Goodwill arising from acquisitions during the year	1,807	5,417	70,694	-	77,918
Foreign currency translation adjustments	344	394	141	663	1,542
Balance as of December 31, 2013	\$ 114,226	\$ 17,780	\$ 76,420	\$34,050	\$242,476
Goodwill arising from acquisition during the year	-	12,157	-	-	12,157
Foreign currency translation adjustments	(56)	(6)	(22)	(114)	(198)
Balance as of December 31, 2014	\$ 114,170	\$ 29,931	\$ 76,398	\$33,936	\$254,435

10 Bank Loans

Summarized below were bank loans as of December 31, 2013 and 2014:

	December 31,	
	2013	2014
Bank of China Limited, New York Branch	\$50,000	\$50,000
Bank of China (Hong Kong) Limited	150,703	96,585
Nanyang Commercial Bank, Ltd.	80,000	80,000
Hongkong and Shanghai Banking Corporation Limited	195,000	30,625
Total bank loans	475,703	257,210
Less: Non-current portion	(215,703)	(197,585)
Current portion	\$260,000	\$59,625

On April 26, 2011, the Company, through its Hong Kong subsidiary, entered into a two-year term loan in the aggregate principal amount of \$35,000 to finance its fiscal year 2010 dividend payment. The loan bears an interest at 2.1% over LIBOR per annum and its arrangement fee amounted to \$70. Such loan was fully settled in 2013.

On July 18, 2011, the Company, through its US subsidiary, entered into a one-year revolving credit facility for an amount of \$50,000 to finance its working capital requirements. The facility was fully drawn on July 22, 2011 and was rolled over in July 2012, 2013 and 2014 respectively. The loan bears an interest at 1.2% over LIBOR per annum in 2014 and was classified as current loan as of December 31, 2013 and 2014. The loan was secured by standby letters of credits with an aggregate amount of not less than \$50,000 issued by Bank of China, Shenzhen Branch, which is procured by its PRC subsidiary, in favor of the lender.

On March 23, 2012, the Company, through its Hong Kong subsidiary, entered into a two-year term loan in the aggregate principal amount of \$50,000 to finance its fiscal year 2011 dividend payment. The loan bears an interest at 3.55% over LIBOR per annum and its arrangement fee amounted to \$250. As of December 31, 2013, the loan was classified as current loan. Such loan was fully settled in 2014.

On May 22, 2012, the Company, through its Hong Kong subsidiary, drew down an aggregate principal amount of \$2,000 from its existing revolving credit facilities to finance its working capital requirements. The revolving loan bears an interest at a 1.4% over LIBOR per annum. On November 23, 2012, such loan was fully repaid.

On March 7, 2013, the Company, through its Hong Kong subsidiary, entered into a three-year term USD denominated loan in an aggregate principal amount of \$60,000 to finance its fiscal year 2012 dividend payment. The loan bears an interest at 1.85% over LIBOR per annum and its arrangement fee amounted to \$895. On September 13, 2013, \$33,718 of the term loan is converted to Euro drawings of €25,000. On December 2, 2014, \$12,250 of the term loan is further converted to Euro drawings of €10,000. Both Euro and US\$ denominated term loans are due on March 8, 2016. The first and second drawing of Euro denominated portion carries interest at 3-month EURIBOR plus 2.5% and 3-month EURIBOR plus 2.3%, respectively. As of December 31, 2013 and 2014, the loan was classified as non-current loan.

On March 25, 2013, the Company, through its Hong Kong subsidiary, entered into a three-year term loan in an aggregate principal amount of \$35,000 to repay the abovementioned \$35,000 loan due in 2013. The loan will be fully repaid in 2016. The loan bears an interest rate at 1.6% over LIBOR per annum and its arrangement fee amounted to \$630. As of December 31, 2013, the loan was classified as non-current loan. During the year ended December 31, 2014, the Company partially repaid the loan in a principal amount of \$4,375. As of December 31, 2014, \$9,625 of the loan was classified as current loan and \$21,000 of the loan was classified as non-current loan.

On June 10, 2013 and June 13, 2013, the Company, through its Hong Kong subsidiary, entered into a three-year term loan in an aggregate principal amount of \$40,000 and of \$80,000 with two individual banks to finance its acquisition of ZONARE Medical Systems, Inc. ("ZONARE") and provision of working capital to ZONARE. The loan bears an interest rate at 1.30% over LIBOR per annum and its aggregate arrangement fee amounted to \$1,440. As of December 31, 2013 and 2014, the loan was classified as non-current loan.

On October 28, 2013, the Company, through its Hong Kong subsidiary, entered into a half-year term loan in an aggregate principal amount of \$160,000 to finance its share repurchase program launched in 2013. (See Note 13 for details). The loan bears an interest at 1% over LIBOR per annum and its arrangement fee amounted to \$320. As of December 31, 2013, the loan was classified as current loan. Such loan was fully repaid in 2014.

All the above financing arrangements do not require pledging any assets of the Company. There is a an aggregate compensating balance arrangement of \$241,500 and \$189,000 as of December 31, 2013 and 2014, respectively on certain of the Company's RMB denominated cash and cash equivalents and RMB denominated financial products in relation to those loans borrowed from Bank of China (Hong Kong) Limited and Nanyang Commercial Bank, Ltd. Their drawings are made available to the Company against RMB denominated deposit and /or RMB denominated financial products for an amount of not less than 105% of the drawing amount having been deposited by its PRC subsidiary with a PRC affiliate of Bank of China (Hong Kong) Limited and Nanyang Commercial Bank, Ltd. The Company is subject to review by the relevant banks with respect to maintenance of the aggregated compensating balances at each month end. The Company has no legal restriction on the withdrawal of these deposits and financial products. During the years ended December 31, 2013 and 2014, the maximum balances of compensating balance arrangement were both \$241,500.

The weighted average interest rate for bank loans outstanding as of December 31, 2013 and 2014 was 1.86% and 1.64%, respectively.

11 Notes payable

December 31,	
2013	2014

Notes payable \$10,945 \$9,234

Notes payable represents bills issued by various banks in favor of the Company's vendors and suppliers as payments for goods and services the Company purchased. The notes payable allows the Company's vendors and suppliers to receive payment in cash from the banks upon presentation on their due dates, which is usually between 60 to 90 days and withdrawal will be made from the Company's bank accounts. Accordingly, no interest will be charged on the bills.

12 Other payables and current liabilities

Other payables and current liabilities consisted of the following:

	December 31,	
	2013	2014
Accrued tender expenses	\$6,863	\$11,051
Accrued construction costs	9,728	36,531
Accrued operating expenses	32,078	39,026
Accrued professional fees	7,197	10,816
Accrued dispute charges	9,700	9,700
Deferred income from government subsidies	19,806	24,731
Guarantee deposits from distributors	13,731	16,168
Accrued interest expenses	1,325	539
Accrued warranty provision (Note 2(o))	13,583	16,824
Accrued sales incentives costs	3,783	1,492
Others	1,157	1,261
Total other payables and current liabilities	\$118,951	\$168,139

13 Share Repurchase

In November 2013, the Company approved a share repurchase program (“2013 Program”), under which the Company is authorized to repurchase up to \$200 million worth of its issued and outstanding ordinary American depositary shares (“ADSs”) on the NYSE Euronext at prevailing market prices from time to time during the period from November 2013 to July 2014 in trades pursuant to a Rule 10b5-1 repurchase plan, or otherwise, in accordance with Rule 10b-18. In March 2014, the Company subsequently approved to increase the size of 2013 Program from \$200 million to \$300 million and extend the effective date to March 31, 2015.

The purpose of the above share repurchase program is to deliver value to the shareholders of the Company. Repurchases will be made at management’s discretion, subject to restrictions on price, volume, and timing. The timing and extent of any purchases will depend upon market conditions and the trading price of its ADSs, as well as other factors. The repurchase program does not obligate the Company to make repurchases at any specific time or situation.

For 2013 Program, the Company repurchased 1,111,664 and 1,959,676 of its outstanding shares of ADSs at a consideration of \$42,369 and \$68,080 and retired 605,121 shares and 2,466,219 shares during the years ended December 31, 2013 and 2014, respectively, resulting in reductions of \$0.078 and \$0.318 in common stock and \$23,577 and \$86,872 in additional paid-in capital as of December 31, 2013 and 2014, respectively. As of December 31, 2013 and 2014, the amount of treasury stock was \$18,792 and \$nil, respectively.

14 Dividends

The Company declared and distributed dividends of \$46,401, \$59,070 and \$58,711 to its shareholders during the years ended December 31, 2012, 2013 and 2014, respectively.

Pursuant to certain provisions as specified in the bank loan agreements as entered into by the Company, there is loan covenant which restricts the Company from declaring dividend over 40% of its net profit in each year.

15 Share-based compensation plan

The 2006 Employee Share Incentive Plan was adopted by the Company’s board of directors in February 2006 and was subsequently amended by the Amended and Restated 2006 Employee Share Incentive Plan (the “Plan”) in September, 2006. The Plan is intended to promote the Company’s success and to increase shareholder value by providing an additional means to attract, motivate, retain and reward selected directors, officers and employees.

Under the Plan, the Company will issue share options or restricted shares to participants and is limited to issuing awards exercisable for or representing in the aggregate no more than 21,000,000 Class A ordinary shares. The Plan will terminate in 2016.

(a) Share Options

On March 6, 2009, the Company granted 27,500 options with an exercise price of \$18.34 under the Plan. These stock options are subject to graded vesting with approximately 20% of the options vesting each year over a five-year period, with its first vesting on December 31, 2009.

On March 11, 2009, the Company's board of directors authorized an option exchange program for certain options granted under the Plan. Under the terms of the exchange, participants were able to tender vested and unvested outstanding options to purchase Class A ordinary shares of the Company which have an exercise price greater than \$24.00 per share in exchange for a lower number of newly granted options. The exercise price of the new options will be the closing price of the Company's common stock on the New York Stock Exchange on the exchange date. The offer expired on March 15, 2009. The replacement options were granted on March 16, 2009. The option exchange has resulted in an increase in the fair value of the options granted under the plan by \$2.3 million, which is charged to the consolidated statements of operations over the remaining vesting periods of the respective share options.

On August 6, 2009, the Company granted 28,200 options with an exercise price of \$29.30 under the Plan. These stock options are subject to graded vesting with approximately 20% of the options vesting each year over a four-year period, with its first vesting on June 30, 2010.

On May 14, 2010, the Company granted 45,000 options with an exercise price of \$32.54 under the Plan. These stock options are subject to graded vesting with approximately 16.67% of the options vesting twice a year over a three-year period, with its first vesting on July 1, 2010.

The Company did not grant any share options during the years ended December 31, 2011, 2012, 2013 and 2014. In December 2013, the Company extended the expiration dates of certain batches of outstanding vested options that have not been exercised by the employees for another two years. The aggregate number of these outstanding vested options is 1,548,502. The difference between the fair value of the modified options and the fair value of the original options (immediately before it was modified) amounting to \$670 was fully charged to the consolidated statements of operations at the date of modification. The Company used the Black-Scholes option pricing model to estimate the fair value of these modified award options and original options (immediately before it was modified) on grant date with the following weighted-average assumptions:

Options	Modified Options	Original Options
Risk-free interest rate	0.78	% 0.12 %
Expected life	2.58 years	0.58 year
Assumed volatility	50.49	% 23.89 %
Expected dividends	1.38	% 1.38 %
Fair value on grant date	\$ 26.89	\$ 26.48

Assumed volatility is derived by referring to the average annualized standard deviation of the share price of the Company's own historical volatility. The expected term has been ascertained based on contractual terms. The risk free interest rate is based on the U.S. treasury yield rate with maturities similar to those of the expected term of the award.

A summary of the activities of share options under the Plan for the year ended December 31, 2014 is presented below:

	Number of Options	Weighted Average Exercise Price
Outstanding as of December 31, 2013	1,969,608	\$ 12.57
Exercised	(350,673)	9.48
Forfeited	-	-
Outstanding as of December 31, 2014	1,618,935	\$ 13.24

The total intrinsic value of share options exercised during the years ended December 31, 2012, 2013 and 2014 was \$32,594, \$40,168 and \$5,933, respectively. The total intrinsic value of exercisable share options was \$73,943, \$46,903 and \$21,596 as of December 31, 2012, 2013 and 2014, respectively. The total intrinsic value of the outstanding share options was \$74,266, \$46,903 and \$21,596 as of December 31, 2012, 2013 and 2014, respectively.

Cash received from exercise of options under all share-based payment arrangements for the years ended December 31, 2012, 2013 and 2014 was \$24,593, \$16,091 and \$3,324, respectively.

As of December 31, 2014, the total unrecognized compensation cost related to non-vested share options granted under the Plan was \$nil.

The following table summarizes information about share options issued under the Plan described above that are outstanding and exercisable as of December 31, 2014:

Range of exercise price	Options Outstanding				Options Exercisable			
	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value	Number of Options	Weighted-Average Exercise Price	Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
\$ 5.00	57,371	\$ 5.00	1.15	\$ 1,228	57,371	\$ 5.00	1.15	\$ 1,228
\$11.00 - \$18.34	1,237,986	11.00	1.69	19,061	1,237,986	11.00	1.69	19,061
\$20.50 - \$29.30	307,271	22.41	0.80	1,307	307,271	22.41	0.80	1,307
\$32.54- \$40.2	16,307	38.80	0.78	-	16,307	38.80	0.78	-
Total	1,618,935	\$ 13.24	1.49	\$ 21,596	1,618,935	\$ 13.24	1.49	\$ 21,596

As of December 31, 2014, share options vested and expected to vest totaled approximately 1.6 million shares, with a weighted-average remaining contractual life of 1.5 years and a weighted-average exercise price of \$13.24 per share and an aggregated intrinsic value of \$21,596.

(b) Restricted Shares Units (“RSU”)

A summary of the activities of the Company’s non-vested RSU under the Plan for the year ended December 31, 2014, is presented below:

	Number of Shares	Weighted Average Grant Date Fair Value
Non-vested as of December 31, 2013	851,825	\$ 33.58
Granted	726,157	34.76
Vested	(582,319)	32.72
Forfeited	(59,950)	34.94
Non-vested as of December 31, 2014	935,713	\$ 34.95

The total fair value of RSU vested during the years ended December 31, 2012, 2013 and 2014 was \$9,563, \$14,278 and \$20,444, respectively.

As of December 31, 2014, there was \$20,237 total unrecognized compensation cost related to non-vested RSU granted under the Plan. That cost is expected to be recognized over a weighted average period of 1.62 years.

16 Basic and diluted earnings per share

The Company is authorized to issue up to 4,000,000,000 Class A ordinary shares and up to 1,000,000,000 Class B ordinary shares, both with par value of HK\$0.001 per share. Each Class A ordinary share is entitled to one vote while each Class B ordinary share is entitled to five votes. Both Class A and Class B ordinary shares are entitled to receive dividends whenever funds are legally available and declared by the Board of Directors of the Company. Holders of Class A ordinary shares and holders of Class B ordinary shares have the same rights and liquidation preferences, except for voting rights. Accordingly, their earnings per share are the same. As of December 31, 2014, there were 88,181,846 Class A ordinary shares and 29,119,907 Class B ordinary shares issued and outstanding. The Company refers to Class A and Class B ordinary shares as ordinary shares throughout the notes to these financial statements, unless otherwise noted.

The following table sets forth the computation of basic and diluted earnings per share:

	Years Ended December 31,		
	2012	2013	2014
Basic earnings per share:			
Numerator			
Net income attributable to Mindray shareholders	\$ 180,209	\$ 224,754	\$ 193,292
Denominator			
Weighted-average ordinary shares outstanding, basic	116,749,213	117,705,414	117,057,116
Basic earnings per share	\$ 1.54	\$ 1.91	\$ 1.65
Diluted earnings per share:			
Numerator			
Net income attributable to Mindray shareholders	\$ 180,209	\$ 224,754	\$ 193,292
Denominator			
Weighted-average ordinary shares outstanding, basic	116,749,213	117,705,414	117,057,116
Effect of dilutive potential ordinary shares attributable to share options and restricted shares	3,065,791	2,346,221	1,355,344
Weighted-average ordinary shares outstanding, diluted	119,815,004	120,051,635	118,412,460
Diluted earnings per share	\$ 1.50	\$ 1.87	\$ 1.63

Share options with anti-dilutive effect were excluded in the computation of diluted earnings per share. As of December 31, 2012, 2013 and 2014, the number of ordinary shares to be purchased under those share options with anti-dilutive effect were 38,807, nil, and 16,307, respectively.

17 Other income, net

Other income, net consisted of the following:

	Years Ended December 31,		
	2012	2013	2014
Government grant and other subsidies	\$ 1,725	\$ 3,972	\$ 7,154
Others, net	(106)	(91)	2,209
Other income, net	\$ 1,619	\$ 3,881	\$ 9,363

18 Staff retirement plan

As stipulated under the rules and regulations in the PRC, the Company's subsidiaries in the PRC are required to contribute certain percentage of payroll costs of its employees to a state-managed retirement schemes operated by the local governments for its employees in the PRC. Other than these contributions, the Company has no further obligation for payment of the retirement benefits.

The cost of the Company's contributions to the staff retirement plans in the PRC amounted to \$10,005, \$13,701 and \$16,181 for the years ended December 31, 2012, 2013 and 2014, respectively. The cost of the Company's contributions to the defined contribution plan outside the PRC amounted to \$3,795, \$4,034 and \$4,673 for the years ended December 31, 2012, 2013 and 2014, respectively.

19 Income taxes

The components of income before income tax expenses were as follows:

	Years Ended December 31,		
	2012	2013	2014
China	\$285,595	\$299,236	\$296,407
Non-China*	(65,944)	(54,429)	(61,933)
Total	\$219,651	\$244,807	\$234,474

The provision for income taxes consists of the following:

	Years Ended December 31,		
	2012	2013	2014
Current:			
China	\$37,540	\$12,389	\$17,110
Non-China*	(144)	855	2,746
Total	\$37,396	\$13,244	\$19,856
Deferred:			
China	\$(3,367)	\$599	\$14,092
Non-China*	3,340	417	1,537
Total	(27)	1,016	15,629
Total provision for income taxes	\$37,369	\$14,260	\$35,485

Remarks* The financial figures are presented on entity level and only consider subsidiaries incorporated outside China.

Mindray International is a tax exempted company incorporated in the Cayman Islands and is not subject to taxation under current Cayman Islands law.

The Company conducts substantial business through Shenzhen Mindray Bio-Medical Electronics Co., Ltd (“Shenzhen Mindray”) which was determined as “New and Hi-Tech Enterprises” (“NHTE”) in October 2008 and was therefore eligible to a preferential enterprise income tax (EIT) of 15% through the end of 2016. The continued qualification for NHTE will still be subject to review by the relevant government authority in the PRC.

Shenzhen Mindray was also awarded “Nationwide Key Software Enterprise” status for the calendar years from 2009 through 2014, which allows Shenzhen Mindray to enjoy a unified 10% EIT rate for these years under the tax policies for software and integrated circuit industries. Currently, the Nationwide Key Software Enterprise status is granted every two years by the relevant government authority in the PRC. Shenzhen Mindray may not be granted this status for any future years. The tax benefits were recognized in the year the status was granted to Shenzhen Mindray.

A summary of tax benefits from “Nationwide Key Software Enterprise” status is presented as below:

Years Ended December 31,

Edgar Filing: Mindray Medical International LTD - Form 20-F

	2012	2013	2014
2011 Tax benefits	\$ -	\$ 7,923	\$ -
2012 Tax benefits	-	11,451	-
2013 Tax benefits	-	7,399	-
2014 Tax benefits	-	-	5,911
Total tax benefits	\$ -	\$ 26,773	\$ 5,911

Shenzhen Mindray Software Technology Co., Ltd (“Shenzhen Mindray Software”) was established in 2011 and is engaged in the development and sale of software applications to Shenzhen Mindray. It started to make profit in 2013 and therefore is entitled to a tax holiday under the EIT law which provided an EIT exemption from 2013 to 2014, and the 50% tax reduction from 2015 through 2017. It was also determined as a NHTE from 2013 to 2015.

Mindray DS USA Inc. (“Mindray DS USA”) and ZONARE Medical Systems, Inc. (“ZONARE”) are companies incorporated in Delaware, United States of America and are currently subject to federal tax and state tax. The combined tax rate of Mindray DS USA is 40.2% for the years presented. The combined tax rate of ZONARE is 38.9% and 38.7% for the years ended December 31, 2013 and 2014, respectively. The federal statute of limitations for the taxing authorities to assess the tax is generally three years from the date the return is filed.

Components of deferred tax assets and liabilities were as follows:

	December 31,	
	2013	2014
Deferred tax assets are analyzed as:		
Accrued employee benefits	\$197	\$2,234
Acquired intangible assets	6,747	6,668
Allowance for doubtful accounts	3,872	3,665
Depreciation of property, plant and equipment	1,551	261
Government subsidies	2,720	3,422
Inventories write-down	1,546	3,255
Sales incentive and warranty accruals	2,535	2,915
Net operating losses	48,772	55,235
Research & experimentation tax credits	1,420	2,254
Others	(260)	(56)
Valuation allowance	(59,515)	(65,051)
Total deferred tax assets, net	\$9,585	\$14,802
Deferred tax liabilities are analyzed as:		
Acquired intangible assets	\$(42,812)	\$(45,681)
Undistributed earnings that may be distributed by the PRC subsidiaries	(3,000)	(23,552)
Net deferred tax liabilities	\$(36,227)	\$(54,431)

	December 31,	
	2013	2014
Deferred tax assets are analyzed as:		
Current	\$9,585	\$14,802
Deferred tax liabilities are analyzed as:		
Non-current	(45,812)	(69,233)
Total	\$(36,227)	\$(54,431)

The EIT law in the PRC imposes a 10% withholding income tax (“WHT”) for dividends declared out of the post-January 1, 2008 earnings by a foreign-invested enterprise (“FIE”) to its immediate holding company outside China. However, any dividends declared out of pre-January 1, 2008 earnings are not subject to any WHT. For certain jurisdictions, such as Hong Kong, which has signed tax treaties with China, the WHT rate may be reduced to 5% if such Hong Kong holding company was considered as beneficial owner of such dividends or its shareholding is not less than 25%.

Certain amounts of undistributed earnings of the Company’s PRC subsidiary as of December 31, 2013 and 2014 may be distributed to its immediate parent companies, i.e. its Hong Kong subsidiaries in the future. Accordingly, a deferred tax liability in relation to such portion was \$3.0 million and \$23.6 million as of December 31, 2013 and 2014, respectively. No deferred tax liabilities for income taxes on the remaining undistributed earnings of the Company’s PRC subsidiaries are recorded as the Company intends to permanently reinvest such remaining undistributed earnings

in the PRC. The total amount of undistributed earnings of the Company's PRC subsidiaries that the Company intends to permanently reinvest in the PRC was \$1.2 billion and \$1.2 billion as of December 31, 2013 and 2014 and the amount of the unrecognized deferred tax liability on these permanently reinvested earnings was \$66.3 million and \$66.4 million as of December 31, 2013 and 2014, respectively.

As of December 31, 2014, the Company had net operating loss carryforwards of \$236,938 that can be used against future tax income, out of which \$115,951 and \$79,840 is in relation to Mindray DS USA and ZONARE respectively. The net operating loss carryforwards of ZONARE are subject to various limitations under Section 382 of the Internal Revenue Code and applicable state tax law. The net operating loss carryforwards in relation to Mindray DS USA and ZONARE will expire in 2029-2034 and 2018-2033, respectively, if not utilized, while the net operating loss carryforwards for other subsidiaries are subject to different expiry dates.

As the Company operates through multiple subsidiaries, the valuation allowance is considered on an individual subsidiary basis. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not (a likelihood of more than 50%) that some portion or all of the deferred tax assets within those loss jurisdictions will not be realized. The Company recorded a valuation allowance of \$59,515 and \$65,051 for those deferred tax assets that do not meet likely than not threshold as of December 31, 2013 and 2014.

Movements in valuation allowance were as follows

	December 31,		
	2012	2013	2014
Balance, beginning of year	\$36,945	\$51,884	\$59,515
Current year net addition	14,939	7,631	5,536
Balance, end of year	\$51,884	\$59,515	\$65,051

Reconciliation of provision for income taxes to the amount computed by applying the PRC enterprise income tax rate to the income before income taxes and non-controlling interests on the consolidated statements of operations is as follows:

	Years Ended December 31,					
	2012		2013		2014	
Income before income taxes and non-controlling interests	\$219,651		\$244,807		\$234,474	
PRC enterprise income tax rate	15	%	15	%	15	%
Income tax at PRC enterprise income tax rate on income before income taxes	36,809		44,435		40,865	
Effect of net income for which no income tax benefit/expense is receivable/payable	(929)	(3,993)	3,933	
Effect of different tax rates in different foreign jurisdictions	(5,192)	(1,286)	130	
Effect of different tax rates applicable to PRC subsidiaries	(68)	(35)	22	
Employee share-based compensation expense	1,833		334		1,715	
(Non-taxable) taxable VAT refund	(3,853)	9,415		-	
Tax incentives relating to research and development expense	(5,958)	(8,565)	(8,038)
(Over) under provision of income taxes in prior years	(212)	(2,159)	(105)
Effect of tax holidays	-		(7,744)	(23,214)
Effect of income tax benefits	-		(26,773)	(5,911)
Effect of deferred tax liabilities on undistributed earnings that may be distributed by the PRC subsidiaries	-		3,000		20,552	
Change in valuation allowance	14,939		7,631		5,536	
Total provision for income taxes	\$37,369		\$14,260		\$35,485	

The additional tax that would otherwise have been payable without tax holidays amounted to approximately \$nil, \$7,744 and \$23,214 in 2012, 2013 and 2014, respectively, representing a reduction in basic earnings per share of \$nil, \$0.07 and \$0.20 in 2012, 2013 and 2014, respectively, or a reduction in diluted earnings per share of \$nil, \$0.06 and \$0.20 in 2012, 2013 and 2014, respectively.

As of December 31, 2013 and 2014, the Company had \$3.7 million and \$5.4 million of unrecognized tax benefits, respectively, included in its current tax liability. A reconciliation of the beginning and ending amount of unrecognized tax benefits was as follows:

	December 31,	
	2013	2014
Unrecognized tax benefits, beginning of year	\$5,484	\$3,659
Gross decrease - prior year tax positions	(1,226)	-
Gross increase - current period tax positions	(599) 1,715
Unrecognized tax benefits, end of year	\$3,659	\$5,374

The Company does not anticipate any significant increases or decreases to its liability for unrecognized tax benefits within the next 12 months.

As of December 31, 2013 and 2014, the amount of interest and penalties related to uncertain tax positions are immaterial.

F-29

20 Acquisitions

The Company accounted for its acquisitions in accordance with ASC 805, “Business Combination” (“ASC 805”). The results of the acquirees’ operations have been included in the consolidated financial statements since the acquisition date. The excess of the fair value of the acquired entities over the fair value of net tangible and intangible assets acquired was recorded as goodwill, which is not deductible for corporate income taxation purposes. The fair value of the acquired entities consists of purchase price and the fair value of non-controlling interests which is measured based on fair value method in accordance with ASC 805 by grossing up the fair value of the controlling interests and taking into consideration control premium discount.

The following table summarizes acquisitions completed during the years ended December 31, 2012, 2013 and 2014:

	Purchase Price	Goodwill	Amortizable Intangibles
2012			
Dragonbio	\$ 35,263	\$ 20,545	\$ 35,153
Other acquisitions	21,025	12,438	13,248
2013			
ZONARE	\$ 101,105	\$ 70,694	\$ 49,100
Other acquisitions	11,284	7,224	8,840
2014			
Long Island	\$ 11,484	\$ 12,157	\$ 10,388

(a) Transactions completed in 2012

1. Acquisition of Dragonbio

The Company, through one of its PRC subsidiaries, acquired 51% equity interest of Wuhan Dragonbio Surgical Implant Co., Ltd. (“Dragonbio”), a domestic medical orthopedic products provider that specializes in trauma, spine, joint and other surgical products in July 2012. The Company expects to gain access to the fast-growing Chinese orthopedic market and potentially expand into additional international markets in the future through the combined business benefits from the transaction.

The total purchase consideration for 51% equity interest of Dragonbio amounted to RMB224,377 (equivalent to \$35,263 at the then-prevailing exchange rate) in cash, which is subject to downward adjustments depending upon Dragonbio meeting its audited sales target in 2012. As of December 31, 2012, the purchase consideration payable was

\$14,402, of which \$14,282 is placed under an escrow account and is classified as restricted investment. Such payable was settled in 2013 and there is no adjustment to the purchase consideration amounts.

The following table summarizes the estimated fair values of the assets acquired, liabilities assumed and non-controlling interests at the date of acquisition.

Current assets	\$9,557
Property, plant, and equipment	2,185
Intangible assets	35,153
Land use rights	1,436
Goodwill	20,545
Total assets acquired	68,876
Current liabilities	(3,030)
Deferred tax liabilities	(5,274)
Net assets acquired	60,572
Non-controlling interests	(25,309)
Total purchase consideration	35,263
Less: Purchase consideration payable	(14,106)
Less: Cash acquired	(1,817)
Total purchase consideration, net of purchase consideration payable and cash acquired	\$19,340

Goodwill associated with Dragonbio is attributable to other segment. Acquired intangibles are amortized on a straight line basis over the estimated useful lives. The estimated amounts recognized on the acquired identifiable intangible assets and their respective lives are shown in the following table:

	Estimated Useful Life	Gross Carrying Amount
Tradenname	15 years	\$ 905
Technology	15 years	20,455
Customer relationships	12 years	13,793
Total		\$ 35,153

2. Acquisition of other PRC entities

In 2012, the Company, through one of its PRC subsidiaries, completed the acquisitions for four other PRC entities, namely, (1) Zhejiang Greenlander Information Technology Co., Ltd ('Greenlander'), a healthcare IT solutions provider specializing in Picture Archiving & Communication System ('PACS') and Radiology Information System ('RIS'); (2) Hunan Changsha Tiandiren Biotech Co., Ltd ('Tiandiren'), a provider of microbiology analysis solutions; (3) Hangzhou Optcla Medical Instrument Co., Ltd ('Optcla'), a provider of rigid endoscopes and related surgical instruments and consumables; and (4) Shanghai Medical Optical Instrument Co., Ltd ('SMOIF'), a provider of flexible endoscopes and related surgical instruments. The acquired % equity interest for these four acquirees were 54.3%, 51.0%, 57.7% and 100%, respectively. The Company expects to benefit from the synergies created by combining its strong engineering, manufacturing, sales and management platforms with the acquirees' technology and expertise in their respective areas.

The total purchase consideration for the above four other PRC entities was RMB132,626 (equivalent to \$21,025 at the then-prevailing exchange rate) in cash, \$2,802 of which relating to the acquisition of one of the entities is subject to downward adjustments depending upon the entity meeting its audited net profit target in 2012. As of December 31, 2012, management estimated that no adjustments were required to the purchase consideration amounts based on the then actual unaudited 2012 results of such entity. During the year ended December 31, 2013, there was an adjustment to the purchase consideration amounted to RMB295 (equivalent to \$48 at the then-prevailing exchange rate) which was recognized as other expenses on the consolidated statements of operations.

Subsequent to the completion of the acquisition, the Company, through one of its PRC subsidiaries, further injected capital in an aggregate amount of RMB11,000 (equivalent to \$1,750 at the then-prevailing exchange rate) to increase its equity interest on Greenlander and Optcla up to 60% in 2012, with a corresponding increase in non-controlling interests of \$623. An additional RMB6,500 (equivalent to \$1,033 at the then-prevailing exchange rate) was further injected to Tiandiren in 2012 based on their respective equity interest, by the Company (through one of its PRC subsidiaries) and its non-controlling interest, of \$527 and \$506, respectively.

In 2014, the Company, through one of its PRC subsidiaries, further purchased equity interest on Optcla up to 85% from its non-controlling interest. The purchase consideration was RMB33,000 (equivalent to \$5,365 at the then-prevailing exchange rate) which was fully settled in 2014.

As of December 31, 2013 and 2014, the total purchase consideration payable was \$213 and \$nil, respectively. The following table summarizes the estimated fair values of the assets acquired, liabilities assumed and non-controlling interests at the date of acquisition:

Current assets	\$6,334
Property, plant, and equipment	1,239
Intangible assets	13,248
Goodwill	12,438
Total assets acquired	33,259
Current liabilities	(1,231)
Deferred tax liabilities	(2,188)
Net assets acquired	29,840
Non-controlling interests	(8,815)
Total purchase consideration	21,025
Less: Purchase consideration payable	(5,485)
Less: Cash acquired	(2,294)
Total purchase consideration, net of purchase consideration payable and cash acquired	\$13,246

Goodwill associated with Tiandiren and the three other PRC entities is attributable to in-vitro diagnostic segment and other segment, respectively. Acquired intangibles are amortized on a straight line basis over the estimated useful lives. The estimated amounts recognized on the acquired identifiable intangible assets and their respective lives are shown in the following table:

	Estimated Useful Life	Gross Carrying Amount
Tradename	9-15 years	\$ 1,712
Technology	6-15 years	4,855
Customer relationships	9-12 years	6,681
Total		\$ 13,248

For all acquisitions completed during the year ended December 31, 2012, the weighted-average useful life of tradename, technology and customer relationships were 13.5 years, 14.7 years and 11.2 years, respectively and the overall weighted-average useful life of acquired intangible assets were 13.2 years.

(b) Transactions completed in 2013

1. Acquisition of ZONARE

In July 2013, the Company, through its Netherlands subsidiary, acquired 100% equity interest of ZONARE Medical Systems, Inc. (“ZONARE”), an ultrasound technology leader in the high-end radiology segment. The Company expects to strengthen its high-end ultrasound R&D and U.S. sales capabilities in order to furthering the Company’s goal of becoming a worldwide leading provider of high-quality imaging products.

The total purchase consideration for 100% equity interest of ZONARE amounted to \$101,105 in cash. The total purchase consideration payable in respect of ZONARE’s acquisition amounted to \$17,382 and \$12,380, and of which \$17,367 and \$12,367 is placed under an escrow account and is classified as restricted cash as of December 31, 2013 and 2014, respectively. The restricted cash held by the escrow agent was exclusively for indemnification claims that may be made by the Company and will be released in various periods throughout 2015 and 2016. During the year ended December 31, 2014, the Company made a claim from escrow account pursuant to the terms of acquisition. The total claim amounted to \$2,719, of which \$1,359 was recognized as other income on the consolidated statements of operations for the year ended December 31, 2014.

In 2014, ZONARE acquired the remaining shares of non-controlling interests of its Germany subsidiary at a consideration of \$445 in cash.

F-32

The following table summarizes the estimated fair values of the assets acquired, liabilities assumed and non-controlling interests at the date of acquisition:

Current assets	\$21,297
Property, plant, and equipment	2,235
Intangible assets	49,100
Goodwill	70,694
Total assets acquired	143,326
Current liabilities	(22,774)
Deferred tax liabilities	(16,694)
Long-term liabilities	(2,478)
Net assets acquired	101,380
Non-controlling interests	(275)
Total purchase consideration	101,105
Less: Purchase consideration payable	(17,382)
Less: Cash acquired	(529)
Total purchase consideration, net of purchase consideration payable and cash acquired	\$83,194

Goodwill associated with ZONARE is attributable to medical imaging systems segment. Acquired intangibles are amortized on a straight line basis over the estimated useful lives. The estimated amounts recognized on the acquired identifiable intangible assets and their respective lives are shown in the following table:

	Estimated Useful Life	Gross Carrying Amount
Technology	1-13 years	\$ 43,800
Customer relationships	12 years	5,300
Total		\$ 49,100

2.

Acquisition of other entities

In January 2013, the Company, through its PRC subsidiary, acquired 51% equity interest in Beijing Precil Instrument Co., Ltd. (“Beijing Precil”), a provider of coagulation analyzers and related products in the PRC. The Company expects to benefit from the synergies created by combining its strong engineering, manufacturing, sales and management platforms with the acquiree’s technology and expertise in the area of coagulation analyzers.

In September 2013, the Company, through one of its Hong Kong subsidiaries, acquired 100% equity interest of Ulco Medical Pty. Ltd. (“Ulco” which is subsequently renamed as “Mindray Medical Australia (Holdings) Pty Ltd.”), an

Australian-based former distributor of Mindray in relation to patient monitoring and life support products since 2007. The Company expects to leverage Ulco's comprehensive sales and services capabilities to further strengthen its market presence in Australia, New Zealand and other Oceania Islands.

The total purchase consideration for the acquisitions in relation to Beijing Precil and Ulco amounted to \$11,284 in cash. Ulco's consideration is subject to adjustments, depending upon 1) its inventory and accounts receivable balances one year after acquisition date, and 2) meeting a targeted net assets value as of acquisition date. As of December 31, 2013, the Company estimated that no adjustments were required to the purchase consideration amount based on the then actual unaudited 2013 results. During the year ended December 31, 2014, there was an adjustment to the purchase consideration amounted to \$101 which was recognized as other income on the consolidated statements of operations.

As of December 31, 2013, the total purchase consideration payable was \$2,862, of which \$546 is placed under an escrow account and is classified as restricted cash-current. Such payable was settled in 2014.

The following table summarizes the estimated fair values of the assets acquired, liabilities assumed and non-controlling interests at the date of acquisitions:

Current assets	\$6,306
Property, plant, and equipment	252
Other assets	83
Intangible assets	8,840
Goodwill	7,224
Total assets acquired	22,705
Current liabilities	(3,052)
Deferred tax liabilities	(1,480)
Long-term liabilities	(81)
Net assets acquired	18,092
Non-controlling interests	(6,808)
Total purchase consideration	11,284
Less: Purchase consideration payable	(2,826)
Less: Cash acquired	(2,604)
Total purchase consideration, net of purchase consideration payable and cash acquired	\$5,854

Goodwill associated with Ulco and Beijing Precil is attributable to patient monitoring and life support devices segment and in-vitro diagnostic products segment, respectively. Acquired intangibles are amortized on a straight line basis over the estimated useful lives. The estimated amounts recognized on the acquired identifiable intangible assets and their respective lives are shown in the following table:

	Estimated Useful Life	Gross Carrying Amount
Tradename	20 years	\$ 1,046
Technology	10 years	1,512
Customer relationships	6 years	6,005
Lease agreement	5 years	277
Total		\$ 8,840

For all acquisitions completed during the year ended December 31, 2013, the weighted-average useful life of tradename, technology, customer relationships and lease agreements were 20.0 years, 12.8 years, 8.8 years and 5.0 years, respectively and the overall weighted-average useful life of acquired intangible assets were 12.1 years.

(c)

Transaction completed in 2014

In March, 2014, the Company, through its PRC subsidiary, acquired 51% equity interest in Shanghai Long Island Biotech. Co., Ltd. (“Long Island”), a provider of coagulation analysis reagents in the PRC. The Company expects to leverage Long Island’s expertise in manufacturing and selling of reagents in growing its business.

The total purchase consideration for acquisition of 51% equity interest of Long Island amounted to RMB70,650 (equivalent to \$11,484 at the then-prevailing exchange rate) in cash. The purchase consideration is subject to adjustments, depending upon the entity meeting its net revenues and accounts receivable balances. As of December 31, 2014, the Company estimated that no adjustments were required to the purchase consideration amount based on actual unaudited 2014 results.

Subsequent to the completion of the acquisition, an additional RMB8,225 (equivalent to \$1,336 at the then-prevailing exchange rate) was further injected to Long Island in 2014 by the Company through one of its PRC subsidiaries and its non-controlling interest, based on their respective equity interest of \$681 and \$655, respectively.

As of December 31, 2014, the total purchase consideration payable was \$4,793, of which \$nil was placed under an escrow account, and the total purchase consideration payable was expected to be settled in 2015.

F-34

The following table summarizes the estimated fair values of the assets acquired, liabilities assumed and non-controlling interests at the date of acquisition:

Current assets	\$1,694
Property, plant, and equipment	1,217
Intangible assets	10,388
Goodwill	12,157
Total assets acquired	25,456
Current liabilities	(2,446)
Deferred tax liabilities	(2,611)
Net assets acquired	20,399
Non-controlling interests	(8,915)
Total purchase consideration	11,484
Less: Purchase consideration payable	(4,793)
Less: Cash acquired	(315)
Total purchase consideration, net of purchase consideration payable and cash acquired	\$6,376

Goodwill associated with Long Island is attributable to in-vitro diagnostic products segment. Acquired intangibles are amortized on a straight line basis over the estimated useful lives. The estimated amounts recognized on the acquired identifiable intangible assets and their respective lives are shown in the following table:

	Estimated Useful Life	Gross Carrying Amount
Tradename	15 years	\$ 845
Technology	15 years	4,116
Customer relationships	13 years	5,427
Total		\$ 10,388

For acquisition completed during the year ended December 31, 2014 the weighted-average useful lives of acquired intangible assets were 14.0 years.

For all acquisitions in 2012, 2013 and 2014, the Company has not prepared a pro-forma condensed combined statement of operations in accordance with ASC 805 as the acquisitions both individually and in the aggregate are not material, where individual and aggregate net revenue and net income of these acquired entities for their respective acquisition years are less than 5% of the Company's consolidated net revenue and net income for the corresponding years.

21 Banking facilities

The Company has an aggregate available banking facilities of \$607,517 and \$581,453 with various banks for loans, bills, letter of guarantee/credit and standby letter of credits facilities, of which \$56,967 and \$244,281 were unutilized as of December 31, 2013 and 2014, respectively. Some of these facilities were secured by corporate guarantees executed by the Company and certain of its subsidiaries. In addition, the Company is required to comply with certain financial covenants imposed by the banks. As of December 31, 2013 and 2014, the Company was in compliance with the financial covenants imposed by the banks.

F-35

22 Commitments and contingencies**(a) Lease commitments**

The Company's existing rental leases do not contain significant restrictive provisions. The following is a schedule by year of future minimum lease obligations under non-cancelable rental operating leases as of December 31, 2014:

Years ending December 31,

2015	\$12,673
2016	9,649
2017	6,372
2018	1,450
2019	488
2020 and thereafter	66
	\$30,698

Rental expenses under operating leases were \$12,049, \$13,758 and \$16,617 for the years ended December 31, 2012, 2013 and 2014, respectively.

(b) Capital commitments

As of December 31, 2014, the Company had outstanding capital commitments for property, plant and equipment totaling \$75,714.

(c) Contingencies

The Company accounts for loss contingencies in accordance with ASC 450, "Contingencies" and other related guidelines. The Company is subject to claims and legal proceedings that arise in the ordinary course of its business operations. Each of these matters is subject to various uncertainties and the outcome of such matters is inherently unpredictable. It is possible that some of these matters may be decided unfavorably to the Company. Set forth below is a description of certain loss contingencies as of December 31, 2014 and management's opinion as to the likelihood of loss in respect of loss contingency.

On December 21, 2012, Masimo Corporation brought an action in the United States District Court for the Central District of California against Mindray DS USA and Shenzhen Mindray. Masimo alleges that Shenzhen Mindray's pulse oximeters and sensors infringe nine Masimo patents relating to pulse oximeters and sensors, and that Shenzhen Mindray breached its Purchase and License Agreement with Masimo dated November 13, 2002, as amended, by failing to use best efforts to promote adoption of Masimo's oximeter technology outside the United States. Shenzhen Mindray's Purchase and License Agreement with Masimo expired on December 31, 2012. The District Court dismissed Mindray DS USA from the litigation on February 28, 2013. Masimo filed a First Amended Complaint against Shenzhen Mindray alone on August 5, 2013 and a Second Amended Complaint against Shenzhen Mindray alone, but adding Masimo International SARL as co-plaintiff, on July 7, 2014. Shenzhen Mindray is vigorously defending itself against Masimo's claims; has asserted counterclaims for declarations of non-infringement and invalidity of all nine asserted patents, and has asserted numerous counterclaims against Masimo, including for antitrust violations and for infringement of two United States patents. Trial has been scheduled for December 1, 2015. As of December 31, 2013 and 2014, the Company accrued \$9,700 dispute charge which represents the Company's estimate of probable loss in relation to current circumstances of the litigation. The Company does not believe that the outcome of this pending litigation will have a material adverse effect on the Company's business, financial position, or results of operations.

In addition, on December 11, 2013, Masimo Corporation brought an action in New Jersey Superior Court, Bergen County, against Mindray DS USA, Shenzhen Mindray, and its holding company, Mindray International. Masimo alleges that Mindray DS USA, Shenzhen Mindray and Mindray International are alter-egos of each other, and that Mindray DS USA has breached its Restated Purchasing and Licensing Agreement with Masimo dated August 17, 1997, as amended ("the DS Agreement"), acquired by Mindray DS USA in 2008 in connection with its acquisition of the Datascope's patient monitoring business. Masimo further alleges that Shenzhen Mindray and Mindray International have conspired with Mindray DS USA to breach the DS Agreement by failing to integrate Masimo SET® technology into all of Mindray DS USA's future pulse oximetry products and by continuing to market Mindray pulse oximetry technology. Mindray DS USA removed the originally filed state court action to the United States District Court for the District of New Jersey on January 17, 2014, and on January 24, 2014, filed a motion asking the New Jersey District Court to stay or dismiss the case. Masimo filed a motion asking the New Jersey District Court to remand the case to the Superior Court. The District Court granted the Masimo's motion to remand on January 7, 2015 without ruling on Mindray DS USA's motion to dismiss. Mindray DS USA again removed the remanded state court action to the United States District Court for the District of New Jersey, and refiled its motion to stay or dismiss the case. On January 29, 2015, Mindray International and Shenzhen Mindray each moved to have the Complaint against them dismissed. Briefing on those motions is completed, and motions are awaiting to be taken up by the District Court. At present, the Company is of the view that this pending litigation is at an early stage and is therefore unable to express a conclusion as to the likelihood of an unfavorable outcome to the Company. The Company does not believe that the outcome of this pending litigation will have a material adverse effect on the Company's business, financial position, or results of operations.

The Company acquired ZONARE in July 2013. On November 1, 2013, HDX Corporation, or HDX, filed a complaint against ZONARE in the Northern District of California, alleging that ZONARE was in breach of a December 11, 2009 Manufacturing Rights Agreement between ZONARE and HDX. HDX's complaint also named three former or current employees of ZONARE as individual defendants. In the complaint, HDX also alleged that ZONARE and the individual defendants engaged in promissory fraud and asserted that the defendants' alleged misrepresentations in connection with the 2009 agreement induced HDX invest in ZONARE. Specifically, HDX asserted claims for breach of contract, intentional fraud, fraudulent concealment and violations of California statutory provisions, and sought both monetary damages and injunctive relief. In January 2014, ZONARE and the individual defendants filed motions with the court to compel arbitration and dismiss HDX fraud-based claims. Subsequently, HDX agreed to refer the matter to arbitration, the court stayed the action pending arbitration and, in February 2014, HDX filed a demand for arbitration with the American Arbitration Association. ZONARE and the individual defendants and HDX have recently in March 2015 agreed to settle and dismiss the arbitration and all claims with prejudice. The settlement amount will be claimed from escrow account established in connection with the acquisition of ZONARE.

On November 11, 2013, Shenzhen Mindray entered into a \$14,750 settlement agreement with an OEM manufacturing customer, Beckman Coulter, Inc. The dispute was an ordinary course commercial dispute that did not involve intellectual property or product liability matters. The Company has since terminated the OEM arrangement with Beckman Coulter, Inc. and does not consider this termination to be material to the Company's business or operations. The dispute charge of \$14,750 was included in the general and administrative expenses on the consolidated statements of operations during the year ended December 31, 2013.

The Company issues indemnifications and warranties in certain instances in the ordinary course of business to certain parties, including its customers and suppliers. It is not possible to make a reasonable estimate of the maximum potential amount for these indemnification and warranties as a result of different clauses are applied to customers and suppliers. The Company has a limited history of prior indemnification and warranty claims and the payments the Company has made under such agreements have not had a material adverse effect to the Company's financial position, results of operations or cash flows. However, to the extent that valid indemnification and warranty claims arise in the future, future payments made by the Company could be significant and could have a material adverse effect on the Company's financial position, results of operations or cash flows. As of December 31, 2014, the Company did not have any material indemnification and warranty claims that were probable or reasonably possible.

23 Distribution of profits

As stipulated by the relevant PRC laws and regulations applicable to the Company's subsidiaries in the PRC, the Company is required to make appropriations from net income as determined in accordance with accounting principles and the relevant financial regulations applicable to PRC enterprise to non-distributable reserves (also referred to as "statutory common reserves") which included a statutory surplus reserve and a statutory welfare reserve as of December 31, 2005. Based on revised PRC Company law which took effect on January 1, 2006, the PRC subsidiaries are no longer required to make appropriations to the statutory welfare reserve but appropriation to the statutory surplus reserve are still required to be made at not less than 10% of the profit after tax as determined under generally accepted accounting principles in the PRC. The appropriations to statutory surplus reserve are required until the balance reaches

50% of the subsidiaries' registered capital.

The statutory surplus reserve is used to offset future extraordinary losses. The subsidiaries may, upon a resolution passed by the shareholders, convert the statutory surplus reserve into capital. The statutory welfare reserve was used for the collective welfare of the employees of subsidiaries. These reserves represent appropriations of retained earnings determined according to PRC law and may not be distributed. There were no appropriations to reserves by the Company other than the Company's subsidiaries in the PRC during any of the years presented. As a result of these laws, the Company's PRC subsidiaries are restricted in their ability to transfer a portion of their reserve either in the form of dividends, loans or advances. The amount of this restricted portion was \$35,416 and \$40,003 as of December 31, 2013 and 2014, respectively.

24 Segment reporting

The Company accounts for segmental reporting under ASC 280, "Segment reporting". It has three reportable segments based on its major product groups: patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. Each reportable segment derives its revenues primarily from the sale of their products. The Company's chief operating decision makers, has been identified as the Co-Chief Executive Officers, review these operating segment results when making resource allocation decisions and evaluating the performance of the Company's business.

The Company does not allocate operating expenses to individual reportable segments when making resource allocation decisions and evaluating its business performance. Accordingly, there are measurement differences between the reportable segments and the consolidated financial statements.

A measure for total assets of the Company's reportable segments was not disclosed because asset information is not included in the measures reviewed by the chief operating decision makers. The following table presented selected financial information relating to the Company's reportable segments for the years ended December 31, 2012, 2013 and 2014:

	Patient Monitoring and Life Support Products	In-vitro Diagnostic Products	Medical Imaging Systems	Others	Total
Years Ended December 31, 2012					
Net revenues	\$ 449,131	\$ 286,075	\$253,234	\$71,614	\$1,060,054
Cost of revenues	(195,333)	(119,420)	(87,983)	(56,653)	(459,389)
Gross profit	\$ 253,798	\$ 166,655	\$ 165,251	\$ 14,961	\$600,665
2013					
Net revenues	\$ 469,689	\$ 335,511	\$303,416	\$105,371	\$1,213,987
Cost of revenues	(199,809)	(141,089)	(112,667)	(73,837)	(527,402)
Gross profit	\$ 269,880	\$ 194,422	\$ 190,749	\$ 31,534	\$686,585
2014					
Net revenues	\$ 485,103	\$ 367,148	\$343,285	\$127,278	\$1,322,814
Cost of revenues	(219,390)	(152,432)	(134,544)	(77,944)	(584,310)
Gross profit	\$ 265,713	\$ 214,716	\$ 208,741	\$ 49,334	\$738,504

Geographic disclosures

The Company's net revenues by geography are based on country of customer destination. The net revenues attributable by the PRC, the United States, Europe and other countries for the years ended December 31, 2012, 2013 and 2014 were as follows:

	Years Ended December 31,		
	2012	2013	2014
Net revenues:			
PRC	\$472,991	\$551,155	\$606,745
United States of America	143,586	160,614	184,775
Europe	100,985	121,262	137,133
Rest of the world	342,492	380,956	394,161
Total net revenues	\$1,060,054	\$1,213,987	\$1,322,814

Long-lived assets located at the respective geographic areas as of December 31, 2013 and 2014 are as follows:

	December 31,	
	2013	2014
Long-lived assets		
PRC	\$342,919	\$434,846
United States	30,110	26,589
Rest of the world	11,144	10,355
Total long-lived assets	\$384,173	\$471,790

For the above table, long-lived assets represents the total assets less current assets, non-current restricted cash, other assets, non-current accounts receivable, net, advances for purchase of property, plant and equipment, intangible assets, net and goodwill.

Major customers

There was no single customer who accounted for 2% or more of the Company's net revenues for the years ended December 31, 2012, 2013 and 2014, respectively.

25 Subsequent Events

On March 9, 2015, the Company declared a cash dividend of \$0.4 per ordinary shares. The cash dividends are payable to shareholders of record as of March 19, 2015.

In March 2015, the Company, through its Hong Kong subsidiary, entered into a three-year term loan in the aggregate principal amount of \$48,000 to finance its fiscal year 2014 dividend payment. The loan bears an interest at 1.2% over LIBOR per annum and its arrangement fee amounted to \$288.

F-39